Chemical diversification and anticancer activity of natural products by Morrison, Karen
  
 
 
 
CHEMICAL DIVERSIFICATION AND ANTICANCER ACTIVITY  
OF NATURAL PRODUCTS 
 
 
 
 
 
 
BY 
 
KAREN C. MORRISON 
 
 
 
 
 
 
 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements 
for the degree of Doctor in Philosophy in Chemistry 
with a minor in Museum Studies 
in the Graduate College of the 
University of Illinois at Urbana-Champaign, 2013 
 
 
 
Urbana, Illinois 
 
 
 Doctoral Committee: 
 
  Professor Paul J. Hergenrother, Chair 
  Professor John Katzenellenbogen 
  Professor Wilfred van der Donk 
  Assistant Professor Douglas Mitchell 
 
  
ii 
 
Abstract 
 
 Natural products have historically formed the backbone of modern drug discovery efforts, 
particularly for cancer and bacterial infections.  Despite this privileged status, difficulties 
associated with the isolation of new natural products or the de novo synthesis of established 
natural products, coupled with a growth in high throughput screening, led to a decreased 
emphasis on natural products for drug discovery during the 1990s.  The last decade has brought a 
renaissance in natural product research in terms of new techniques for isolation, synthesis, and 
biological characterization and with it a renewed appreciation for the importance of these 
complex molecules. 
 The chapters herein reflect this interest in natural products as important tools for drug 
discovery.  Chapter 1 highlights the synthetic utility of natural products for the creation of 
complex small molecules for screening libraries.  Chapter 2 details specific work with the natural 
product gibberellic acid for the synthesis of complex and diverse compounds, and chapter 3 
covers the screening of these compounds and the biological characterization of a primary hit, 
GEM-1.  Chapters 4 and 5 focus on the anticancer characterization of two classes of natural 
products: the epipolythiodiketopiperazines alkaloids and the iridoids prismatomerin and 
plumericin, respectively.  Finally, chapter 6 describes the development of a new analytical 
method for the cellular analysis of a common target of natural products, the biopolymer tubulin. 
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Chapter 1: Development of Complex Small Molecules for Drug Discovery 
 
1.1 Synthesis of Complex Molecules for Screening Libraries 
 Natural products (NPs) have traditionally formed the backbone of modern drug discovery 
programs.  The fruits of this effort include well known drugs such as paclitaxel (anticancer), 
artemisinin (antimalarial), daptomycin (antibacterial), and morphine (analgesic), as shown in 
Figure 1.1.  Indeed, from the 1940s to 2010, 41% of anticancer and 65% of antibacterial small 
molecule drugs were either NPs or semisynthetic derivatives of NPs.
1
 
 
 
Figure 1.1. Structures of paclitaxel, artemisinin, daptomycin, and morphine. 
 
1.1.1 Justification for Synthesis of Complex Molecules for Screening Libraries 
 Despite their rich history in drug discovery, the 1990s saw a movement away from NPs 
and toward the screening of collections of synthetic compounds.  This was due to several factors, 
including the increasing difficulty of identifying new NPs
2-3
 and the development of synthetic 
2 
 
methods to rapidly create large collections of compounds.
4-5
  The libraries of organic compounds 
constructed in this high-throughput fashion are comprised of compounds that are easy to 
assemble, and thus can be synthesized via automated, combinatorial, or parallel synthesis.  Such 
compounds tend to be structurally different than NPs: complexity of ring systems, percentage of 
carbons that are sp
3
-hybridized, heteroatom content, and number of stereocenters are all 
markedly different in collections of synthetic compounds as compared to NPs.
6
  These structural 
differences lead to different interactions with macromolecular receptors, resulting in differences 
in biological activity.
7-9
  Based on this realization, there has been a movement to develop 
synthetic compounds that have complexity comparable to that of NPs.  This strategy would 
provide compounds that represent the best of both worlds: structurally complex compounds with 
physicochemical properties analogous to those of NPs, accessed as rapidly as the other synthetic 
compounds. 
 
1.1.2 Synthetic Techniques for Synthesizing Complex Molecules from Simple Starting 
Materials 
 The facile creation of large numbers of complex and diverse small molecules is an 
enormous challenge and represents one of the frontier problems in modern synthetic chemistry, 
medicinal chemistry, and chemical biology. Diversity-oriented synthesis (DOS), in which 
complex compounds are rapidly assembled from simple starting materials,
10-12
 has been widely 
adopted, and compounds generated from DOS efforts have been identified as hits in a diverse 
array of screens.
13-16
  Other strategies, including function-oriented synthesis (FOS),
17
 biology-
oriented synthesis (BiOS),
18
 biosynthetic engineering,
19
 and differential functionalization of the 
periphery of NPs
20-21
 also show promise.  These strategies (DOS,
13, 16, 22-24
 FOS,
17, 25
 and BiOS
18, 
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26-27
) have been extensively reviewed elsewhere, but a brief discussion of DOS, FOS, and 
differential functionalization of NPs, along with some key examples, will be provided below. 
 
1.1.2.1 Diversity-Oriented Synthesis 
 The build-couple-pair strategy of DOS has been used to great effect in the construction of 
large compound libraries composed of stereochemically complex small molecules.  Complex 
building blocks are first assembled (build) and then coupled to create the carbon backbone 
(couple).  Finally, intramolecular complexity-generating reactions install skeletal diversity (pair).  
By performing these reactions on a solid support, the synthesis and screening of large numbers of 
compounds in biological assays is possible. 
 One of the earliest examples of this strategy was the synthesis of over two million small 
molecules from a tricyclic derivative of shikimic acid.
28
  Since then, further efforts have 
broadened the scope and application of DOS to numerous polycyclic structures.  To date, this 
approach has been used by scores of research groups for the construction of complex small 
molecules. 
 An advantage of installing molecular complexity during the synthesis of small molecules 
is that theoretically every stereoisomer of a compound can be synthesized and tested.  This 
unbiased synthetic approach acknowledges that the spatial positioning of groups is often crucial 
for interactions with biological targets and takes this into account early in the discovery process.  
Recent work from the Schreiber lab has highlighted the importance of having all stereoisomers 
of a molecule in their investigations of modulators of the sonic hedgehog pathway.
15
  All eight 
stereoisomers of their bicyclic scaffold were synthesized and screened.  As shown in Figure 1.2, 
the stereochemistry of the lead compound (BRD50837) was crucial for its activity, with the RSR 
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isomer showing a 5-fold improvement over the SSR isomer, and a 70-fold improvement over the 
inactive derivatives. 
 
 
Figure 1.2. Structure of BRD50837 and activity against the sonic hedgehog pathway as a 
function of the stereochemistry.
15
 
 
1.1.2.2 Function-Oriented Synthesis 
 The aim of FOS is to simplify extremely complex NPs to modified structures that retain 
the key pharmacophores.  The Wender lab has pioneered this effort in the synthesis of simpler 
bryostatin analogs for applications in cancer, Alzheimer’s, and AIDS research.  Bryostatin is a 
complex 26-carbon macrocyclic NP with eleven stereocenters and three imbedded pyrans 
(Figure 1.3).  Although bryostatin is highly potent, one ton of the marine bryozoan Bugula 
neritina is needed to obtain one gram of material, and synthetic efforts are lengthy
29-31
 and 
currently cannot provide sufficient quantities for Phase II/III studies.  As a result, Wender and 
coworkers identified the key functional groups of bryostatin that are necessary for its activity and 
have synthesized a number of analogs that capitalize on the function of bryostatin while 
substantially reducing its complexity (Figure 1.3).
32
  These efforts have resulted in highly active 
compounds for the treatment of HIV
33
 and certain types of cancer.
34
  Despite the successful 
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application of FOS to bryostatin, this strategy is more amenable for the optimization of NPs with 
known activity, rather than the generation of new molecules for screening against novel targets. 
 
 
Figure 1.3. Structure of bryostatin 1 and simplified derivatives that retain key pharmacophoric 
elements (highlighted in yellow). 
 
1.1.2.3 Differential Functionalization of Natural Products 
 One extension of DOS has included the differential functionalization of the periphery of 
NPs or related materials for the generation of large, complex libraries.  Two notable examples 
are libraries based on galanthamine
20
 and carpanone
21
 skeletons that contained >2500 and 
>10,000 members, respectively (Figure 1.4).  Both efforts utilized carbon frameworks 
reminiscent of the NP that were attached to solid supports and then appended with amines, acyl 
chlorides, and other functional groups in a split-pool synthesis.  Although large numbers of 
molecules were generated, the carbon cores were identical for all members of the library.  
Despite this limitation, both compound collections were screened and contained small molecules 
that modulated the Golgi complex in cells. 
6 
 
 
Figure 1.4. Synthesis of libraries of complex small molecules modeled after NPs.  A) 
Galanthamine-based libraries.
20
  B) Carpanone-based libraries.
21
 
 
1.1.3 Summary 
 Together, these techniques provide a number of methods for the synthesis of complex 
small molecules that can be further screened against biological targets.  DOS, FOS, and others 
have been validated in numerous assays; however, all require the iterative construction of 
complex scaffolds throughout the synthetic route.  As a result, top-down techniques may provide 
access to novel classes of small molecules that are complementary to those discussed above. 
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1.2 Natural Products as Starting Points for the Synthesis of Complex and Diverse 
Compounds 
1.2.1 General Strategy 
 In using NPs as the starting points for complex molecule synthesis, synthetic chemists 
can add diversity to the complexity installed in Nature.  Examples of this approach fall into two 
broad categories: the use of a single reactive group on a NP to alter the structure (Figure 1.5A), 
and the use of multiple reactive groups (Figure 1.5B). 
 
1.2.1.1 Diversifying Natural Products through a Single Transformation 
 The earliest ad hoc attempts to modulate the structures of NPs utilized molecules with a 
single reactive group.  The application of a single transformation class then results in multiple 
different products (Figure 1.5A).  The forerunners in this area generated multiple products in one 
reaction, leading to difficult separations or modest yields.  Efforts in the mid-2000s employed 
reagent control to afford products in a selective fashion, and work since 2011 have systematized 
this process to clearly and predictably create complex small molecules. 
 
1.2.1.2 Diversifying Natural Products through Multiple Transformations 
 In contrast to the single transformation model, use of multiple structural transformations 
(Figure 1.5B) relies on NPs with rich functional diversity.  Initial investigations focused on the 
elaboration of NPs for total syntheses or to optimize the activity or selectivity of the original NP 
through structural modifications.  Recent efforts in this area have formalized this process of 
multiple structural transformations to several highly complex NPs.  Application of this method to 
other NPs should allow for the construction of multiple classes of complex small molecules.  
8 
 
Further maturation of the field from creating scaffolds to generating small libraries based on 
these novel structures will ultimately allow for the generation of large numbers of complex and 
diverse compounds. 
  
 
Figure 1.5. Classes of structural transformations for modifying natural products. 
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1.2.2 Single Structural Transformations 
1.2.2.1 Lathyrane diterpenes 
 The lathyrane diterpenes are a class of NPs isolated from the seeds of caper spurge 
Euphorbia lathyris (Scheme 1.1).  These complex tricyclic small molecules can be recovered in 
multigram quantities (0.25% yield by mass),
35
 making them useful starting materials to convert 
into other complex compounds.  Although these NPs contain multiple functional groups, the 
reactive cyclopropane enone and either epoxide (L1, 1-1) or exocyclic olefin (L3, 1-2) serve as 
the key reactive groups that drive the transformations of these NPs.  In a 2001 report by Sterner 
and coworkers,
36
 L1 and L3 were modified on gram-scale via acid-catalyzed reactions to a variety 
of new structures.  In both cases, the opening of the cyclopropane ring is stabilized by the enone, 
and subsequent collapse of the extended charged species results in 2-3 polycyclic structures from 
each transformation, generally in comparable yields (for example, 1-3 and 1-4 from 1-1, and 1-5 
and 1-6 from 1-2).  While stereoselectivity is not attained, this dramatic restructuring of the 
macrocycle is impressive and achieves synthetically-useful yields.  Sterner and coworkers also 
identified additional transformation products resulting from terpenes in which the enone had 
been reduced to an allylic alcohol (not shown).
36
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Scheme 1.1. Structural transformation of lathyrane diterpenes via acid-catalyzed rearrangements. 
 
1.2.2.2 Isosteviol and steviol 
 Isosteviol (1-7) and steviol (1-8) are diterpenes derived from the readily-available 
trisaccharide natural sweetener stevioside.  While both 1-7 and 1-8 are mostly chemically inert, 
they possess a ketone or alkene, respectively, allowing for diversification of the NPs.  Georg and 
coworkers used a systematic application of the Beckmann rearrangement of protected versions of 
11 
 
both molecules (1-9 and 1-10) to achieve a variety of nitrogen insertion (1-11, 1-12, 1-14, 1-15) 
and rearrangement products (1-13 and 1-16), as shown in Scheme 1.2.
37
  Following oxime or 
imine formation, regioselective ring expansions and fragmentations result in six distinct 
molecular frameworks. 
 
 
Scheme 1.2. Beckmann rearrangements and fragmentations of isosteviol and steviol. 
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1.2.2.3 R-(+)-sclareolide 
 The sesquiterpene R-(+)-sclareolide (1-17) is a common NP used in the fragrance 
industry and in chemical synthesis as a commercial chiral pool starting material.  Apart from the 
lactone, 1-17 is chemically inert, making it an excellent candidate for single transformation 
structural changes.  In 2003, de la Torre and Garcia devised an elimination-[2+2] 
photocycloaddition reaction scheme to transform 1-17 to highly reactive cyclobutanes (1-21 and 
1-22, Scheme 1.3).
38
  Unlike in the modification of 1-1/1-2 and 1-7/1-8, sclareolide is elaborated 
onto several diverse scaffolds through a reagent control strategy.  For example, addition of either 
allylmagnesium chloride or lithiated cyclopentene to alkene 1-18, followed by photochemical 
activation, results in cyclobutanes 1-21 (via 1-19) and 1-22 (via 1-20).  The combination of 
scaffold diversification and derivatization offers an interesting opportunity for building 
polycyclic systems.
39
  However, this NP offers limited flexibility for other scaffold classes. 
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Scheme 1.3. Elimination and light-catalyzed ring fusions from R-(+)-sclareolide. 
 
1.2.2.4 Bryonolic acid 
 Bryonolic acid (1-23), a pentacyclic triterpenoid, is found in the sprouts of the common 
zucchini and isolable in multigram quantities (1.34% yield by mass)
40
 and contains a unique 
double bond fusion between the steroidal B and C rings.  A protected version of bryonolic acid 
(1-24) renders this alkene the primary reactive site.  Building off of earlier ad hoc work with 
lanosterol, Tochtrop and coworkers systematically explored the oxidative cleavage of bryonolic 
acid across the central B-C rings (Scheme 1.4).
41-42
  Treatment with ruthenium chloride yields 
three distinct products (1-25 to 1-27).  The newly created macrocycle (1-25) can undergo a 
14 
 
transannular aldol fusion to give products such as 1-28 and 1-29 in varying ratios, depending on 
the conditions used.
41-42
  By altering the oxidation patterns, as well as the conditions used to form 
additional rings across the core of bryonolic acid, several unique scaffolds can be formed. 
 
 
Scheme 1.4. Oxidative cleavage and transannular fusion from bryonolic acid. 
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1.2.2.5 Fumagillol 
 The NP fumagillin, derived from Aspergillus fumigatus, is easily obtained from 
fermentation and is further hydrolyzed to the diepoxide fumagillol on a multigram scale (1-30, 
Scheme 1.5).  The epoxides can be chemically functionalized separately from the alkene and 
alcohol.  Additionally, modifications of the alkene and alcohol in later synthetic steps enables 
additional points for derivatization.  In work done by Porco, Snyder, and coworkers, nucleophilic 
addition to the disubstituted epoxide, followed by Lewis acid-directed cyclization, forms two 
divergent bicyclic systems with a varied substitution at the amine (1-31 and 1-32, R=aryl, 
benzyl, and alkyl).
43
  The choice of Lewis acid directs the formation of either the five- or six-
membered ring with selectivities ranging from 2.06:1 to >20:1 for the isolated product.  Careful 
selection of the reactive amine promotes further cyclizations with the trisubstituted alkene, such 
as lactone formation with D-phenylalanine to form 1-33 or hydroxylalkoxylation with 
ethylaniline to form 1-34.  Together, this work is the most general example of a single chemical 
transformation generating multiple scaffolds. 
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Scheme 1.5. Transformation of fumagillol via catalyst-selective nucleophilic addition and 
cyclization. 
 
1.2.2.6 Summary of Single Transformations 
 In the five examples described above, transformations are applied to a NP, resulting in 
dramatically different scaffolds.  However, there are a limited number of structures that can be 
made, restricting both the diversity and number of compounds that can be created.  On average 
fewer than twenty compounds were synthesized in each of the previous five examples, and most 
of these contain similar or identical cores.  As a result, transformations that can be applied 
17 
 
independently to multiple regions of a NP offer new opportunities for complex library 
development. 
 
1.2.3 Multiple Structural Transformations 
1.2.3.1 Zerumbone 
 The cyclic sesquiterpene zerumbone (1-35), isolated from the rhizome of wild ginger in 
0.3-0.4% yield by mass,
44
 is one of the earliest examples of the application of multiple structural 
transformations in the generation of novel complex scaffolds.
45
  In work by Kitayama and 
coworkers, transformed scaffolds of 1-35 were synthesized for the synthesis of more complex 
NPs (Scheme 1.6).  By capitalizing on the different steric and electronic environment of the three 
alkenes, selective brominations, cyanations, and cleavages are all possible in order to synthesize 
a tricyclic ether (1-36),
46
 a transannular cyclopropane (1-37),
44
 and a linear product (1-38),
47
 
depending on the order of the reactions.  Each of these reaction sequences dramatically alters the 
original structure of zerumbone and relies on a variety of different synthetic transformations.  
However, further refinements would be necessary in order to fully apply this NP for libraries in 
the pursuit of drug discovery. 
18 
 
 
Scheme 1.6. Multiple structural transformations from zerumbone in 3 steps. 
 
1.2.3.2 Naltrexone 
 The synthetic opiate naltrexone (1-39), which is structurally similar to the NP morphine, 
is used clinically to treat alcohol and opioid dependence.  The Nagase group has identified 
numerous transformations that reorganize the ring structure of naltrexone in order to enhance the 
safety and selectivity of naltrexone for specific opioid receptors (Scheme 1.7).
48
  From a 
synthetic standpoint, however, these transformations create dramatically altered products that 
could be tested for novel biological activity.  These include elimination of the D-ring (1-40)
49
 
and formation of additional ether rings through a D-ring cleaved intermediate (1-41 and 1-42).
49-
50
  Transformation of the C-ring to a diene (1-43) enables a further Diels-Alder reaction, 
followed by further rearrangements, to afford cyclopropane δ-lactone 1-44.51-52  Unfortunately, 
19 
 
there are relatively few positions for further derivatization of these scaffolds, which would make 
the use of this chemistry for library generation more difficult. 
 
 
Scheme 1.7. Multiple structural transformations from naltrexone in three or more steps. 
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1.2.3.3 Gibberellic acid 
 Gibberellic acid (1-45) is a tetracyclic diterpene hormone used agriculturally on ton scale 
to promote plant germination and growth.  As a NP for transformation into complex and diverse 
structures, gibberellic acid contains a number of advantageous features that enable several 
divergent transformations across all the ring systems.  These include the secondary allylic 
alcohol, A-ring lactone, and tertiary allylic alcohol on the C/D rings.  Beginning from several 
classical degradation reactions using acid, base, or hydrazine, Hergenrother and coworkers 
synthesized 19 divergent structures in 3-5 steps from the parent NP (Scheme 1.8).
53
  These 
include acetalization of the A-ring (1-46), aromatization of the A-ring with ring expansion of the 
D-ring (1-47), and cleavage of the B-ring to the diketone (1-48).  Several other structures from 
gibberellic acid were further elaborated to small libraries, resulting in >45 total complex 
molecules synthesized, validating this NP as scaffold for drug discovery efforts.  These synthetic 
efforts using gibberellic acid will be discussed in greater detail in chapter 2. 
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Scheme 1.8. Multiple structural transformations of gibberellic acid in 3-5 steps. 
 
1.2.3.4 Adrenosterone 
 Adrenosterone (1-49), which is naturally produced in the adrenal cortex and is 
commercially available in gram quantities, contains three ketones.  Each ketone has a unique 
pattern of reactivity, allowing for selective functionalization and manipulation of each ring.  
Hergenrother and coworkers applied a variety of transformations, including oxidative cleavages 
and Baeyer-Villiger oxidation (1-50), Beckmann fragmentations (1-51), and epoxidations (1-52), 
to synthesize 18 complex scaffolds from adrenosterone (Scheme 1.9).
53
  A total of 70 complex 
compounds based on several scaffolds were prepared from adrenosterone in sufficient quantities 
for biological testing. 
 
22 
 
 
Scheme 1.9. Multiple structural transformations of adrenosterone in 3 steps. 
 
1.2.3.5 Quinine 
 The readily-available NP quinine (1-53) has been used for a variety of purposes, 
including as an antimicrobial and a bitter agent for tonics.  Quinine also possesses structural 
features that prime this NP for several distinct structural transformations, including a tertiary 
amine, a secondary alcohol, and an olefin.  Hergenrother and coworkers utilized these functional 
groups to promote selective cleavage and rearrangement to the S-alkyl thiocarbamate (1-54), 
Hofmann-type elimination and ring closing metathesis (1-55), and Grignard addition followed by 
hemiaminal ether formation (1-56) on quinine (Scheme 1.10).
53
  Altogether, 12 distinct scaffolds 
were constructed, and thiocarbamate 1-54 was further functionalized to over thirty derivatives. 
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Scheme 1.10. Multiple structural transformations of quinine in 1-4 steps. 
 
1.2.3.6 Summary of Multiple Transformations 
 In the five examples described above, multiple classes of structural transformations are 
applied to each NP or NP scaffold.  Although the earliest examples of this approach did not 
incorporate positions for library synthesis, the recent systematization of this approach and its 
application to gibberellic acid, adrenosterone, and quinine led to the construction of >160 
complex and diverse compounds.
53
  This work suggests that NPs could serve as efficient starting 
materials for the creation of libraries of complex molecules. 
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1.2.4 Outlook on the Field 
 The population of compound screening collections with complex and diverse members is 
a challenging endeavor.  Numerous synthetic strategies, including DOS,
16, 22, 24
 FOS,
17
 and 
BiOS,
18
 have been proposed to address this need.  Two developing strategies using NPs for the 
generation of complex and diverse compounds rearrange NPs to distinct scaffolds amenable for 
library construction.  The first strategy utilizes a single class of reaction, such as epoxide opening 
or acid catalysis, to give different types of products, depending on the conditions.  This approach 
of transforming NPs has provided a number of interesting and useful scaffolds, but it typically 
affects only one portion of the molecule and generally utilizes relatively unfunctionalized NPs to 
ensure selectivity.  A second class of transformations is the systematic reorganization of multiple 
rings or functional groups on a NP in order to affect the entire molecule.  Recent work with 
gibberellic acid, adrenosterone, and quinine has expanded this strategy to the development of up 
to 19 scaffolds from one NP and the synthesis of small libraries to access >160 compounds. 
 Similar approaches to transform the core structure of a small molecule could be applied 
to numerous NPs, although several criteria should ideally be met for these approaches to be 
successful.  First, the NP must be available in sufficient quantity, either commercially or through 
isolation, to enable the generation of novel structures on large enough scale for further biological 
analysis.  Second, the NP should contain functional groups amenable for structural 
transformations, rather than for derivatization alone.  For example, a ketone offers opportunities 
for Baeyer-Villiger and Beckmann ring expansions (as shown with adrenosterone, steviol, and 
isosteviol) or ring contractions (as with the lathyrane terpenes and zerumbone), whereas a 
carboxylic acid lends itself more easily to simple amidations or esterifications (as with the 
functionalization of gibberellic acid or adrenosterone compounds).  Similarly, epoxides are 
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useful functional groups for forming new rings or contracting macrocycles, as highlighted by the 
lathyrane diterpenes and fumagillol.  Alkenes provide a versatile handle for rearranging NPs, as 
they can be used for forming new rings or cleaving existing rings.  Impressively, isolated alkenes 
and conjugated ketones were used in the transformation of each of the NPs highlighted in this 
review.  Strained ring systems and heterocycles provide further handles for manipulating NPs.  
Although there are a finite number of NPs that exist in sufficient quantities for application in this 
area, there are enough compounds of interest to occupy organic chemists for some time. 
 The full application of these approaches for the creation of screening collections 
populated by large numbers of complex and diverse compounds necessitates the synthesis of 
scores of derivatives for each scaffold.  Derivatization further allows for the tailoring of chemical 
properties, such as size, shape, and polarity, for the generation of focused libraries.  As a result, 
the selection of NPs containing sites for diversification or the installation of new functional 
groups during the transformation process is ideal.  Using NPs as starting materials should be a 
valuable method that is complementary to DOS and others for the synthesis of libraries of highly 
complex and diverse compounds. 
 
1.3 Evaluation of Techniques for Developing Complex Libraries 
 Although the use of NPs to create stereochemically complex and structurally diverse 
compounds for screening collections is still a developing area of research, it is instructive to 
evaluate how these efforts fit in with more established techniques, such as DOS and FOS.  
Ultimately, these different approaches are largely complementary, and enable different 
explorations of chemical space in small molecules libraries. 
 
26 
 
1.3.1 Synthetic Ease and Library Size 
 The synthetic tractability of these three approaches varies widely, depending on the 
specific compounds being explored.  However, there are some trends that can be identified.  
Compounds synthesized via FOS are notable in that they require substantially fewer steps than 
the de novo synthesis of the parent NP.  For example, various members of the bryostatin family 
have been synthesized in 39
31
 to 70
29
 steps.  Bryostatin 1, which is one of the most complex 
members of the family, was first synthesized in 2011 in 46 steps,
30
 21 years after the first 
member of the family, highlighting the synthetic challenge of this class.  In contrast, the 
compounds designed through FOS can be synthesized in 30 or fewer steps in generally high-
yielding reactions.
54
  This improvement is a substantial advance for biology with bryostatin but 
is not amenable for the synthesis of general libraries in a tractable fashion. 
 In contrast, DOS routes tend to be more concise than FOS.  All eight stereoisomers in the 
case of the sonic hedgehog pathway modulators were synthesized in 8-9 steps in generally high 
yields.
15
  However, both complexity- and diversity-generating synthetic steps are required for 
DOS, demanding longer routes.  The libraries based on galanthamine and carpanone required 5 
and 10 steps to access the complex parent scaffold.
20-21
  Further split-pool synthesis then 
provided access to thousand-member libraries in five or fewer steps.
20-21
  DOS routes tend to be 
highly efficient for the number of compounds synthesized. 
 Of the routes highlighted in section 1.2 for the construction of complex molecules 
through the reorganization of NPs, all are performed in fewer than 10 steps, and most are in 
fewer than five.  Since this approach only diversifies the compounds and can build on preexisting 
complexity, fewer synthetic steps are generally necessary.  The tradeoff is that the reactions tend 
to be less robust and can be lower-yielding than the DOS reactions.  Additionally, the library 
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sizes currently achieved in these routes is relative small – tens to hundreds, rather than thousands 
or millions of compounds.  
 
1.3.2 Complexity 
 The complexity of a small molecule can be measured by a number of different factors, 
including the number of interlocking ring structures, sp
3
 centers, and stereogenic centers.  
Although the first criteria can be estimated through visual inspection, the latter two factors are 
easily accessible through computation and are known to serve as surrogates for molecular 
complexity.  The Hergenrother and Schreiber labs have previously analyzed commercial 
screening collections and NPs to compounds derived from DOS or complex small molecules 
derived from the reorganization of NPs.
14, 53, 55
  In general, commercial collections are primarily 
composed of compounds lacking stereogenic centers, whereas NPs are rich in stereocenters.  
Compounds derived from DOS fall in the region between these two groups, which could be 
expected given that the complexity of the molecules is installed during their synthesis.  In 
contrast, the reorganization of NPs to generate novel compounds generally gives molecules that 
have comparable complexity to NPs in general.  Although no analyses of the complexity of 
compounds derived from FOS have been performed, it would be expected that most compounds 
would have lower complexity than the parent NP, given the goals of the FOS approach. 
 
1.3.3 Diversity 
 Although visual inspection of a class of compounds can provide some insight into their 
diversity, computational approaches measuring the similarity of molecular connectivities can 
provide a more mature analysis of compound diversity.
8, 56-57
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1.3.3.1 Tanimoto Connectivity for Analysis of Diversity 
 Tanimoto similarity coefficients,
58
 which are generated from connectivity fingerprints, 
enable comparisons across different compounds.  This approach was used successfully to 
analyze the diversity of compounds generated from gibberellic acid (1-45), adrenosterone (1-49), 
and quinine (1-53).
53
  In general, the molecules derived from the reorganization of those three 
NPs were highly divergent from each other and the parent NP (average values of 0.15, 0.15, and 
0.22 for 1-45, 1-49, and 1-53, respectively).
53
  Application of the Tanimoto analysis to a 
selection of the other NPs in Section 1.2 shows a similar level of diversity (Figure 1.6).  NPs that 
were modulated with multiple structural transformations (1-35, 1-38, 1-45, 1-49, and 1-53) show 
a high degree of diversity, both within a structural class and across structural classes.  
Unsurprisingly, NPs that underwent a single type of transformation (1-1, 1-7, 1-17, 1-23, and 1-
30) are more similar within their structural class of compounds (average Tanimoto values of 0.34 
versus 0.19).  This suggests that the application of multiple transformations ultimately enhances 
the overall diversity of a compound set. 
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Figure 1.6. Tanimoto similarity coefficients for select compounds from Section 1.2. 
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 The application of the Tanimoto similarity analysis does have some limitations.  In the 
DOS example of screening collections for the sonic hedgehog pathway,
15
 all eight stereoisomers 
would be identical in the Tanimoto analysis, despite the fact that the compounds occupy very 
different regions of space and behave very differently in biological systems.   
 
1.3.3.2 Principle Component Analysis and Moment of Inertia for Analysis of Diversity 
 Two alternate computational methods that have been used to characterize the diversity of 
a set of compounds are principle component analysis (PCA) and moment of inertia (MoI).  PCA 
uses numerous physical molecular properties to determine a compound’s location in chemical 
space,
24, 59
 whereas MoI analyzes the absolute shape of a molecule;
60
 both of these techniques 
have been discussed in more detail in Timothy A. Flood, Jr.’s thesis.  PCA and MoI have been 
used to evaluate the diversity of DOS-based libraries, indicating that these compounds are highly 
diverse.
55, 61
  Similar analyses were performed for molecules derived from gibberellic acid, 
adrenosterone, and quinine, showing a high degree of compound diversity (see Timothy A. 
Flood, Jr.’s thesis). 
 
1.3.3.3 Summary of Diversity 
 The diversity of compound collections derived from DOS and NP scaffolds is generally 
quite high, as analyzed by Tanimoto similarity coefficients, PCA, and MoI.  In contrast, FOS-
derived compounds tend to be more similar to one another, owing to the aim of mimicking the 
biological activity and structure of the parent NP.  Indeed, DOS and NP scaffold approaches 
have very different goals than FOS in terms of library generation and identifying new activity, 
which is reflected in the types of compounds that are synthesized. 
31 
 
1.3.4 Summary 
 The reorganization of NPs to complex and diverse scaffolds is a highly complementary 
technique to the well-established methods of DOS and FOS.  Whereas FOS works to improve the 
ratio of compound activity to complexity, the reorganization of NPs capitalizes on the 
complexity of NPs to generate new libraries for dissimilar biological targets.  Additionally, this 
approach and DOS achieve different levels of diversity, complexity, and library size.  DOS 
typically generates larger libraries of medium complexity; the diversification of NPs gives 
smaller libraries of high complexity with a high degree of diversity.  By applying both 
approaches in library design, it should be possible to sufficiently populate screening libraries 
with complex small molecules in order to discover compounds that interact with difficult targets.  
 
1.4 Materials and Methods 
Tanimoto similarity coefficients were calculated using Discovery Studio 2.5 (Accelrys, San 
Diego, CA).  Compounds were imported as individual *.sdf files and analyzed to “Find Similar 
Molecules by Fingerprints.”  The minimum similarity was set to 0, and the structures were 
analyzed using ECFP_6 molecular fingerprints. 
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Chapter 2: Complexity to Diversity – A Method to Rapidly Assemble 
Complex Molecular Scaffolds from Natural Products 
 
Portions are reprinted with permission from Huigens, R.W. III; Morrison, K.C.; Hicklin, R.W.; 
Flood, T.A. Jr.; Richter, M.F.; Hergenrother, P.J. “A Ring Distortion Strategy to Construct 
Stereochemically Complex and Structurally Diverse Compounds from Natural Products” Nature 
Chem. 2013, 5, 195-202. 
 
2.1 Introduction 
 The need for, and benefit of, libraries of complex and diverse compounds was covered in 
Chapter 1.  Our approach to creating complex compounds for screening libraries focuses on a 
top-down synthetic route using natural products as starting materials, and their conversion on 
five or fewer steps to diverse compounds, leading to compounds with natural product-like 
properties that are structurally-distinct from the parent natural products.
1
  This approach is 
termed complexity-to-diversity (CtD), as complex natural products are transformed into sets of 
small molecules that are both complex and diverse.  Once compounds have been synthesized, all 
compounds produced as a part of this effort are subjected to a number of phenotype-based assays 
in order to identify and study compounds with potent or interesting biological activity (see 
Chapter 3). 
 
2.2 Complexity to Diversity – Definition, Rules, Selection Process 
 In the complexity to diversity paradigm, natural products are transformed through a series 
of ring distortion reactions to create new structures that are complex and diverse from the parent 
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natural product and one another.  These ring distortions (Figure 2.1) include ring expansions and 
contractions, ring fusions, ring cleavages, and ring rearrangements. 
 
 
Figure 2.1. Ring distortion strategies for complexity to diversity. 
 
 
2.2.1 Strategic Rules for Complexity to Diversity 
 There are a number of common chemical motifs that can be used as strategic elements for 
performing ring distortion reactions (Figure 2.2).  Ring expansions are most often associated 
with oxidative insertions near carbonyls, such as a Baeyer-Villager ring expansion from a ketone 
to a lactone, or a Beckmann rearrangement to form a lactam.  Although the regioselectivity of the 
Baeyer-Villager reaction is dependent on the steric environment of the ketone, the 
regioselectivity for lactam formation can be guided based on which reagents are used.  Finally, 
the opening of a cyclopropane ring can also result in a one carbon ring expansion. 
 Ring cleavage reactions can be performed from a variety of substrates.  Oxidative 
cleavage of alkenes or diols results in free carbonyls or acids.  Alternatively, nucleophilic 
opening of lactams or lactones can also be employed to cleave rings.  Finally, in strained or 
bicyclic systems, nucleophilic additions to C-N bonds can also result in ring cleavage. 
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 The most versatile and diverse type of ring distortions is ring fusion.  Cycloadditions, 
either through dienes or isolated alkenes, is a facile way of introducing additional carbon units 
into the core scaffold.  Alternatively, long alkyl chains can be connected either through 
anhydrides and imines, or through ring closing metathesis.  Carbonyls can be converted to ether 
rings following the addition of ethylene glycol or other similar reagents.  Finally, intramolecular 
aldol reactions can fuse macrocycles into smaller rings. 
 Ring contraction and ring rearrangement reactions are often highly substrate-specific, and 
therefore it is difficult to identify a unified set of strategic elements for these transformations.  
However, it is possible to perform a two-step ring contraction on a ring containing a double bond 
through application of ring cleavage (via oxidation) followed by ring fusion (via an aldol 
reaction). 
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Figure 2.2.  Strategic elements for ring distortion reactions. 
 
2.2.2 Compound Selection for Complexity to Diversity 
 Many natural products are amenable to this CtD approach.  Shown in Figure 2.3 are the 
natural products that have been selected as starting points within the Hergenrother lab.  The top 
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row contains compounds that have five or more distinct cores derived through the CtD approach.  
In contrast, the bottom row highlights compounds that have been previously investigated 
(brucine and isosorbide) or are currently being pursued (artemisinin, pleuromutilin, and 
lovastatin).  Brucine and isosorbide were part of our early CtD efforts, but were eventually 
deemed to be too inert and complex, or too simple, to fully employ this strategy. 
 
 
Figure 2.3. Natural products selected by the Hergenrother lab for the CtD approach.  Top row: 
Natural products with ≥ 5 distinct scaffolds following ring distortion reactions.  Bottom row: 
Natural products evaluated in the lab through August 2013. 
 
 In light of some of these early failures, we have established a number of requirements for 
natural product selection for CtD.  First, this strategy requires that the natural product be 
available on large scale, either through commercial means or through isolation from common 
materials.  Since many of the synthetic sequences are three or more steps, availability of the 
natural product is crucial for this approach to be tractable and scalable.  Second, orthogonal 
functional groups within the natural product are desirable, as this allows for selective chemical 
modifications of the core structure of the natural product.  We often take advantage of subtle 
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differences in reactivity; for example, each of the three carbonyls on adrenosterone can be 
functionalized sequentially on the basis of their relative steric environments.  Finally, a dense, 
interlocking ring structure is ideal for this approach, as it maximizes the impact of changes to the 
core.  Simple compounds such as isosorbide are more difficult to dramatically transform using 
the strategies discussed in Section 2.2.1.  However, these criteria are guidelines, rather than strict 
rules.  The application of C-H oxidation chemistry or ring formation reactions would allow for 
this approach to be used for functional group-poor natural products or macrocycles. 
 Keeping these criteria in mind, Figure 2.4 highlights a number of classes of natural 
products that would be amenable to CtD.  These include alkaloids, unfunctionalized terpenes, 
various polycyclic natural products, and macrocycles. 
 
 
Figure 2.4.  Natural products amenable to the CtD approach.  A. Alkaloids.  B. Unfunctionalized 
terpenes.  C. Polycyclic natural products.  D. Macrocycles. 
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 Since the ultimate goal of CtD is to create an array of compounds that are diverse from 
the parent natural product and each other, the associated synthetic strategy is highly flexible.  In 
general, it is best to evaluate several one-step reactions from the natural product in order to 
gauge the reactivity patterns of the compound prior to creating a detailed synthetic plan.  As a 
result, the degradation literature is a highly useful starting point for planning new routes. 
 
2.3 Gibberellic Acid 
 Gibberellic acid (G, Figure 2.5) is a plant hormone isolated from Gibberella fujikuroi
2
 
and produced industrially
3
 on the ton scale.  Gibberellic acid contains a tetracyclic diterpene core 
with a fused lactone, two allylic alcohols, an exocyclic olefin, and a carboxylic acid, enabling 
selective and independent functionalization of each ring of the core structure via a variety of ring 
system distortion reactions and making G an ideal natural product for CtD. 
 
 
Figure 2.5. Gibberellic acid and important functional groups. 
 
2.3.1 Synthesis of Complex and Diverse Structures from Gibberellic Acid 
 In order to apply CtD to gibberellic acid, a number of known degradation reactions were 
used as synthetic starting points (Figure 2.6).  These degradation reactions allow for the direct 
manipulation of the carbon skeleton and create synthetic handles for further elaboration.  Many 
of these degradations affect the ester ring, either through direct elimination to form gibberellenic 
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acid (Figure 2.6A
4
) or elimination and sequential reduction (Figure 2.6E, G, and I).  These 
processes expose another carboxylic acid, and in the case of the Zn reduction, introduce a 
synthetically useful diene.  Other pathways utilize a series of acid catalyzed reactions to either 
aromatize the A-ring to allogibberic acid or gibberic acid (Figure 2.6B, C) or rearrange the C/D 
ring system (Figure 2.6C, F).  This simplification of the gibberellic functional groups allows for 
the selective modification of the C/D rings.  Degradation reactions using sodium hydroxide result 
in ester rearrangement to isogibberellic acid and furher cleavage (Figure 2.6D, H), resulting in a 
newly reactive diene and a diol.  Finally, decarboxylation of the free acid (Figure 2.6J) provides 
a synthetic handle to modify the central B ring. 
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Figure 2.6. Summary of known degradation reactions originating directly from gibberellic acid.  
A. Hydrazine-promoted elimination.
4
  B. Acid-catalyzed decarboxylation.
5
  C. Acid-catalyzed 
decarboxylation and Wagner-Meerwein rearrangement.
5
  D. Base-catalyzed ester 
rearrangement.
6
  E. Isomerization and reduction of ester.
7
  F. Acid-catalyzed rearrangement.
8
  G. 
Metal reduction.
9
  H. Base-catalyzed ester rearrangement and hydrolysis.
6
  I. Ester elimination 
and reduction.
10-11
  J. Decarboxylation.
12-13
 
 
 Several of these known degradation reactions of G
4-5, 14-15
 were exploited in the 
construction of complex and diverse scaffolds in three to five steps from gibberellic acid (Figure 
2.7, G1-G6). 
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Figure 2.7. Six highly complex structures (G1-G6) are synthesized in 3-5 steps from gibberellic 
acid. 
 
 In keeping with the ultimate goal of synthesizing highly complex compounds for 
screening collections, all intermediates en route to G1-G6 are equally interesting, both 
structurally and for the identification of novel bioactive compounds (Figure 2.8). 
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Figure 2.8. In the course of synthesizing the six compounds in Figure 2.3, thirteen additional 
highly complex structures were also made. 
 
2.3.1.1 Synthesis and Stereochemical Determination of G1 
 The first CtD compound based on gibberellic acid began with hydrazine-promoted 
elimination of the lactone on G to afford gibberellenic acid,
4
 followed by methylation and 
acetylation, to afford triene G7 (Scheme 2.1). Treatment with mCPBA yields an intermediate 
epoxide with complete selectivity for the tetrasubstituted olefin which, when subjected to 
oxidative cleavage conditions using PCC, produces diketone G1.  
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Scheme 2.1. Synthesis of diketone G1. 
 
 We originally attempted to use NOEs between the A- and C-rings of the gibberane core 
to determine the stereochemistry of epoxide G14, but this approach proved to be unsuccessful.  
Therefore, the two products following the PCC oxidative cleavage of G14 were used to assign 
the epoxide stereochemistry (Scheme 2.2).  Oxidative cleavage of epoxides using PCC proceeds 
through a nucleophilic attack of the epoxide.
16
  The chromium-oxide cannot undergo a simple 
oxidation.  As a result, when PCC attacks at the B/C-ring fusion, the C-C bond of the B-ring is 
broken, leaving an allylic carbocation on the A-ring, which collapses through the loss of a proton 
to form G1.  In contrast, when PCC attacks at the A/B-ring fusion, the resulting carbocation from 
B-ring cleavage would be an unstabilized secondary cation.  Instead, an allylic rearrangement 
leads to a trisubstituted alkene, and the secondary alcohol can oxidize to give G15.  Due to the 
stereochemical course of this reaction, the chirality of the allylic alcohol on the B/C-ring bridge 
in G15 will be the same as epoxide G14. 
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Scheme 2.2. Mechanism of PCC oxidative cleavage and resulting products depending on the 
course of epoxide attack. 
 
 The protons on the A/B-ring bridge, the D-ring, and the C-ring adjacent to the allylic 
alcohol of G15 were all clearly distinguishable, allowing for the stereochemistry to be 
determined.  When the alcohol is in the R-configuration, the protons on the C- and D-rings are in 
close proximity and have a strong NOE (Figure 2.9).  Similarly, the proton on the A/B-ring 
bridge and the D-ring methylene protons will also be near in space.  In contrast, if the allylic 
alcohol is in the S-configuration, these protons are pushed apart, and no NOE should be 
observed.  Irradiation at these positions showed clear NOEs between these protons (Figure 2.9), 
confirming the R-configuration of the allylic alcohol. 
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Figure 2.9. Confirmation of G15 stereochemistry by NOE.  The interaction between the green 
and purple protons (shown on the NOE NMRs) is only possible if the allylic alcohol is in the R 
configuration.  Likewise, the NOE between the purple proton and the bridgehead proton between 
a A- and B-rings can only occur if the allylic alcohol is R. 
 
2.3.1.2 Synthesis and Stereochemical Determination of G2 
 In the course of purifying G1 on silica gel, it was noticed that the diketone was 
transformed into a new compound.  By driving this reaction with acid, it was determined that the 
A-ring ketone tautomerizes and collapses onto the C-ring ketone to form hemiketal G2 as a 
single stereoisomer (Scheme 2.3).  The incorporation of a highly acidic workup to the PCC 
cleavage of epoxide G14 enables the direct access of hemiketal G2. 
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Scheme 2.3. Synthesis of ketal G2. 
 
 The structure of G2 was confirmed using a variety of spectroscopic techniques (Figure 
2.10).  First, the A- and D-ring protons were fully assigned using COSY.  This allowed for the 
mapping of all new quaternary carbons in G2 using HMBC, which was particularly important for 
the newly formed hemiketal and alkene.  Once these correlations were mapped, the NOE 
between a D-ring methylene proton and the hemiketal proton at 6.43 ppm could be easily 
assigned. 
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Figure 2.10. Assignment of ketal G2.  The key COSY correlations are shown for the A-ring 
(red) and D-ring (blue).  The major HMBC correlations, particularly those to the ketal and alkene 
at the A/B-ring fusion, are shown.  Finally, the NOE between the methylene protons of the D-
ring and the ketal proton are shown in orange.  (Additional correlations to the B-ring are also 
depicted in green and blue, confirming the orientation of the orange proton.) 
 
2.3.1.3 Synthesis and Stereochemical Determination of G3 
 The exposure of gibberellic acid to basic conditions leads to lactone rearrangement and 
the generation of alkene G8 (isogibberellic acid, Scheme 2.4).
15
  Amidation of G8, followed by 
treatment with trifluoroperacetic acid provides G3 via epoxidation of both alkenes and Wagner-
Meerwein rearrangement to afford the primary alcohol.  The NOE between the proton adjacent 
to the epoxide ring and one of the methylene protons on the D-ring confirmed that the attack of 
the epoxide occurred from the top face of the molecule (Figure 2.11). 
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Scheme 2.4. Synthesis of epoxide G3. 
 
 
 
Figure 2.11. Stereochemical determination of G3.  The key COSY correlations for the A, B, and 
D-rings enable the NOE correlation between the proton adjacent to the epoxide ring (purple) to 
one of the methylene protons on the D-ring (blue).  These protons can be further mapped to the 
amide adjacent to the B-ring (green) and the A-ring methyl group. 
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2.3.1.4 Synthesis and Stereochemical Determination of G4 
 The prolonged exposure of G to base leads to the cleavage of the lactone ring to provide 
diol G9 (Scheme 2.5).
17
 Methylation of the carboxylic acids, followed by oxidative cleavage of 
the diol with sodium periodate and subsequent intramolecular [4+2] cycloaddition provides 
acetal G4.  The two alcohols of G9 are both in the equatorial position, which allows for sodium 
periodate to affect the oxidative cleavage; lead tetracetate and iodobenzene diacetate also 
promote this cleavage.  A single stereoisomer is obtained from this reaction, as the proton on the 
B-ring directs the saturated aldehyde to approach the α,β-unsaturated aldehyde from the bottom 
face of the molecule.  This structure is clearly resolved by 
1
H and 
13
C NMR based on the 
chemical shifts of the acetyl and electron-rich A-ring alkene. 
 
Scheme 2.5: Synthesis of acetal G4 and stereochemical course of the intramolecular [4+2] 
cycloaddition. 
 
2.3.1.5 Synthesis and Stereochemical Determination of G5 
 The treatment of gibberellic acid with dilute hydrochloric acid results in the elimination 
of the lactone and decarboxylation to aromatize the A-ring, enabling the isolation of allo-
gibberic acid (G10, Scheme 2.6).
5
  Esterification followed by oxidative rearrangement with 
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DDQ
18
 gives [2.2.2]-bicycle G5.  Initially, DDQ oxidizes the benzylic position of G18; however, 
a subsequent oxidation at the allylic position leads to the collapse of the tertiary alcohol and a 
stereospecific Wagner-Meerwein rearrangement to afford the observed product.  The structure of 
G5 was assigned based on key COSY correlations between the bridgehead proton and 
trisubstituted alkene and HMBC correlations to the newly-formed ketone on the free acid (Figure 
2.12). 
 
 
Scheme 2.6. Synthesis of ketone G5, and mechanism for the formation of G5. 
 
 
 
Figure 2.12.  Key COSY (red) and HMBC (blue) correlations for the [2.2.2]-bicycle. 
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2.3.1.6 Synthesis and Stereochemical Determination of G6 
 Gibbereic acid (G11, Scheme 2.7) is formed following the exposure of gibberellic acid to 
refluxing hydrochloric acid; this results in aromatization and a stereospecific Wagner-Meerwein 
rearrangement to give the α-methyl ketone product.5 Amidation through an intermediate acyl 
chloride followed by Baeyer-Villiger oxidation produces lactone G6.  The direction of oxygen 
insertion was clearly distinguished by 
1
H and 
13
C NMR by the deshielding of the C-ring methyl 
group and the adjacent quaternary carbon. 
 
 
Scheme 2.7. Synthesis of lactone G6. 
 
2.3.2 Evaluating Compound Complexity and Diversity 
 The CtD approach enables the synthesis of a variety of complex and diverse small 
molecules; however, it is important to quantify these criteria in order to evaluate the 
effectiveness of our approach.  Gratifyingly, metrics that are associated with compound 
complexity (including fraction of sp
3
-hybridized carbons
19
 and the number of chiral centers in a 
molecule) indicate that the compounds depicted in Figure 2.8 show an increase in complexity 
relative to traditional screening libraries.  The gibberellic acid set has an average Fsp
3
 of 0.62, 
and an average chiral count of 6.3, reflecting the higher complexity achieved in this approach as 
compared to the compounds found in commercially-available libraries (Chembridge
20
: Fsp
3
: 
0.23, Chiral: 0.24). 
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 The diversity of the compounds can be analyzed using a Tanimoto similarity 
coefficient.
21
  This technique analyzes the two-dimensional connectivity within a molecule, and 
compares it to other molecules.  In this analysis, a score of 1.0 would indicate identical 
compounds, and a score of 0.0 would indicate that the two molecules have no 3-bond 
attachments in common.  As shown in Figure 2.13, the compounds shown in Figure 2.7 have 
very low similarity scores, and the entire gibberellic acid set is fairly diverse as well.  A more 
complete analysis can be found in Timothy A. Flood’s thesis. 
 
 
Figure 2.13. Tanimoto analysis of diversity for the gibberellic acid set shown in Figure 2.8. 
 
 
2.3.3 Synthesis of Derivatives Based on Gibberellic Acid Scaffolds 
 In order to show that this approach is amenable for the synthesis of libraries, G10 and 
G11 were chosen as starting points for small libraries.  (Michelle F. Richter has also built 
synthetic libraries from G8 and G10.) 
G G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14 G15 G16 G17 G18 G19
G 1 0.14 0.16 0.18 0.38 0.09 0.14 0.14 0.35 0.32 0.28 0.17 0.26 0.21 0.16 0.15 0.27 0.27 0.21 0.13 G
G1 0.14 1 0.29 0.09 0.17 0.09 0.11 0.37 0.13 0.13 0.12 0.12 0.16 0.21 0.32 0.29 0.11 0.18 0.11 0.12 G1
G2 0.16 0.29 1 0.09 0.19 0.1 0.11 0.32 0.14 0.14 0.14 0.12 0.16 0.21 0.37 0.35 0.12 0.19 0.14 0.1 G2
G3 0.18 0.09 0.09 1 0.15 0.07 0.14 0.08 0.17 0.13 0.1 0.14 0.11 0.1 0.1 0.1 0.32 0.13 0.09 0.15 G3
G4 0.38 0.17 0.19 0.15 1 0.1 0.12 0.21 0.25 0.27 0.24 0.13 0.19 0.28 0.23 0.23 0.22 0.36 0.22 0.11 G4
G5 0.09 0.09 0.1 0.07 0.1 1 0.16 0.1 0.1 0.1 0.18 0.17 0.1 0.11 0.09 0.1 0.1 0.11 0.4 0.17 G5
G6 0.14 0.11 0.11 0.14 0.12 0.16 1 0.09 0.15 0.14 0.37 0.41 0.1 0.1 0.1 0.1 0.16 0.13 0.31 0.64 G6
G7 0.14 0.37 0.32 0.08 0.21 0.1 0.09 1 0.14 0.15 0.12 0.1 0.31 0.45 0.37 0.33 0.12 0.23 0.12 0.1 G7
G8 0.35 0.13 0.14 0.17 0.25 0.1 0.15 0.14 1 0.56 0.32 0.19 0.25 0.2 0.13 0.16 0.67 0.45 0.24 0.15 G8
G9 0.32 0.13 0.14 0.13 0.27 0.1 0.14 0.15 0.56 1 0.34 0.19 0.3 0.23 0.14 0.17 0.4 0.64 0.25 0.14 G9
G10 0.28 0.12 0.14 0.1 0.24 0.18 0.37 0.12 0.32 0.34 1 0.57 0.21 0.18 0.12 0.14 0.25 0.29 0.59 0.39 G10
G11 0.17 0.12 0.12 0.14 0.13 0.17 0.41 0.1 0.19 0.19 0.57 1 0.15 0.12 0.1 0.12 0.15 0.16 0.36 0.66 G11
G12 0.26 0.16 0.16 0.11 0.19 0.1 0.1 0.31 0.25 0.3 0.21 0.15 1 0.64 0.15 0.17 0.18 0.23 0.15 0.11 G12
G13 0.21 0.21 0.21 0.1 0.28 0.11 0.1 0.45 0.2 0.23 0.18 0.12 0.64 1 0.23 0.25 0.18 0.31 0.16 0.1 G13
G14 0.16 0.32 0.37 0.1 0.23 0.09 0.1 0.37 0.13 0.14 0.12 0.1 0.15 0.23 1 0.38 0.12 0.22 0.11 0.09 G14
G15 0.15 0.29 0.35 0.1 0.23 0.1 0.1 0.33 0.16 0.17 0.14 0.12 0.17 0.25 0.38 1 0.14 0.25 0.13 0.1 G15
G16 0.27 0.11 0.12 0.32 0.22 0.1 0.16 0.12 0.67 0.4 0.25 0.15 0.18 0.18 0.12 0.14 1 0.38 0.22 0.16 G16
G17 0.27 0.18 0.19 0.13 0.36 0.11 0.13 0.23 0.45 0.64 0.29 0.16 0.23 0.31 0.22 0.25 0.38 1 0.26 0.14 G17
G18 0.21 0.11 0.14 0.09 0.22 0.4 0.31 0.12 0.24 0.25 0.59 0.36 0.15 0.16 0.11 0.13 0.22 0.26 1 0.32 G18
G19 0.13 0.12 0.1 0.15 0.11 0.17 0.64 0.1 0.15 0.14 0.39 0.66 0.11 0.1 0.09 0.1 0.16 0.14 0.32 1 G19
G G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14 G15 G16 G17 G18 G19
1.00
0.00
0.50
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 Exposure of G10 to NBS leads to the formation of a bromonium ion, which then 
undergoes a Wagner-Meerwein rearrangement to afford β-bromo ketone G10e in good yield 
(Scheme 2.8). 
 
 
Scheme 2.8. Synthesis of G10e from G10 following treatment with NBS. 
 
 Libraries from G11 (Scheme 2.9) were synthesized via amidation with either 3,5- or 2,4-
dibromobenzylamine, followed by Baeyer-Villiger ring expansion to give G19a, G19b, G6a, 
and G6b, respectively.  Additionally, G19 could be directly oxidized with DDQ to give 
desaturated G19c. 
 
59 
 
 
Scheme 2.9. Synthesis of derivatives with the G11 scaffold. 
 
2.3.4 Unproductive Routes 
 In addition to the routes described above, a number of other methods were used to distort 
the gibberellic acid ring system to access diverse new ring scaffolds (Figure 2.14).  However, 
these routes were generally less successful than those leading to the compounds in Figure 2.8. 
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 Briefly, these routes can be divided into five broad categories: lactone opening or 
cleavage, anhydride/imide formation, C/D ring cleavage, oxidative cleavage and expansion, and 
decarboxylation.  For the lactone opening, we envisioned that a nucleophilic attack on the 
lactone by an amine or sulfide.  To affect the anhydride formation, gibberellenic acid could be 
treated with catalytic acid, which would result in a Wagner-Meerwein rearrangement of the C/D 
rings, epimerization of the B-ring carboxylic acid, and cyclization.  The addition of a primary 
amine would result in the imide.  Although the C-ring is relative inert, DDQ oxidation of 
gibberic acid followed by oxidative cleavage would result in the spiro-fused tricycle.  Oxidative 
cleavages could proceed from either gibberellic acid or isogibberellic acid, resulting in simplified 
core systems; alternatively, extensive oxidation of the A-ring would result in a new lactone.  
Finally, application of the known decarboxylation procedure
12-13
 would provide entry into the B-
ring.  However, the initial reactions toward each of these routes were unsuccessful, low yielding, 
or inconsistent in forming product.  It is possible that further exploration of some of these routes 
would prove amenable for the synthesis of additional compounds from the gibberellic acid core. 
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Figure 2.14. Additional routes for CtD using gibberellic acid as a starting point. 
 
 
2.4 Isosorbide 
 Isosorbide, a sugar derivative that is inexpensive and readily-available, was chosen as a 
simple natural product in initial CtD experiments (Figure 2.15).  A mononitrate derivative of 
isosorbide is used clinically for the treatment of angina-pectoris,
22
 and isosorbide itself has been 
used for the synthesis of chiral ligands
23-24
 and novel β-lactam compounds.25  Isosorbide contains 
two ether rings and two secondary alcohols that are pseudosymmetrical, thereby enabling the 
selective chemical modification of this simple yet stereochemically-dense natural product. 
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2.4.1 Initial Routes for Isosorbide 
 Several initial routes were envisioned for isosorbide (Figure 2.15).  These could be divided 
into four strategies – derivatization of the secondary alcohols, ring fusion across the isosorbide 
bicycle, ring fusion directly to the core, or ring substitution to replace atoms in the core. 
 
 
Figure 2.15. Proposed structural rearrangements for isosorbide (I), demonstrating core structures 
that could be readily accessed in 2-5 steps from the parent molecule. 
 
 
2.4.2 Isosorbide Triazole Library 
 Initial efforts toward diversifying the structure of isosorbide focused on building 
pseudosymmetric triazole libraries.  Isosorbide was first bis-propargylated in excellent yield 
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(Scheme 2.10), and then a variety of [3+2] copper-catalyzed cycloadditions were performed 
using freshly-prepared azides to generate a 12-compound library (Table 2.1). 
 
 
Scheme 2.10. Synthetic route to triazole library via bis-propargylated I1. 
 
 
Table 2.1. Alkyne-based isosorbide [3+2] cycloaddition derivatives 
 
  
2.4.3 Azide Displacement of Core 
 In order to generate a complementary triazole library, it was envisioned that tosylation 
followed by azide displacement would enable an alternate spatial placement of the R-groups.  To 
this end, isosorbide was bistosylated to give I14 (Figure 2.16) on a gram scale.  Isosorbide was 
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also monotosylated to give endo-I15 and exo-I16 in a 4:1 ratio.  Interestingly, the endo hydroxyl 
group is preferentially tosylated due to its enhanced nucleophilicity.  This is due to the hydrogen 
bond between the endo hydroxyl proton and the oxygen in the adjoining ether ring, which, under 
highly basic conditions, is more reactive (Figure 2.16). 
 
 
Figure 2.16. Synthesis of tosylated isosorbide derivatives. 
 
 The structures of I15 and I16 were further verified through azide-displacement studies 
(Scheme 2.12).  When treated with ten equivalents of sodium azide, bistosylated I14 shows 
conversion primarily to monoazide I17 (with a 10% yield of the bisazide).  This is consistent 
with a more facile attack of the azide from the exo face of the bicycle.  As expected, endo-tosyl 
I15 is displaced by sodium azide to form I18, whereas identical conditions show no conversion 
from starting material for I16 to I19.  To confirm this reactivity, mono- and bis-tosylated 
isomannide (IM1 and IM2, respectively) were also subjected to sodium azide.  Although IM2 
was poorly reactive, bisazide IM3 formed in moderate yield, indicating that attack from the less 
hindered exo face is required for reactivity. 
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Scheme 2.11. Azide displacement of tosylated isosorbide and isomannide derivatives only 
occurs from the exo face. 
 
 These azides could be taken forward for additional click chemistry to install functional 
groups selectively (ie, [3+2] cycloaddition on the azide, followed by alcohol functionalization). 
 
2.4.4 Isosorbide Ring Opening 
 A strategy for modifying the isosorbide core utilizes the iodide-promoted ring-opening of 
isosorbide (Scheme 2.12).
26
  Iodide attack opens the ether ring, which is trapped by acetone to 
append a new ring to isosorbide (I20).  The resulting iodide is displaced by the secondary 
alcohol to form epoxide I21, which can be further functionalized to install nucleophiles.  
Although the first two steps of this route worked well in our hands, the nucleophile addition was 
poorly selective and did not yield usable products. 
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Scheme 2.12. Iodide-promoted ring opening and epoxide formation from isosorbide. 
 
2.5 Conclusion 
 The complexity to diversity paradigm enables the rapid synthesis of a number of 
divergent and structurally complex small molecules by performing ring distortion reactions on 
readily-available natural products.  This approach has been validated with gibberellic acid, 
adrenostrerone (performed by Dr. Robert W. Huigens III), and quinine (performed by Robert W. 
Hicklin), and should be amenable to a number of other complex natural products.  Although 
isosorbide lacks much of the complexity present in these other molecules, it does provide a 
number of opportunities for diversifying small molecule libraries, and our initial results suggest 
that a number of approaches would be amenable to further functionalization. 
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2.6 Methods and Characterization 
Chemical reagents were purchased from commercial sources and used without further 
purification.  Gibberellic acid (90% purity) was purchased from AK Scientific.  Isosorbide and 
isomannide were purchased from Sigma Aldrich.  Anhydrous solvents used during these studies 
were dried after being passed through columns with activated alumina.   
1
H NMR and 
13
C NMR experiments were recorded on Varian Unity spectrometers at 400 MHz 
and 500 MHz and 125 MHz, respectively.  Spectra were obtained in the following solvents 
(reference peaks also included for 
1
H and 
13
C NMRs): CDCl3 (
1
H NMR: 7.26 ppm; 
13
C NMR: 
77.23 ppm), d6-DMSO (
1
H NMR: 2.50 ppm; 
13
C NMR: 39.52 ppm), d6-acetone (
1
H NMR: 2.05 
ppm; 
13
C NMR: 206.26 ppm).  NMR experiments were performed at room temperature.  
Chemical shift values are reported in parts per million (ppm) for all 
1
H NMR and 
13
C NMR 
spectra.  
1
H NMR multiplicities are reported as: s = singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet, br = broad.  All melting points were uncorrected and obtained using a Digimelt 
MPA 160. 
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Synthesis of Gibberellic Acid-Based Compounds 
 
 
Procedure: Gibberellic acid (3.99 g, 11.5 mmol) was added to a round bottom flask with stir 
bar, and suspended in hydrazine monohydrate (18 mL).  The reaction refluxed at 110 °C for 30 
minutes, after which the reaction was cooled for 5 minutes in an ice bath.  Following cooling, the 
reaction was diluted in ice water and acidified to pH 3 with concentrated hydrochloric acid.  The 
aqueous phases were extracted with ethyl acetate (5x), and the combined organic layers were 
washed with brine, dried over magnesium sulfate, and concentrated.  White solid precipitated out 
during the concentration process to afford known compound G12 as a white solid (2.06 g, 51.6% 
yield).
4
 
 
1
H NMR (d6-acetone, 500 MHz): δ 6.32 (d, J = 9.7 Hz, 1H), 5.91 (dd, J = 9.7, 5.5 Hz, 1H), 5.14 
(t, J = 2.4 Hz, 1H), 4.91 (t, J = 2.4 Hz, 1H), 4.33 (d, J = 5.6 Hz, 1H), 3.98 (s, 1H), 3.72 (d, J = 
8.5 Hz, 1H), 3.57 (dd, J = 8.5, 4.4 Hz, 1H), 2.61 (dd, J = 16.1, 6.2 Hz, 1H), 2.51 (dt, J = 16.5, 3.0 
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Hz, 1H), 2.20 (t, J = 3.5 Hz, 1H), 2.18 (dd, J = 9.0, 2.5 Hz, 1H), 2.11 - 1.98 (m, 2H), 1.79 - 1.63 
(m, 3H), 1.28 (s, 3H). 
13
C NMR (d6-acetone, 125 MHz): δ 176.4, 175.9, 156.2, 139.8, 130.5, 128.2, 124.1, 105.7, 79.2, 
69.8, 56.4, 53.1, 50.0, 49.8, 48.5, 40.7, 40.0, 21.2, 20.5. 
HRMS(ESI): m/z calc. for C19H22O6Na [M+Na]
+
: 369.1314, found: 369.1315. 
Melting point: 189-191 °C. 
 
 
Procedure: In an oven-dried round bottom flask with stir bar under argon, G12 (521 mg, 1.50 
mmol) was dissolved in toluene (18 mL) and methanol (3 mL).  (Trimethylsilyl)diazomethane (2 
M in hexanes, 1.8 mL, 3.60 mmol) was added dropwise at room temperature, and the reaction 
was stirred for 1 hour at room temperature.  The reaction was concentrated, and then dissolved in 
pyridine (9 mL).  Acetic anhydride (1.5 mL, 15.9 mmol) and 4-(dimethylamino)-pyridine (53.1 
mg, 0.43 mmol) were added, and the reaction was allowed to stir overnight at room temperature.  
After 14 hours, the reaction was quenched with chilled hydrochloric acid to pH 3.  The aqueous 
phase was extracted with ethyl acetate (4x), and the combined organic layers were washed with 
brine, dried over magnesium sulfate, and concentrated.  Purification by flash silica 
chromatography (5:1 hexanes/ethyl acetate) afforded G7 as a white solid (445 mg, 65% yield). 
Note: G13 could be isolated and purified following esterification with 
(trimethylsilyl)diazomethane by flash silica chromatography (3:1 hexanes/ethyl acetate) to afford 
pure product. 
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1
H NMR (CDCl3, 500 MHz): δ 6.36 (d, J = 9.5 Hz, 1H), 5.96 (dd, J = 9.7, 5.6 Hz, 1H), 5.16 (t, J 
= 2.5 Hz, 1H), 4.98 (t, J = 2.2 Hz, 1H), 4.33 (d, J = 5.5 Hz, 1H), 3.73 (s, 3H), 3.63 (d, J = 8.4 Hz, 
1H), 3.59 (s, 3H), 3.49 (dd, J = 8.4, 4.4 Hz, 1H), 2.61 (dd, J = 16.3, 6.4 Hz, 1H), 2.30 (dt, J = 
16.5, 2.8 Hz, 1H), 2.24 (dq, J = 16.5, 2.1 Hz, 1H), 2.19 (dd, J = 10.4, 2.8 Hz, 1H), 2.13 - 2.02 
(m, 1H), 1.84 (td, J = 11.9, 6.4 Hz, 1H), 1.77 - 1.58 (br s, partially buried, 1H), 1.76 (dd, J = 
10.4, 2.4 Hz, 1H), 1.74 - 1.70 (m, 2H), 1.25 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ
 
175.1, 174.9, 154.5, 140.3, 128.6, 126.8, 124.8, 106.4, 79.3, 
69.9, 56.3, 52.6, 52.0, 51.8, 49.7, 49.3, 48.1, 39.4, 39.2, 20.9, 19.9. 
HRMS(ESI): m/z calc. for C21H26O6Na [M+Na]
+
: 397.1627, found: 397.1629. 
Melting point: 81-82 °C. 
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1
H NMR (CDCl3, 500 MHz): δ 6.43 (d, J = 9.6 Hz, 1H), 5.90 (dd, J = 9.6, 5.6 Hz, 1H), 5.55 (d, 
J = 5.6 Hz, 1H), 5.08 (dd, J = 3.3, 1.8 Hz, 1H), 5.02 (t, J = 2.0 Hz, 1H), 3.74 (s, 3H), 3.70 (d, J = 
8.6 Hz, 1H), 3.64 - 3.59 (m, 1H), 3.62 (s, 3H), 2.69 (dd, J = 10.5, 2.9 Hz, 1H), 2.62 (dd, J = 16.2, 
6.3 Hz, 1H), 2.39 - 2.29 (m, 2H), 2.25 (dd, J = 16.1, 2.1 Hz, 1H), 2.21 - 2.11 (m, 2H), 2.08 (s, 
3H), 2.05 (s, 3H), 1.70 (ddd, J = 10.8, 7.1, 2.6 Hz, 1H), 1.17 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 175.0, 173.8, 170.6, 169.9, 150.6, 140.6, 126.8, 126.2, 125.3, 
106.7, 85.9, 71.2, 57.2, 52.0, 52.0, 49.0, 48.9, 48.5, 47.9, 38.9, 36.9, 22.3, 21.3, 20.7, 19.9. 
HRMS(ESI): m/z calc. for C25H30O8Na [M+Na]
+
: 481.1838, found: 481.1837. 
 
 
Procedure: In an oven-dried vial with stir bar, G7 (120 mg, 0.26 mmol) was dissolved in 
dichloromethane (10.5 mL).  Sodium bicarbonate (89 mg, 1.06 mmol) and m-
chloroperoxybenzoic acid (69 mg, 0.31 mmol calculated at 77% purity) were added sequentially, 
and the reaction was allowed to stir at room temperature for 7 hours.  The reaction was washed 
sequentially with saturated aqueous sodium thiosulfate, saturated aqueous sodium bicarbonate, 
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and brine, dried over magnesium sulfate, and concentrated.  Flash silica chromatography (3:1 
hexanes/ethyl acetate) afforded G14 as a white solid (95 mg, 76% yield). 
Note: Although the absolute stereochemistry could not be directly determined for this 
compound, the product of the oxidation and allylic rearrangement of G14 following treatment 
with PCC afforded G15, whose stereochemistry could be assigned. 
 
1
H NMR (CDCl3, 500 MHz): δ 6.32 (dd, J = 9.8, 5.1 Hz, 1H), 5.77 (d, J = 9.0 Hz, 1H), 5.71 (d, 
J = 5.6 Hz, 1H), 5.09 (t, J = 2.6 Hz, 1H), 5.00 (t, J = 2.3 Hz, 1H), 3.72 (s, 3H), 3.70 (s, 3H), 3.06 
(d, J = 10.5 Hz, 1H), 2.94 (d, J = 10.5 Hz, 1H), 2.56 (tt, J = 12.5, 6.1 Hz, 1H), 2.47 (dd, J = 10.8, 
1.6 Hz, 1H), 2.44 (dd, J = 10.8, 2.3 Hz, 1H), 2.25 (dd, J = 17.2, 2.4 Hz, 1H), 2.17 (t, J = 2.4 Hz, 
1H), 2.14 - 2.07 (m, 1H buried under methyl), 2.10 (s, 3H), 2.06 (s, 3H), 1.64 (td, J = 14.3, 12.3, 
5.9 Hz, 2H), 1.15 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 173.7, 173.4, 170.3, 169.7, 149.3, 134.7, 125.2, 106.7, 85.8, 
72.1, 70.4, 65.7, 52.3, 52.2, 51.4, 47.6, 44.5, 44.3, 41.9, 35.4, 35.0, 22.1, 22.1, 21.2, 19.5. 
HRMS(ESI): m/z calc. for C25H31O9 [M+H]
+
: 475.1968, found: 475.1971. 
HRMS(ESI): m/z calc. for C25H30O9Na [M+Na]
+
: 497.1788, found: 497.1790. 
Melting point: 62-64 °C. 
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Procedure:
 
In an oven-dried round bottom flask with stir bar, dissolved G14 (97.6 mg, 0.21 
mmol) in dichloromethane (7 mL) and added powdered molecular sieves (160 mg) followed by 
pyridinium chlorochromate (97.5 mg, 0.45 mmol).  The reaction was refluxed at 45 °C for 2.5 
hours, and was then diluted with ether and filtered over a silica plug to remove the chromium.  
Purification by flash silica chromatography (4:1 to 3:1 hexanes/ethyl acetate) afforded G1 as a 
white solid (29.0 mg, 29% yield in 90% purity determined by 
1
H NMR integrations) and G15, 
which is the product of allylic oxidation and rearrangement, was also recovered as a pure white 
solid (52.8 mg, 52%). 
Note: G1 was not stable to chromatography or storage at room temperature, and would gradually 
convert to G2 over time.  There was a significant contaminant signal in the 
13
C NMR spectra for 
G1 that could not be removed at 56.4 ppm.  G15 was used for assigning the absolutely 
stereochemistry of the precursor epoxide G14.  The assignment of the stereochemistry of the 
tertiary alcohol is based on the NOEs observed across the C/D bicycle.  A comparison is 
provided to the opposite diastereomer to identify the interactions that are not observed but would 
be expected if the alcohol was in the opposite configuration. 
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1
H NMR (CDCl3, 500 MHz): δ 6.49 (dd, J = 10.3, 2.1 Hz, 1H), 6.38 (t, J = 2.2 Hz, 1H), 5.91 
(dd, J = 10.3, 2.1, Hz, 1H), 5.17 (t, J = 2.6 Hz, 1H), 5.13 (t, J = 2.2 Hz, 1H), 3.79 (d, J = 11.8 Hz, 
1H), 3.66 (s, 3H), 3.59 (s, 3H), 3.12 (dt, J = 17.5, 2.5 Hz, 1H), 3.04 (dq, J = 17.5, 1.5 Hz, 1H), 
2.92 (d, J = 11.7 Hz, 1H), 2.55 - 2.38 (m, 2H), 2.29 - 2.18 (m, 2H), 2.07 (s, 3H), 2.02 (m, 3H 
singlet buried in multiplet, 4H), 1.79 (ddd, J = 10.3, 7.1, 3.5 Hz, 1H), 1.32 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 209.2, 198.7, 172.5, 172.2, 170.0, 169.9, 148.8, 141.7, 130.4, 
107.2, 84.5, 69.8, 55.1, 52.7, 51.9, 51.6, 45.3, 43.8, 36.7, 35.6, 33.6, 29.9, 22.1, 21.1, 19.1. 
HRMS(ESI): m/z calc. for C25H30O10Na [M+Na]
+
: 513.1737, found: 513.1746. 
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1
H NMR (CDCl3, 500 MHz): δ 6.01 (d, J = 2.6, 0.9 Hz, 1H), 5.62 (d, J = 0.9 Hz, 1H), 5.03 (t, J 
= 2.5 Hz, 1H), 4.92 (t, J = 2.1 Hz, 1H), 3.75 (s, 3H), 3.69 (s, 3H), 3.63 (dd, J = 11.1, 2.7 Hz, 1H), 
3.60 (d, J = 11.1 Hz, 1H), 3.52 (br s, 1H), 2.88 (dd, J = 10.8, 2.6 Hz, 1H), 2.71 (ddd, J = 12.7, 
11.7, 5.2 Hz, 1H), 2.33 (dt, J = 17.7, 2.8 Hz, 1H), 2.19 - 2.14 (m, 1H buried under methyl), 2.18 
(s, 3H), 2.07 (s, 3H), 2.07 - 2.01 (m, 1H buried under methyl), 1.95 (ddd, J = 14.0, 5.3, 1.8 Hz, 
1H), 1.66 (td, J = 13.4, 5.7 Hz, 1H), 1.55 - 1.42 (m, 1H), 1.21 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 192.0, 174.8, 173.2, 171.1, 169.8, 169.6, 148.7, 121.5, 105.7, 
86.3, 79.9, 74.2, 55.1, 53.3, 52.5, 47.0, 45.1, 37.5, 35.1, 33.5, 29.9, 27.9, 22.3, 21.0, 19.7. 
HRMS(ESI): m/z calc. for C25H31O10 [M+H]
+
: 491.1917, found: 491.1916. 
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Procedure: In an oven-dried round bottom flask with stir bar, dissolved G14 (100.3 mg, 0.21 
mmol) in dichloromethane (7 mL) and added powdered molecular sieves (100 mg) followed by 
pyridinium chlorochromate (98.0 mg, 0.46 mmol).  The reaction was refluxed for 2.5 hours, at 
which point hydrochloric acid (1 M, 8 mL) was added.  The reaction stirred overnight at room 
temperature, and was then extracted with dichloromethane (3x).  Purification by flash silica 
chromatography (4:1 to 3:1 hexanes/ethyl acetate) afforded G2 as a white solid (20.4 mg, 20% 
yield). 
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1
H NMR (CDCl3, 500 MHz): δ 6.43 (s, 1H), 5.99 (dd, J = 9.9, 4.4 Hz, 1H), 5.92 (d, J = 9.9 Hz, 
1H), 5.68 (d, J = 4.5 Hz, 1H), 5.00 (q, J = 2.6 Hz, 2H), 3.76 (s, 3H), 3.66 (s, 3H), 3.23 (s, 1H), 
2.63 (dt, J = 16.7, 3.0 Hz, 1H), 2.49 (ddd, J = 16.7, 3.7, 2.0 Hz, 1H), 2.28 - 2.20 (m, 3H), 2.12 - 
2.05 (m, 1H), 2.03 (s, 6H), 1.84 (td, J = 13.9, 6.6 Hz, 1H), 1.61 - 1.55 (m, 1H), 1.27 (s, 3H). 
.13
C NMR (CDCl3, 125 MHz): δ 176.6, 174.0, 170.4, 169.6, 149.4, 145.1, 127.6, 126.8, 106.0, 
103.0, 98.7, 85.2, 71.2, 53.1, 52.7, 50.3, 48.5, 45.1, 44.9, 35.7, 35.0, 32.8, 22.2, 21.1, 15.9. 
HRMS(ESI): m/z calc. for C25H30O10Na [M+Na]
+
: 513.1737, found: 513.1741. 
 
 
Procedure: Gibberellic acid (1.002 g, 2.89 mmol) and sodium hydroxide (954 mg, 23.9 mmol) 
were dissolved in water (500 mL) in a round bottom flask.  After stirring at room temperature for 
1.5 hours, the reaction was acidified to pH 3 and extracted with ethyl acetate (5x).  The organic 
layers were dried over magnesium sulfate and concentrated to afford known compound G8 as a 
white solid (771 mg, 77% yield).
15
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1
H NMR (d6-acetone, 500 MHz): δ 5.80 (dt, J = 5.2, 2.6 Hz, 1H), 5.10 - 5.06 (m, 1H), 4.93 - 
4.90 (m, 1H), 4.70 (t, J = 5.3 Hz, 1H), 4.28 (d, J = 5.3 Hz, 1H), 3.33 (dd, J = 6.1, 2.7 Hz, 1H), 
2.81 (br s, 1H), 2.68 (dt, J = 16.4, 3.0 Hz, 1H), 2.61 - 2.55 (m, 1H), 2.44 (d, J = 6.1 Hz, 1H), 
2.33 - 2.24 (m, 1H), 1.99 - 1.89 (m, 1H), 1.77 - 1.62 (m, 3H), 1.51 (dd, J = 11.0, 3.1 Hz, 1H), 
1.49 - 1.42 (m, 1H), 1.34 (ddd, J = 10.9, 2.8, 1.1 Hz, 1H), 1.16 (s, 3H). 
13
C NMR (d6-acetone, 125 MHz): δ 177.5, 176.0, 155.7, 151.9, 114.6, 106.3, 79.0, 75.8, 74.9, 
49.9, 49.8, 49.6, 49.1, 46.7, 46.3, 39.9, 38.6, 19.4, 17.4. 
HRSM(ESI): m/z calc. for C19H22O6Na [M+Na]
+
: 369.1314, found: 369.1317. 
 
 
Procedure: In an oven-dried flask, G8 (128.4 mg, 0.37 mmol) and benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (213.0 mg, 0.41 mmol) were dissolved in 
dichloromethane (4 mL).  Diisopropylethylamine (200 µL, 1.15 mmol) was added, and the 
reaction was stirred at room temperature for 2 hours.  After complete complexation by TLC, 
cyclohexanemethylamine (50 µL, 0.38 mmol) and additional diisopropylethylamine (50 µL, 0.29 
mmol) were added, and the reaction was allowed to stir at room temperature for 16 hours.  The 
reaction was quenched with water, extracted with ethyl acetate (3x), and concentrated.  
Purification by flash silica chromatography (1:1 to 1:2 hexanes/ethyl acetate) afforded pure G16 
as a white solid (138.4 mg, 85% yield). 
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1
H NMR (CDCl3, 500 MHz): δ 6.17 (t, J = 5.9 Hz, 1H), 5.77 (dt, J = 5.0, 2.4 Hz, 1H), 5.10 (t, J 
= 2.5 Hz, 1H), 4.97 (t, J = 2.0 Hz, 1H), 4.77 (t, J = 5.3 Hz, 1H), 4.24 (d, J = 5.3 Hz, 1H), 3.33 
(dd, J = 5.9, 2.6 Hz, 1H), 3.14 (dt, J = 13.3, 6.6 Hz, 1H), 3.06 (dt, J = 13.3, 6.0 Hz, 1H), 2.82 - 
2.74 (m, 1H), 2.51 (dt, J = 16.5, 2.9 Hz, 1H), 2.38 - 2.28 (m, 1H), 2.30 - 2.05 (br s, buried, 1H), 
2.24 (d, J = 5.9 Hz, 1H), 1.97 - 1.86 (m, 1H), 1.78 - 1.62 (m, 7H), 1.58 - 1.52 (m, 1H), 1.51 (dd, 
J = 11.1, 2.7 Hz, 1H), 1.46 (ddp, J = 11.0, 7.0, 3.6 Hz, 1H), 1.34 (dd, J = 11.0, 2.7 Hz, 1H), 1.29 
- 1.10 (m, 3H singlet buried, 7H), 1.00 - 0.85 (m, 2H). 
13
C NMR (CDCl3, 125 MHz): δ 177.9, 174.0, 153.9, 153.4, 113.1, 107.0, 79.2, 75.8, 74.3, 51.4, 
49.5, 49.0, 48.7, 46.3, 45.7, 45.7, 39.1, 38.1, 37.5, 31.1 (2), 26.6, 26.0 (2), 18.9, 17.2. 
HRMS(ESI): m/z calc. for C26H36NO5 [M+H]
+
: 442.2593, found: 442.2585. 
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Procedure: In a vial with a stir bar, loaded hydrogen peroxide (30% in water, 15.4 µL, 0.14 
mmol), trifluoroacetic anhydride (100 µL, 0.72 mmol), and trifluoroacetic acid (110 µL, 1.44 
mmol) were dissolved in dichloromethane.  Amide G16 was added in one portion and allowed to 
react for 15 minutes.  The reaction was then washed with water (2x) and saturated aqueous 
sodium bicarbonate.  Purification by flash silica chromatography (1:1 to 1:2 hexanes/ethyl 
acetate) afforded pure G3 as a white solid (14.8 mg, 73% yield). 
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1
H NMR (CDCl3, 500 MHz): δ 6.33 (t, J = 5.8 Hz, 1H), 4.92 (dd, J = 5.7, 3.4 Hz, 1H), 4.22 (br 
s, 1H), 4.01 (br s, 1H), 3.81 (d, J = 11.6 Hz, 1H), 3.74 (d, J = 3.4 Hz, 1H), 3.42 (d, J = 11.6 Hz, 
1H), 3.26 (dt, J = 13.5, 6.9 Hz, 1H), 3.22 (d, J = 3.7 Hz, 1H), 3.03 (dt, J = 13.5, 5.7 Hz, 1H), 
2.99 (dd, J = 12.5, 5.0 Hz, 1H), 2.76 (d, J = 3.8 Hz, 1H), 2.26 (dd, J = 11, 8 Hz, 1H), 2.26 (d, J = 
18.8 Hz, 1H), 1.91 (d, J = 18.8 Hz, 1H), 1.76 - 1.56 (m, 7H), 1.52 - 1.45 (m, 1H), 1.40 - 1.32 (m, 
1H), 1.27 - 1.12 (m, buried methyl, 8H), 1.02 - 0.90 (m, 3H). 
13
C NMR (CDCl3, 125 MHz): δ
 
219.1, 177.6, 172.8, 76.9, 71.5, 67.9, 63.8, 56.4, 56.3, 50.5, 
48.7, 46.6, 46.4, 46.0, 45.2, 43.6, 40.6, 38.0, 31.1 (2), 30.6, 26.6, 26.0 (2), 19.2, 17.7. 
HRMS(ESI): m/z calc. for C26H36NO7 [M+H]
+
: 474.2492, found: 474.2493. 
 
 
Procedure: Gibberellic acid (2.008 g, 5.80 mmol) and sodium hydroxide (955 mg, 23.9 mmol) 
were dissolved in water (230 mL, 0.1 M NaOH) and stirred at room temperature for 17.5 hours.  
The reaction was cooled in an ice bath and quenched with hydrogen chloride (1 M, 40 mL) to a 
final pH of 2.  The reaction was extracted with ethyl acetate (5x) and concentrated.  The organic 
layer was then triturated with hexanes to afford known compound G9 as a white solid (1.403 g, 
66% yield).
17
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1
H NMR (d6-DMSO, 500 MHz): δ 12.32 (s, 2H), 5.21 (q, J = 2.9 Hz, 1H), 5.08 (br m, 1H), 5.00 
(m, 1H), 4.87 (m, 1H), 4.76 (s, 1H), 3.88 (q, J = 2.8 Hz, 1H), 3.70 (d, J = 3.1 Hz, 1H), 2.88 - 
2.83 (m, 1H), 2.75 (d, J = 6.0 Hz, 1H), 2.55 - 2.45 (m, 1H), 2.36 - 2.31 (m, 1H), 2.13 (dd, J = 
16.1, 2.6 Hz, 1H), 1.85 - 1.78 (m, 1H), 1.63 (dd, J = 11.1, 2.7 Hz, 1H), 1.61 - 1.48 (m, 2H), 1.42 
- 1.35 (m, 1H), 1.31 (d, J = 10.5 Hz, 1H), 1.15 (s, 3H). 
13
C NMR (d6-acetone, 125 MHz): δ 177.1, 176.2, 155.7, 143.2, 115.6, 105.4, 78.7, 75.2, 71.2, 
50.0, 49.6, 48.9, 47.3, 46.7, 46.6, 39.5, 38.2, 21.2, 18.8. 
HRMS(ESI): m/z calc. for C19H24O7Na [M+Na]
+
: 387.1420, found: 387.1420. 
Melting point: 143-145 °C. 
 
 
Procedure: In an oven-dried round bottom flask with a stir bar under argon, loaded G9 (55.4 
mg, 0.15 mmol) and dissolved in toluene (1.5 mL) and methanol (0.5 mL).  Added 
trimethylsilyldiazomethane (2 M in hexanes, 160 µL, 0.32 mmol) and allowed to stir for 1 hour, 
at which point the reaction was concentrated.  The solid residual was redissolved in 
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dichloromethane (1.5 mL) and water (0.5 mL).  Sodium periodate (65.2 mg, 0.31 mmol) was 
added in a single portion, and the reaction was heated at 40 °C for 6 hours.  The reaction was 
then cooled, extracted with ethyl acetate (3x) and concentrated.  Purification by flash silica 
chromatography (2:1 hexanes/ethyl acetate) afforded pure G4 as a white solid (36.2 mg, 61% 
yield). 
Note: G17 could be isolated and purified following esterification with 
(trimethylsilyl)diazomethane by flash silica chromatography (2:1 hexanes/ethyl acetate) to afford 
pure product. 
 
1
H NMR (CDCl3, 500 MHz): δ 5.44 (q, J = 2.3 Hz, 1H), 5.12 (t, J = 2.5 Hz, 1H), 4.99 (t, J = 2.1 
Hz, 1H), 4.16 (m, 1H), 3.87 (d, J = 4.5 Hz, 1H), 3.72 (s, 3H), 3.66 (s, 3H), 3.10 (d, J = 6.6 Hz, 
1H), 2.59 - 2.48 (m, 3H), 2.28 - 2.15 (m, 2H), 1.97 (dd, J = 14.4, 6.1 Hz, 1H), 1.80 (td, J = 11.4, 
6.1 Hz, 1H), 1.75 - 1.67 (m, 1H), 1.65 (dd, J = 10.7, 2.9 Hz, 1H), 1.61 - 1.49 (m, 3H), 1.39 - 1.35 
(m, 1H), 1.36 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 176.4, 175.4, 154.0, 142.6, 116.2, 106.8, 79.2, 75.2, 70.3, 52.2, 
52.0, 50.9, 49.7, 48.9, 48.0, 47.3, 46.1, 39.1, 37.7, 20.3, 18.9.  
HRMS(ESI): m/z calc. for C21H28O7Na [M+Na]
+
: 415.1733, found: 415.1734. 
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1
H NMR (CDCl3, 125 MHz): δ 6.27 (d, J = 5.9 Hz, 1H), 6.09 (s, 1H), 5.16 (t, J = 1.4 Hz, 1H), 
5.02 (d, J = 5.9 Hz, 1H), 4.94 (t, J = 2.0 Hz, 1H), 3.69 (s, 3H), 3.68 (s, 3H), 3.11 (d, J = 6.6 Hz, 
1H), 2.42 - 2.36 (m, 2H), 2.27 (dt, J = 15.8, 3.0 Hz, 1H), 2.11 - 2.02 (m, 1H), 2.00 - 1.85 (m, 
2H), 1.77 (dd, J = 7.8, 5.5 Hz, 1H), 1.71 - 1.63 (m, 2H), 1.63 - 1.58 (m, 1H), 1.57 (s, 3H), 1.52 - 
1.46 (m, 1H). 
13
C NMR (CDCl3, 125 MHz): δ 174.6, 173.4, 155.6, 142.8, 108.1, 106.9, 103.9, 92.7, 78.8, 66.7, 
63.4, 54.5, 52.1, 52.0, 51.6, 49.6, 48.1, 42.3, 38.7, 22.3, 18.1. 
HRMS (ESI): m/z calc. for C21H26O7Na [M+Na]
+
: 413.1576, found: 413.1578. 
Melting point: 136-137 °C. 
 
 
Procedure: Gibberellic acid (1.404 g, 4.05 mmol) was dissolved in hydrochloric acid (1.2 M, 20 
mL) in a round bottom flask and heated for 2.75 hours at 65 °C.  The reaction was cooled, and 
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the solid precipitate was filtered and washed with water.  G10, a known compound, was isolated 
as a white solid (863 mg, 75% yield).
5
  
 
1
H NMR (d6-acetone, 500 MHz): δ 10.97 (br s, 1H), 7.10 (t, J = 7.5 Hz, 1H), 6.98 (d, J = 7.6 Hz, 
1H), 6.95 (d, J = 7.4 Hz, 1H), 4.99 (dt, J = 2.7, 1.4 Hz, 1H), 4.70 (t, J = 2.0 Hz, 1H), 3.98 (s, 
1H), 2.88 (dd, J = 12.6, 5.0 Hz, 1H), 2.31 - 2.21 (m, 3H), 2.20 (s, 3H), 2.08 - 1.99 (m, 2H), 1.93 
(td, J = 12.2, 5.1 Hz, 1H), 1.89 (dd, J = 10.3, 2.6 Hz, 1H), 1.71 - 1.62 (m, 1H), 1.54 (qd, J = 12.7, 
5.1 Hz, 1H). 
13
C NMR (d6-acetone, 125 MHz): δ 172.7, 155.9, 145.7, 139.7, 135.8, 129.3, 127.9, 120.3, 
103.1, 80.6, 55.2, 53.8, 52.7, 49.1, 40.7, 34.9, 22.8, 20.0. 
HRMS(ESI): m/z calc. for C18H21O3 [M+H]
+
: 285.1491, found: 285.1491. 
HRMS(ESI): m/z calc. for C18H20O3Na [M+Na]
+
: 307.1310, found: 307.1307. 
Melting point: 188-190 °C. 
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Procedure: In an oven-dried vial with stir bar, G10 (48.7 mg, 0.17 mmol) and 4-nitrobenzyl 
bromide (92.0 mg, 0.43 mmol) were dissolved in acetone (1 mL).  Potassium carbonate (120.9 
mg, 0.88 mmol) was then added, and the reaction stirred at room temperature for 15.5 hours.  
The reaction was diluted with water and extracted with ethyl acetate (2x).  Purification by flash 
silica chromatography (4:1 to 3:1 hexanes/ethyl acetate) afforded pure G18 as a white solid (65.3 
mg, 91% yield). 
 
1
H NMR (CDCl3, 500 MHz): δ 8.23 (d, J = 8.5 Hz, 2H), 7.57 (d, J = 8.5 Hz, 2H), 7.14 (t, J = 7.5 
Hz, 1H), 7.01 (d, J = 7.6 Hz, 1H), 6.94 (d, J = 7.4 Hz, 1H), 5.36 (d, J = 13.2 Hz, 1H), 5.27 (d, J = 
13.2 Hz, 1H), 4.98 (t, J = 2.7 Hz, 1H), 4.72 (t, J = 2.2 Hz, 1H), 4.05 (s, 1H), 2.85 (dd, J = 12.6, 
4.9 Hz, 1H), 2.25 (ddt, J = 12.6, 5.2, 2.7 Hz, 1H), 2.16 (dd, J = 6.6, 2.5 Hz, 1H), 2.13 (d, J = 2.5 
Hz, 1H), 2.09 (s, 3H), 2.05 (dt, J = 18, 3.0 Hz, 1H), 1.97 (dd, J = 12.4, 4.3 Hz, 1H), 1.95 - 1.92 
(m, 1H), 1.73 (ddd, J = 9.6, 5.3, 2.3 Hz, 1H), 1.63 (dd, J = 12.7, 5.2 Hz, 1H), 1.57 (dd, J = 12.6, 
5.0 Hz, 1H).  
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13
C NMR (CDCl3, 125 MHz): δ 171.1, 154.11, 148.0, 144.5, 143.0, 138.0, 135.0, 129.2, 129.0, 
127.8, 124.0 (2), 120.0, 103.5, 80.6, 65.3, 65.3, 54.7, 53.7, 52.3, 49.0, 39.6, 34.3, 22.1, 20.0. 
HRMS(ESI): m/z calc. for C25H26NO5 [M+H]
+
: 420.1811, found: 420.1810. 
 
 
Procedure: In an oven-dried vial with stir bar, G18 (35.0 mg, 0.083 mmol) and 2,3-dichloro-
5,6-dicyanobenzoquinone (39.0 mg, 0.172 mmol) were dissolved in toluene (1.5 mL) and heated 
at 80 °C for 15 hours.  The reaction was cooled and diluted with ethyl acetate.  The organic layer 
was washed with saturated aqueous ammonium chloride (2x) and water (4x), and concentrated.  
Purification by flash silica chromatography (4:1 to 3:1 hexanes/ethyl acetate) afforded pure G5 
as a white solid (25.5 mg, 74% yield). 
 
1
H NMR (CDCl3, 500 MHz): δ 8.23 (d, J = 8.5 Hz, 2H), 7.52 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 
7.6 Hz, 1H), 7.27 (t, J = 7.5 Hz, 1H), 7.13 (d, J = 7.4 Hz, 1H), 6.35 (d, J = 6.4 Hz, 1H), 5.32 (m, 
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2H), 5.11 (t, J = 2.5 Hz, 1H), 4.86 (t, J = 2.5 Hz, 1H), 4.13 (s, 1H), 3.78 (d, J = 6.5 Hz, 1H), 2.51 
(d, J = 17.8 Hz, 1H), 2.39 (dt, J = 15.7, 2.1 Hz, 1H), 2.34 (dq, J = 15.7, 2.5 Hz, 1H), 2.22 (dd, J 
= 17.8, 3.1 Hz, 1H), 2.10 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 205.7, 171.1, 153.2, 148.1, 142.6, 142.0, 139.7, 136.5, 136.0, 
131.0, 129.3, 129.3 (2), 124.0 (2), 119.3, 112.9, 111.7, 65.5, 60.3, 55.5, 48.9, 45.7, 35.5, 19.0. 
HRMS(ESI): m/z calc. for C25H22NO5 [M+H]
+
: 416.1498, found: 416.1494. 
 
 
Procedure: Gibberellic acid (959 mg, 2.77 mmol) was suspended in aqueous hydrochloric acid 
(2.4 M, 150 mL) in a round bottom flask and refluxed for 2 hours.  The solid crust that formed 
during the course of the reaction was periodically broken up with a glass rod.  After refluxing, 
the reaction was filtered hot, and the solid was washed with water to provide known compound 
G11 as a white solid (298 mg, 38% yield).
5
 
 
1
H NMR (CDCl3, 500 MHz): δ 7.22 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 7.6 Hz, 1H), 7.00 (d, J = 7.5 
Hz, 1H), 4.21 (s, 1H), 3.04 (t, J = 7.8 Hz, 1H), 2.74 (d, J = 17.9 Hz, 1H), 2.51 (dd, J = 17.8, 3.6 
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Hz, 1H), 2.25 (s, 3H), 2.15 - 2.07 (m, 1H), 2.05 (dd, J = 12.1, 3.8 Hz, 1H), 1.90 (dq, J = 14.3, 8.1 
Hz, 1H), 1.83 - 1.73 (m, 1H), 1.64 (ddd, J = 13.5, 7.5, 5.5 Hz, 1H), 1.40 (d, J = 12.1 Hz, 1H), 
1.07 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 221.6, 177.0, 146.2, 137.2, 135.4, 129.2, 128.6, 120.7, 55.8, 
51.4, 50.7, 50.0, 48.2, 39.1, 34.6, 23.0, 21.8, 19.7. 
HRMS(ESI): m/z calc. for C18H21O3 [M+H]
+
: 285.1491, found: 285.1492. 
HRMS(ESI): m/z calc. for C18H20O3Na [M+Na]
+
: 307.1310, found: 307.1312. 
 
 
Procedure: In an oven-dried round bottom flask, G11 (799.5 mg, 2.81 mmol) was dissolved in 
tetrahydrofuran (60 mL).  Thionyl chloride (450 µL, 6.20 mmol) was added, and the reaction 
was refluxed for 50 minutes.  The reaction was then cooled in an ice bath, at which point 
triethylamine (900 µL, 6.46 mmol) and isobutylamine (950 µL, 9.47 mmol) were added and the 
reaction was allowed to warm to room temperature for 1 hour.  The reaction was quenched with 
water, extracted with ethyl acetate (3x), and purified by flash silica chromatography using 4:1 to 
3:1 hexanes/ethyl acetate to afford pure G19 as a white solid (569.6 mg, 60% yield). 
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1
H NMR (CDCl3, 500 MHz): δ 7.22 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 7.5 Hz, 1H), 7.01 (d, J = 7.5 
Hz, 1H), 5.55 (br s, 1H), 4.01 (s, 1H), 3.12 (t, J = 6.4 Hz, 2H), 2.94 (t, J = 8.0 Hz, 1H), 2.71 (d, J 
= 17.7 Hz, 1H), 2.43 (dd, J = 17.7, 3.7 Hz, 1H), 2.23 (s, 3H), 2.10 (dq, J = 9.0, 7.8 Hz, 1H), 1.96 
(dd, J = 12.0, 3.7 Hz, 1H), 1.87 - 1.71 (m, 3H), 1.68 - 1.59 (m, 1H), 1.47 (d, J = 12.0 Hz, 1H), 
1.05 (s, 3H), 0.90 (d, J = 2.2 Hz, 3H), 0.88 (d, J = 2.2 Hz, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 222.0, 171.4, 147.2, 137.9, 135.6, 129.4, 128.7, 121.1, 58.5, 
52.0, 51.6, 49.4, 48.1, 47.3, 38.6, 34.5, 29.9, 28.6, 23.5, 21.8, 20.5, 19.5. 
HRMS(ESI): m/z calc. for C22H30NO2 [M+H]
+
: 340.2277, found: 340.2267. 
Melting point: 168-170 °C. 
 
 
Procedure: An oven-dried vial with stir bar was loaded with G19 (51.4 mg, 0.15 mmol) and 
dissolved in dichloromethane (4 mL).  The reaction was cooled to 0 °C in an ice bath, and 
sodium carbonate (127.1 mg, 1.20 mmol) and peracetic acid (32% in acetic acid, 170 µL, 0.81 
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mmol) were added.  The reaction stirred for 15 hours, during which time it was allowed to warm 
to room temperature.  Saturated aqueous sodium bicarbonate was added to quench the reaction.  
The reaction was acidified to pH 3, and the aqueous layer was extracted with ethyl acetate (3x).  
The combined organic layers were washed with brine, dried over magnesium sulfate, and 
concentrated.  Purification by flash silica chromatography (3:1 to 2:1 hexanes/ethyl acetate) 
afforded G6 as a white solid (16.0 mg, 30% yield).  Unreacted starting material was also 
recovered as a white solid (7.7 mg). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.21 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 7.6 Hz, 1H), 7.03 (d, J = 7.4 
Hz, 1H), 5.64 (t, J = 6.0 Hz, 1H), 3.47 (s, 1H), 3.24 (dt, J = 13.1, 6.4 Hz, 1H), 3.13 (ddd, J = 
13.2, 7.1, 5.8 Hz, 1H), 2.95 (d, J = 17.5 Hz, 1H), 2.90 (d, J = 6.5 Hz, 1H), 2.72 (dd, J = 17.5, 2.8 
Hz, 1H), 2.35 - 2.19 (m, 1H), 2.22 (s, 3H), 1.94 (ddt, J = 15.3, 12.1, 5.8 Hz, 1H), 1.89 - 1.77 (m, 
2H), 1.68 (dd, J = 14.0, 2.9 Hz, 1H), 1.49 - 1.37 (m, 2H), 1.33 (s, 3H), 0.96 (s, 3H), 0.94 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 171.5, 169.2, 144.4, 137.9, 136.0, 129.9, 128.1, 119.8, 81.8, 
60.2, 48.3, 47.5, 46.9, 40.6, 35.9, 33.1, 29.9, 29.1, 28.6, 20.5, 19.6, 19.0. 
HRMS(ESI): m/z calc. for C22H30NO3 [M+H]
+
: 356.2226, found: 356.2219. 
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Procedure: In an oven-dried 7 mL vial with stir bar, G10 (20.7 mg, 0.073 mmol), N-
bromosuccinamide (15.8 mg, 0.089 mmol), and benzoyl peroxide (0.1 mg, 0.0004 mmol) were 
dissolved in carbon tetrachloride (0.5 mL).  The reaction was heated at 67 °C for 24 hours, after 
which the reaction was concentrated and purified directly using flash silica chromatography (3:1 
hexanes/ethyl acetate to ethyl acetate) to afford G10e as a white solid (19.8 mg, 75%). 
1
H NMR (CDCl3, 500 MHz): δ 7.23 (t, J = 7.5 Hz, 1H), 7.09 (d, J = 7.5 Hz, 1H), 6.99 (d, J = 7.5 
Hz, 1H), 4.25 (s, 1H), 3.57 (d, J = 10.4 Hz, 1H), 3.35 (d, J = 10.4 Hz, 1H), 3.06 (t, J = 7.8 Hz, 
1H), 2.76 (d, J = 17.8 Hz, 1H), 2.57 (dd, J = 17.8, 3.5 Hz, 1H), 2.27 (s, 3H), 2.18 (td, J = 7.0, 3.4 
Hz, 1H), 2.14 (dd, J = 12.2, 3.5 Hz, 1H), 1.93 - 1.81 (m, 3H), 1.81 - 1.72 (m, 1H). 
HRMS(ESI): m/z calc. for C18H20O3Br [M+H]
+
: 363.0596, found: 363.0586. 
 
 
General procedure for the preparation of amides from G11: In an oven-dried round bottom 
flask with stir bar, G11 (1 equiv.) was dissolved in tetrahydrofuran (0.05 M).  Thionyl chloride 
(1.2 equiv.) was added, and the reaction was refluxed for 30 minutes.  The reaction was then 
cooled in an ice bath, at which point triethylamine (2.2 equiv.) and amine (1.5 equiv.) were 
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added and the reaction was allowed to warm to room temperature for 1 hour.  The reaction was 
quenched with water, extracted with ethyl acetate (3x), and purified by flash silica 
chromatography (hexanes/ethyl acetate) to provide the amide. 
 
 
G19a: Prepared from 3,5-dichlorobenzylamine.  
Yield: 26.6 mg, 35%. 
1
H NMR (CDCl3, 500 MHz): δ 7.27 (t, J = 1.9 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.20 (s, 1H), 
7.19 (s, 1H), 7.07 (d, J = 7.5 Hz, 1H), 7.01 (d, J = 7.6 Hz, 1H), 5.90 (br s, 1H), 4.49 (dd, J = 
14.9, 6.4 Hz, 1H), 4.36 (dd, J = 14.9, 6.0 Hz, 1H), 4.07 (s, 1H), 2.95 (t, J = 8.5 Hz, 1H), 2.70 (d, 
J = 15.1 Hz, 1H), 2.44 (dd, J = 17.6, 3.7 Hz, 1H), 2.17 (s, 3H), 2.10 (tt, J = 7.3, 3.5 Hz, 1H), 1.89 
(dd, J = 11.9, 3.5 Hz, 1H), 1.83 - 1.72 (m, 2H), 1.63 (dt, J = 6.4, 3.3 Hz, 1H), 1.38 (d, J = 11.5 
Hz, 1H), 1.04 (s, 3H). 
HRMS(ESI): m/z calc. for C25H26NO2Cl2 [M+H]
+
: 442.1341, found: 442.1342. 
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G19b: Prepared from 2,4-dichlorobenzylamine.  
Yield: 202.9 mg, 73%. 
1
H NMR (CDCl3, 500 MHz): δ 7.46 (d, J = 8.2 Hz, 1H), 7.37 (d, J = 2.1 Hz, 1H), 7.23, (dd, J = 
8.2, 2.1 Hz, 1H) 7.21 (t, J = 7.5 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 5.98 
(s, 1H), 4.51 (dd, J = 14.8, 6.2 Hz, 1H), 4.48 (dd, J = 14.8, 6.2 Hz, 1H), 3.99 (s, 1H), 2.92 (t, J = 
8.0 Hz, 1H), 2.65 (d, J = 17.7 Hz, 1H), 2.42 (dd, J = 17.6, 3.7 Hz, 1H), 2.12 - 2.06 (m, 1H), 2.08 
(s, 3H), 1.85 - 1.69 (m, 3H), 1.64 - 1.54 (m, 1H), 1.17 (d, J = 12.0 Hz, 1H), 0.96 (s, 3H). 
HRMS(ESI): m/z calc. for C25H26NO2Cl2 [M+H]
+
: 442.1341, found: 442.1350. 
 
 
Procedure: In an oven-dried vial with stir bar, G19 (15.3 mg, 0.048 mmol) and 2,3-dichloro-
5,6-dicyanobenzoquinone (12.2 mg, 0.054 mmol) were dissolved in toluene (0.5 mL) and 
refluxed for 20 hours.  The reaction was then diluted with ethyl acetate, washed with saturated 
aqueous ammonium chloride (2x) and water (2x), and concentrated.  Purification by flash silica 
chromatography (4:1 hexanes/ethyl acetate) afforded G19c as a white solid (12.4 mg, 82%). 
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1
H NMR (CDCl3, 500 MHz): δ 7.32 (d, J = 7.7 Hz, 1H), 7.26 (t, J = 7.5 Hz, 1H), 7.13 (d, J = 7.4 
Hz, 1H), 5.97 (t, J = 3.6 Hz, 1H), 4.96 (t, J = 6.1 Hz, 1H), 3.90 (s, 1H), 3.08 (dt, J = 13.4, 6.7 Hz, 
1H), 2.89 (ddd, J = 12.8, 6.8, 5.5 Hz, 1H), 2.49 (d, J = 17.4 Hz, 1H), 2.43 (dd, J = 17.4, 3.3 Hz, 
1H), 2.34 - 2.23 (m, 3H), 2.27 (s, 3H), 1.86 (dd, J = 11.3, 3.3 Hz, 1H), 1.69 - 1.58 (m, 1H), 1.20 
(s, 3H), 0.76 (d, J = 6.5 Hz, 3H), 0.75 (d, J = 6.5 Hz, 3H). 
HRMS(ESI): m/z calc. for C22H28NO2 [M+H]
+
: 338.2120, found: 338.2112.  
 
 
General procedure for the preparation of lactones from G19: In oven-dried vial with stir bar, 
G19a or G19b (1 equiv.) was dissolved in dichloromethane (0.05 M).  The reaction was cooled 
to 0 °C in an ice bath, and sodium carbonate (7.5 equiv.) and peracetic acid (32% in acetic acid, 
5 equiv.) were added.  The reaction stirred for 15 hours, during which time it was allowed to 
warm to room temperature.  Saturated aqueous sodium bicarbonate was added to quench the 
reaction.  The reaction was acidified to pH 3, and the aqueous layer was extracted with ethyl 
acetate (3x).  The combined organic layers were washed with brine, dried over magnesium 
sulfate, and concentrated.  Purification by flash silica chromatography (hexanes/ethyl acetate) 
afforded the lactone along with unreacted starting material. 
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G6a: Prepared from G19a.  
Yield: 10.4 mg, 38%, 79% brsm. 
1
H NMR (CDCl3, 500 MHz): δ 7.29 (t, J = 1.9 Hz, 1H), 7.23 (s, 1H), 7.22 (s, 1H), 7.20 (t, J = 
7.9 Hz, 1H), 7.05 (d, J = 7.5 Hz, 1H), 7.03 (d, J = 7.5 Hz, 1H), 6.29 (br s, 1H), 4.60 (dd, J = 
14.8, 6.8 Hz, 1H), 4.31 (dd, J = 14.9, 5.4 Hz, 1H), 3.55 (s, 1H), 2.92 (d, J = 17.6 Hz, 1H), 2.89 
(s, 1H), 2.70 (dd, J = 17.6, 2.8 Hz, 1H), 2.22 (ddt, J = 15.1, 5.0, 2.4 Hz, 1H), 2.14 (s, 3H), 1.92 
(ddt, J = 15.1, 12.0, 5.8 Hz, 1H), 1.84 (dq, J = 14.0, 2.6 Hz, 1H), 1.64 (d, J = 14.0 Hz, 1H), 1.45 
- 1.39 (m, 1H), 1.39 - 1.35 (m, 1H), 1.31 (s, 3H). 
HRMS(ESI): m/z calc. for C25H26NO3Cl2 [M+H]
+
: 458.1290, found: 458.1291. 
 
 
G6b: Prepared from G19b. 
Yield: 9.1 mg, 23%, 34% brsm. 
1
H NMR (CDCl3, 500 MHz): δ 7.46 (d, J = 8.2 Hz, 1H), 7.40 (d, J = 2.1 Hz, 1H), 7.24 (dd, J = 
8.2, 2.1 Hz, 1H), 7.19 (t, J = 7.5 Hz, 1H), 7.03 (d, J = 7.5 Hz, 1H), 7.01 (d, J = 7.5 Hz, 1H), 6.16 
(t, J = 5.4 Hz, 1H), 4.61 (dd, J = 14.4, 6.4 Hz, 1H), 4.47 (dd, J = 14.4, 5.6 Hz, 1H), 3.49 (s, 1H), 
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2.90 (d, J = 17.6 Hz, 1H), 2.89 (s, 1H), 2.69 (dd, J = 17.6, 2.8 Hz, 1H), 2.29 - 2.14 (m, 2H), 2.04 
(s, 3H), 1.91 (ddt, J = 15.2, 12.1, 5.9 Hz, 1H), 1.85 - 1.77 (m, 1H), 1.56 (d, J = 14.2 Hz, 1H), 
1.38 (td, J = 13.5, 5.4 Hz, 1H), 1.25 (s, 3H). 
HRMS(ESI): m/z calc. for C25H26NO3Cl2 [M+H]
+
: 458.1290, found: 458.1290. 
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Synthesis of Isosorbide-Based Compounds 
 
 
I1 
Procedure: Solid isosorbide (1.00 g, 6.85 mmol) and sodium hydride (60% in mineral oil, 0.821 
g, 20.5 mmol) were loaded in an oven-dried 40 mL Teflon-sealed vial with stirbar.  The vial was 
purged and refilled with argon three times, and then cooled vial to 0 °C in an ice bath.  
Tetrahydrofuran (24 mL) was added, and the reaction mixture was allowed to stir at 0 °C for 30 
minutes.  Propargyl bromide (80% in toluene, 2.30 mL, 20.6 mmol) was added dropwise.  
Following addition, the reaction mixture was stirred for 17 hours at 70 °C.  The reaction mixture 
was cooled to room temperature and quenched with saturated aqueous ammonium chloride (25 
mL).  The mixture was taken up in dichloromethane (50 mL), at which point the organic layer 
was separated.  The aqueous layer was extracted a second time with dichloromethane (50 mL).  
The organic layers were combined and washed with saturated aqueous sodium bicarbonate (20 
mL), dried over magnesium sulfate, filtered, and concentrated.  The residue was purified by flash 
chromatography on silica gel (EtOAc/hexanes 1:3) to yield the product as a yellow oil (1.26 g, 
83.0%). 
1
H NMR (CDCl3, 500 MHz): δ 4.68 (t, J = 4.5 Hz, 1H), 4.57 (d, J = 4 Hz, 1H), 4.35 (dd, J = 2.5, 
16 Hz, 1H), 4.29-4.25 (m, 1H), 4.28 (dd, J = 2.5, 16 Hz, 1H), 4.22-4.17 (m, 3H), 4.04-3.95 (m, 
2H), 3.64 (t, J = 8 Hz, 1H), 2.47 (t, J = 2.5 Hz, 1H), 2.46 (t, J = 2.5 Hz, 1H). 
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13
C NMR (CDCl3, 126 MHz): δ 86.2, 83.4, 80.4, 79.4, 79.2, 78.8, 75.3, 75.1, 73.3, 70.1, 57.8, 
57.0. 
HRMS(CI): m/z calc. for C12H15O4 [M+H]
+
: 223.09704, found: 222.09677. 
 
 
 
 
General procedure for the synthesis of benzyl azides: The benzyl bromide (0.37 mmol) was 
added to an oven-dried 7 mL vial with stirbar, and then dissolved in dimethylformamide (2.5 
mL).  Sodium azide (1.84 mmol) was added in a single portion, and then the vial was capped and 
stirred overnight at 70 °C.  The reaction was then cooled to room temperature, diluted with ethyl 
acetate (5 mL), and washed with saturated aqueous sodium bicarbonate (2 mL), at which point 
salts crashed out of solution.  Any remaining DMF was removed by washing the organic layer 
with water (3 x 2 mL).  The organic layer was dried over magnesium sulfate, concentrated, and 
used without further purification. 
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General procedure for the synthesis of alkyl azides: The primary alcohol (0.37 mmol) was 
added to an oven-dried 7 mL vial with stirbar, and then dissolved in dicholormethane (2.5 mL).  
Triethylamine (1.08 mmol) was added to the stirring solution, and the solution was then cooled 
to 0 °C in an ice bath.  Methane sulfonyl chloride (0.56 mmol) was added at 0 °C, and the 
solution stirred for 5 minutes before the ice bath was removed and the reaction was allowed to 
warm to room temperature.  After two hours, the reaction was quenched with 0.5 M HCl (1 mL).  
The organic layer was removed, and the aqueous layer was extracted with dichloromethane (1 
mL).  The organic layers were combined and concentrated. 
The resulting residue was dissolved in dimethylformamide (3 mL), and sodium azide (1.84 
mmol) was added in a single portion, after which then the vial was capped and stirred overnight 
at 70 °C.  The reaction was then cooled to room temperature, diluted with diethyl ether (5 mL), 
and washed with saturated aqueous sodium bicarbonate (2 mL), at which point salts crashed out 
of solution.  Any remaining DMF was removed by washing the organic layer with water (4 x 2 
mL).  The organic layer was dried with brine (2 mL), concentrated, and used without further 
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purification, with the exception of the 4-hydroxy-phenyl and 3-pyridal primary azides, which 
were purified by flash chromatography on silica gel. 
 
 
 
 
General procedure for the synthesis of acyl azides: The primary amine (2.00 mmol) was 
loaded in an oven-dried 7 mL vial with a stirbar and dissolved in dichloromethane (3 mL).  
Triethyl amine (2.87 mmol) was added, and then the solution was cooled to 0 °C in an ice bath.  
Chloroacetyl chloride (2.97 mmol) was added dropwise, and the reaction was allowed to stir at 0 
°C for another 15 minutes before the ice bath was removed and the reaction allowed to warm to 
room temperature.  After 5 hours, the reactions were quenched by the addition of 0.5 M HCl (2 
mL).  The organic layer was separated and concentrated. 
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 The resulting residue was taken forward directly for the azide displacement of the acyl 
chloride in all cases except the 1-amino-2-indanol and 4-nitroaniline materials, in which cases a 
smaller portion (roughly on a 1:10 scale) of the isolated acyl chloride was taken forward. 
 The acyl chloride was dissolved in dimethylformamide (4 mL), and sodium azide (10.0 
mmol) was added in a single portion.  The reaction was heated to 80 °C overnight, after which 
the reaction was diluted with ether (30 mL) and washed with water (4 x 20 mL) and brine (10 
mL).  The azide was concentrated and used without further purification. 
 
 
General procedure for bis [3+2] cycloadditions: In a 7-mL vial with stirbar, azide I1 (0.14 
mmol) was loaded and dissolved in 0.2 mL of a solution of dialkyne (0.045 mmol) in 
dichloromethane.  A solution of sodium ascorbate (0.027 mmol) in water (0.2 mL) and ethanol 
(0.2 mL) was added to the alkyne.  The reaction was stirred at room temperature for 5 minutes, 
and then copper sulfate (0.014 mmol) was added in one portion, at which point the reaction 
continued to stir at room temperature for 24 hours.  The reaction was quenched by adding 
dichloromethane and concentrating reaction mixture, and was purified directly by flash 
chromatography on silica gel. 
 
103 
 
 
I2 
Yield: Isolated as a white powder (41.4 mg, 63% yield). 
1
H NMR (CDCl3, 500 MHz): δ 7.50 (s, 1H), 7.44 (s, 1H), 7.40-7.34 (m, 6H), 7.30-7.25 (m, 4H), 
5.52 (s, 4H), 4.79 (d, J = 12.3 Hz, 1H), 4.70 (d, J = 12.3 Hz, 1H), 4.67 (d, J = 12.0 Hz, 1H), 4.64 
(d, J = 12.2 Hz, 1H), 4.59 (t, J = 4.4 Hz, 1H), 4.52 (bd, J = 4.2 Hz, 1H), 4.15 (ddd, J = 4.6, 6.9, 
7.7 Hz, 1H), 4.10-4.05 (m, 1H), 3.94 (d, J = 3.0 Hz, 2H), 3.88 (dd, J = 6.8, 8.7 Hz, 1H), 3.54 (t, J 
= 8.3 Hz, 1H). 
13
C NMR (CDCl3, 126 MHz): δ 145.1, 145.0, 134.4, 129.1 (2C), 129.1 (2C), 128.8, 128.8, 128.1 
(2C), 128.1 (2C), 122.8, 122.4, 86.036, 84.0, 80.2, 79.6, 73.2, 69.8, 63.8, 63.1, 54.2 (2C). 
HRMS(ESI): m/z calc. for C26H29Br2N6O4 [M+H]
+
: 489.2250, found: 489.2248. 
 
 
I3 
Yield: Isolated as a colorless oil (70.5 mg, 81% yield). 
1
H NMR (CDCl3, 500 MHz): δ 7.51-7.47 (m, 5H – aryl + triazole), 7.44 (s, 1H), 7.16-7.11 (m, 
4H), 5.46 (s, 4H), 4.79 (d, J = 12.3 Hz, 1H), 4.69 (d, J = 12.4 Hz, 1H), 4.67 (d, J = 12.1 Hz, 1H), 
4.63 (d, J = 12.4 Hz, 1H), 4.57 (t, J = 4.2 Hz, 1H), 4.51 (bd, J = 4.2 Hz, 1H), 4.14 (ddd, J = 4.7, 
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7.0, 7.9 Hz, 1H), 4.08 (t, J = 3.1 Hz, 1H), 3.93 (d, J = 3.1 Hz, 2H), 3.88 (dd, J = 6.9, 8.8 Hz, 1H), 
3.54 (t, J = 8.4 Hz, 1H). 
13
C NMR (CDCl3, 126 MHz): δ 145.3 (2C), 133.4 (2C), 132.3 (4C), 129.7 (4C), 124.9, 123.0, 
121.6, 86.0, 84.1, 80.2, 79.7, 73.2, 69.8, 63.8, 63.0, 53.5 (2C). 
HRMS(ESI): m/z calc. for C26H27Br2N6O4 [M+H]
+
: 645.0461, found: 645.0458. 
 
 
I4 
Yield: Isolated as a white solid (19.8 mg, 59% yield). 
1
H NMR (CDCl3, 500 MHz): δ 7.89 (dd, J = 3.6, 7.8 Hz, 2H), 7.60 (s, 1H), 7.55 (s, 1H), 7.34 
(dt, J = 5.2, 7.2 Hz, 2H), 7.15-7.09 (m, 2H), 7.05 (dd, J = 7.1, 12.9 Hz, 2H), 5.61 (bs, 4H), 4.80 
(d, J = 12.5 Hz, 1H), 4.71 (d, J = 12.5 Hz, 1H), 4.68 (d, J = 16.5 Hz, 1H), 4.65 (d, J = 16.5 Hz, 
1H), 4.60 (t, J = 4.5 Hz, 1H), 4.52 (d, J = 4.5 Hz, 1H), 4.17-4.13 (m, 1H), 4.10-4.07 (m, 1H), 
3.95 (d, J = 3 Hz, 2H), 3.88 (dd, J = 6.5, 8.5 Hz, 1H), 3.55 (t, J = 8.5 Hz, 1H). 
13
C NMR (CDCl3, 126 MHz): δ 140.0, 137.2, 130.5, 129.9, 129.1, 123.1, 122.8, 98.8, 86.2, 84.2, 
80.3, 79.7, 73.4, 69.9, 63.9, 63.1, 58.4. 
HRMS(ESI): m/z calc. for C26H27N6O4I2 [M+H]
+
: 741.0183, found: 741.0175. 
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I5 
Yield: Isolated as a white solid (9.9 mg, 34% yield). 
1
H NMR (CDCl3, 500 MHz): δ 8.26 (dd, J = 2.5, 9 Hz, 1H), 8.24 (dd, J = 2.5, 9 Hz, 1H), 8.06 
(d, J = 2.5 Hz, 1H), 8.04 (d, J = 2.5 Hz, 1H), 7.62 (s, 1H), 7.57 (s, 1H), 7.01 (d, J = 9 Hz, 1H), 
7.00 (d, J = 9 Hz, 1H), 5.57 (bs, 4H), 4.80 (d, J = 12.5 Hz, 1H), 4.72 (d, J = 12.5 Hz, 1H), 4.68 
(d, J = 15 Hz, 1H), 4.65 (d, J = 15 Hz, 1H), 4.57 (t, J = 4.5 Hz, 1H), 4.51 (d, J = 4 Hz, 1H), 4.17-
4.13 (m, 1H), 4.09-4.07 (m, 2H), 3.99 (s, 3H), 3.98 (s, 3H), 3.95-3.92 (m, 2H), 3.87 (dd, J = 7, 9 
Hz, 1H), 3.54 (t, J = 8.5 Hz, 1H). 
13
C NMR (CDCl3, 126 MHz): δ 126.6, 125.8, 125.7, 124.2, 123.2, 122.9, 110.7, 86.1, 84.1, 80.4, 
79.7, 73.3, 69.9, 64.0, 63.1, 56.6, 48.5. 
HRMS(ESI): m/z calc. for C28H31N8O10 [M+H]
+
: 639.2163, found: 639.2160. 
 
 
I6 
Yield: Isolated as a white solid (23.4 mg, 79% yield). 
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1
H NMR (CDCl3, 500 MHz): δ 7.60-7.51 (m, 4H), 7.48 (s, 1H), 7.43 (s, 1H), 7.40-7.33 (m, 2H), 
5.72 (bs, 4H), 4.76 (d, J = 12.5 Hz, 1H), 4.67 (d, J = 12.5 Hz, 1H), 4.64 (d, J = 18 Hz, 1H), 4.61 
(d, J = 18 Hz, 1H), 4.55 (t, J = 4.5 Hz, 1H), 4.49 (d, J = 4 Hz, 1H), 4.13-4.08 (m, 1H), 4.07-4.03 
(m, 1H), 3.90 (d, J = 3.5 Hz, 2H), 3.84 (dd, J = 6.5, 8.5 Hz, 1H), 3.51 (t, J = 8.5 Hz, 1H). 
13
C NMR (CDCl3, 126 MHz): δ 131.5, 131.4, 122.6, 122.4, 122.3, 120.2, 120.1, 86.1, 84.1, 80.2, 
79.6, 73.3, 69.8, 63.9, 63.1, 44.1. 
HRMS(ESI): m/z calc. for C28H25N6O4F8 [M+H]
+
: 661.1810, found: 661.1813. 
 
 
I7 
Yield: Isolated as a white solid (22.6 mg, 85% yield). 
1
H NMR (CDCl3, 500 MHz): δ 7.86-7.79 (m, 6H), 7.76-7.72 (m, 2H), 7.54-7.49 (m, 5H), 7.45 
(s, 1H), 7.36-7.31 (m, 2H), 5.66 (bs, 4H), 4.77 (d, J = 12.5 Hz, 1H), 4.67 (d, J = 12.5 Hz, 1H), 
4.64 (d, J = 17.5 Hz, 1H), 4.62 (d, J = 17.5 Hz, 1H), 4.57 (t, J = 4.5 Hz, 1H), 4.49 (d, J = 4.5 Hz, 
1H), 4.14-4.09 (m, 1H), 4.07-4.04 (m, 1H), 3.90 (d, J = 3 Hz, 2H), 3.84 (dd, J = 6.5, 8.5 Hz, 1H), 
3.52 (t, J = 8.5 Hz, 1H). 
13
C NMR (CDCl3, 126 MHz): δ 133.2, 131.8, 129.2, 129.2, 127.9, 127.8, 127.5, 127.5, 126.7, 
125.4, 125.3, 122.8, 122.5, 86.1, 84.1, 80.2, 79.7, 73.2, 69.9, 63.9, 63.1, 54.4. 
HRMS(ESI): m/z calc. for C34H33N6O6 [M+H]
+
: 589.2563, found: 589.2559. 
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I8 
Yield: Isolated as a white solid (20.6 mg, 80% yield). 
1
H NMR (CDCl3, 500 MHz): δ 7.73 (s, 1H), 7.67 (s, 1H), 7.36-7.28 (m, 6H), 7.25 (d, J = 7.5 Hz, 
4H), 4.84 (d, J = 12.4 Hz, 1H), 4.73 (d, J = 12.5 Hz, 1H), 4.69 (d, J = 4.1 Hz, 1-2H), 4.65 (t, J = 
4.3 Hz, 1H), 4.55 (t, J = 4.7 Hz, 4H), 4.50 (d, J = 1.9 Hz, 4H), 4.17 (ddd, J = 4.6, 6.9, 7.6 Hz, 
1H), 4.13-4.10 (m, 1H), 4.00 (dd, J = 1.7, 10.2 Hz, 1H), 3.97 (dd, J = 3.9, 10.2 Hz, 1H), 3.88 
(dd, J = 6.8, 8.6 Hz, 1H), 3.83 (t, J = 4.9 Hz, 4H), 3.58 (t, J = 8.3 Hz, 1H). 
13
C NMR (CDCl3, 126 MHz): δ 137.3 (2C), 128.5 (4H), 128.0 (2C), 127.7 (4C), 124.0 (2C), 
123.7 (2C), 86.2, 84.0, 80.4, 79.5, 73.4 (2C), 73.3, 70.0, 68.3 (2C), 63.8, 63.0, 50.4 (2C). 
HRMS(ESI): m/z calc. for C30H37N6O6 [M+H]
+
: 577.2775, found: 577.2763. 
 
 
I9 
Yield: Isolated as a white solid (10.0 mg, 41% yield). 
1
H NMR (CDCl3, 500 MHz): δ 7.58 (s, 1H), 7.50 (s, 1H), 7.19 (ddd, J = 5.3, 7.4, 8.4 Hz, 4H), 
6.76 (dt, J = 4.0, 7.3 Hz, 2H), 6.60 (ddd, J = 1.1, 2.0, 8.7 Hz, 4H), 4.80 (d, J = 12.4 Hz, 1H), 4.73 
(d, J = 12.4 Hz, 1H), 4.67 (s, 1H), 4.66 (s, 1H), 4.57-4.47 (m, 8H), 4.15-4.10 (m, 1H), 4.10-4.07 
(m, 1H), 3.97 (dd, J = 2.0, 10.3 Hz, 1H), 3.94 (dd, J = 3.8, 10.2 Hz, 1H), 3.89 (dd, J = 6.8, 8.7 
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Hz, 1H), 3.67 (overlapping triplets, J = 4.2, 6.1 Hz, 4H), 3.56 (t, J = 8.4 Hz, 1H), 2.81 (s, 
fractional peak). 
13
C NMR (CDCl3, 126 MHz): δ 146.6, 144.9, 144.7, 129.5, 123.8, 123.4, 118.5, 113.1, 113.1, 
86.9, 84.1, 80.3, 79.7, 73.3, 69.9, 63.9, 63.1, 49.3, 43.9, 43.8. 
HRMS(ESI): m/z calc. for C28H35N8O4 [M+H]
+
: 547.2781, found: 547.2773. 
 
 
I10 
Yield: Isolated as a white solid (18.1 mg, 70% yield). 
1
H NMR (CDCl3, 500 MHz): δ 7.54 (s, 1H), 7.48 (s, 1H), 5.59 (s, 2H), 4.89-4.83 (m, 3H), 4.81 
(d, J = 12.7 Hz, 1H), 4.73 (d, J = 12.4 Hz, 1H), 4.67 (d, J = 3.3 Hz, 2H), 4.62 (t, J = 4.3 Hz, 1H), 
4.52 (d, J = 4.4 Hz, 1H), 4.17-4.11 (m, 1H), 4.10-4.07 (m, 1H), 3.98 (dd, J = 2.7, 10.7 Hz, 1H), 
3.95 (dd, J = 3.7, 10.0 Hz, 1H), 3.87 (dd, J = 6.8, 8.7 Hz, 1H), 3.55 (t, J = 8.5 Hz, 1H), 2.40-2.34 
(m, 2H), 2.30 (bq, J = 18 Hz, 4H), 2.13-2.07 (m, 2H), 2.01 (t, J = 5.7 Hz, 2H), 1.22 (s, 3H), 1.21 
(s, 3H), 1.11 (d, J = 9.0 Hz, 2H), 0.74 (s, 6H). 
13
C NMR (CDCl3, 126 MHz): δ 144.9, 144.8, 142.1, 142.0, 123.0, 122.7, 122.3, 86.2, 83.9, 80.3, 
79.4, 73.3, 69.9, 63.9, 63.1, 55.3, 43.5, 40.5, 38.0, 31.7, 31.3, 25.9, 20.9. 
HRMS(ESI): m/z calc. for C32H45N6O4 [M+H]
+
: 577.3502, found: 577.3492. 
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I11 
Yield: Isolated as a colorless oil (6.7 mg, 15% yield). 
1
H NMR (CDCl3, 500 MHz): δ 7.66 (s, 1H), 7.59 (s, 1H), 7.20 (t, J = 7.9 Hz, 4H), 6.75 (t, J = 
7.3 Hz, 2H), 6.64 (d, J = 8.3 Hz, 4H), 5.12 (s, 4H), 4.85 (d, J = 12.5 Hz, 1H), 4.75 (d, J = 12.5 
Hz, 1H), 4.71 (dd, J = 5.1, 11.3 Hz, 2H), 4.61 (t, J = 4.3 Hz, 1H), 4.53 (d, J = 4.3 Hz, 1H), 4.40 
(dd, J = 5.1, 9.6 Hz, 4H), 4.18-4.13 (m, 1H), 4.13-4.09 (m, 2H), 4.00 (d, J = 1.7, 10.3 Hz, 1H), 
3.96 (dd, J = 3.8, 10.2 Hz, 1H), 3.89 (dd, J = 6.6, 8.7 Hz, 2H), 3.58 (t, J = 8.2 Hz, 1H), 3.45 (dd, 
J = 5.1, 10.3 Hz, 4H). 
13
C NMR (CDCl3, 126 MHz): δ 166.3, 166.3, 145.3, 145.2, 129.4, 124.4, 124.0, 118.3, 118.3, 
113.0, 113.0, 86.0, 84.1, 80.3, 79.7, 73.3, 69.9, 64.9, 64.9, 63.8, 63.0, 50.7, 42.5. 
HRMS(ESI): m/z calc. for C32H39N8O6 [M+H]
+
: 663.2891, found: 663.2896. 
 
 
I12 
Yield: Compound was purified by filtration from crude reaction and isolated as a brown solid 
(34.5 mg, 82% yield). 
1
H NMR (DMSO-d6, 500 MHz): δ 8.82 (dd, J = 5.3, 10.8 Hz, 2H), 8.08 (s, 2H), 7.34 (t, J = 7.4 
Hz, 4H), 7.28 (d, J = 7.2 Hz, 4H), 7.26 (t, J = 7.2 Hz, 2H), 5.16 (s, 4H), 4.70 (d, J = 11.6 Hz, 
1H), 4.64 (t, J = 4.3 Hz, 1H), 4.60 (s, 2H), 4.56 (d, J = 11.8 Hz, 1H), 4.49 (d, J = 3.9 Hz, 1H), 
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4.32 (d, J = 5.7 Hz, 4H), 4.10 (dd, J = 6.0, 12.5 Hz, 1H), 4.07-4.04 (m, 1H), 3.90 (d, J = 9.4 Hz, 
1H), 3.81-3.75 (m, 2H), 3.42 (t, J = 8.0 Hz, 1H). 
13
C NMR (DMSO-d6, 126 MHz): δ 165.3, 138.6, 128.2, 127.2, 126.8, 125.5, 85.3, 82.9, 79.7, 
78.8, 72.4, 69.3, 62.5, 61.6, 51.4, 42.2. 
HRMS(ESI): m/z calc. for C30H35N8O6 [M+H]
+
: 603.2680, found: 603.2683. 
 
 
I13 
Yield: Isolated as a white solid (16.1 mg, 32% yield). 
1
H NMR (CDCl3, 500 MHz): δ 7.68 (s, 1H), 7.61 (s, 1H), 7.20 (t, J = 7.9 Hz, 2H), 6.76 (dt, J = 
2.1, 7.6 Hz, 2H), 6.69-6.64 (m, 4H), 6.00 (bs, 2H), 4.98 (d, J = 3.0 Hz, 2H), 4.97 (s, 2H), 4.83 (d, 
J = 12.4 Hz, 1H), 4.73 (d, J = 12.3 Hz, 1H), 4.68 (d, J = 3.1 Hz, 2H), 4.62 (t, J = 4.5 Hz, 1H), 
4.54 (d, J = 4.4 Hz, 1H), 4.16 (dt, J = 4.6, 7.0 Hz, 1H), 4.13-4.10 (m, 1H), 3.97 (d, J = 2.5 Hz, 
2H), 3.90 (dd, J = 6.7, 9.9 Hz, 1H), 3.79 (overlapping s, 6H), 3.60 (dd, J = 7.9, 8.6 Hz, 1H), 
3.52-3.46 (m, 4H), 2.75 (dt, J = 3.1, 7.0 Hz, 4H). 
13
C NMR (CDCl3, 126 MHz): δ 164.9, 164.8, 159.9, 139.7, 139.7, 129.7, 124.4, 124.1, 121.0, 
114.4, 112.1, 86.2, 84.2, 80.4, 79.8, 73.3, 70.2, 63.8, 62.9, 55.2, 53.1, 40.8, 35.3. 
HRMS(ESI): m/z calc. for C34H43N8O8 [M+H]
+
: 691.3204, found: 691.3201. 
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Procedure: To a solution of isosorbide (1.03 g, 7.07 mmol) in pyridine (12 mL) cooled to 0 °C 
in an ice bath, paratoluenesulfonyl chloride (3.26 g, 17.1 mmol) was added in a single portion.  
The reaction mixture was stirred for 18 hours, warming gradually to room temperature.  The 
reaction mixture was concentrated and purified directly by flash chromatography on silica 
(EtOAc/hexanes 1:2).  The product was then recrystallized from ethyl acetate with hexanes to 
give the product as a white solid (1.75 g, 54.5%). 
1
H NMR (CDCl3, 500 MHz): δ 7.81 (d, J = 8 Hz, 2H), 7.78 (d, J = 8 Hz, 2H), 7.36 (d, J = 8 Hz, 
2H), 7.35 (d, J = 8 Hz, 2H), 4.89-4.83 (m, 2H), 4.61 (t, J = 4.5 Hz, 1H), 4.49 (d, J = 4.5 Hz, 1H), 
3.95 (d, J = 11 Hz, 1H), 3.87 (dd, J = 4, 12 Hz, 1H), 3.85 (dd, J = 6.5, 10 Hz, 1H), 3.70 (dd, J = 
6.5, 10 Hz, 1H), 2.46 (bs, 6H). 
13
C NMR (CDCl3, 126 MHz): δ 145.6, 145.5, 133.2, 133.1, 130.2 (2C), 130.1 (2C), 128.1 (2C), 
128.0 (2C), 85.7, 83.4, 80.5, 78.4, 73.4, 69.9, 21.8 (2C). 
HRMS(ESI): m/z calc. for C20H23O8S2 [M+H]
-
: 455.0834, found: 455.0825. 
 
 
 
112 
 
 
Procedure: To a solution of isosorbide (0.994 g, 6.80 mmol) in pyridine (12 mL) cooled to 0 °C 
in an ice bath, paratoluenesulfonyl chloride (1.30 g, 6.80 mmol) was added in a single portion.  
The reaction mixture was stirred for 16 hours, warming gradually to room temperature.  The 
reaction mixture was concentrated and purified directly by flash chromatography on silica 
(EtOAc/hexanes 1:2 to 1:1.5).  After 2 columns, two pure isomers were isolated as a white 
solids: endo I15 (0.736 g, 36.1%) and exo I16 (0.180 g, 8.8%). 
 
I15 
1
H NMR (CDCl3, 500 MHz): δ 7.83 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 4.88 (dt, J = 
5.8, 11.5 Hz, 1H), 4.64 (t, J = 4.7 Hz, 1H), 4.37 (d, J = 4.3 Hz, 1H), 4.30 (bs, 1 H), 3.90-3.88 (m, 
3H), 3.85 (dd, J = 6.5, 9.7 Hz, 1H), 3.71 (dd, J = 6.5, 9.7 Hz, 1H), 2.45 (s, 3H). 
13
C NMR (CDCl3, 126 MHz): δ 145.16 (s, 1C), 133.15 (s, 1C), 129.88 (d, J = 9.5 Hz, 2C), 
127.94 (d, J = 11.3 Hz, 2C), 87.96 (s, 1C), 79.97 (s, 1C), 78.72 (d, J = 7.1 Hz, 1C), 76.25 (d, J = 
2.4 Hz, 1C), 75.90 (t, J = 10.5 Hz, 1C), 69.55 (t, J = 11.9 Hz, 1C), 21.67 (q, J = 3.7 Hz, 1C). 
HRMS(ESI): m/z calc. for C13H17O6S [M+H]
+
: 301.0746, found: 301.0743. 
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I16 
1
H NMR (CDCl3, 500 MHz): δ 7.80 (d, J = 8.3Hz, 2H), 7.37 (d, J = 8.2Hz, 2H), 4.93 (d, J = 
3.3Hz, 1H), 4.62 (t, J = 4.8Hz, 1H), 4.48 (d, J = 4.5Hz, 1H), 4.31-4.25 (m, 1H), 4.09 (d, J = 11.1 
Hz, 1H), 3.89 (dd, J = 3.4, 11.0 Hz, 1H), 3.85 (dd, J = 6.2, 9.6 Hz, 1H), 3.50 (dd, J = 5.9, 9.5 Hz, 
1H), 2.46 (s, 3H), 2.45 (d, J = 11.0 Hz, 1H). 
13
C NMR (CDCl3, 126 MHz): δ 145.40 (s, 1C), 133.16 (s, 1C), 130.10 (d, J = 7.3 Hz, 2C), 
127.87 (d, J = 9.5 Hz, 2C), 85.44 (d, 1C), 83.68 (d, J = 8.5 Hz, 1C), 81.91 (s, 1C), 73.53 (t, J = 
11.6 Hz, 1C), 73.14 (t, J = 8.6 Hz, 1C), 72.18 (s, 1C), 21.69 (q, J = 3.7 Hz, 1C). 
HRMS(ESI): m/z calc. for C13H17O6S [M+H]
+
: 301.0746, found: 301.0745. 
 
 
Procedure: To a stirred solution of bistosylated isosorbide (1.01 g, 2.22 mmol) in 
dimethylformamide (20 mL), added sodium azide (0.516 g, 7.93 mmol) in one portion, and 
heated reaction at 75 °C for 16 hours.  The reaction was then diluted with diethyl ether (50 mL), 
washed five times with water (40 mL), and washed once with brine (40 mL).  The organic layer 
was dried with magnesium sulfate, filtered and concentrated.  The residue was purified by flash 
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chromatography on silica gel (EtOAc/hexanes 1:9 to 1:1) to yield first the bisazide as a colorless 
oil (51.4 mg, 11.8%), followed by the monoazide as a white solid (422 mg, 58.4%). 
 
I17 
1
H NMR (CDCl3, 500 MHz): δ 7.80 (d, J = 8.3Hz, 2H), 7.37 (d, J = 8.0Hz, 2H), 4.90 (d, J = 3.6 
Hz, 1H), 4.62 (d, J = 3.7 Hz, 1H), 4.58 (d, J = 3.7 Hz, 1H), 4.04 (d, J = 3.9 Hz, 1H), 3.99 (d, J = 
11.1 Hz, 1H), 3.90 (d, J = 10.2 Hz, 1H), 3.84 (dd, J = 3.5, 17.0 Hz, 1H), 3.82 (dd, J = 3.5, 17.0 
Hz, 1H), 2.47 (s, 3H). 
13
C NMR (CDCl3, 126 MHz): δ 145.45 (s, 1C), 133.12 (s, 1C), 130.12 (d, J = 9.8 Hz, 2C), 
127.86 (d, J = 11.4 Hz, 2C), 85.90 (s, 1C), 85.20 (s, 1C), 82.71 (d, J = 9.1 Hz, 1C), 72.48 (t, J = 
10.6 Hz, 1C), 71.69 (t, J = 11.3 Hz, 1C), 65.50 (d, J = 8.0 Hz, 1C), 21.70 (q, J = 4.0 Hz, 1C). 
HRMS(ESI): m/z calc. for C13H15N3O5SNa [M+Na]
+
: 348.0630, found: 348.0628. 
 
I17-bisazide 
1
H NMR (CDCl3, 500 MHz): δ 4.80 (t, J = 4.6 Hz, 1H), 4.50 (d, J = 4.3 Hz, 1H), 4.09-4.01 (m, 
3H), 3.96-3.89 (m, 2H), 3.68 (dt, J = 5.6, 10.0 Hz, 1H). 
13
C NMR (CDCl3, 126 MHz): δ 86.9, 82.8, 72.8, 70.1, 66.1, 62.2. 
HRMS(ESI): m/z calc. for C6H9N6O2 [M+H]
+
: 197.0787, found: 197.0793. 
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Procedure: To a solution of monotosylated isosorbide I15 (49.2 mg, 0.164 mmol) in 
dimethylformamide (1.7 mL), added sodium azide (114 mg, 1.75 mmol) and heated reaction 
mixture at 75 °C for 44 hours.  The reaction was diluted with diethyl ether (5 mL), and washed 
five times with water (4 mL) and brine (3 mL).   The organic layer was dried over magnesium 
sulfate, filtered, and concentrated to yield the product as a colorless oil (3.2 mg, 12%). 
1
H NMR (CDCl3, 500 MHz): δ 4.69 (d, J = 3.8 Hz, 1H), 4.57 – 4.53 (m, 1H), 4.35 (d, J = 3.8 
Hz, 1H), 4.06 – 4.00 (m, 1H), 3.93 – 3.89 (m, 1H), 3.88 – 3.80 (m, 2H). 
 
 
Procedure: To a solution of monotosylated isosorbide I16 (49.3 mg, 0.164 mmol) in 
dimethylformamide (1.7 mL), added sodium azide (119 mg, 1.82 mmol) and heated reaction 
mixture at 75 °C for 44 hours.  The reaction was diluted with diethyl ether (5 mL), and washed 
five times with water (4 mL) and brine (3 mL).   The organic layer was dried over magnesium 
sulfate, filtered, and concentrated to yield starting material only. 
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Procedure: Using the published procedure,
26
 isosorbide (1.475 g, 10.1 mmol) and sodium iodide 
(3.017 g, 20.1 mmol) were loaded into a 100 mL round bottom flask with a stirbar, and the flask 
was flushed with argon.  The solids were dissolved in acetonitrile (36 mL).  Acetone was added 
(1.5 mL, 20.4 mmol), followed by trimethylsilylchloride dropwise (2.55 mL, 20 mmol).  The 
reaction was covered with foil, and stirred for 14 hours at room temperature.  The reaction was 
quenched with ether and saturated aqueous sodium carbonate, at which point water was added 
and he extraction was extracted with ether.  The organic layers were washed with saturated 
aqueous sodium thiosulfate and brine, dried over brine, filtered, and concentrated to give a clean 
product (2.880 g, 91%). 
1
H NMR (CDCl3, 500 MHz): δ 4.82 (dd, J = 6.2, 3.7 Hz, 1H), 4.72 (dd, J = 6.2, 3.7 Hz, 1H), 
4.09 (d, J = 10.8 Hz, 1H), 3.92 – 3.86 (m, 1H), 3.54 (dd, J = 6.0, 3.5 Hz, 1H), 3.52 (dd, J = 10.5, 
3.5 Hz, 1H), 3.46 (dd, J = 10.5, 4.5 Hz, 1H), 3.43 (dd, J = 10.5, 5.0 Hz, 1H), 3.00 (d, J = 3.0 Hz, 
1H), 1.48 (s, 3H), 1.32 (s, 3H). 
 
 
Procedure: Using the published procedure,
26
 sodium hydride (162.3 mg, 4.06 mmol) was loaded 
in an oven-dried 25 mL round bottom flask and flushed with argon.  Tetrahydrofuran (4 mL) was 
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added to give a suspension, and the reaction was cooled in an ice/water bath.  In a separate oven-
dried flask, iodide I20 (1.0345 g, 3.29 mmol) was loaded, flushed with argon, and dissolved in 
tetrahydrofuran (4 mL).  The iodide solution was added to the sodium hydride solution dropwise 
via cannula, and the iodide flask was rinsed with tetrahydrofuran (1 mL).  The ice bath was 
removed, and the reaction stirred at room temperature for 6 hours.  The reaction was quenched 
by adding ether (5 mL), cooling to 0 °C, and adding saturated aqueous ammonium chloride.  The 
organic layer was washed with brine, then the combined aqueous layers were extracted with 
dichloromethane.  All of the organic layers were dried with sodium sulfate, filtered, and 
concentrated to give a white solid (488.7 mg, 79.7%). 
1
H NMR (CDCl3, 500 MHz): δ 4.80 (dd, J = 3.7, 6.1 Hz, 1H), 4.70 (dd, J = 3.8, 6.1 Hz, 1H), 
4.11 (d, J = 10.8 Hz, 1H), 3.51 (s, 1H), 3.28 (ddd, J = 2.7, 4.3, 6.9 Hz, 1H), 3.03 (dd, J = 3.8, 6.8 
Hz, 1H), 2.90 (t, J = 4.5 Hz, 1H), 2.66 (dd, J = 2.7, 4.8 Hz, 1H), 1.53 (s, 3H), 1.34 (s, 3H). 
 
 
Procedure: To a solution of isomannide (0.501 g, 3.43 mmol) in pyridine (6 mL) cooled to 0 °C 
in an ice bath, paratoluenesulfonyl chloride (1.65 g, 8.64 mmol) was added in a single portion.  
The reaction mixture was stirred for 13.5 hours, warming gradually to room temperature.  The 
reaction mixture was concentrated and purified directly by flash chromatography on silica 
(EtOAc/hexanes 1:2) to yield the product as a white solid (1.55 g, 99.1%). 
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1
H NMR (CDCl3, 500 MHz): δ 7.80 (d, J = 8.3 Hz, 4H), 7.34 (d, J = 8.2 Hz, 4H), 4.87-4.81 (m, 
2H), 4.48-4.45 (m, 2H), 3.91 (dd, J = 6.7, 9.6 Hz, 2H), 3.72 (dd, J = 7.7, 9.5 Hz, 2H), 2.49 (s, 
6H). 
13
C NMR (CDCl3, 126 MHz): δ 145.3 (2C), 133.0 (2C), 129.9 (4C), 128.0 (4C), 79.9 (2C), 77.8 
(2C), 70.1 (2C), 21.7 (2C). 
HRMS(ESI): m/z calc. for C20H23O8S2 [M+H]
+
: 455.0834, found: 455.0830. 
 
 
Procedure: To a solution of isomannide (0.505 g, 3.46 mmol) in pyridine (6 mL) cooled to 0 °C 
in an ice bath, paratoluenesulfonyl chloride (0.662 g, 3.47 mmol) was added in a single portion.  
The reaction mixture was stirred for 13.5 hours, warming gradually to room temperature.  The 
reaction mixture was concentrated and purified directly by flash chromatography on silica 
(EtOAc/hexanes 1:1) to yield the desired monotosylated product as a white solid (0.401 g, 
38.6%) along with some bistosylated material as a white solid (0.304 g, 19.3%). 
1
H NMR (CDCl3, 500 MHz): δ 7.83 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 4.91 (ddd, J = 
5.2, 6.7, 7.4 Hz, 1H), 4.49 (t, J = 4.9 Hz, 1H), 4.43 (t, J = 5.1 Hz, 1H), 4.29 (dtd, J = 5.6, 6.8, 8.4 
Hz, 1H), 4.03 (dd, J = 6.6, 9.3 Hz, 1H), 3.96 (dd, J = 6.4, 9.4 Hz, 1H), 3.79 (dd, J = 7.6, 9.3 Hz, 
1H), 3.55 (dd, J = 7.2, 9.4 Hz, 1H), 2.48 (s, 1H), 2.46 (s, 3H). 
13
C NMR (CDCl3, 126 MHz): δ 145.2, 133.1, 129.9 (2C), 128.0 (2C), 81.4, 80.0, 78.3, 74.1, 
72.3, 70.1, 21.7. 
HRMS(ESI): m/z calc. for C13H17O6S [M+H]
+
: 301.0746, found: 301.0738. 
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Procedure: To a solution of bistosylated isomannide (75.0 mg, 0.165 mmol) in 
dimethylformamide (1.7 mL), added sodium azide (106 mg, 1.62 mmol) and heated reaction 
mixture at 75 °C for 16 hours.  The reaction was diluted with diethyl ether (5 mL), and washed 
five times with water (4 mL) and brine (3 mL).   The organic layer was dried over magnesium 
sulfate, filtered, and concentrated to yield the product as a colorless oil (17.5 mg, 54.0%). 
1
H NMR (CDCl3, 500 MHz): δ 4.62 (bs, 2H), 4.07 (d, J = 3.8 Hz, 2H), 3.94 (dd, J = 1.5, 10.2 
Hz, 2H), 3.90 (dd, J = 4.1, 10.2 Hz, 2H). 
13
C NMR (CDCl3, 126 MHz): δ 86.0, 71.9, 65.7. 
 
 
Procedure: To a solution of monotosylated isomannide (47.6 mg, 0.158 mmol) in 
dimethylformamide (1.7 mL), added sodium azide (53.2 mg, 0.818 mmol) and heated reaction 
mixture at 75 °C for 16 hours.  The reaction was diluted with diethyl ether (5 mL), and washed 
five times with water (4 mL) and brine (3 mL).   The organic layer was dried over magnesium 
sulfate, filtered, and concentrated to show trace product. 
 
 
120 
 
2.7 References 
1. Huigens, R. W., 3rd; Morrison, K. C.; Hicklin, R. W.; Flood, T. A., Jr.; Richter, M. F.; 
Hergenrother, P. J., A ring-distortion strategy to construct stereochemically complex and 
structurally diverse compounds from natural products. Nat Chem 2013, 5, 195-202. 
2. Curtis, P. J.; Cross, B. E., Gibberellic acid.  A new metabolite from the culture of filtrates of 
gibberella fujikuroi. Chem. Ind. 1954, 1066. 
3. Rodrigues, C.; Vandenberghe, L. P.; de Oliveira, J.; Soccol, C. R., New perspectives of 
gibberellic acid production: a review. Crit Rev Biotechnol 2012, 32, 263-273. 
4. Grove, J. F.; Mulholland, T. P. C., Gibberellic Acid. Part 12. The stereochemistry of 
allogibberic acid. J. Chem. Soc. 1960, 3007-3022. 
5. Cross, B. E., Gibberellic acid. Part I. J Chem Soc 1954, 4670-4676. 
6. Cross, B. E.; Grove, J. F.; Morrison, A., Gibberelic Acid. Part 18. Some Rearrangements of 
Ring A. J Chem Soc 1961, 2498-2515. 
7. Nie, X.; Xie, W.; Lin, G.; Song, M.; Pan, X., Concise Synthesis of 3-Hydroxy-Δ1.10−12,16-
cyclogibberellin 12 Dimethyl Ester—A Trachylobagibberellin Analogue. Synth Commun 
1995, 25, 4053-4062. 
8. Speake, R. N., 2. Gibberellic acid. Part XIX. The degradation of gibberellic acid in sulphuric 
acid. J Chem Soc 1963, 7-15. 
9. Shimano, M.; Nagaoka, H.; Yamada, Y., Synthesis of Gibberellin-A1, Gibberellin-A5, 
Gibberellin-A55 and Gibberellin-A60 - Metal-Ammonia Reduction of Gibberellic-Acid and 
Its Derivative. Chem Pharm Bull 1990, 38, 276-278. 
10. Corey, E. J.; Brennan, T. M.; Carney, R. L., Stereospecific elaboration of the A ring of 
gibberellic acid by partial synthesis. J Am Chem Soc 1971, 93, 7316-7317. 
11. Baynham, M. K.; Hanson, J. R., An unusual gibberellin transannular ketol. J Chem Soc, 
Perkin Trans 1 1984, 2859-2861. 
12. Lischewski, M., Gibberellins. Part 119. Isotope labeling of gibberellin A5. Z Chem 1988, 28, 
215-216. 
13. Lischewski, M., Gibberellins. 87. Partial synthesis of 7-norgibberellin A3 (GA3). Z Chem 
1982, 22, 141-142. 
14. Mulholland, T. P. C., Gibberellic Acid. Part 9. The structure of allogibberic acid. J. Chem. 
Soc. 1958, 2693-2701. 
15. Henderson, J. H.; Graham, H. D., A possible mechanism for biological and chemical activity 
of gibberellic acid. Nature 1962, 193, 1055-1056. 
121 
 
16. Antonioletti, R.; D'Auria, M.; De Mico, A.; Piancatelli, G.; Scettri, A., Oxidative C-C 
Cleavage of Phenyloxiranes by Pyridinium Chlorochromate. Synthesis 1983, 1983, 890-891. 
17. Cross, B. E.; Grove, J. F.; Morrison, A., Gibberellic Acid. 18. Some rearrangements of ring 
A. J. Chem. Soc. 1961, 2498-2515. 
18. Cross, B. E.; Markwell, R. E., Rearrangements of the gibbane skeleton during reactions with 
2,3-di-chloro-5,6-dicyanobenzoquinone. J. Chem. Soc. Perk. T. 1973, 1, 1476-1487. 
19. Yan, A.; Gasteiger, J., Prediction of aqueous solubility of organic compounds based on a 3D 
structure representation. J Chem Inf Comput Sci 2003, 43, 429-434. 
20. Feher, M.; Schmidt, J. M., Property distributions: differences between drugs, natural 
products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2003, 43, 
218-227. 
21. Rogers, D. J.; Tanimoto, T. T., A Computer Program for Classifying Plants. Science 1960, 
132, 1115-1118. 
22. Stauch, M.; Grewe, N., [The effect of isosorbide nitrate, isosorbide-2- and 5-mononitrate on 
the exertion ECG and on the hemodynamics during atrial stimulation in patients with angina 
pectoris]. Z Kardiol 1979, 68, 687-693. 
23. Guillarme, S.; Mai Nguyen, T. X.; Saluzzo, C., New chiral ligands from isosorbide: 
application in asymmetric transfer hydrogenation. Tetrahedron: Asymmetry 2008, 19, 1450-
1454. 
24. Nguyen Van Buu, O.; Aupoix, A.; Vo-Thanh, G., Synthesis of novel chiral imidazolium-
based ionic liquids derived from isosorbide and their applications in asymmetric aza Diels–
Alder reaction. Tetrahedron 2009, 65, 2260-2265. 
25. Shaikh, A. L.; Kale, A. S.; Shaikh, M. A.; Puranik, V. G.; Deshmukh, A. R. A. S., 
Asymmetric synthesis of β-lactams by [2+2] cycloaddition using 1,4:3,6-dianhydro-d-
glucitol (isosorbide) derived chiral pools. Tetrahedron 2007, 63, 3380-3388. 
26. Ejjiyar, S.; Saluzzo, C.; Amouroux, R., O4,O5-Isopropylidene-1,2:3,6-dianhydro-D-glucitol 
from Isosorbide. Org. Synth. 2000, 77, 91-94. 
 
  
122 
 
Chapter 3: Identification of a Novel Anticancer Compound Using a 
Complexity to Diversity Approach 
 
3.1 Introduction 
 In 2011, 575,313 people in the United States died of cancer, making it the second leading 
cause of death that year.
1
  Although tremendous progress has been made in the early detection 
and treatment of cancer, leading to a reduction in mortality rates,
1
 there is still a pressing need to 
identify new anticancer strategies.  Cancer is a complex, widespread disease with numerous 
characteristics, cause, and prognoses;
2
 as a result, successes in the treatment of one subclass of 
cancer do not often translate to others.  For example, while the five-year survival rate from 2001 
through 2007 for local breast cancer was 99%, it was only 37% for local cancers of the 
esophagus and 22% for local pancreatic cancer.
3
  This statistic is even more sobering for 
metastasized cancers, where the five-year survival rates are 3% (esophagus) and 2% (pancreatic); 
even breast cancer, which is highly treatable when found early, has a 23% five-year survival rate 
for patients with metastatic disease.
3
  Furthermore, many cancers are refractory to 
chemotherapies or, upon relapse, develop resistance to those agents.
4
  In order to combat these 
evolving limitations of cancer treatment, we and others aim to develop new anticancer 
compounds that target this collection of diseases in novel or unusual ways.   
 
3.1.1 Targeting Unusual Modes of Cell Death for Cancer Treatment 
 One of the most common phenotypes for anticancer agents is their induction of apoptosis 
in cells.
5
  Apoptosis is a form of programmed cell death wherein cellular proteases (caspases) are 
activated and go on to process a host of substrates.
6
  This results in characteristic physiological 
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changes in the cells, including cell blebbing, cell shrinkage, inversion of the cell membrane, and 
DNA condensation, ultimately resulting in cell death.
6-7
  Induction of cell death via apoptosis is 
thought to be beneficial because it can reduce inflammation in tissues and utilizes well-defined 
cell machinery to execute death.
6
 
 Despite these advantages, not all cancers respond well to agents that induce apoptosis.  
This is due to a variety of factors, including ABC export pumps,
8
 mutations in cellular targets,
4, 9
 
or poor selectivity between normal and cancerous tissues, resulting in dose-limiting toxicity.
10
  
Additionally, many cancers also contain mutations in the apoptotic machinery, leading to a 
decreased sensitivity to these agents.
11-12
  As a result, identification of compounds with novel or 
unusual mechanisms of cell death is useful in order to overcome the limitations of current 
apoptosis-inducing compounds.
5
 
 One alternative non-apoptotic cell death pathway is necrosis.
13-14
  Originally, necrotic cell 
death was viewed as a pro-inflammatory, unregulated process characteristic to tissues.
6
  Within 
the last two decades, however, detailed biochemical studies have highlighted the extensive 
regulation associated with necrotic cell death and have identified a number of proteins involved 
in this pathway.
5, 15
  These discoveries, along with the identification of numerous other pathways 
of small-molecule-induced death,
16
 have suggested that compounds with novel phenotypes for 
inducing cell death may lead to the development of new anticancer agents.
5
 
 
3.1.2 Complex Small Molecules as Anticancer Agents 
 As summarized in Chapter 1, we hypothesize that natural product-like libraries will bind 
to more complex macromolecules in cells and should enhance the likelihood of identifying novel 
anticancer agents relative to traditional screening libraries.   We have implemented a novel 
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approach, termed Complexity to Diversity (CtD, see Chapter 2), that allows access to 
stereochemically-rich and structurally complex compounds through the top-down manipulation 
of abundant, readily available natural products.
17
  As summarized in this chapter, the screening 
of compounds generated through CtD has led to the identification of a novel anticancer 
compound, GEM-1, synthesized from gibberellic acid.  Following extensive biological 
characterization, we have determined that GEM-1 induces apoptotic cell death at some but not 
all treatment concentrations, induces cell death via electrophilic modification, and may serve as a 
viable anticancer lead based on preliminary murine models. 
 
3.2 Identification of GEM-1 and Initial Characterization 
3.2.1 Cell-based Screening to Identify GEM-1  
 The complex compounds synthesized through the CtD paradigm
17
 were evaluated for 
their ability to induce death of human lymphoma U-937 cells in culture (Figure 3.1). Through 
this screen, gibberellic enone methylester (GEM-1) was identified as a potent inducer of cell 
death.  This compound is related to gibberellic acid,
18
 a natural plant hormone that is used 
industrially to promote seedling growth.
19
  Although GEM-1 has been synthesized previously 
and is known to not induce plant growth,
20-21
 to the best of our knowledge it has never been 
previously tested for its ability to induce cell death in cancer cells. 
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Figure 3.1.  Identification of a structurally complex, potent antitumor small molecule (GEM-1, 
insert).  Assessment of the ~170 complex small molecules
17
 (at a concentration of 2 μM) versus 
U-937 (human lymphoma) cells.  Compounds were incubated with cells for 48 hours and death 
was assessed via the MTS assay. 
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3.2.2 Determination of Potency of GEM-1 in a Panel of Cell Culture Lines 
 After its initial identification, GEM-1 was evaluated in a panel of cell lines to determine 
its potency and, if applicable, specificity.  As shown in Table 3.1, GEM-1 demonstrates 
reasonable potency against all cell lines tested.  Generally, the best activity is seen against blood 
lines (U-937 and EL-4) or compounds that rapidly divide (B16-F10), but even in the least 
sensitive cell lines, such as A549, GEM-1 retains single-digit micromolar potency. 
 
Table 3.1. GEM-1 induces death in a panel of cancer cell lines.  Dose-response curves were 
generated and used to obtain IC50 values for GEM-1 against several cancer cell lines, in 72 hr 
experiments with death assessed by either MTS (U-937 and EL4) or SRB (HeLa, NCI-H1299, 
MCF7, B16-F10, and A549). 
Cell Line 72-hour IC50 (μM) 
U-937 (lymphoma) 1.2 ± 0.2 
HeLa (cervical) 4.2 ± 0.4 
NCI-H1299 (NSC lung) 2.4 ± 0.8 
MCF7 (breast) 3.7 ± 0.5 
B16-F10 (murine melanoma) 1.0 ± 0.4 
EL4 (murine lymphoma) 0.9 ± 0.1 
A549 (lung) 5.9 ± 0.4 
 
3.2.3 Determination of GEM-1 Selectivity 
 In order to demonstrate selectivity for cancerous over normal cells, GEM-1 was tested 
for its ability to induce hemolysis in red blood cells.  Following treatment with high 
concentrations of GEM-1 (33 and 333 μM), no hemolysis was observed (Figure 3.2).  This 
suggests that GEM-1 does not simply induce lysis and cell death. 
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Figure 3.2. GEM-1 does not induce hemolysis of red blood cells, even at high concentrations.  
Error bars represent standard deviation, n=3. 
 
3.2.4 GEM-1 Mode of Cell Death 
 As mentioned in section 3.1.1, it is useful to identify anticancer agents that induce 
different forms of cell death.  GEM-1 was evaluated for its ability to induce apoptosis in U-937 
cells at a range of concentrations and was found to induce both classic apoptotic and non-
apoptotic cell death across a narrow concentration window. 
 
3.2.4.1 Annexin V Exposure 
 The mode of cell death induced by treatment with GEM-1 was initially analyzed by flow 
cytometry based on the relative timing of phosphatidylserine exposure and membrane 
permeabilization (via Annexin V and propidium iodidate staining).  At high concentrations of 
GEM-1, cells undergo non-apoptotic death within 6 hours (Figure 3.3).  This is in contrast with 
staurosporine, a known cytotoxin which induces apoptosis.  Although this phenotype was 
initially identified with 25 μM treatment, similar results were seen at concentrations as low as 7.5 
μM GEM-1 (Figure 3.4) 
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Figure 3.3. GEM-1, in contrast with staurospoine (STS, a known apoptotic inducer), does not 
induce the classic Annexin V positive, propidium iodide (PI) negative apoptotic hallmark at high 
concentrations.  U-937 cells were treated with STS (5 μM) or GEM-1 (25 μM) for 6 hours, and 
after Annexin V/PI staining were analyzed by flow cytometry.  Shown are representative data of 
three independent experiments. 
 
 
Figure 3.4. GEM-1 does not induce classic Annexin V positive, propidium iodide (PI) negative 
apoptotic hallmarks at concentrations as low as 7.5 μM.  Cell death is partially prevented with 
the pancaspase inhibitor Q-VD-OPh (QVD, 5 μM).  U-937 cells were treated with compound for 
24 hours and after Annexin V/PI staining were analyzed by flow cytometry.  Shown are 
representative data from three independent experiments. 
 
 However, at lower concentrations of GEM-1 (5 μM and below), the mode of cell death 
switches from non-apoptotic to classical apoptotic death (Figure 3.5).  In this case, exposure of 
phosphatidylserine prior to membrane permeabilization is clearly visible following a 24-hour 
treatment.  Additionally, cotreatment with the pancaspase inhibitor Q-VD-OPh protects from 
GEM-1 induced cell death, further confirming the activation of the apoptotic pathway under 
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these conditions.  This is in contrast to the minimal protection of QVD against GEM-1 at 
concentrations that do not induce apoptosis (Figure 3.4) 
 
 
Figure 3.5. GEM-1 induces apoptosis at lower concentrations (2.5 and 5 μM) in U-937 cells at 
24 hours, as assessed by Annexin V/PI staining.  This cell death is prevented by cotreatment with 
the pancaspase inhibitor Q-VD-OPh (5 μM, QVD). 
 
3.2.4.2 Western Blot Analysis of Activated Proteins 
 Analysis of the cleavage patterns of proteins within the cell further confirms this 
bifurcated mechanism.  High concentrations of GEM-1 do not induce procaspase-3 activation or 
PARP-1 processing, even at time points and concentrations that kill the cells (Figure 3.6).  In 
contrast, staurosporine does induce activation of procaspase-3 and cleavage of PARP-1 during 
the same period. 
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Figure 3.6. GEM-1, in contrast with STS, does not induce activation of procaspase-3, or 
cleavage of PARP-1.  U-937 cells were treated with STS (5 μM) or GEM-1 (25 μM) for 2, 4, or 
6 hours, and cleavage of procaspase-3 and PARP-1 was assessed by Western blotting.  Even at 6 
hr and 25 μM (a time and concentration sufficient to induce considerable cell death, as per Figure 
3.3), procaspase-3 and PARP-1 are not cleaved in GEM-1-treated cells.  Data shown are 
representative data of three independent experiments. 
 
 When GEM-1 was tested at lower concentrations, however, clear activation of caspase-3 
and cleavage of PARP-1 was observed (Figure 3.7).  This result is consistent with the AnnV/PI 
data shown in Figure 3.4.  Additionally, cotreatment with Q-VD-OPh also leads to the reduction 
in protein processing within cells, as would be expected. 
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Figure 3.7. At lower concentrations, GEM-1 induces cleavage of capsases and PARP-1, and this 
cleavage can be prevented by cotreatment with Q-VD-OPh (5 μM) in U-937 cells at 24 hours.  
Staurosporine (STS) was used as a positive control for apoptosis, and hemin was included as a 
control for HO-1 induction studies (see section 3.5.1.1). 
 
 
3.2.5 Summary of Discovery 
 GEM-1 was identified as a novel anticancer agent with general potency in a range of 
cancer cell lines.  Interestingly, GEM-1 induces both apoptotic and non-apoptotic cell death 
across a narrow window of concentrations, as confirmed by phosphatidylserine exposure and 
protein cleavage.  Although there are several examples of both organic and metalloid compounds 
that induce non-apoptotic or necrotic death, most of these molecules have been poorly 
characterized.  This includes the incorrect use of DNA dyes as an indicator of necrosis,
22
 rather 
than as measures of membrane permeabilization, and the evaluation of compounds at a single 
high concentration.
23-25
  A recent study by Ramos and coworkers, however, did determine that 
englerin A induced necrosis or apoptosis depending on the cell line tested,
25
 suggesting that 
numerous factors play a role in the mechanism of small molecule-induced cell death.  In the case 
of GEM-1, the difference in the induction of apoptotic or non-apoptotic death may result instead 
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from the extent of cellular damage prior to further death signaling.  Importantly, GEM-1 does 
not induce lysis in red blood cells, suggesting that the non-apoptotic mechanism does not result 
from direct lysis of the cancer cells. 
 
3.3 Structure-Activity Relationship 
3.3.1 Reactivity of Enone to Thiols 
 Based on the structure of GEM-1, we hypothesized that the A-ring enone may be 
important for its activity in cells.  This is consistent with a previously reported anticancer 
compound that contains the gibberane core (GA-13315), although the activity of these 
compounds is hypothesized to be derived from the exocyclic enone on the cylopentane D-ring, 
rather than the A-ring enone (Figure 3.8).
26-27
 
 
 
Figure 3.8. Structure of GA-13315, a known cytotoxin derived from gibberellic acid, compared 
to GEM-1.  The activity of GA-13315 is hypothesized to originate from the exocyclic enone 
(blue), rather than the endocyclic enone (red).   
 
 In order to probe whether the A-ring enone was sufficiently electrophilic to react with 
cellular nucleophiles, GEM-1 was treated in vitro with glutathione.  Exposure of GEM-1 to 
gluthathione results in covalent conjugation between the two species, as determined by mass 
spectrometry (Figure 3.9). 
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Figure 3.9. Glutathione addition to GEM-1 following a 60-minute incubation, as determined by 
LCMS.  The glutathione conjugate elutes at 2.92 minutes based on the M+H peak. 
 
3.3.2 Synthesis of GEM-1 Derivatives 
 In order to determine whether this functional group was required for compound 
cytotoxicity, 18 derivatives of GEM-1 were synthesized in 1-3 steps from gibberellic acid (G).  
As shown in Scheme 3.1, GEM-1 is prepared in two steps from gibberellic acid through the 
intermediate allylic alcohol (GEM-2). 
 
 
Scheme 3.1. Synthesis of GEM-1 from gibberellic acid.  The naming nomenclature for the four 
rings in gibberellic acid is shown in blue. 
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 The first set of derivatives prepared tested the tolerance of substitutions on the ester 
functionality GEM-1.  The free acid, GEM-3, was prepared via direct oxidation of gibberellic 
acid using pyridine to solubilize G.  PyBOP was then used as a coupling agent to create amide 
and esters (GEM-4, GEM-5, and GEM-6, Scheme 3.2).  Alternatively, GEM-3 could be 
directly alkylated with either benzyl bromide or propargyl bromide to yield GEM-7 and GEM-8 
in good yield (Scheme 3.2).  In order to evaluate the importance of the A-ring enone, gibberellic 
acid was also benzylated and propargylated to afford GEM-9 and GEM-10.   
 
 
Scheme 3.2. Synthetic route to GEM-1 derivatives with various esters and amides. 
 
 In order to probe the importance of the C/D ring system on GEM-1’s activity, four 
derivatives were prepared using several different electrophiles to promote a Wagner-Meerwein 
rearrangement.  These derivatives were synthesized directly from GEM-1, and afforded bromide 
GEM-11, iodide GEM-12, primary alcohol GEM-13, and α-methyl ketone GEM-14 in 
uniformly good yields (Scheme 3.3). 
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Scheme 3.3. Synthetic routes to GEM-1 derivatives with C/D ring rearrangements. 
 
 The tertiary alcohol of GEM-1 could also be directly functionalized to append an acetate 
(GEM-15) or a sulfonyl (GEM-16) in good yield (Scheme 3.4). 
 
Scheme 3.4. Functionalization of the tertiary alcohol of GEM-1. 
 
 In order to directly probe the importance of the enone, GEM-1 was selectively reduced to 
the ketone (GEM-17, Scheme 3.5).  Originally, Stryker’s reagent was used as the reducing 
reagent; however, the reaction stalled after partial conversion and removal of triphenylphosphine 
during purification was challenging.  As a result, L-selectride was used instead to promote the 
reduction.  This gave GEM-17 in a reasonable yield, but also gave the complete reduction 
product (GEM-18) and the 1,2-reduction product (GEM-19) as an inseparable 1:2 mixture in 
55% yield.  The stereochemistry of the 1,2 reduction was determined by 1D-NOE on the mixture 
(Figure 3.10). 
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Scheme 3.5. Synthesis of isolated A-ring ketone from GEM-1. 
 
 
Figure 3.10. 1D-NOE to determine the stereochemistry of GEM-18 and GEM-19.  Irradiation at 
the A-ring protons for clearly shows reduction from the top face of the molecule for both 
molecules. 
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 More complex derivatives of GEM-1 were also synthesized to further probe the 
importance of the A-ring enone.  Gibberellenic acid and hydrolyzed allogibberellic acid were 
methylated with TMS-diazomethane and oxidized with DMP to give GEM-20 and GEM-21.  
Although both of these compounds contain an enone, they both lack the appended lactone.  
Additionally, GEM-20 contains an extended enone, and GEM-21’s enone is more hindered than 
that of GEM-1. 
 
 
Scheme 3.6. Synthesis of GEM-1 derivatives with alternate cores. 
 
3.3.3 Evaluation of GEM-1 SAR 
 Following their synthesis, 16 GEM-1 derivatives were evaluated for their activity against 
U-937 and HeLa cells.  These data show that certain substitutions of GEM-1 are remarkably 
well-tolerated (Figure 3.11). 
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Figure 3.11. Cell culture activity of GEM-1 derivatives against U-937 and HeLa cells following 
a 72-hour continuous treatment.  IC50 values in μM are shown with the standard deviation shown 
in parenthesis, n ≥3. 
 
 Within the ester and amide series, only the free acid (GEM-3) is completely inactive; this 
may be due to poor permeability into cells.  Benzylic or propargyl substitutions are both well 
tolerated, although the benzyl amide (GEM-5) does show a reduction in potency.  Acetylation or 
mesylation of the tertiary alcohol does not affect the potency of the compound (GEM-15 and 
GEM-16), nor do Wagner-Meerwein rearrangements of the C and D rings (GEM-11 and GEM-
14). 
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 In contrast, modifications of the A-ring dramatically affects the activity of these 
compounds.  Reduction of the enone to the allylic alcohol (GEM-2, GEM-9, and GEM-10) 
completely abolishes activity, as does reduction to the isolated ketone (GEM-17).  However, the 
presence of an enone does not guarantee activity.  Removal of the lactone to form the extended 
dienone (GEM-20) or the trisubstituted enone (GEM-21) both lead to elimination of activity.  
Interestingly, the activity of gibberellic acid as a growth promoter is dependent on both the 
position of the lactone and the presence of a hydroxyl group on the A-ring.
28
  Together, these 
data suggest that while the enone is important for the anticancer activity of GEM-1, the steric 
and electronic environment around the enone also plays a role. 
 
3.3.4 Mode of Action of Active Derivatives 
 All active compounds were further assessed for their ability to induce the similar non-
apoptotic death observed for higher concentrations of GEM-1.  As shown for representative 
compounds (Figure 3.12), the active compounds induce non-apoptotic death based on the timing 
of exposure of phosphatidylserine and membrane permeabilization. 
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Figure 3.12. Induction of non-apoptotic death following treatment with 25 μM compound after 2 
hours in U-937 cells.  Following treatment, cells were stained with Annexin V-FITC and 
propidium iodide (PI).  Typically, cells undergoing apoptosis show staining with Annexin V 
prior to incorporation of PI. 
 
3.3.5 Summary of SAR 
 The synthesis of numerous GEM-1 derivatives has enabled the identification of key 
features necessary for activity (Figure 3.13), and the most active compounds also induce non-
apoptotic cell death at high concentrations in U-937 cells.  As hypothesized, the enone is 
necessary for activity; however, the presence of the lactone and other steric and electronic 
considerations are also important.  Beyond the A-ring, however, a variety of substitutions are 
well-tolerated, suggesting sites for the synthesis of labeled derivatives. 
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Figure 3.13. Summary figure of SAR for GEM-1. 
 
3.4 Cell Morphology and Mitochondrial Response with GEM-1 
 In order to further investigate the cell death induced by GEM-1, the morphology of cells 
following treatment was evaluated.  This provides information regarding which specific 
organelles are affected, and can suggest specific mechanisms for how cells progress to death.  
For example, by visualizing the extent of chromatin condensation or tubulin polymerization, it is 
possible to clarify molecular modes of action (apoptosis and mitochondrial poison, respectively). 
 
3.4.1 Transmission Electron Microscopy with GEM-1 
 Transmission electron microscopy (TEM) is a powerful tool for observing subcellular 
organelles and membranes in cells.  Typically, samples are treated, fixed with a mixture of 
formaldehyde and glutaraldehyde, and stained with osmium tetroxide.  Extremely thin slices are 
then cut and visualized under vacuum with an electron beam.  This process allows for incredibly 
detailed resolution within the cells. 
 TEM images of untreated U-937 cells (Figure 3.14) clearly display a large nucleus and 
irregular cell membrane.  Both of these are characteristic of leukemia cells.
29-30
  Normal U-937 
cells also show numerous small mitochondria distributed throughout the cell.  Treatment with 
staurosporine induces apoptosis, as evidenced by extensive chromatin condensation in the 
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nucleus and rounding of the cell membrane.  Hydrogen peroxide treatment results in 
permeabilization of all cell membranes, leading to a “frothy” appearance.  Treatment with GEM-
1, however, induces rounding and substantial cell swelling without any chromatin condensation.  
Additionally, the mitochondria begin to fuse into large superstructures that are predominantly 
located on one side of the cell (Figure 3.14 and 3.15). 
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Figure 3.14. GEM-1 induces mitochondrial reorganization in U-937 cells prior to cell death.  
Representative whole cell TEM images of U-937 cells treated with DMSO, STS (1.5 μM, 6 
hours), hydrogen peroxide (0.1%, 4 hours), and GEM-1 (10 μM, 6 hours).  The nuclear 
membrane is indicated by the black open arrow, and mitochondria are shown with the red closed 
arrow.  Whereas STS-treated show chromatin condensation typical of apoptosis (*), and 
hydrogen peroxide-treated cells show permeabilization typical of necrosis (†), GEM-1 treated 
cells show cell rounding and expansion, and mitochondrial migration and fusion (blue arrow).  
Images were taken so as to show entire cells.  The images have been scaled such that all scale 
bars are 2 μm and are the same size. 
 
2 µm
DMSO STS (1.5 μM, 6 hours)
H2O2 (0.1%, 4 hours) GEM-1 (10 μM, 6 hours)
2 µm
2 µm
2 µm
†
†
†
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*
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Figure 3.15. Magnified images from Figure 3.14 highlighting the mitochondria.  U-937 cells 
treated with DMSO, STS (1.5 μM, 6 hours), and hydrogen peroxide (0.1%, 4 hours) all contain 
normal, small, isolated mitochondria.  In contrast, GEM-1 (10 μM) treatment results in 
mitochondrial migration and fusion.  The nuclear membrane is indicated by the black open 
arrow, and mitochondria are shown with the red closed arrow.  All scale bars are 1 μm. 
 
 
DMSO STS (1.5 μM, 6 hours)
H2O2 (0.1%, 4 hours) GEM-1 (10 μM, 6 hours)
1 µm 1 µm
1 µm 1 µm
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 In order to visualize this change in mitochondrial morphology, higher magnification 
images were taken.  These cell images show that the mitochondria fusion is dose- and time-
dependent (Figure 3.16A and B, respectively), and ultimately results in the specific 
permeabilization of the mitochondria prior to disruption of the nuclear or cellular membrane. 
 
Figure 3.16. GEM-1 induces mitochondria reorganization in U-937 cells prior to outer 
membrane permeabilization.  Representative TEM images of the mitochondria of U-937 cells 
treated with GEM-1 show a (A) dose- and (B) time-dependent fusion and permeabilization of 
mitochondria prior to nuclear permeabilization.  At lower concentrations, the mitochondria fuse 
into large superstructures.  However, at high concentrations, the mitochondria begin to lose their 
integrity and ultimately permeabilize.  Representative mitochondria in each cell are indicated by 
the red arrow.  All scale bars are 1 μm. 
 
GEM-1 (5 μM, 6 hours) GEM-1 (10 μM, 6 hours)
GEM-1 (25 μM, 1 hour) GEM-1 (25 μM, 2 hours) GEM-1 (25 μM, 4 hours)
GEM-1 (1 μM, 6 hours)
1 µm
A)
B)
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3.4.2 Mitochondrial Morphology with Mitotracker and GEM-1 
 This unusual effect on the mitochondria was confirmed using confocal microscopy and 
dual staining with Mitotracker Red and Hoechst.  Cells treated with GEM-1 show a time-
dependent migration of the mitochondria to one side of the cell as well as overall depletion of 
mitochondrial levels (Figure 3.17). 
 
 
Figure 3.17. Confocal microscopy using Mitotracker Red and Hoechst stains confirms the 
mitochondrial relocalization in U-937 cells following treatment with GEM-1.  Cells were treated 
with GEM-1 (10 μM) for 1-4 hours, costained, fixed, and attached to poly-L-lysine coated 
coverslips.  Cells at longer treatments with GEM-1 that show localization of the mitochondria to 
one portion of the cells are highlighted in green boxes.  All scale bars are 20 μm. 
 
 
 
20 μm
DMSO GEM-1 (10 μM) 2 hrs
GEM-1 (10 μM) 3 hrs GEM-1 (10 μM) 4 hrs
GEM-1 (10 μM) 1 hr
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3.4.3 Depolarization of Isolated Mitochondria 
 In order to determine whether the unusual mitochondria morphology observed by TEM 
and confocal is the result of a direct interaction with GEM-1, mitochondria were isolated from 
U-937 cells.  Cells were treated with GEM-1, and the integrity of the mitochondrial membrane 
potential was measured by flow cytometry (Figure 3.18).  Antimycin A, a DNA-damaging agent 
known to depolarize mitochondrial membranes, served as a positive control in this assay (Figure 
3.18a).
31
  Treatment with GEM-1 (25 μM) rapidly induces the loss of membrane potential within 
15 minutes and is complete by 45 minutes (Figure 3.18b).  Although this is much faster than the 
change in mitochondrial organization seen in cells, this experiment does suggest that the isolated 
effects on the mitochondria in the cellular milieu may be the result of a direct GEM-1 
interaction. 
 
 
Figure 3.18. Isolated mitochondria rapidly depolarize following treatment with GEM-1.  U-937 
cells were treated with either antimycin A (AntA, 2 μM), a DNA-damaging agent that leads to 
mitochondrial depolarization, or GEM-1 (25 μM).  The cells were then stained with 
tetramethylrhodamine, ethyl ester (TMRE, 20 nM) and analyzed by flow cytometry.  (A) Isolated 
mitochondria following a 30-minute treatment.  (B) Depolarization of isolated mitochondria 
treated with GEM-1 (25 μM) after 0, 15, 30, 45, or 60 minutes. 
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3.4.4 Summary of Morphology and Mitochondrial Function 
 Mitochondria play a key role in cellular metabolism, redox homeostasis, and cell death.
32-
36
  Mitochondrial morphology is dynamically controlled by a variety of proteins that control the 
rate of fusion and fission between organelles.
32-33, 35-38
  Classically, alterations in the 
fusion/fission rate have been associated with mitochondrial dysfunction and disease phenotypes 
such as myopathy and diabetes.
37
  More recently, mitochondrial shape and structure have been 
tied to mechanisms of cancer development, resistance, and death.
32, 34, 36, 39
  Relative to normal 
tissues, cancers show changes in mitochondrial membrane potential and reactive oxygen species 
levels, and dysregulations in mitochondrial apoptotic signaling.
34
  As a result, it has been 
suggested that altering the mitochondrial morphology may serve as a selective anticancer 
strategy.
32, 34, 39
  Indeed, numerous mitochondriotoxic compounds are currently in preclinical or 
clinical trials.
34
 
 To the best of our knowledge, the extensive mitochondrial fusion prior to cristae collapse, 
cell permeabilization, and death observed following GEM-1 treatment is unprecedented in the 
literature.  Indeed, many anticancer drugs result in mitochondrial fission and cristae collapse 
prior to cell death.
32-33, 35
  As a result, GEM-1 may serve as a useful tool to further study 
mitochondrial morphology and as an anticancer agent. 
 
3.5 Transcript Profiling and Electrophilic Response with GEM-1 
3.5.1 Transcript Profiling and Up-Regulation of HO-1 
 Genome-level analyses of the transcriptional response of cells following compound 
treatment can suggest the mechanism of cellular action.
40
  U-937 cells were treated with GEM-1 
for 6 hours at 10 μM after which the total RNA was isolated.  At this concentration, cells are still 
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viable at 6 hours, but still demonstrate a non-apoptotic phenotype at 24 hours.  Interestingly, a 
number of additional oxidative and electrophilic stress factors were up-regulated following 
treatment with GEM-1 (Table 3.2).  In contrast, the down-regulated transcripts are mostly RNA 
fragments and transcription factors (Table 3.3). 
 
Table 3.2. Transcript profiling with GEM-1 suggests an electrophilic activation of cells 
following treatment.  Top 20 up-regulated genes in U-937 cells following treatment with GEM-1 
(10 μM, 6 hours).  Transcripts associated with oxidative or electrophilic stress are highlighted in 
red. 
 
Symbol Description Fold-change P-value 
HMOX1 heme oxygenase (decycling) 1 30.0 1.12*10
-6
 
RN7SK RNA, 7SK small nuclear 20.8 1.17*10
-6
 
HSPA1A heat shock 70kDa protein 1A 12.8 3.44*10
-5
 
DUSP1 dual specificity phosphatase 1 9.7 2.08*10
-5
 
BAG3 BCL2-associated athanogene 3 8.7 3.91*10
-7
 
HSPA1B heat shock 70kDa protein 1B 8.4 1.50*10
-5
 
RGS2 regulator of G-protein signaling 2, 24kDa 8.1 1.50*10
-5
 
ADM adrenomedullin 7.9 2.08*10
-5
 
OSGIN1 oxidative stress induced growth inhibitor 1 7.7 1.94*10
-3 
HSPA7 heat shock 70kDa protein 7 (HSP70B) 7.0 1.54*10
-2 
ZFAND2A zinc finger, AN1-type domain 2A 6.7 1.25*10
-5
 
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 6.4 3.22*10
-5
 
RNA5S9 RNA, 5S ribosomal 9 5.5 1.32*10
-2 
RN7SK RNA, 7SK small nuclear 5.2 9.38*10
-3 
ATF3 activating transcription factor 3 5.2 3.28*10
-3 
CLK1 CDC-like kinase 1 4.9 2.22*10
-3 
ACTA1 actin, alpha 1, skeletal muscle 4.8 6.86*10
-7
 
FOS FBJ murine osteosarcoma viral oncogene homolog 4.7 3.01*10
-2 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 4.5 2.08*10
-3 
HPS5 Hermansky-Pudlak syndrome 5 4.2 6.61*10
-5
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Table 3.3. Transcript profiling with GEM-1 suggests an electrophilic activation of cells 
following treatment.  Top 20 down-regulated genes in U-937 cells following treatment with 
GEM-1 (10 μM, 6 hours). 
 
Symbol Description Fold-change P-value 
MTRNR2L1 MT-RNR2-like 1 -5.2 4.42*10
-4 
MIR17HG miR-17-92 cluster host gene (non-protein coding) -5.2 3.22*10
-5
 
PDE4B phosphodiesterase 4B, cAMP-specific -3.3 1.76*10
-4 
SNORD36C small nucleolar RNA, C/D box 36C -3.2 1.36*10
-2 
SNORA24 small nucleolar RNA, H/ACA box 24 -3.0 5.39*10
-3 
MIR155HG MIR155 host gene (non-protein coding) -2.8 9.39*10
-3 
GOLGA8IP golgin A8 family, member I, pseudogene -2.6 3.59*10
-2 
LCMT2 leucine carboxyl methyltransferase 2 -2.6 2.07*10
-2 
CREBZF CREB/ATF bZIP transcription factor -2.6 1.36*10
-2 
NME3 NME/NM23 nucleoside diphosphate kinase 3 -2.5 4.05*10
-3
 
SNORD87 small nucleolar RNA, C/D box 87 -2.4 2.80*10
-2
 
PPP1R3D protein phosphatase 1, regulatory subunit 3D -2.4 4.97*10
-2
 
EPOR erythropoietin receptor -2.4 4.03*10
-2
 
LINC00116 long intergenic non-protein coding RNA 116 -2.4 2.94*10
-4
 
HOXA13 homeobox A13 -2.3 4.70*10
-3
 
MED7 mediator complex subunit 7 -2.2 4.24*10
-2
 
MARS2 methionyl-tRNA synthetase 2, mitochondrial -2.2 8.63*10
-3
 
CCDC71 coiled-coil domain containing 71 -2.2 3.77*10
-2
 
SNORA18 small nucleolar RNA, H/ACA box 18 -2.1 6.64*10
-3
 
RUNDC1 RUN domain containing 1 -2.1 2.38*10
-3
 
 
 
3.5.1.1 Upregulation of HO-1 
 Analysis of the transcriptional response of U-937 cells treated with GEM-1 shows the 
substantial up-regulation of the gene HMOX-1.  The translated protein, HO-1, is a transcriptional 
factor that is responsive to increased levels of oxidative or electrophilic stress.  The increased 
production of HO-1 following treatment with GEM-1 was confirmed by Western blot (Figure 
3.19).  This induction is dose-dependent; however, at higher concentrations, the cells begin to 
die; this results in the degradation of HO-1. 
151 
 
 
Figure 3.19. GEM-1 induces HO-1 expression in a dose-dependent manner (6 hours, U-937 
cells).  At higher concentrations, the cells begin to die, resulting in the reduction of HO-1 levels.  
Hemin was used as a positive control for HO-1 induction. 
 
3.5.1.2 Comparison of Transcriptional Response to Keap1-Nrf2 Pathway 
 As GEM-1 is known to act as an electrophile in vitro (see section 3.3.1), and its SAR 
confirms the importance of the enone for its biological activity, we hypothesized that GEM-1 
may activate the Keap1-Nrf2 pathway.  This pathway is a classical sensor of electrophilic and 
oxidative stress, and the upregulation of HO-1 is often correlated with this pathway.
41-43
  A 
number of genes are transcriptionally linked to the Keap1-Nrf2 pathway and generally transcribe 
antioxidants (peroxiredoxin, PRDX1; thioredoxin, TXN), glutathione synthases (glutamate-
cysteine ligase, GCLC and GCLM; glutathione reductase, GSR), metabolic enzymes (NAD(P)H 
dehydrogenase, NQO1; aldehyde oxidase 1, AOX1; transketolase, TKT; glucose-6-phosphate 
dehydrogenase, G6PD), and heme metabolites (heme oxygenase 1, HMOX1; biliberdin 
reductase B, BLVRB; ferrochelatase, FECH).
43
  However, the only shared gene between the 
transcript profile of GEM-1 treated cells and this pathway is HMOX-1.  As HMOX-1 is induced 
by numerous transcription factors and kinases, including NFκB and protein kinases A,44 this 
suggests that GEM-1 may not activate the Keap1-Nrf2 pathway. 
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3.5.2 ROS Induction with GEM-1 
 As oxidative stress is one of the most common causes for up-regulation of HO-1 and 
related proteins,
43-44
 GEM-1 was evaluated for its ability to induce reactive oxygen species 
(ROS).   
 
3.5.2.1 Antioxidants 
 A number of known antioxidants, including sodium pyruvate, TEMPOL, Tiron, Mn(II) 
tetra(4-benoic acid) porphyrin chloride (MnTBAP), and N-acetyl cysteine, were evaluated for 
their ability to protect against GEM-1 cell death.  Q-VD-OPh, a pan-caspase inhibitor that does 
not protect against high concentrations of GEM-1 induced cell death (see section 3.2.4.1), was 
used as a positive control.  The only antioxidant which protected cells from cell death at 24 hours 
by AnnV/PI staining was N-acetyl cysteine (5 mM NAC, Figure 3.20).  This protection was 
further verified based on the shift on the GEM-1 IC50 with or without NAC (Figure 3.21). 
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Figure 3.20. NAC, unlike other antioxidants or Q-VD-OPh, completely protects from GEM-1 
death at 24 hours.  U-937 cells were tested at the concentrations indicated and analyzed by 
Annexin V-FITC and propidium iodide staining on a flow cytometer. 
 
 
 
 
Figure 3.21. Protection against GEM-1 induced death at 24 hours with NAC (5 mM) in U-937 
cells as assessed by MTS.  The purple diamonds are GEM-1 alone, and the orange circles are the 
co-administration of GEM-1 and NAC. 
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 As shown in section 3.3.1, however, thiols are known to react with the enone in GEM-1.  
In order to test whether this protection was due to the antioxidant properties of NAC or its 
nucleophilicity, GEM-1 and NAC were premixed in a 1:1 or 1:4 mixture for 2 hours prior to 
treatment (Figure 3.22).  Cells were then treated for 24 hours at 25 μM, resulting in a complete 
loss in activity.  Treatment of cells with this low concentration of NAC is not sufficient to protect 
against ROS.  As a result, this loss in activity is consistent with the SAR of GEM-1 and with 
NAC acting as a nucleophile rather than as an antioxidant. 
 
 
Figure 3.22. Pretreatment of GEM-1 and NAC in a 1:1 mixture (25 μM each) results in 
complete protection from cell death.  GEM-1 was mixed with either water or NAC for 2 hours at 
37 °C prior to treatment in U-937 cells and analyzed after 24 hours by Annexin V-FITC and 
propidium iodide. 
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3.5.2.2 Whole cell ROS levels 
 To further explore the role of ROS in the activity of GEM-1, whole cells were evaluated 
using a ROS-sensitive dye dihydroethidium (DHE).  When exposed to reactive oxygen species, 
such as hydroxide radical, dihydroethidium is oxidized to the fluorescent ethidium, which can be 
visualized by flow cytometry.  In contrast to treatment with the known ROS generator DNQ,
45
 
treatment with GEM-1 shows a slight decrease in the overall levels of cellular ROS (Figure 
3.23).  This may result from the activation of other antioxidant signals within the cells, leading to 
an overall decrease in cellular ROS. 
 
 
Figure 3.23. In comparison to DNQ, GEM-1 does not induce ROS in U-937 cells as analyzed 
by dihydroethidium (DHE).  Cells were pretreated with DHE (0.29 μM) and then added to 
compounds in flow cytometry tubes.  Samples were read immediately after adding cells and at 
20, 40, and 60 minutes for ethidium fluorescence on a flow cytometer.  The absolute 
fluorescence was normalized based on the initial reading and the DMSO control for each 
timepoint.  Error bars represent standard deviation, n=3.  * p<0.05. 
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3.5.2.3 Mitochondrial ROS levels 
 Similarly, treatment of isolated mitochondria with GEM-1 also inducesa slight decrease 
in their overall ROS levels (Figure 3.24), even at the same concentrations that induce 
mitochondria depolarization (see Figure 3.18).  This suggests that ROS is not a causative agent 
in GEM-1 activity in cells. 
 
 
Figure 3.24. Representative data for deduction in ROS levels in isolated mitochondria after 30 
minutes using dihydroethidium (DHE).  Isolated mitochondria were prepared and treated with 10 
μM DHE and compound in flow cytometry tubes.  Samples were read after 30 minutes on a flow 
cytometer for ethidium fluorescence.  The unstained sample received no DHE.  Antimycin A was 
used as a positive control for a mitochondrial depolarizer that does not induce ROS. 
 
3.5.3 Connectivity Map 
 In order to draw correlations from the transcriptional response to known small molecules, 
the top up- and down-regulated transcripts were entered into the Connectivity Map Database.  
This database compares the genetic signature of the treatment to over 6000 known compounds in 
a variety of cell lines.  A correlation of one (1) indicates a perfect alignment, whereas a 
correlation of negative one (-1) indicates an anti-alignment.  Since a number of factors can 
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influence the specific transcripts that are affected, scores of greater than 0.6 are generally 
considered to be strong matches.
40, 46-47
  
 
3.5.3.1 Small Molecule Electrophiles with Similar Action to GEM-1 
 Using the transcript profiling results generated for GEM-1 (see Tables 3.2 and 3.3), a 
connectivity map was generated for known bioactive compounds (Table 3.4).  This analysis 
ranks compounds based on both their mean connectivity as well as the number of instances of 
that compound in the CMAP database. 
 
Table 3.4. Connectivity map analysis shows a high correlation between GEM-1 and other 
electrophiles.  The top 14 compounds whose transcriptional response correlates with GEM-1 are 
ordered based on mean correlation.  The rank is a factor of both the mean score and the number 
of instances of the compound in the CMAP database.  Thus, celastrol has a rank of 547 due to its 
single instance in the database, despite its high mean correlation score. 
rank cmap name mean n p 
547 celastrol 0.924 1 --- 
1 piperlongumine 0.923 2 <0.00002 
2 parthenolide 0.741 4 <0.00002 
17 puromycin 0.74 4 0.00012 
44 menadione 0.739 2 0.00618 
12 MG-262 0.702 3 0.00004 
549 MG-132 0.701 1 --- 
550 1,5-isoquinolinediol 0.69 1 --- 
3 lanatoside C 0.66 6 <0.00002 
10 phenoxybenzamine 0.647 4 0.00002 
26 1,4-chrysenequinone 0.644 2 0.00165 
551 HC toxin 0.628 1 --- 
16 thiostrepton 0.605 4 0.0001 
48 5224221 0.6 2 0.00734 
 
 Three compounds showed a high degree of similarity to GEM-1 in this analysis: 
parthenolide, piperlongumine, and celastrol (Figure 3.25).  Structurally, these compounds all 
contain an enone, and this moiety is known to be important for each compound’s activity.  
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Although puromycin and menadione showed similar correlations, they were excluded from this 
initial analysis.  Puromycin is an antibiotic which inhibits protein synthesis but does not contain 
an enone.  Menadione contains a quinone; however, it operates primarily through the generation 
of ROS which is inconsistent with the activity of GEM-1.  
 
 
Figure 3.25. Structures of top three hits from connectivity map. 
 
3.5.3.2 Comparative Activity of GEM-1 to Electrophiles 
 GEM-1 was tested in several head-to-head comparisons with these three electrophiles, 
and although their transcriptional responses are similar, GEM-1 differs from these compounds in 
terms of its mode of killing cancer cells.  Parthenolide, piperlongumine, and celastrol all induce 
apoptotic cell death at high concentrations at both 6 and 24 hours (Figure 3.26).  Additionally, 
this same phenotype can be seen with lower concentrations, and can be prevented via Q-VD-OPh 
cotreatment. 
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Figure 3.26. Celastrol, piperlongumine, and parthenolide all induce apoptosis in U-937 cells at 6 
and 24 hours.  U-937 cells were treated at the concentrations indicated and at the indicated time 
were analyzed by Annexin-V FITC and propidium iodide (PI) on a flow cytometer. 
 
3.5.4 Summary of Transcript Profiling and Electrophilic Response 
 Transcript profiling of GEM-1 provided a more detailed picture of its action in cells.  
Although GEM-1 does induce an electrophilic response in cells, cells treated with GEM-1 do not 
generate ROS and differ in a subtle ways from cells treated with other electrophiles.  This 
suggests that the electrophilic action of GEM-1 in cells is unique. 
 
3.6 Subcellular Localization 
 The cellular localization of compound following treatment can be an important piece of 
data for determining how a compound behaves in cells.  Since GEM-1 contains an electrophilic 
site, we proposed to use a labeled derivative in cell lysate or whole cells to determine where the 
compound interacted and begin to identify a specific target. 
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3.6.1 Synthesis of Labeling Derivatives 
 By taking advantage of the hypothesized covalent modification of GEM-1 in cells, we 
synthesized GEM-8 on a larger scale via propargylation of gibberellic acid followed by 
oxidation using DMP (Scheme 3.7).  GEM-8 was then further functionalized with an azido 
biotin or azido coumerin (Scheme 3.8) to afford GEM-22 and GEM-23, respectively.  However, 
both GEM-22 and GEM-23 showed weak activity in cells (IC50 > 25 μM in HeLa and U-937); 
as a result, GEM-8 was used to probe cells and was post-functionalized in order to visualize its 
subcellular localization.  Labeled derivatives could also be used for target identification 
experiments. 
 
 
Scheme 3.7.  Larger scale (150 mg final) synthesis of GEM-8 via propargylation and oxidation 
from gibberellic acid. 
 
 
 
Scheme 3.8. Synthesis of biotin-labeled or coumarin-labeled GEM-1 derivatives. 
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3.6.2 GEM-1 Labeling by Western Blot 
 Initially, whole U-937 cells were treated with GEM-8 for 1 hour, lysed, and labeled with 
an azido biotin to enable visualization of any protein conjugates.  Gratifyingly, GEM-8 does 
label cells within 1 hour at 5 μM (Figure 3.27A).  Cotreatment with GEM-1 competes for the 
reactive protein sites and diminishes cellular labeling without affecting the overall protein levels 
(Figure 3.27).  However, these compounds show broad functionalization of proteins within the 
cell, suggesting that GEM-1 may not have a single cellular target. 
 
 
Figure 3.27. GEM-8 extensively labels U-937 cells, and this labeling is competed away with 
GEM-1 following a 1 hour treatment.  A) GEM-8 labels U-937 cells at 5 μM, and this labeling 
can be competed with a cotreatment of GEM-1.  GEM-8 was visualized by post-functionalizing 
the lysate with a biotin-azide. B) Lysates show even protein levels at all concentrations of 
compound treatments as determined by Coomassie staining.   
 
 
3.6.3 GEM-1 Labeling by Microscopy 
 The extensive labeling of cells following GEM-8 treatment can also be visualized by 
microscopy.  In HeLa cells, GEM-8 shows localization throughout the cytoplasm, and this 
labeling is can be competed away with excess GEM-1 (Figure 3.28). 
D
M
SO
GEM-8
(1 μM)
GEM-8
(5 μM)
−    1    2    10           −     5   10  μM GEM-1
150
75
37
25
10
150
75
37
25
10
D
M
SO
GEM-8
(1 μM)
GEM-8
(5 μM)
−    1   2  10      −    5  10 μM GEM-1
A) B)
162 
 
 
Figure 3.28. Treatment with GEM-8 extensively labels HeLa cells.  Cells were cotreated with 
GEM-1 and GEM-8 for 1 hour.  Treatment with GEM-1 competes with the binding of GEM-8, 
resulting in a reduction in overall fluorescence.  Cells were visualized by post-functionalizing 
GEM-8 with a biotin-azide and streptavidin-FITC (green).  Nuclei were stained with propidium 
iodide (red). 
 
3.6.4 GEM-1 Labeling by Microscopy with Related Electrophiles 
 In order to determine whether the extensive cytosolic labeling by GEM-8 could also be 
blocked by the electrophiles identified through transcript profiling, pathenolide and 
piperlongumine were coincubated with GEM-8 and visualized by microscopy.  As shown in 
20 μm
GEM-8 (5 μM) + GEM-1 (5 μM)
DMSO GEM-8 (5 μM)
GEM-8 (5 μM) + GEM-1 (10 μM)
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Figure 3.29, both compounds block staining in the cytosol, albeit less effectively than GEM-1.  
This is consistent with the hypothesis that GEM-1 shares some, but not all, of the same cellular 
targets as these other electrophiles. 
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Figure 3.29.  Cotreatment of HeLa cells for 1 hour with GEM-8 (5 μM) and various 
electrophiles competes with cellular labeling.  Cells were visualized by post-functionalizing 
GEM-8 with a biotin-azide and streptavidin-FITC (green).  Nuclei were stained with propidium 
iodide (red).  A) Representative microscopy images showing both FITC and PI channels.  B) 
Images from A) with FITC channel only. 
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3.6.5 Labeling Summary 
 GEM-1 rapidly reacts with cellular substrates, as demonstrated by analyses of cell lysates 
and whole cells.  This suggests that GEM-1 may not have a single protein target within the cells, 
but confirms that GEM-1 does act as an electrophile within cells. 
 
3.7 in vivo Efficacy 
 In order to determine the translational potential of GEM-1, the compound was evaluated 
in mice.  Murine models provide important information on the stability of compounds in vivo 
and in certain cases can determine whether novel mechanisms of action are useful for anticancer 
agents. 
 
3.7.1 GEM-1 Maximum Tolerated Dose 
 The tolerability of GEM-1 was tested in C57/black mice.  GEM-1 was formulated in 
hydroxypropyl-beta-cyclodextrin (HPβCD) and administered in the intraperitoneal cavity (i.p.).  
As shown in Table 3.5, the single maximum tolerated dose (MTD) for GEM-1 was 30 mg/kg.  
Although the initial group of 3 mice for the 15 mg/kg group did lose one mouse several days 
after the treatment finished, a second cohort showed no weight loss or severe symptoms.  As a 
result, the 5-day MTD was established at 15 mg/kg. 
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Table 3.5. GEM-1 MTD studies in C57/black mice.  Compound was administered i.p. to cohorts 
of three mice, and their response and weight was monitored following treatment. 
Treatment 
Number of 
Treatments 
Surviving 
Mice Response 
5 mg/kg 5 3/3 Transient lethargy 
10 mg/kg 5 3/3 Mild lethargy, 10 min recovery 
15 mg/kg 5 5/6 Mild lethargy, 15 min recovery 
20 mg/kg 4 0/3 Lethargy, 1-4 hr recovery, weight loss 
30 mg/kg 2 1/3 Lethargy, 1-4 hr recovery, weight loss 
62.5 mg/kg 1 1/3 Extreme lethargy, no recovery 
 
 
3.7.2 GEM-1 EL-4 Murine Model 
 GEM-1 was assessed in a challenging murine tumor model, using EL4 (murine 
lymphoma) and C57/black mice with a fully intact immune system. After implantation of tumor 
cells, mice were treated with GEM-1 at 30 mg/kg on days 1 and 4, and 20 mg/kg on day 8.  
After 12 days mice were sacrificed and tumors were excised and weighed. As shown in Figure 
3.30, just three treatments of GEM-1 retard tumor growth over 40% in this aggressive syngeneic 
model. 
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Figure 3.30. EL4 syngeneic tumor model.  C57/BL-6 mice were inoculated with 10x10
6
 U-937 
cells in their right flank.  The mice were divided into two treatment groups (n=8) and treated 
with either vehicle (200 mg/mL β-cyclodextrin in water) or GEM-1 (30 mg/kg GEM-1 in 
vehicle) on days 1 and 4.  On day 8, the mice were further treated with either vehicle or 20 
mg/kg GEM-1.  Mice were sacrificed on day 12, and their tumors were removed and weighed.  
Error bars represent standard error of the mean.  Inset image shows representative tumors from 
one mouse of each treatment group. 
 
3.7.3 Summary of Murine Model 
 Our initial success with GEM-1 in the EL-4 murine model suggests that compounds 
which electrophilically modify proteins and induce non-apoptotic cell death may be effective 
anticancer agents.  However, GEM-1 does result in some lethargy and weight loss at effective 
concentrations, suggesting that further optimization may be needed for translation of this 
compound to the clinic. 
 
3.8 Conclusion 
 The implementation and screening of compounds generated under the CtD paradigm has 
enabled the discovery of a novel anticancer compound, GEM-1.  This compound induces both 
apoptotic and non-apoptotic cell death that appear to be mediated through similar pathways.  In 
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particular, the mitochondria are dramatically and directly affected by GEM-1.  The enone of 
GEM-1 was determined to be necessary for its activity in cells.  By using labeled derivatives of 
GEM-1, and by taking advantage of the covalent conjugation of cellular nucleophiles, it was 
discovered that GEM-1 does not localize to any region of the cell.  GEM-1 was validated in an 
aggressive murine model, suggesting that this novel mechanism may be amenable for translation 
into the clinic. 
 
3.9 Methods 
General Biological Method Information 
For biological assays, hemin, staurosporine, dihydroethidium, TMRE, mitotracker red, celastrol, 
piperlongumine, parthenolide, propidium iodide, phenazine methosulfate, and Cocktail Set III 
Protease Inhibitor were purchased from Sigma Aldrich.  Q-VD-OPh was purchased from 
Calibiochem.  Whole blood was purchased from Bioreclamation.  Antibodies were purchased 
from Cell Signaling.  The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium salt was obtained from Promega.  Optical densities were recorded 
on a Spectramax Plus 384 (Molecular Devices, Sunnyvale, CA).  Flow cytometry was performed 
on a BD Biociences LSR II (San Jose, CA) and the data was analyzed as described using 
FACSDiva software (San Jose, CA). 
 
Cell Culture Information 
Cells were grown in media supplemented with fetal bovine serum (FBS) and antibiotics (100 
µg/mL penicillin and 100U/mL streptomycin).  Specifically, experiments were performed using 
the following cell lines and media compositions:  U-937, HeLa, NCI-H1299, EL4, A549 (RPMI-
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1640 + 10% FBS), B16-F10 (DMEM + 10% FBS), and MCF7 (EMEM + 10% FBS).  Cells were 
incubated at 37 °C in a 5% CO2, 95% humidity atmosphere. 
 
Screening protocol for identifying new anticancer compounds in U-937 cells 
In a 96-well plate, compounds were pre-added as DMSO stocks in singlicate to achieve a final 
concentration of 1%.  DMSO and media alone served as the live and death control, respectively.  
U-937 (5,000 cells/well) cells were distributed in 100 µL media to the compound-containing 
plate.  After 48 hours, cell viability was assessed by adding 20 µL of a PMS/MTS solution
48
  to 
each well, allowing the dye to be developed at 37°C until the live control had processed MTS, 
and reading the absorbance at λ = 490 nm.  IC50 values were determined using TableCurve (San 
Jose, CA). 
 
72-IC50 value determination for adherent cells using Sulforhodamine B (SRB) 
Adherent cells (HeLa, MCF7, NCI-H1299, B16-F10, and A549) were added into 96-well plates 
(5,000 cells/well) in 100 µL media and were allowed to adhere for 3 hours.  Compounds were 
solubilized  in DMSO as 100x stocks.  GEM-1 was tested over a range of concentrations in 
quintuplicate replicates between 0-100 µM (1% DMSO final) on a half-log scale. DMSO and 
media only served as the live and death control, respectively.  After 72 hours, the plates were 
evaluated using the SRB colorimetric assay as described previously.   Briefly, media was 
removed from the plate, and cells were fixed by the addition of 100 µL cold 10% trichloroacetic 
acid in water.  After an overnight incubation at 4 °C, the plates were washed in water and 
allowed to dry.  Sulforhordamine B was added as a 0.057% solution in 1% acetic acid (100 µL), 
incubated at room temperature for 30 minutes, washed in 1% acetic acid, and allowed to dry.  
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The dye was solubilized by adding 10 mM Tris base solution (pH 10.5, 200 µL) and incubating 
at room temperature for 30 minutes.  Plates were read at λ = 510 nm.  IC50 values were 
determined from three or more separate experiments using TableCurve (San Jose, CA). 
 
IC50 value determination for non-adherent cells using MTS 
In a 96-well plate, compounds were pre-added as DMSO stocks in quintuplicate replicates to 
achieve a final concentration of 1%.  DMSO and media alone served as the live and death 
control, respectively.  EL-4 (5,000 cells/well) or U-937 (5,000 cells/well) cells were distributed 
in 100 µL media to the compound-containing plate.  After 72 hours, cell viability was assessed 
by adding 20 µL of a PMS/MTS solution
48
  to each well, allowing the dye to be developed at 
37°C until the live control had processed MTS, and reading the absorbance at λ = 490 nm.  IC50 
values were determined using TableCurve (San Jose, CA). 
 
Hemolysis assay using human erythrocytes 
To prepare the erythrocytes, 0.1 mL of human blood was centrifuged (10,000 g, 2 min).  The 
pellet was washed three times with saline (0.9% NaCl) via gentle resuspension and 
centrifugation (10,000 g, 2 min).  Following the final wash, the erythrocytes were resuspended in 
0.4 mL red blood cell (RBC) buffer (10 mM Na2HPO4, 150 mM NaCl, 1 mM MgCl2, pH 7.4). 
DMSO stocks of compounds were added to 0.5 mL tubes in singlicate (1 μL, 3.3% DMSO final).  
The stocks were diluted with 19 μL RBC buffer.  Positive control tubes contained DMSO in 
water, and negative control tubes contained DMSO in RBC buffer.  A suspension of washed 
erythrocytes (10 μL) was added to each tube, and samples were incubated at 37 °C for 2 hours.  
Samples were centrifuged (10,000 g, 2 min), and the supernatant was transferred to a clear, 
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sterile 384-well plate.  The absorbance of the supernatants was measured at λ = 540 nm, and 
percent hemolysis was calculated relative to the average absorbance values measured for the 
controls. 
 
Apoptosis in U-937  cells with Annexin V-FITC and propidium iodide (AnnV/PI) 
DMSO stocks of compounds were added to a 24-well plate in singlicate (0.2% DMSO final).  
For caspase-dependent protection studies, samples were co-treated with 5 µM QVD-OPh.  After 
compound addition, 0.25 mL of a U-937 cell suspension (250,000 cells/mL) was added and 
allowed to incubate for the indicated time.  Following treatment, the cell suspensions were 
transferred to flow cytometry tubes and pelleted (500 g, 5 min).  The media was removed by 
aspiration, and cells were resuspended in 500 µL AnnV binding buffer (10 mM HEPES, pH 7.4, 
140 mM NaCl, 2.5 mM CaCl2) with 2 µg/mL PI and 1:167 dilution of AnnV.  Samples were 
analyzed using flow cytometry. 
 
Western Blot Analysis 
DMSO stocks of compounds were added to a 12-well plate in singlicate (0.2% DMSO final).  
For caspase-dependent protection studies, samples were co-treated with 5 µM QVD-OPh.  After 
compound addition, 1.5 mL of a U-937 cell suspension (250,000 cells/mL) was added and 
allowed to incubate for the indicated time.  Following treatment, the cell suspensions were 
transferred to 2 mL tubes and pelleted (600 g, 3 min).  The media was removed via aspiration, 
and the cells were washed with PBS and transferred to 1.7 mL tubes.  The cells were lysed by 
adding 40 µL of RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% TX-100, 0.5% sodium 
deoxycholate, 0.1% SDS) with 1% Cocktail Set III Protease Inhibitor.  Each sample was then 
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vigorously vortexed twice for 15 seconds, with a 15-minute incubation on ice following each 
vortex.  The cellular debris was pelleted (16,100 g, 5 min), and then 33 µL of the protein 
suspension was transferred to fresh 0.5 mL tubes.  The protein levels were quantified using a 
standard BCA (Thermo Scientific), after which the samples were diluted with deionized water to 
achieve equal protein concentrations for all samples. 
 Prior to analyzing the samples, 6x Laemmli sample buffer (350 mM Tris, pH 6.8, 12% 
SDS, 0.012% bromophenol blue, 47% glycerol) with 5% β-mercaptoethanol was added to each 
sample to achieve a final 1x concentration, after which the samples were incubated at 95 °C for 5 
minutes to denature the protein samples.  30-50 µg of protein was added onto a 15-well 4-20% 
Tris-HCl gel and run for 1 hour at 120 V.  Equilibrated gel in Towbin transfer buffer (192 mM 
glycine, pH 8.3, 25 mM Tris-Cl, 20% methanol) for 30 minutes, and then transferred gel to a 
PVDF membrane for 2 hours at 60 V. 
 Generally, blots were probed as followed.  The blot was blocked overnight at 4 °C with a 
blocking agent in 0.1% Tris-Buffered Saline Tween-20 (TBST) and then probed for the primary 
antibody at a given dilution with a blocking agent in 0.1% TBST overnight at 4 °C for PARP 
(5% milk, 1:1000 dilution), caspase-3 (5% milk, 1:1000 dilution), HO-1 (5% BSA, 1:1000 
dilution) and β-actin (5% BSA, 1:5000).  The blot was washed with TBST, and then probed with 
a secondary rabbit HRP antibody (1:10,000, Cell Signaling) in 0.05% TBST for 1 hour at room 
temperature.  The blot was washed with TBST and PBS, and then visualized with Pico 
luminescent substrate kit (Thermo Scientific). 
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LCMS analysis of GSH addition to GEM-1 
In a 0.5 mL tube, GEM-1 (15 μL of a 10 mM DMSO stock) and glutathione (GSH, 7.5 μL of a 
30 mM water stock) were mixed.  An aliquot (2.5 μL) was immediately removed, diluted in 
MeOH (500 μL), and run on the LCMS.  GEM-1 and GSH were incubated at room temperature, 
and additional aliquots were removed and analyzed at 30 and 60 minutes.  Conjugation between 
GEM-1 and GSH was determined based on the major TIC peak which contained a mass 
consistent with the conjugate. 
 
Transmission Electron Microscopy 
In 100 cm cell culture dishes, compounds stocks were loaded in DMSO (0.25% final volume).  A 
freshly prepared U-937 cell suspension (500,000 cells/mL, 10 mL) was added, and the cells were 
incubated for the indicated period of time.  Following incubation, cells were pelleted in 15 mL 
conical tubes, transferred to a 1.7 mL tube, and washed with HBSS.  Karnovsky’s fixative (0.25 
mL) was added to the cell pellets and mixed gently with a pipet, and samples were stored at 4 °C.  
The preparation and imaging of samples was performed by the Center for Microanalysis of 
Materials of the Frederick Seitz Materials Research Laboratory Central Facilities, University of 
Illinois.  Images of several cells in each sample were taken, and images are representative images 
from replicate experiments. 
 
Mitotracker in U-937 cells 
DMSO stocks of compounds (0.1% final volume) were added to a 24-well plate.  1 mL of a 
freshly prepared U-937 cell suspension (500,000 cells/mL) was added at the indicated time such 
that all samples could be processed at the same time.  Following treatment, cells were transferred 
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to 1.7 mL tubes and pelleted.  The media was aspirated and replaced with 1 mL PBS with 1:1000 
Hoechst and 1:4000 mitotracker red.  Samples were incubated at 37 °C for 10 minutes and then 
pelleted.  The cell pellets were resuspended in formaldehyde (4.7% in PBS, 1 mL) and incubated 
for 15 minutes over ploy-L-lysine coated coverslips in a 12-well plate.  Cells were pelleted onto 
the coverslips (500 g, 3 min) and mounted to slides with Dako fluorescent mounting medium.  
Samples were visualized with using confocal microscopy. 
 
Isolation of Mitochondria 
U-937 cells were frown to confluency in a T-75 flask (30 million cells), collected by 
centrifugation, and washed twice with PBS.  Cells were resuspended in ice cold hypotonic lysis 
buffer (10 mM HEPES, pH 7.5, 1 mM DTT, 1 mM PMSF, 5 mM MgCl2, 1:100 protease 
inhibitor cocktail III) in 7 μL per 1 million cells (220 μL).  Cells were then lysed by passing the 
suspension through a 26-guage needle fifteen times.  Cold isolation buffer (0.6 mL; 10 mM 
HEPES, pH 7.5, 250 mM sucrose, 1 mM DTT, 1 mM PMSF, 5 mM MgCl2, and 1:100 protease 
inhibitor cocktail III) was added and mixed by inversion.  The samples were centrifuged (500 g, 
10 min, 4 °C), and the supernatant was transferred to a fresh 1.7 mL tube.  The mitochondria 
were then centrifuged (10,000 g, 5 min, 4 °C) and the supernatant aspirated.  The mitochondria 
were resuspended in washing buffer (0.5 mL; 10 mM HEPES, pH 7.5, 50 mM KCl, 5 mM 
EDTA) and incubated on ice for 2 min before centrifuging (12,600 g, 5 min, 4 °C).  The 
mitochondria were resuspended in 75 μL flow cytometry assay buffer (10 mM HEPES, pH 7.5, 
250 mM sucrose, 5 mM sodium succinate, 0.5 mM MgCl2, and 0.1 mM K2HPO4).  The 
concentration of the mitochondria was determined by lysing 7 μL of mitochondria in 14 μL of 
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RIPA buffer and quantifying protein levels by BCA.  Generally, mitochondria were used the 
same day they were isolated, although they could be flash-frozen and stored at -80 °C. 
 
Mitochondria membrane potential or ROS in isolated mitochondria 
In labeled flow cytometry tubes, loaded DMSO stocks (0.25% DMSO final), flow cytometry 
assay buffer (170 μL; 10 mM HEPES, pH 7.5, 250 mM sucrose, 5 mM sodium succinate, 0.5 
mM MgCl2, and 0.1 mM K2HPO4), 0.1 μg/mL rotenone, and 20 μl of 1% w/v BSA in flow 
cytometry assay buffer.  Added fluorescent probe (1000x stock, 20 nM TMRE or 10 μM DHE 
final concentration) and 10 μL mitochondria suspension (0.125 mg/mL, prepared as described 
above).  Incubated at 37 °C for 30 minutes, then analyzed samples by flow cytometry. 
 
Transcript Profiling 
U-937 cells (3,000,000 cells/sample) were incubated in the presence of GEM-1 (10 μM) or 
DMSO vehicle (0.2% final DMSO v/v) for 6 h in a 12-well plate. Aliquots (500 μL) were taken 
at 6 and 24 hours and assessed for viability by annexin V/propidium iodide (AV/PI) staining and 
flow cytometry in order to ensure that the compounds were non-toxic at 6 hours and toxic at 24 
hours. After 6 hours, 5 mL of cells were pelleted and RNA isolated with on column DNase 
digestion. RNA integrity was assessed using an Agilent Bioanalyzer.  Following RNA isolation, 
whole genome transcript profiling was performed on the Illumina HumanHT-12 bead array for 
compounds and DMSO control from three independent experiments. The raw bead-level files 
were processed with Illumina® BeadStudio 3, Gene Expression Module v3.2.61, without 
background correction or normalization, to get one value per beadtype for each array. These 
48,803 beadtype values were then input into R, using the beadarray package
49
 from the 
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Bioconductor +Project.  The vsn algorithm was used for background correction,
50
 12 
normalization and transformation of the beadtype values to the glog2 scale. Differential 
expression was assessed using a mixed linear model using the Limma package, which uses an 
empirical Bayes correction that helps to improve power by borrowing information across 
beadtypes.
51
  All the desired pair-wise comparisons between the 8 treatment groups (control + 
GEM-1 + unrelated compounds) were pulled as contrasts from the model and the p-values were 
corrected for multiple hypotheses testing using the False Discovery Rate method separately for 
each contrast.
52
 
 
Antioxidant Protection by AnnV/PI 
In a 24-well plate, DMSO stocks of antioxidants (0.2% DMSO final) were mixed with 1 mL of a 
fresh U-937 cell suspension (500,000 cells/mL) and incubated at 37 °C for 2 hours.  Then, 2.5 
μL of either DMSO or GEM-1 (10 mM DMSO stock) was mixed with the samples and allowed 
to incubate for 24 hours.  The cell suspension was removed, transferred to flow cytometry tubes, 
and pelleted (500 g, 3 min).  The media was removed by aspiration, and cells were resuspended 
in 200 µL AnnV binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) with 2 
µg/mL PI and 1:167 dilution of AnnV.  Samples were analyzed using flow cytometry. 
 
Antioxidant Protection by IC50 Modulation 
In a 96-well plate, compounds were pre-added as DMSO stocks in triplicate replicates to achieve 
a final concentration of 1%.  DMSO and media alone served as the live and death control, 
respectively.  U-937 (10,000 cells/well) cells were treated with a cytoprotective agent (eg, 5 mM 
NAC) and then distributed in 100 µL media to the compound-containing plate.  After 24 hours, 
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cell viability was assessed by adding 20 µL of a PMS/MTS solution
48
  to each well, allowing the 
dye to be developed at 37°C until the live control had processed MTS, and reading the 
absorbance at λ = 490 nm.  IC50 values were determined using TableCurve (San Jose, CA). 
 
Antioxidant Protection by NAC Pretreatment by AnnV/PI 
0.5 mL tubes were loaded with 2.5 μL of either DMSO or GEM-1 (10 mM DMSO stock) and 2.5 
μL of water or 10 mM NAC (1:1).  Samples were incubated for 2 hours at 37 °C and then added 
to 1 mL of a fresh U-937 cell suspension (500,000 cells/mL).  The cell suspensions were 
incubated at 37 °C.  At each indicated time, an aliquot of the cell suspension (0.2 mL) was 
removed, transferred to flow cytometry tubes, and pelleted (500 g, 3 min).  The media was 
removed by aspiration, and cells were resuspended in 500 µL AnnV binding buffer (10 mM 
HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) with 2 µg/mL PI and 1:167 dilution of AnnV.  
Samples were analyzed using flow cytometry. 
 
Determining ROS Levels in Whole Cells with DHE 
DMSO stocks of compounds (1% final DMSO concentration) were loaded into flow cytometry 
tubes.  A fresh U-937 cell suspension was washed in HBSS and then resuspended in HBSS 
(500,000 cells/mL) with a 1:35,000 dilution of a 10 mM dihydroethidium (DHE).  Immediately 
prior to reading samples, the cell suspension (0.495 mL) was added to samples and analyzed by 
flow cytometer for ethidium fluorescence.  Samples were wrapped in foil and incubated at 37 °C 
between readings at 20, 40, and 60 minutes.  Samples were gated for live cells, and the final 
fluorescence was normalized to the DMSO control for each timepoint and the initial fluorescence 
for each sample. 
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Connectivity Map 
To facilitate mapping of the results from gene expression profiling with those of the Connectivity 
Map database, probes were matched from Illumina’s Human HT-12 array to Affymetrix’s 
U133Plus2.0 array. The top 150 up- and down-regulated probe set IDs according to fold-change 
which mapped onto the Affymetrix array were used as seeds for the connectivity map (CMAP) 
database matching.  The top single-instance and cell-line specific matches are reported. 
 
GEM-1 Labeling of Cells by Western 
DMSO stocks of compounds (GEM-8 or GEM-1) were loaded in a 24-well plate.  1.5 mL of a 
fresh U-937 cell suspension (500,000 cells/mL) was added to the samples.  Following a 1 hour 
incubation, cells were transferred to 1.7 mL tubes, pelleted, and aspirated media.  The cells were 
lysed by adding 40 µL of RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% TX-100, 0.5% 
sodium deoxycholate, 0.1% SDS) with 1% Cocktail Set III Protease Inhibitor.  Each sample was 
then vigorously vortexed twice for 15 seconds, with a 15-minute incubation on ice following 
each vortex.  The cellular debris was pelleted (16,100 g, 5 min), and then 30 µL of the protein 
suspension was transferred to fresh 0.5 mL tubes.  A biotylated azide was clicked on to GEM-8 
using 0.7 μL copper staining solution (1.5 mg CuSO4, 4.5 mg sodium ascorbate, and 3.0 mg 
TCEP in 0.3 mL H2O) and 0.1 μL biotin-azide (10 mM in EtOH) for 1 hour at RT. 
 Prior to analyzing the samples, 6x Laemmli sample buffer (350 mM Tris, pH 6.8, 12% 
SDS, 0.012% bromophenol blue, 47% glycerol) with 5% β-mercaptoethanol was added to each 
sample to achieve a final 1x concentration, after which the samples were incubated at 95 °C for 5 
minutes to denature the protein samples.  15 μL of protein was added onto two 15-well 12% 
Tris-HCl gel and run for 1 hour at 120 V.  One gel was stained with Coomassie overnight and 
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visualized to determine protein loaded.  The second gel was equilibrated in Towbin transfer 
buffer (192 mM glycine, pH 8.3, 25 mM Tris-Cl, 20% methanol) for 30 minutes, and then 
transferred gel to a PVDF membrane for 2 hours at 60 V.  The blot was blocked for 2 hours in 
5% BSA in 0.1% Tris-Buffered Saline Tween-20 (TBST) and then probed with an anti-biotin-
HRP antibody in blocking medium at 1:5000 overnight at 4 °C.  The blot was washed with 
TBST and PBS, and then visualized with Pico luminescent substrate kit (Thermo Scientific). 
 
GEM-1 Labeling of Cells by Confocal Microscopy 
In a 6-well plate, cover slips were loaded and covered with a fresh HeLa cell suspension 
(200,000 cells/mL, 3 mL).  The plates were returned to the incubator overnight for cells to 
adhere.  Once cells had grown to 85% confluency, all wells were treated with GEM-8 (5 μM), 
and GEM-1 (5 or 10 μM) was also added to cotreatment wells.  Following a one hour 
incubation, the media was removed and the cells were fixed with 1 mL of 4.7% formaldehyde in 
PBS for 15 minutes at RT.  The cells were permeabilized with 0.1% TX-100 in PBS for 10 
minutes at RT and then treated with 50 μg/mL RNAseA in PBS (200 μL) for 1 hour at RT.  The 
cells were then blocked with 2% BSA in PBS for 30 minutes at RT.  A biotylated azide was 
clicked on to GEM-8 using 200 μL of PBS with 2.8 μL copper staining solution (1.5 mg CuSO4, 
4.5 mg sodium ascorbate, and 3.0 mg TCEP in 0.3 mL H2O) and 0.4 μL biotin-azide (10 mM in 
EtOH).  After 30 minutes at RT, the copper solution was removed and the samples were probed 
overnight with 1:250 streptavidin-FITC in 2% BSA in TBST at RT.  Samples were washed with 
PBS (3x) and TBST (1x) and then stained with 150 μL 50 μg/mL PI in PBS for 5 minutes at RT.  
Samples were washed again with PBS (2x) and then mounted onto slides with Dako fluorescent 
mounting medium.  Samples were imaged using confocal microscopy. 
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 GA-4 MTD Determination in C57BL/6 Mice 
The maximum tolerated dose (MTD) for GA-4 was determined in C57BL/6.  In groups of three, 
mice were treated with 5 mg/kg GA-4 (formulated at 2 mg/mL in 200 mg/mL HPβCD in water) 
and monitored for any signs of toxicity.  The dose was then escalated, and mice were again 
monitored for any signs of toxicity.  The MTD was determined as the highest treatment group for 
which all three mice survived the treatment.  The single day MTD was determined to be 30 
mg/kg. 
 
EL4 Mouse Model in C57/BL-6 Mice 
Plasmocin-treated EL4 cells were prepared in HBSS following several washes at a concentration 
of 100 million cells/mL.  C57BL/6 mice were sedated (ketamine/xylazine) and inoculated with 
100 µL of cell suspension (10 million cells) subcutaneously into the right flank (day 0).  Within 
four hours of inoculation, the injection bulb was no longer present, and by the following 
morning, soft tumors had appeared.  Mice were divided into two treatment groups: vehicle and 
treatment (n=8 per group).  GA-4 was formulated in 200 mg/mL HPβCD at 2 mg/mL in water.  
Mice were treated on days 1, 4, and 8 with either vehicle (HPβCD alone) or GA-4 (30 mg/kg on 
days 1 and 4, and 20 mg/kg on day 8).  Mice were monitored for general signs of toxicity, and 
had recovered within one hour of treatment.  After 11 days, the largest tumors had reached 
maximal size.  The mice were sacrificed and tumors were excised and weighed. 
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Chemical Synthesis of GEM-1 and Associated Derivatives 
 
General Chemistry Methods 
Chemical reagents were purchased from commercial sources and used without further 
purification.  Gibberellic acid (90% purity) was purchased from AK Scientific.  Anhydrous 
solvents used during these studies were dried after being passed through columns with activated 
alumina.   
 1
H NMR and 
13
C NMR experiments were recorded on Varian Unity spectrometers at 400 
MHz and 500 MHz and 125 MHz, respectively.  Spectra were obtained in the following solvents 
(reference peaks also included for 
1
H and 
13
C NMRs): CDCl3 (
1
H NMR: 7.26 ppm; 
13
C NMR: 
77.23 ppm), d6-DMSO (
1
H NMR: 2.50 ppm; 
13
C NMR: 39.52 ppm), and d6-acetone (
1
H NMR: 
2.05 ppm; 
13
C NMR: 206.26 ppm).  NMR experiments were performed at room temperature.  
Chemical shift values are reported in parts per million (ppm) for all 
1
H NMR and 
13
C NMR 
spectra.  
1
H NMR multiplicities are reported as: s = singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet, br = broad. 
 
 
 
Procedure: To a solution of gibberellic acid (1.01 g, 2.90 mmol) in acetone (10 mL) was added 
methyl iodide (450 µL, 7.23 mmol) and potassium carbonate (2.02 g, 14.6 mmol).  Following 
addition of the potassium carbonate, the reaction became warm, and stirred for 36 hours at room 
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temperature.  The reaction mixture was concentrated and purified directly by flash 
chromatography on silica gel (hexanes/ethyl acetate 2:1 to ethyl acetate).  Recrystallization with 
hexanes from ethyl acetate gave GEM-2 as a white solid (0.974 g, 93%). 
 
1
H NMR (CDCl3, 500 MHz): δ 6.32 (d, J = 9.3 Hz, 1H), 5.91 (dd, J = 9.3, 3.7 Hz, 1H), 5.28 (t, J 
= 2.5 Hz, 1H), 4.97 (d, J = 2.1 Hz, 1H), 4.16 (dd, J = 7.3, 3.7 Hz, 1H), 3.74 (s, 3H), 3.21 (d, J = 
10.7 Hz, 1H), 2.80 (d, J = 10.8 Hz, 1H), 2.22 (dd, J = 15.7, 2.2 Hz, 1H), 2.16 (dt, J = 15.7, 3.0 
Hz, 1H), 2.12 - 2.02 (m, 3H), 1.97 - 1.90 (m, 3H), 1.86 (d, J = 7.3 Hz, 1H), 1.84 - 1.77 (m, 1H), 
1.75 (d, J = 11.0 Hz, 1H), 1.72 – 1.66 (m, 1H), 1.25 (s, 3H).  
13
C NMR (CDCl3, 125 MHz): δ 178.5, 172.7, 157.2, 133.3, 132.6, 107.8, 90.6, 78.4, 70.1, 53.7, 
53.0, 52.4, 51.3, 50.9, 50.7, 45.1, 43.3, 38.5, 17.2, 14.6. 
HRMS(EI): m/z calc. for C20H24O6 [M]
+
: 360.1573, found: 360.1560. 
Melting point: 189-190 °C. 
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Procedure: To a solution of gibberellic acid methyl ester GEM-2 (254 mg, 0.704 mmol) in 
dichloromethane (5 mL) cooled to 0 °C in an ice bath was added Dess-Martin periodinane (470 
mg, 1.11 mmol).  The reaction warmed to room temperature following the addition, and stirred 
for 21 hours.  The reaction was quenched with saturated aqueous sodium thiosulfate (4 mL) and 
saturated aqueous sodium bicarbonate (4 mL), and extracted with ethyl acetate (3x).  The 
combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and 
concentrated.  The residue was purified by flash chromatography on silica gel (ethyl 
acetate/hexanes 1:2 to 1:1) to yield GEM-1 as a white solid (179 mg, 71%). 
 
1
H NMR (d6-DMSO, 500 MHz): δ 7.65 (d, J = 9.4 Hz, 1H), 6.09 (d, J = 9.4 Hz, 1H), 5.16 - 5.14 
(m, 1H), 4.93 (s, 1H), 4.87 (br s, 1H), 3.67 (s, 3H), 3.57 (d, J = 10.6 Hz, 1H), 2.85 (d, J = 10.6 
Hz, 1H), 2.24 (dd, J = 15.0, 1.5 Hz, 1H), 2.17 - 2.12 (m, 1H), 2.00 (dt, J = 12.8, 2.8 Hz, 1H), 
1.99 - 1.92 (m, 1H), 1.82 (dd, J = 10.7, 2.4 Hz, 1H), 1.79 - 1.72 (m, 2H), 1.70 (d, J = 10.8 Hz, 
1H), 1.63 (dt, J = 12.3, 9.4 Hz, 1H), 1.10 (s, 3H). 
1
H NMR (CDCl3, 500 MHz): δ 7.26 (d, J = 9.4 Hz, 1H), 6.05 (d, J = 9.4 Hz, 1H), 5.30 (dd, J = 
3.1, 1.9 Hz, 1H), 4.99 (dd, J = 2.7, 1.6 Hz, 1H), 3.74 (s, 3H), 3.52 (d, J = 10.5 Hz, 1H), 2.90 (d, J 
= 10.5 Hz, 1H), 2.23 (dq, J = 15.5, 2.1 Hz, 1H), 2.19 (t, J = 2.8 Hz, 1H), 2.18 - 2.12 (m, 1H), 
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2.10 (dd, J = 11.0, 2.5 Hz, 1H), 2.07 - 1.99 (m, 2H), 1.89 - 1.82 (m, 1H), 1.82 - 1.74 (m, 2H), 
1.69 (s, 1H), 1.27 (s, 3H). 
13
C NMR (d6-DMSO, 125 MHz): δ 192.2, 173.1, 171.2, 157.2, 149.3, 127.8, 106.6, 90.0, 76.4, 
64.3, 60.9, 52.0, 50.9, 49.9, 49.1, 44.0, 42.2, 38.6, 16.4, 11.2. 
HRMS(EI): m/z calc. for C20H22O6 [M]
+
: 358.1416, found: 358.1404. 
Melting point: 180-182 °C. 
 
 
Procedure: In a 100 mL round bottom flask with stirbar, gibberellic acid (506.1 mg, 1.46 mmol) 
was dissolved in dichloromethane (10 mL) and pyridine (300 μL, 3.71 mmol).  Dess-Martin 
periodinane (756.0 mg, 1.78 mmol) was added in one portion, and the reaction stirred for 16 
hours at room temperature.  The reaction was concentrated and purified by flash silica 
chromatography (chloroform/methanol/acetic acid 95:5:0.1) to yield GEM-3 as a white solid 
(334.5 mg, 66.5%). 
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1
H NMR (d6-acetone, 500 MHz): δ 7.60 (d, J = 9.4 Hz, 1H), 6.05 (d, J = 9.4 Hz, 1H), 5.25 – 
5.21 (m, 1H), 4.90 (d, J = 2.1 Hz, 1H), 3.57 (d, J = 10.6 Hz, 1H), 2.87 (d, J = 10.6 Hz, 1H), 2.38 
(dt, J = 15.6, 2.9 Hz, 1H), 2.29 (dq, J = 15.6, 2.1 Hz, 1H), 2.23 (dd, J = 11.6, 6.1 Hz, 1H), 2.09 
(qd, J = 6.8, 6.2, 1.8 Hz, 2H), 1.99 (dd, J = 11.0, 2.8 Hz, 1H), 1.96 (s, 1H), 1.95 – 1.92 (m, 1H), 
1.88 (dd, J = 10.9, 1.4 Hz, 1H), 1.86 – 1.74 (m, 2H), 1.22 (s, 3H). 
13
C NMR (d6-acetone, 125 MHz): δ 193.0, 173.9, 172.6, 158.6, 149.7, 129.1, 107.1, 90.6, 78.0, 
65.7, 62.7, 52.4, 51.8, 50.1, 45.4, 43.5, 39.6, 17.6, 11.9. 
HRMS(ESI): m/z calc. for C19H20O6Na [M+Na]
+
: 367.1158, found: 367.1164. 
 
 
 
Procedure: GEM-3 (18.1 mg, 0.053 mmol) and PyBOP (30.0 mg, 0.058 mmol) were loaded in 
an oven-dried 7 mL vial with stirbar and dissolved in dichloromethane (0.6 mL).  
Diisopropylethylamine (32 μL, 0.184 mmol) was added and the reaction stirred at room 
temperature for 1 hour.  One drop of diisopropylethylamine and trichloroethanol (7 μL, 0.073 
mmol) were added, and the reaction stirred for 17 hours at room temperature.  The reaction was 
quenched with water (1 mL) and extracted with ethyl acetate (3x).  The combined organic layers 
were dried over magnesium sulfate, filtered, and concentrated.  The residue was purified by flash 
chromatography on silica gel (ethyl acetate/hexanes 1:2 to 2:3) to yield GEM-4 as a colorless oil 
(3.6 mg, 14%). 
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1
H NMR (CDCl3, 500 MHz): δ 7.27 (d, J = 9.5 Hz, 1H), 6.08 (d, J = 9.4 Hz, 1H), 5.32 (dd, J = 
3.2, 1.8 Hz, 1H), 5.00 (br s, 1H), 4.85 (d, J = 12.0 Hz, 1H), 4.73 (d, J = 12.0 Hz, 1H), 3.54 (d, J 
= 10.5 Hz, 1H), 3.06 (d, J = 10.6 Hz, 1H), 2.35 (dt, J = 15.5, 2.9 Hz, 1H), 2.29 – 2.24 (m, 1H), 
2.17 (dd, J = 10.7, 2.9 Hz, 2H), 2.14 – 2.09 (m, 1H), 2.08 (d, J = 5.3 Hz, 1H), 2.07 – 2.01 (m, 
1H), 1.90 – 1.76 (m, 2H), 1.32 (s, 3H), 1.30 – 1.20 (m, 1H). 
13
C NMR (CDCl3, 125 MHz): δ 191.4, 173.0, 169.9, 156.1, 147.3, 129.5, 108.5, 89.5, 78.1, 74.8, 
65.1, 62.3, 51.8, 51.6, 50.4, 45.2, 43.2, 38.1, 17.3, 11.9.  (Missing CCl3 peak at ~95 ppm) 
HRMS(ESI): m/z calc. for C21H22O6Cl3 [M+H]
+
: 475.0482, found: 475.0476. 
 
 
Procedure: GEM-3 (15.1 mg, 0.044 mmol) and PyBOP (26.3 mg, 0.051 mmol) were loaded in 
an oven-dried 7 mL vial with stirbar and dissolved in dichloromethane (0.6 mL).  
Diisopropylethylamine (32 μL, 0.184 mmol) was added and the reaction stirred at room 
temperature for 1 hour.  One drop of diisopropylethylamine and benzylamine (7 μL, 0.064 
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mmol) were added, and the reaction stirred for 17 hours at room temperature.  The reaction was 
quenched with water (1 mL) and extracted with ethyl acetate (3x).  The combined organic layers 
were dried over magnesium sulfate, filtered, and concentrated.  The residue was purified by flash 
chromatography on silica gel (ethyl acetate/hexanes 2:3 to 1:1) to yield GEM-5 as a colorless oil 
(1.7 mg, 9%). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.36 – 7.29 (m, 2H), 7.29 – 7.23 (m, 4H), 6.05 (d, J = 9.4 Hz, 
1H), 5.85 (br s, 1H), 5.27 (t, J = 2.5 Hz, 1H), 4.98 (d, J = 2.2 Hz, 1H), 4.60 (dd, J = 14.5, 6.4 Hz, 
1H), 4.31 (dd, J = 14.5, 5.0 Hz, 1H), 3.70 (d, J = 9.8 Hz, 1H), 2.55 (d, J = 9.8 Hz, 1H), 2.36 – 
2.24 (m, 3H), 2.14 – 2.06 (m, 3H), 2.06 – 1.98 (m, 1H), 1.82 (dddd, J = 21.0, 16.7, 13.2, 8.5 Hz, 
2H), 1.60 (d, J = 7.0 Hz, 1H), 1.27 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 222.6, 177.6, 169.6, 156.4, 147.4, 137.7, 129. 5, 129.1 (2C), 
128.2, 128.2 (2C), 107.9, 78.4, 65.3, 62.8, 54.0, 51.5, 50.2, 46.2, 44.4, 43.3, 38.2, 29.9, 17.3, 
11.7. 
HRMS(EI): m/z calc. for C26H28NO5 [M+H]
+
: 434.1967, found: 434.1970. 
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Procedure: GEM-3 (15.0 mg, 0.044 mmol) and PyBOP (30.0 mg, 0.058 mmol) were loaded in 
an oven-dried 7 mL vial with stirbar and dissolved in dichloromethane (0.6 mL).  
Diisopropylethylamine (32 μL, 0.184 mmol) was added and the reaction stirred at room 
temperature for 1 hour.  One drop of diisopropylethylamine and nonylamine (11 μL, 0.060 
mmol) were added, and the reaction stirred for 17 hours at room temperature.  The reaction was 
quenched with water (1 mL) and extracted with ethyl acetate (3x).  The combined organic layers 
were dried over magnesium sulfate, filtered, and concentrated.  The residue was purified by flash 
chromatography on silica gel (ethyl acetate/hexanes 1:3 to 2:3) to yield GEM-6 as a colorless oil 
(5.6 mg, 27%). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.27 (d, J = 9.4 Hz, 1H), 6.05 (d, J = 9.4 Hz, 1H), 5.64 (t, J = 5.9 
Hz, 1H), 5.27 (t, J = 2.5 Hz, 1H), 5.00 (d, J = 2.1 Hz, 1H), 3.67 (d, J = 9.8 Hz, 1H), 3.32 (dq, J = 
13.6, 7.1 Hz, 1H), 3.25 – 3.17 (m, 1H), 2.52 (d, J = 9.8 Hz, 1H), 2.30 (dd, J = 5.5, 2.6 Hz, 2H), 
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2.16 – 2.06 (m, 4H), 2.06 – 2.00 (m, 1H), 1.90 – 1.78 (m, 1H), 1.76 (s, 1H), 1.64 – 1.58 (m, 1H), 
1.49 (t, J = 7.0 Hz, 2H), 1.34 – 1.21 (m, 15H), 0.88 (t, J = 6.9 Hz, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 191.8, 174.0, 169.7, 156.5, 147.4, 129.4, 107.8, 90.2, 78.4, 65.4, 
62.7, 54.0, 51.4, 50.2, 46.3, 43.3, 40.1, 38.3, 32.1, 29.8, 29.7, 29.5, 29.4, 27.1, 22.9, 17.3, 14.3, 
11.6. 
HRMS(ESI): m/z calc. for C28H40NO5 [M]
+
: 470.2906, found: 470.2909. 
 
 
Procedure: To a solution of GEM-3 (27.1 mg, 0.079 mmol) in acetone (1 mL) was added 
potassium carbonate (64.5 mg, 0.467 mmol) and benzyl bromide (30 μL, 0.252 mmol).  The 
reaction stirred for 16 hours at room temperature and was quenched with water (1 mL) and 
extracted with ethyl acetate (3x).  The combined organic layers were dried over magnesium 
sulfate, filtered, and concentrated.  The residue was purified by flash chromatography on silica 
gel (ethyl acetate/hexanes 1:4 to 2:3) to yield GEM-7 as a white solid (22.9 mg, 70.0%). 
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1
H NMR (CDCl3, 500 MHz): δ 7.39 – 7.35 (m, 3H), 7.35 – 7.31 (m, 2H), 7.24 (d, J = 9.4 Hz, 
1H), 6.04 (d, J = 9.3 Hz, 1H), 5.26 (dd, J = 3.1, 1.8 Hz, 1H), 5.22 (d, J = 12.0 Hz, 1H), 5.12 (d, J 
= 12.0 Hz, 1H), 4.91 (d, J = 2.1 Hz, 1H), 3.52 (d, J = 10.4 Hz, 1H), 2.91 (d, J = 10.5 Hz, 1H), 
2.17 – 2.11 (m, 2H), 2.11 – 2.07 (m, 2H), 2.05 – 1.99 (m, 2H), 1.86 – 1.79 (m, 1H), 1.78 – 1.72 
(m, 2H), 1.63 (s, 1H), 1.21 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 191.7, 173.2, 171.2, 156.4, 147.4, 135.2, 129.4, 129.0, 128.9 
(2C), 128.8 (2C), 108.0, 89.5, 78.1, 67.5, 65.1, 62.4, 51.8, 51.7, 50.3, 45.3, 43.0, 38.1, 17.2, 11.6. 
HRMS(ESI): m/z calc. for C26H27O6 [M+H]
+
: 435.1808, found: 435.1805. 
 
 
Procedure: To a solution of GEM-3 (24.8 mg, 0.072 mmol) in acetone (1 mL) was added 
potassium carbonate (58.5 mg, 0.423 mmol) and propargyl bromide (24 μL, 0.180 mmol, 80% in 
toluene).  The reaction stirred for 16 hours at room temperature and was quenched with water (1 
mL) and extracted with ethyl acetate (3x).  The combined organic layers were dried over 
magnesium sulfate, filtered, and concentrated.  The residue was purified by flash 
chromatography on silica gel (ethyl acetate/hexanes 1:4 to 2:3) to yield GEM-8 as a white solid 
(20.0 mg, 73.3%).   
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1
H NMR (CDCl3, 500 MHz): δ 7.26 (d, J = 9.4 Hz, 1H), 6.06 (d, J = 9.4 Hz, 1H), 5.31 (dd, J = 
3.2, 1.8 Hz, 1H), 4.99 (d, J = 2.2 Hz, 1H), 4.77 (dd, J = 15.5, 2.5 Hz, 1H), 4.71 (dd, J = 15.5, 2.5 
Hz, 1H), 3.53 (d, J = 10.5 Hz, 1H), 2.93 (d, J = 10.5 Hz, 1H), 2.50 (t, J = 2.4 Hz, 1H), 2.32 (dt, J 
= 15.6, 3.0 Hz, 1H), 2.26 – 2.19 (m, 1H), 2.13 (ddd, J = 14.1, 7.6, 3.0 Hz, 2H), 2.08 – 2.03 (m, 
2H), 1.88 – 1.81 (m, 2H), 1.78 (ddt, J = 13.0, 7.1, 2.5 Hz, 1H), 1.74 – 1.67 (m, 1H), 1.28 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 191.6, 173.1, 170.6, 156.4, 147.3, 129.5, 108.2, 89.4, 78.1, 77.5, 
77.0, 75.9, 65.1, 62.3, 52.9, 51.7, 51.4, 50.4, 45.2, 43.0, 38.1, 17.2, 11.7. 
HRMS(ESI): m/z calc. for C22H23O6 [M]
+
: 383.1495, found: 383.1485. 
 
 
Procedure: To a solution of gibberellic acid (106.8 mg, 0.308 mmol) in acetone (3 mL) was 
added potassium carbonate (210.9 mg, 1.53 mmol) and benzyl bromide (400 μL, 3.36 mmol).  
The reaction stirred for 16 hours at room temperature and was quenched with water (3 mL) and 
extracted with ethyl acetate (3x).  The combined organic layers were dried over magnesium 
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sulfate, filtered, and concentrated.  The residue was purified by flash chromatography on silica 
gel (ethyl acetate/hexanes 2:3) to yield GEM-9 as a white solid (115.0 mg, 85.4%). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.38 – 7.32 (m, 5H), 6.32 (d, J = 9.3 Hz, 1H), 5.90 (dd, J = 9.3, 
3.7 Hz, 1H), 5.24 (t, J = 2.5 Hz, 1H), 5.22 (d, J = 12.3 Hz, 1H), 5.13 (d, J = 12.1 Hz, 1H), 4.89 
(br s, 1H), 4.15 (dd, J = 7.3, 3.7 Hz, 1H), 3.21 (d, J = 10.8 Hz, 1H), 2.82 (d, J = 10.8 Hz, 1H), 
2.19 – 2.11 (m, 2H), 2.10 – 2.02 (m, 2H), 1.94 – 1.88 (m, 2H), 1.84 – 1.61 (m, 2H), 1.56 (d, J = 
4.7 Hz, 2H), 1.25 (dd, J = 6.1, 2.5 Hz, 1H), 1.19 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 178.5, 172.1, 157.1, 135.6, 133.2, 132.6, 128.9 (2C), 128.8, 
128.7 (2C), 107.6, 90.5, 78.4, 70.1, 67.2, 53.7, 53.1, 51.4, 50.9, 50.8, 45.2, 43.1, 38.3, 17.2, 14.6. 
HRMS(ESI): m/z calc. for C26H29O6 [M+H]
+
: 437.1964, found: 437.1967. 
 
 
Procedure: To a solution of gibberellic acid (113.7 mg, 0.328 mmol) in acetone (3 mL) was 
added potassium carbonate (244.6 mg, 1.78 mmol) and propargyl bromide (90 μL, 0.80 mmol, 
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80% in toluene).  The reaction stirred for 16 hours at room temperature and was quenched with 
water (3 mL) and extracted with ethyl acetate (3x).  The combined organic layers were dried 
over magnesium sulfate, filtered, and concentrated.  The residue was purified by flash 
chromatography on silica gel (ethyl acetate/hexanes 2:3) to yield GEM-10 as a white solid (37.7 
mg, 29.9%). 
 
1
H NMR (d6-acetone, 500 MHz): δ 6.38 (dd, J = 9.3, 1.0 Hz, 1H), 5.90 (dd, J = 9.3, 3.6 Hz, 1H), 
5.20 (ddd, J = 3.1, 1.9, 1.0 Hz, 1H), 4.89 – 4.84 (m, 1H), 4.81 (dd, J = 5.7, 2.5 Hz, 2H), 4.69 (d, 
J = 6.9 Hz, 1H), 4.05 (t, J = 3.5 Hz, 1H), 3.86 (s, 1H), 3.27 (d, J = 10.8 Hz, 1H), 3.07 (t, J = 2.5 
Hz, 1H), 2.74 (d, J = 10.8 Hz, 1H), 2.32 – 2.25 (m, 1H), 2.25 – 2.19 (m, 1H), 2.03 – 1.97 (m, 
2H), 1.97 – 1.91 (m, 2H), 1.86 – 1.80 (m, 1H), 1.80 – 1.75 (m, 1H), 1.75 – 1.67 (m, 1H), 1.17 (s, 
3H). 
13
C NMR (d6-acetone, 125 MHz): δ 178.2, 171.3, 158.1, 133.4, 132.1, 106.2, 90.4, 76.0, 69.5, 
69.4, 53.0, 52.1, 51.4, 51.0, 50.7, 44.9, 44.8, 43.1, 39.2, 39.2, 17.0, 14.4. 
HRMS(ESI): m/z calc. for C22H24O6Na [M+Na]
+
: 407.1471, found: 407.1476. 
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Procedure: In an oven-dried 7 mL vial with stirbar, GEM-1 (42.2 mg, 0.118 mmol) and N-
bromosuccinimide (26.8 mg, 0.151) were suspended in carbon tetrachloride (2 mL) and heated at 
80 °C for 17 hours.  The crude reaction was concentrated and purified by flash chromatography 
on silica gel (ethyl acetate/hexanes 1:2) to yield GEM-11 as a white solid (39.9 mg, 77.5%). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.35 (d, J = 9.4 Hz, 1H), 6.09 (d, J = 9.4 Hz, 1H), 3.78 (s, 3H), 
3.56 (d, J = 6.9 Hz, 1H), 3.51 (d, J = 10.6 Hz, 1H), 3.42 (d, J = 10.6 Hz, 1H), 3.08 (dd, J = 18.9, 
3.8 Hz, 1H), 2.81 (d, J = 6.9 Hz, 1H), 2.32 – 2.25 (m, 2H), 2.20 (dd, J = 11.6, 1.9 Hz, 1H), 2.15 
– 2.09 (m, 1H), 1.83 (dd, J = 11.4, 3.8 Hz, 1H), 1.79 – 1.68 (m, 2H), 1.68 – 1.63 (m, 1H), 1.36 
(s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 213.3, 191.9, 172.9, 172.3, 145.7, 129.7, 88.3, 64.3, 64.2, 55.4, 
52.8, 51.3, 51.1, 50.7, 49.4, 44.4, 35.6, 33.1, 19.1, 11.6. 
HRMS(ESI): m/z calc. for C20H22O6Br [M+H]
+
: 437.0600, found: 437.0602. 
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Procedure: In a foil-wrapped oven-dried 7 mL vial with stirbar, GEM-1 (30.4 mg, 0.085 mmol) 
and N-iodosuccinimide (115.0 mg, 0.511) were suspended in dichloromethane (1 mL) and heated 
at 55 °C for 20 hours.  The crude reaction was concentrated and purified by flash 
chromatography on silica gel (ethyl acetate/hexanes 1:2) to yield GEM-12 as a dark oil (33.2 
mg, 80.8%). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.35 (d, J = 9.4 Hz, 1H), 6.09 (d, J = 9.4 Hz, 1H), 3.79 (s, 3H), 
3.56 (d, J = 6.9 Hz, 1H), 3.29 (d, J = 10.5 Hz, 1H), 3.25 (d, J = 10.5 Hz, 1H), 3.10 (dd, J = 18.9, 
3.9 Hz, 1H), 2.81 (d, J = 7.0 Hz, 1H), 2.29 (d, J = 5.7 Hz, 1H), 2.26 (d, J = 12.6 Hz, 1H), 2.15 – 
2.06 (m, 2H), 1.81 (dd, J = 11.4, 3.8 Hz, 1H), 1.78 – 1.70 (m, 2H), 1.69 – 1.64 (m, 1H), 1.36 (s, 
3H). 
13
C NMR (CDCl3, 125 MHz): δ 212.7, 191.9, 172.9, 172.3, 145.7, 129.8, 88.2, 64.4, 64.2, 54.7, 
52.9, 51.3 (2C), 50.7, 49.3, 46.4, 34.6, 19.2, 11.6, 9.8. 
HRMS(ESI): m/z calc. for C20H22O6I [M+H]
+
: 485.0461, found: 485.0460. 
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Procedure: Hydrogen peroxide (30 μL, 0.265 mmol, 30%), trifluoroacetic anhydride (190 μL, 
1.37 mmol), and trifluoroacetic acid (210 μL, 2.74 mmol) were mixed in a 7 mL vial and cooled 
to 0 °C.  The reaction was diluted with dichloromethane (2 mL), after which GEM-1 (25.5 mg, 
0.071 mmol) was added in one portion.  After 5 minutes, the reaction was quenched by washing 
the reaction with water (2x) and saturated aqueous sodium bicarbonate (1x).  The crude reaction 
was concentrated and purified by flash chromatography on silica gel (ethyl acetate) to yield 
GEM-13 as a colorless oil (16.1 mg, 60.5%). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.36 (d, J = 9.4 Hz, 1H), 6.09 (d, J = 9.4 Hz, 1H), 3.79 – 3.68 
(m, 2H), 3.75 (s, 3H), 3.58 – 3.52 (m, 2H), 3.04 (dd, J = 19.0, 4.0 Hz, 1H), 2.82 (d, J = 7.0 Hz, 
1H), 2.33 (dd, J = 13.0, 4.1 Hz, 1H), 2.26 (d, J = 19.0 Hz, 1H), 2.19 (dd, J = 11.3, 1.9 Hz, 1H), 
2.16 – 2.10 (m, 1H), 1.89 – 1.82 (m, 1H), 1.69 (qd, J = 13.3, 5.1 Hz, 1H), 1.62 (dd, J = 11.3, 3.9 
Hz, 1H), 1.46 (td, J = 13.1, 5.6 Hz, 1H), 1.36 (s, 3H). 
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13
C NMR (CDCl3, 125 MHz): δ 217.7, 192.0, 173.0, 172.5, 145.8, 129.7, 88.5, 64.4, 64.4, 64.2, 
56.6, 52.8, 52.0, 51.2, 50.8, 49.7, 42.6, 30.5, 19.1, 11.6. 
HRMS(ESI): m/z calc. for C20H23O7 [M+H]
+
: 375.1444, found: 375.1451. 
 
 
Procedure: In an oven-dried 7 mL vial with stirbar, GEM-1 (27.0 mg, 0.075 mmol) and p-
toluenesulfonic acid (4.8 mg, 0.025) were suspended in toluene (1 mL) and heated at 115 °C for 
3 hours.  The crude reaction was concentrated and purified by flash chromatography on silica gel 
(ethyl acetate/hexanes 1:2 to 2:3) to yield GEM-14 as a white solid (21.6 mg, 80.0%). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.35 (d, J = 9.4 Hz, 1H), 6.07 (d, J = 9.4 Hz, 1H), 3.75 (s, 3H), 
3.54 (d, J = 7.0 Hz, 1H), 3.00 (dd, J = 18.8, 3.9 Hz, 1H), 2.79 (d, J = 7.0 Hz, 1H), 2.25 (dd, J = 
13.0, 4.2 Hz, 1H), 2.22 (d, J = 18.8 Hz, 2H), 2.07 – 2.01 (m, 1H), 1.86 (dd, J = 11.4, 1.6 Hz, 
1H), 1.73 – 1.64 (m, 3H), 1.35 (s, 3H), 1.07 (s, 3H). 
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13
C NMR (CDCl3, 125 MHz): δ 217.2, 192.1, 173.0, 172.5, 145.9, 129.6, 88.5, 64.4, 64.1, 52.7, 
51.3, 51.1, 50.9, 50.7, 49.7, 47.6, 35.4, 19.7, 19.4, 11.6. 
HRMS(ESI): m/z calc. for C20H23O6 [M+H]
+
: 359.1495, found: 359.1495. 
 
 
Procedure: In an oven-dried 7 mL vial with stirbar, GEM-1 (28.8 mg, 0.080 mmol) was 
dissolved in pyridine (1 mL).  Acetic anhydride (100 μL, 1.06 mmol) and 4-
dimethylaminopyridine (10.0 mg, 0.082 mmol) were added to the reaction and stirred for 6 hours 
at room temperature.  The reaction was quenched with 1 M HCl (0.5 mL) and extracted with 
ethyl acetate (3x).  The organic layers were collected, concentrated, and purified by flash 
chromatography on silica gel (ethyl acetate/hexanes 4:1 to 3:1) to yield GEM-15 as a colorless 
oil (23.2 mg, 72.0%). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.24 (d, J = 9.4 Hz, 1H), 6.04 (d, J = 9.4 Hz, 1H), 5.19 (dd, J = 
3.2, 1.6 Hz, 1H), 5.05 – 4.98 (m, 1H), 3.73 (s, 3H), 3.52 (d, J = 10.6 Hz, 1H), 2.89 (d, J = 10.6 
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Hz, 1H), 2.45 – 2.40 (m, 1H), 2.38 (dd, J = 10.9, 2.5 Hz, 1H), 2.34 – 2.30 (m, 1H), 2.23 (dt, J = 
15.1, 3.0 Hz, 1H), 2.18 – 2.16 (m, 1H), 2.09 (dd, J = 10.6, 1.9 Hz, 1H), 2.07 – 2.01 (m, 1H), 2.03 
(s, 3H), 1.85 – 1.74 (m, 2H), 1.26 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 191.7, 173.1, 171.7, 170.1, 153.0, 147.4, 129.4, 108.8, 89.5, 
84.0, 65.1, 62.3, 52.7, 51.5, 51.4, 50.9, 42.7, 40.2, 36.3, 22.2, 17.0, 11.6. 
HRMS(ESI): m/z calc. for C22H25O7 [M+H]
+
: 401.1600, found: 401.1601. 
 
 
Procedure: In an oven-dried 7 mL vial with stirbar, GEM-1 (29.2 mg, 0.081 mmol) was 
dissolved in pyridine (1 mL).  Methanesulfonyl chloride (60 μL, 0.775 mmol) was added in one 
portion, and the reaction was stirred for 15 hours at room temperature.  In order to increase 
conversion, 4-dimethylaminopyridine (17.9 mg, 0.147 mmol) was added and the reaction stirred 
for another 7 hours.  The reaction was quenched with 6 M HCl (2 mL) and extracted with ethyl 
acetate (3x).  The combined organic layers were washed with brine, concentrated, and purified 
by flash chromatography on silica gel (ethyl acetate/hexanes 1:3 to 1:1) to yield GEM-12 as an 
oil (25.1 mg, 70.5%). 
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1
H NMR (CDCl3, 500 MHz): δ 7.24 (d, J = 9.4 Hz, 1H), 6.05 (d, J = 9.4 Hz, 1H), 5.39 (dd, J = 
3.2, 1.7 Hz, 1H), 5.16 (t, J = 2.0 Hz, 1H), 3.75 (s, 3H), 3.52 (d, J = 10.4 Hz, 1H), 3.04 (s, 3H), 
2.92 (d, J = 10.4 Hz, 1H), 2.62 (ddd, J = 12.8, 8.3, 2.5 Hz, 1H), 2.56 – 2.47 (m, 2H), 2.25 (dt, J = 
15.3, 3.0 Hz, 1H), 2.19 (dd, J = 15.2, 2.0 Hz, 1H), 2.16 – 2.10 (m, 1H), 2.07 (q, J = 5.6 Hz, 1H), 
2.05 – 1.96 (m, 1H), 1.83 (dddd, J = 12.5, 7.1, 5.5, 2.3 Hz, 1H), 1.27 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 191.5, 172.9, 171.5, 151.2, 147.0, 129.5, 111.2, 91.1, 89.3, 65.1, 
62.3, 52.8, 51.3, 51.0, 50.8, 42.3, 41.6, 41.1, 37.3, 17.1, 11.6. 
HRMS(ESI): m/z calc. for C21H25O8S [M+H]
+
: 437.1270, found: 437.1271. 
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Procedure: In an oven-dried round bottom flask with a stirbar under argon, dissolved GEM-1 
(49.0 mg, 0.137 mmol) in tetrahydrofuran (1 mL) and cooled to -78 °C.  L-selectride (0.15 mL, 
1.0 M in THF) was added dropwise, and the reaction continued to stir at -78 °C for 1 hour.  The 
reaction was quenched with saturated aqueous ammonium chloride (1 mL), warmed to room 
temperature, and extracted with ethyl acetate (3x).  The combined organic layers were 
concentrated and purified by flash chromatography on silica gel (ethyl acetate/hexanes 1:2 to 
1:1) to yield GEM-17 as a white solid (15.7 mg, 31.8%) and GEM-18 and GEM-19 as an 
inseparable mixture (27.2 mg, 55.2%, 1:2 mixture of GEM-18:GEM-19). 
Note:  Although GEM-18 and GEM-19 could not be separated by chromatography, most 
1
H 
signals and all 
13
C signals could be assigned based on the ratio of peaks.  Due to substantial 
overlaps in the aliphatic region in the 
1
H NMR, this entire region has been assigned as a 
multiplet. 
 
1
H NMR (CDCl3, 500 MHz): δ 5.26 (t, J = 1.9 Hz, 1H), 4.98 (t, J = 1.9 Hz, 1H), 3.72 (s, 3H), 
3.07 (d, J = 9.3 Hz, 1H), 2.80 (d, J = 9.3 Hz, 1H), 2.67 – 2.59 (m, 2H), 2.49 (ddd, J = 13.8, 7.9, 
2.3 Hz, 1H), 2.23 (dt, J = 15.5, 2.9 Hz, 1H), 2.19 (q, J = 2.1 Hz, 1H), 2.17 – 2.11 (m, 1H), 2.07 
(ddd, J = 14.5, 7.6, 3.6 Hz, 1H), 2.04 – 1.94 (m, 1H), 1.94 – 1.88 (m, 2H), 1.83 – 1.68 (m, 4H), 
1.19 (s, 3H). 
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13
C NMR (CDCl3, 125 MHz): δ 200.3, 174.1, 172.4, 156.1, 107.9, 92.6, 78.3, 63.2, 57.7, 52.5, 
52.4, 51.6, 51.5, 46.1, 43.0, 38.3, 34.9, 31.0, 17.8, 10.5. 
HRMS(ESI): m/z calc. for C20H25O6 [M+H]
+
: 361.1651, found: 361.1668. 
HRMS(ESI): m/z calc. for C20H24O6Na [M+Na]
+
: 383.1471, found: 383.1472. 
 
 
1
H NMR (CDCl3, 500 MHz): δ 5.24 (t, J = 2.5 Hz, 1H), 4.95 (dt, J = 4.4, 2.0 Hz, 1H, GEM-18), 
3.72 (s, 3H), 3.67 (dt, J = 10.2, 6.6 Hz, 1H), 2.75 (d, J = 10.1 Hz, 1H), 2.54 (d, J = 9.8 Hz, 1H), 
2.23 (dt, J = 14.2, 5.6 Hz, 1H), 2.20 – 1.44 (m, 14H), 1.17 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 177.4, 173.1, 156.7, 107.6, 92.6, 78.4, 73.2, 57.4, 54.6, 52.7, 
52.4, 50.9, 45.7, 43.2, 36.8, 29.9, 29.7, 24.9, 17.6, 13.0. 
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1
H NMR (CDCl3, 500 MHz): δ 6.21 (dd, J = 9.3, 1.9 Hz, 1H), 5.86 (dd, J = 9.3, 2.6 Hz, 1H), 
5.26 (dd, J = 3.1, 1.9 Hz, 1H), 4.95 (dt, J = 4.4, 2.0 Hz, 1H), 4.26 (t, J = 2.2 Hz, 1H), 3.73 (s, 
3H), 2.93 (d, J = 10.6 Hz, 1H), 2.76 (d, J = 10.1 Hz, 1H), 2.20 – 1.44 (m, 11H), 1.28 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 176.7, 172.6, 156.9, 133.3, 130.8, 107.9, 90.1, 78.3, 73.7, 57.9, 
55.3, 52.4, 51.3, 51.1, 45.1, 43.2, 38.4, 30.2, 17.3, 14.4. 
 
 
Procedure: In a 100 mL round bottom flask, gibberellic acid (1.010 g, 2.92 mmol) was 
suspended in acetone (30 mL), after which potassium carbonate (2.00 g, 14.5 mmol) and 
propargyl bromide (2.50 mL, 22.8 mmol, 80% in toluene) were added.  The reaction stirred for 
20 hours at room temperature, and then the reaction was quenched with water (20 mL) and 
extracted with ethyl acetate.  The combined organic layers were concentrated and purified by 
flash silica chromatography (ethyl acetate/hexanes 2:3 to 1:0) to yield GEM-10 as a white solid 
(393.2 mg, 35.1%).  GEM-10 (210.1 mg, 0.547 mmol) was dissolved in dichloromethane (5 mL) 
in a 30 mL round bottom flask.  Dess–Martin periodinane (386.2 mg, 0.911 mmol) was added in 
one portion and the reaction stirred for 21 hours at room temperature.  The reaction was 
quenched for 1 hour with saturated aqueous sodium bicarbonate (4 mL) and saturated aqueous 
sodium thiosulfate (4 mL).  The reaction was extracted with ethyl acetate (3x), concentrated, and 
purified by flash silica chromatography (ethyl acetate/hexanes 1:2 to 3:4) to yield GEM-8 as a 
white solid (147.5 mg, 70.6%). 
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Procedure: In an oven-dried 7 mL vial with stirbar, gibberellenic acid (46.7 mg, 0.135 mmol) 
was dissolved in toluene (1.5 mL) and methanol (0.5 mL).  Trimethylsilyl diazomethane (160 
μL, 0.32 mmol, 2 M in hexanes) was added dropwise and the reaction stirred for 45 minutes at 
room temperature.  The reaction was concentrated and resuspended in dichloromethane (1 mL).  
Dess–Martin periodinane (77.0 mg, 0.182 mmol) was added in one portion and the reaction 
stirred for 17 hours at room temperature.  The reaction was quenched for 1 hour with saturated 
aqueous sodium bicarbonate (1 mL) and saturated aqueous sodium thiosulfate (1 mL).  The 
reaction was extracted with ethyl acetate (3x), concentrated, and purified by flash silica 
chromatography (ethyl acetate/hexanes 1:2 to 1:1) to yield GEM-20 as a white solid (27.0 mg, 
53.8%). 
 
1
H NMR (CDCl3, 500 MHz): δ 7.22 (dd, J = 9.7, 0.8 Hz, 1H), 6.01 (d, J = 9.7 Hz, 1H), 5.20 (t, J 
= 2.6 Hz, 1H), 5.01 (t, J = 2.6 Hz, 1H), 3.74 (s, 3H), 3.66 (dd, J = 8.3, 4.0 Hz, 1H), 3.61 (s, 3H), 
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3.47 (d, J = 8.3 Hz, 1H), 2.71 (dd, J = 16.4, 6.2 Hz, 1H), 2.35 – 2.28 (m, 2H), 2.24 (dd, J = 10.6, 
2.8 Hz, 1H), 2.17 (dddd, J = 16.3, 12.1, 7.9, 4.3 Hz, 1H), 1.89 (td, J = 11.9, 6.3 Hz, 1H), 1.83 – 
1.78 (m, 1H), 1.77 (dd, J = 10.6, 1.9 Hz, 1H), 1.32 (s, 3H). 
13
C NMR (CDCl3, 125 MHz): δ 196.2, 174.0, 171.3, 153.6, 147.4, 138.0, 126.9, 126.2, 106.9, 
79.0, 57.3, 57.0, 54.0, 52.5 (2C), 52.3, 49.5, 39.2, 39.2, 21.4, 18.6. 
HRMS(ESI): m/z calc. for C21H24O6Na [M+Na]
+
: 395.1471, found: 395.1458. 
 
 
Procedure: In an oven-dried 7 mL vial with stirbar, hydrolyzed allogibberellic acid (47.0 mg, 
0.129 mmol) was dissolved in toluene (1.5 mL) and methanol (0.5 mL).  Trimethylsilyl 
diazomethane (150 μL, 0.30 mmol, 2 M in hexanes) was added dropwise and the reaction stirred 
for 1 hour at room temperature.  The reaction was concentrated and resuspended in 
tetrahydrofuran (2 mL).  Manganese dioxide (122.0 mg, 1.40 mnol) was added in one portion 
and the reaction stirred in the dark for 40 hours at room temperature.  The reaction was 
concentrated and purified by flash silica chromatography (ethyl acetate/hexanes 1:3 to 1:0) to 
yield GEM-21 as a white solid (9.8 mg, 22%). 
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1
H NMR (CDCl3, 500 MHz): δ 5.87 (td, J = 2.5, 1.0 Hz, 1H), 5.14 (dd, J = 3.2, 2.0 Hz, 1H), 
5.02 (t, J = 2.2 Hz, 1H), 4.03 (d, J = 1.0 Hz, 1H), 3.76 (s, 3H), 3.67 – 3.64 (m, 1H), 3.65 (s, 3H), 
3.60 (dd, J = 5.0, 2.7 Hz, 1H), 3.06 (d, J = 4.9 Hz, 1H), 2.84 (d, J = 7.3 Hz, 1H), 2.67 (dt, J = 
16.4, 3.0 Hz, 1H), 2.27 (dq, J = 16.4, 2.1 Hz, 1H), 1.99 (dd, J = 14.8, 5.8 Hz, 1H), 1.81 – 1.63 
(m, 2H), 1.62 – 1.54 (m, 1H), 1.43 – 1.39 (m, 1H), 1.39 – 1.36 (m, 1H), 1.37 (s, 3H), 1.18 – 1.14 
(m, 1H). 
13
C NMR (CDCl3, 125 MHz): δ 196.3, 175.1, 173.5, 167.1, 153.3, 116.9, 107.3, 79.2, 74.7, 52.5, 
52.4, 51.2, 50.0, 49.2, 49.0, 47.4, 47.3, 38.8, 37.3, 20.0, 18.7. 
HRMS(ESI): m/z calc. for C21H27O7 [M+H]
+
: 391.1757, found: 391.1765. 
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Procedure: In a 7 mL vial with stirbar, dissolved biotin-azide (11.0 mg, 0.0337 mmol) and 
GEM-8 (21.9 mg, 0.057 mmol) in dichloromethane (0.2 mL), then added sodium ascorbate (5.8 
mg, 0.029 mmol), water (0.2 mL), and ethanol (0.2 mL).  The reaction was allowed to stir for 5 
minutes, after which copper sulfate (4.2 mg, 0.0168 mmol) was added.  The reaction stirred for 
24 hours at room temperature, and then was concentrated and purified by flash silica 
chromatography (ethyl acetate/methanol 100:0 to 80:20) to afford GEM-22 as a white solid 
(13.2 mg, 55%).  GEM-22 was highly insoluble in organic solvents. 
1
H NMR (d6-acetone, 500 MHz): δ 8.12 (s, 1H), 7.60 (d, J = 9.4 Hz, 1H), 7.52 – 7.44 (m, 2H), 
6.05 (d, J = 9.4 Hz, 1H), 5.92 (br s, 1H), 5.77 (br s, 1H), 5.33 (d, J = 12.6 Hz, 1H), 5.24 (d, J = 
12.7 Hz, 1H), 5.20 (t, J = 2.2 Hz, 1H), 4.84 (br s, 1H), 4.51 (ddd, J = 7.6, 3.6, 2.4 Hz, 1H), 4.45 
(t, J = 6.8 Hz, 2H), 4.34 (ddd, J = 7.4, 4.4, 1.9 Hz, 1H), 3.61 (d, J = 10.6 Hz, 1H), 2.93 (dd, J = 
12.6, 5.0 Hz, 1H), 2.89 (d, J = 10.8 Hz, 1H), 2.70 (d, J = 12.6 Hz, 1H). 
 
 
 
Procedure: In a 7 mL vial with stirbar, dissolved coumarin-azide (24.9 mg, 0.076 mmol) and 
GEM-8 (40.9 mg, 0.107 mmol) in dichloromethane (0.2 mL), then added sodium ascorbate (9.7 
mg, 0.049 mmol), water (0.2 mL), and ethanol (0.2 mL).  The reaction was allowed to stir for 5 
minutes, after which copper sulfate (6.2 mg, 0.025 mmol) was added.  The reaction stirred for 24 
hours at room temperature, and then was concentrated and purified by flash silica 
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chromatography (ethyl acetate/methanol 95:5 to 80:20) to afford GEM-23 as a yellow solid 
(40.4 mg, 75.1%). 
HRMS(ESI): m/z calc. for C38H42N5O9 [M+H]
+
: 712.2983, found: 712.2977. 
 
 
Procedure: Gibberellic acid (114.1 mg, 0.329 mmol) and PyBOP (180.5 mg, 0.347 mmol) were 
loaded in an oven-dried 7 mL vial with stirbar and dissolved in dichloromethane (3 mL).  
Diisopropylethylamine (175 μL, 1.01 mmol) was added and the reaction stirred at room 
temperature for 1 hour, during which time the reaction became clear and colorless.  Benzyl 
amine (60 μL, 0.549 mmol) was added, and the reaction stirred for 18 hours at room temperature.  
An insoluble white precipitate was visible in the reaction.  The reaction was quenched with 1 M 
HCl (2 mL) and extracted with ethyl acetate (3x).  The solid precipitate stayed in the organic 
layer, and was filtered, washed with water, and dried over P2O5 to afford GEM-24 as a white 
solid (62.5 mg, 43.6%). 
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1
H NMR (d4-methanol, 500 MHz): δ 7.32 – 7.28 (m, 4H), 7.24 (ddt, J = 9.0, 3.6, 1.7 Hz, 1H), 
6.38 (dd, J = 9.3, 1.0 Hz, 1H), 5.87 (dd, J = 9.3, 3.6 Hz, 1H), 5.16 (t, J = 2.5 Hz, 1H), 4.89 (d, J 
= 2.1 Hz, 1H), 4.40 (d, J = 14.8 Hz, 1H), 4.35 (d, J = 14.7 Hz, 1H), 3.98 (d, J = 3.6 Hz, 1H), 3.28 
(d, J = 10.2 Hz, 1H), 2.67 (d, J = 10.1 Hz, 1H), 2.21 (p, J = 2.4 Hz, 2H), 1.98 (dd, J = 10.1, 6.6 
Hz, 2H), 1.95 – 1.90 (m, 1H), 1.90 – 1.84 (m, 1H), 1.81 – 1.70 (m, 2H), 1.65 (d, J = 10.7 Hz, 
1H), 1.18 (s, 3H). 
13
C NMR (d4-methanol, 125 MHz): δ 181.3, 173.5, 158.2, 140.0, 134.1, 133.2, 129.5 (2C), 128.8 
(2C), 128.3, 107.1, 92.9, 78.8, 70.8, 55.0, 54.4, 53.5, 52.2, 51.9, 46.2, 44.5, 44.4, 39.7, 18.0, 
15.0. 
HRMS(ESI): m/z calc. for C26H30NO5 [M+H]
+
: 436.2124, found: 436.2118. 
 
 
Procedure: GEM-24 (40.0 mg, 0.092 mmol) was dissolved in dichloromethane (1 mL) in a 
dried 7 mL vial.  Dess–Martin periodinane (65.1 mg, 0.153 mmol) was added in one portion and 
the reaction stirred for 6 hours at room temperature.  The reaction was quenched for 1 hour with 
saturated aqueous sodium bicarbonate (0.5 mL) and saturated aqueous sodium thiosulfate (0.5 
mL).  The reaction was extracted with ethyl acetate (3x), concentrated, and purified by flash 
silica chromatography (ethyl acetate/hexanes 1:2 to 1:1) to yield GEM-5 as a white solid (23.7 
mg, 59.5%). 
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Chapter 4: Biochemical Evaluation of 
Epipolythiodiketopiperazine Compounds 
 
Portions are reprinted with permission from Boyer, N.; Morrison, K. C.; Kim, J.; Hergenrother, 
P. J.; Movassaghi, M. “Synthesis and Anticancer Activity of Epipolythiodiketopiperazine 
Alkaloids,” Chem. Sci. 2013, 4, 1646-1657. 
 
4.1 Epipolydiketopiperazine Background 
 Epipolydiketopiperazines (ETPs) are members of the alkaloid class of natural products 
that contain and intramolecular polysulfide bridge at the α,α’-positions of a cyclodipeptide 
(Figure 1).
1
  This class of natural products encompasses a wide range of structural features, with 
both monomeric and dimeric units containing varying degrees of oxygenation.  Although ETPs 
have numerous reported biological activities,
1
 no comparative analysis of the structure-activity 
relationship of any ETP had been performed prior to 2013, largely due to the absence of a large 
collection of structurally-related ETP alkaloids that could be tested in a single set of assays. 
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Figure 4.1. Representative epithiodiketopiperazines. Adapted from Boyer et al.
2
 
 
4.1.1 Anticancer activity of ETPs 
 One of the most promising biological properties of the ETP alkaloids is their anticancer 
activity.  The first reported and most studied of the ETPs is gliotoxin (4-1).
1
  Gliotoxin is known 
to have a wide range of biological activities and selectively kills hematopoietic cells via 
apoptosis.
3
  Although concerns have been raised about the general in vivo toxicity of gliotoxin,
4
 
efficacy in xenograft studies
5-6
 suggest that this class of compounds may have therapeutic 
potential. 
 The more complex chaetocin and verticllin classes of ETPs have shown similarly broad 
spectra of activity.  Previous reports have shown reasonable potency against HeLa cells for 4-2 
(300 nM),
7
 4-3 (30 nM),
8
 and 4-4, 4-5, and 4-6 (20-50 nM),
9
 and Chaetocin A (4-4) has 
demonstrated activity versus myeloma cell lines.
10
  However, access to a greater diversity of 
analogs in order to achieve more promising pharmacological activity is greatly desired. 
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 The polysulfide bridge present in most ETP alkaloids is considered to be the critical 
pharmacophore for this biological activity.
1
  A recent report demonstrated the ability of an 
isolated ETP ring appended to a simple carbon tether to inhibit the hypoxia-inducible 
transcription factor and reduce tumor growth in a mouse breast cancer model.
11
  Additionally, it 
has been observed by Numata and others that dimers typically have one order of magnitude more 
potent activity compared to monomeric analogs, suggesting the possibility of a synergistic 
effect.
12-17
  However, the impact of the remaining carboskeleton on the activity of natural ETP 
alkaloids is poorly understood. 
 At least three modes of cell death induction have been suggested in the literature for 
ETP-containing natural products.
3, 18-19
  The first proposed pathway is the generation of reactive 
oxygen species following redox cycling and induction of oxidative stress, DNA strand cleavage, 
and apoptosis.  This suggestion arose due to the observation of ROS upon treatment with certain 
ETPs;
10, 20-22
 however, it is not clear if the observed ROS is a cause of cell death or if it is the 
natural result of apoptosis.  The second proposed pathway is the covalent modification and 
inhibition of cellular proteins via mixed disulfides between cysteine residues on proteins
23-24
 or 
through catalytic crosslinking of cysteines within a protein.
25
  The final proposed pathway is a 
disruption of the global tertiary structure of proteins containing a Zn
2+
-binding cysteine-histidine 
rich protein domain via a zinc ion ejection mechanism.
25
  Although there is no clear evidence 
that one of these pathways is the predominant mechanism of ETP activity, or that a single 
compound exclusively uses one pathway, it is possible that ETPs broad spectrum of activity is 
tied to their lack of a single protein target.  Full translational development of these compounds 
requires a better understanding of the interplay between structure and activity of the ETP 
alkaloids, and ideally a more complete elucidation of their mode of action. 
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4.1.2 Current Work to Evaluate Natural and Unnatural ETPs for Anticancer Activity  
 Recently, the Movassaghi group reported the enantioselective total synthesis of several 
members of the ETP class,
26-27
 including (+)-12,12’-dideoxyverticillin A (4-3), (+)-chaetocin A 
(4-4), (+)-chaetocin C (4-5), and (+)-12,12’-dideoxychetracin A (4-6), using a Lewis acid-
promoted C3-nucleophilic substitution.
28
 This synthetic methodology offers a unique opportunity 
to create multiple derivatives for the evaluation against cancer cell lines in culture.  With the 
ultimate goal of identifying ETP derivatives worthy of evaluation in vivo, a large set of natural 
and unnatural ETPs was synthesized by the Movassaghi lab (Figure 4.2) and tested at UIUC for 
their ability to induce cell death in two human cancer cell lines.  A subset of these compounds 
was tested in an additional three human cancer cell lines, enabling the establishment of an 
extensive structure-activity relationship.  After verifying that the ETPs were not hemolytic, 
representative compounds from the monomer and dimer classes were further evaluated for their 
ability to induce caspase-dependent apoptosis.  Further investigations into the mode of action of 
these compounds indicate that the dimeric and monomeric ETPs may act in cells through 
different mechanisms.  The high potency and broad activity of ETP-containing alkaloids 
suggests that they may have considerable translational potential.
2
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Figure 4.2. Structures of synthesized natural and unnatural ETP alkaloids.  Adapted from Boyer 
et al.
2
 
 
4.2 Evaluation of Activity 
4.2.1 Initial Screening in HeLa and U-937 Cells 
 In order to determine which ETP derivatives contained activity against cancer cells, all 
compounds received from the Movassaghi group (Figure 4.2) were screened at 0.1, 1, and 10 µM 
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for 24 hours in a 96-well format.  Compounds that showed activity at 1 µM or below were 
further at a range of concentrations to generate logistical dose-response curves from which IC50 
values could be calculated (Table 4.1).  Interestingly, dimers with an intact reactive sulfide 
bridge showed the highest level of activity in these two cell lines.  Derivatives lacking sulfur (4-
21 through 4-23, 4-47 through 4-59) were completely inactive, as would be expected based on 
previous reports.  Monomers with non-bridging sulfur linkages containing functional groups that 
could be bioactivated (4-44 through 4-46) show moderate to good activity. 
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Table 4.1. Assessment of the 60 ETPs and DKPs from Figure 4.2 for anticancer activity against 
U-937 (hystiocytic lymphoma) and HeLa (cervical carcinoma) human cancer cell lines after a 
72-hour exposure.
a 
Cmpd U-937 HeLa 
 
Cmpd U-937 HeLa 
 
Cmpd U-937 HeLa 
Dimers with sulfide bridges 
 
Sarcosine-derived monomers 
 
Sarcosine-derived monomers 
4-3 15.5 ± 2.9 7.2 ± 3.0 
 
with sulfur-containing bridges cont. 
 
without sulfur 
4-4 0.81 ± 0.15 6.9 ± 2.0 
 
4-28 8.3 ± 3.3 137 ± 86 
 
4-47 >10,000 >10,000 
4-5 0.75 ± 0.13 6.3 ± 0.6 
 
4-29 24.5 ± 7.4 123 ± 29 
 
4-48 >10,000 >10,000 
4-6 1.3 ± 0.5 5.6 ± 1.0 
 
4-30 5.0 ± 1.3 44.9 ± 1.3 
 
4-49 >10,000 >10,000 
4-14 0.18 ± 0.06 0.087 ± 0.058 
 
4-31 20.7 ± 6.4 1530 ± 440 
 
4-50 >10,000 >10,000 
4-15 4.7 ± 1.3 14.1 ± 7.4 
 
4-32 14.8 ± 3.1 26.8 ± 4.8 
 
4-51 >10,000 >10,000 
4-16 9.7 ± 2.1 70 ± 20 
 
4-33 5.0 ± 2.1 22 ± 11 
 
4-52 >10,000 >10,000 
4-17 8.9 ± 2.3 28.1 ± 2.2 
 
4-34 59 ± 23 550 ± 33 
 
4-53 >10,000 >10,000 
4-18 2.9 ± 2.1 1.1 ± 0.8 
 
4-35 21.3 ± 8.7 56 ± 21 
 
4-54 >10,000 >10,000 
Sulfur-containing dimers 
 
4-36 3.8 ± 0.9 33 ± 13 
 
4-55 >10,000 >10,000 
4-19 >10,000 >10,000 
 
4-37 5.5 ± 1.3 37 ± 15 
 
4-56 >10,000 >10,000 
4-20 >10,000 >10,000 
 
4-38 82 ± 28 465 ± 37 
 
4-57 >10,000 >10,000 
Dimers without sulfur 
 
Sarcosine-derived monomers 
 
4-58 >10,000 >1,000 
4-21 >10,000 >10,000 
 
with non-bridging sulfurs 
 
4-59 >1,000 >1,000 
4-22 >10,000 >10,000 
 
4-7 >10,000 >10,000 
 
Alanine-derived monomers 
4-23 >10,000 >10,000 
 
4-39 >10,000 >10,000 
 
with sulfur-containing bridges 
Sarcosine-derived monomers 
 
4-40 >1,000 >1,000 
 
4-60 56 ± 23 67 ± 11 
with sulfur-containing bridges 
 
4-41 >10,000 >10,000 
 
4-61 >1,000 >1,000 
4-10 17.4 ± 1.1 117 ± 26 
 
4-42 >10,000 >10,000 
 
4-62 >1,000 >1,000 
4-24 5.9 ± 1.4 75 ± 10 
 
4-43 >10,000 >10,000 
 
4-63 >1,000 >1,000 
4-25 710 ± 130 1476 ± 180 
 
4-44 4.1 ± 0.5 17.3 ± 4.5 
 
4-64 24 ± 12 25.3 ± 2.0 
4-26 2.8 ± 0.3 41.7 ± 5.7 
 
4-45 14.5 ± 9.1 13.7 ± 2.3 
 
4-65 >1,000 >1,000 
4-27 36.6 ± 2.4 27.5 ± 9.2 
 
4-46 20.4 ± 9.0 36.6 ± 3.9 
 
4-66 >1,000 >1,000 
        
4-67 >1,000 >1,000 
 
≤1 nM 1<x≤10 nM 10<x≤50 nM 50<x≤150 nM 150<x≤1,000 nM >1,000 nM 
 
a
 72-hour IC50 values (in nM) as determined by MTS (U-937) and SRB (HeLa).  Error is standard deviation (SD) of 
the mean, n ≥ 3.  Adapted from Boyer et al.2 
 
4.2.2 Determination of Potency in a Panel of Cell Culture Lines 
 To expand our analysis of the ETP alkaloids and to further probe their potential as 
anticancer agents, 25 of the most potent derivatives were further tested in culture against three 
supplementary human cancer cell lines (H460, lung carcinoma; 786-O, renal carcinoma; MCF-7, 
breast carcinoma).  These results are shown in Table 4.2. 
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Table 4.2.  Assessment of the top 25 compounds for cytotoxicity in five human cell lines (U-937 
(hystiocytic lymphoma), HeLa (cervical carcinoma), H460 (lung carcinoma), 786-O (renal 
carcinoma), and MCF-7 (breast carcinoma)), after a 72-hour exposure.
a 
Cmpd U-937 HeLa H460 786-O MCF7 
Dimers with sulfide bridges 
4-3 15.5 ± 2.9 7.2 ± 3.0 42 ± 15 33.5 ± 12.6 28.4 ± 4.5 
4-4 0.81 ± 0.15 6.9 ± 2.0 53 ± 23 26.5 ± 7.7 50 ± 16 
4-5 0.75 ± 0.13 6.3 ± 0.6 26.0 ± 9.3 14.6 ± 0.8 27 ± 11 
4-6 1.3 ± 0.5 5.6 ± 1.0 39.3 ± 41 16.0 ± 2.4 22.5 ± 6.0 
4-14 0.18 ± 0.06 0.087 ± 0.058 1.53 ± 0.85 1.55 ± 0.77 1.65 ± 0.51 
4-15 4.7 ± 1.3 14.1 ± 7.4 140 ± 82 95 ± 23 77 ± 36 
4-16 9.7 ± 2.1 70 ± 20 187 ± 79 204 ± 40 263 ± 98 
4-17 8.9 ± 2.3 28.1 ± 2.2 179 ± 88 189 ± 26 >333 
4-18 2.9 ± 2.1 1.1 ± 0.8 18.5 ± 2.7 14.9 ± 4.4 10.7 ± 8.1 
Sarcosine-derived monomers with sulfur-containing bridge 
4-10 17.4 ± 1.1 117 ± 26 215 ± 100 181 ± 26 156 ± 18 
4-26 2.8 ± 0.3 41.7 ± 5.7 66 ± 19 62.7 ± 7.6 67 ± 19 
4-27 36.6 ± 2.4 27.5 ± 9.2 146.4 ± 6.9 145 ± 10 151 ± 31 
4-28 8.3 ± 3.3 137.7 ± 85.9 277 ± 43 344 ± 20 309 ± 31 
4-29 24.5 ± 7.4 123 ± 29 348 ± 110 168 ± 34 217 ± 35 
4-30 5.0 ± 1.3 44.9 ± 1.3 277 ± 44 162 ± 35 152 ± 42 
4-31 20.7 ± 6.4 1530 ± 440 >1000 368 ± 78 218 ± 97 
4-32 14.8 ± 3.1 26.8 ± 4.8 31.8 ± 2.5 66 ± 23 61 ± 11 
4-33 5.0 ± 2.1 22.2 ± 10.9 46.7 ± 5.3 83 ± 18 63 ± 16 
4-35 21.3 ± 8.7 56 ± 21 123 ± 50 64 ± 20 93 ± 34 
4-36 3.8 ± 0.9 33 ± 13 190 ± 61 133 ± 10 163 ± 7 
4-37 5.5 ± 1.3 37 ± 15 119 ± 25 139 ± 3 145 ± 18 
Sarcosine-derived monomers with non-bridging sulfur 
4-44 4.1 ± 0.5 17.3 ± 4.5 149 ± 59 151 ± 7 103 ± 37 
4-45 14.5 ± 9.1 13.7 ± 2.3 252 ± 37 376 ± 120 373 ± 75 
Alanine-derived monomers with sulfur-containing bridge 
4-60 56 ± 23 67 ± 11 165 ± 65 907 ± 48 327 ± 36 
4-64 24 ± 12 25.3 ± 2.0 222 ± 72 266 ± 85 210 ± 73 
 
≤1 nM 1<x≤10 nM 10<x≤50 nM 50<x≤150 nM >150 nM 
 
a
 72-hour IC50 values (in nM) as determined by MTS (U-937) and SRB (HeLa, H460, 786-O, and MCF-7).  Error is 
standard deviation (SD) of the mean, n ≥ 3.  Adapted from Boyer et al.2 
 
 All of the ETPs retain similar patterns of potency across all five cell lines.  Some 
compounds, such as 4-14, retain higher levels of activity in all of the cell lines, whereas others 
(eg, 4-17 or 4-31) appear to have more selective activity.  Generally, the U-937 and HeLa cell 
lines were most sensitive to the ETP class of compounds. 
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4.2.3 Structure-Activity Relationship 
 These data enabled the generation of an extensive SAR for the monomeric and dimeric 
ETPs.  As mentioned previously, the homodimers are the most potent compounds, with the 
N1,N1’-benzenesulfonylated analog (4-14) of (+)-12,12’-dideoxyverticillin A (4-3) showing the 
best activity in all five cell lines (structures are shown in Figure 4.3).  The monomeric ETPs also 
showed reasonable potency, albeit reduced relative to the homodimers.  This is consistent with 
previous reports that typically dimeric ETPs show an order of magnitude increase in potency 
relative to their monomeric analogs. 
 
 
Figure 4.3. Structures of dimer ETPs 4-3 and 4-14. 
 
 In comparing the homodimers, hydroxylation on the C17 position (4-4, 4-5, and 4-6) 
improves the potency relative to the dehydroxylated derivatives (4-3), whereas acylation (4-15 
and 4-16) decreases compound potency, although not to the same degree as the dehydroxylated 
derivative (4-3).  This suggests that some substitution is tolerated on this site, and indicates that a 
hydroxylated derivative of 4-14, our most potent compound, would be an interesting lead. 
 Within the monomeric class, various aromatic substitutions were well-tolerated at the C3-
position (4-24, 4-26, 4-32, and 4-33) and had IC50 values within the same order of magnitude.  In 
contrast, alkyl groups at the C3-position (4-61 and 4-65) showed substantially lower potencies, 
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and halides showed intermediate potency (4-30, 4-31, and 4-35), suggesting that steric bulk at 
the C3-position is important for compound activity.  Additionally, methyl substitution at C15 in 
the monomeric class (4-60 vs 4-24, and 4-64 vs 4-36) substantially reduces the potency of these 
compounds, which is consistent with the results observed for the dimeric class. 
 Our studies show that substitution at N1 and N1’ can enhance the anticancer activity of 
the alkaloids, although this is more consistent with the benzenesulfonyl substitution.  For 
example, 4-14 is two orders of magnitude more potent than the corresponding secondary aniline 
4-3.  This same pattern is observed in the monomers, although the magnitude of the effect is 
smaller. 
 While prior studies have demonstrated that having no sulfur atoms on the ETP ring 
results in a complete loss of biological activity,
4, 29
 our SAR demonstrates that sulfuration is not 
sufficient for potent activity.  Derivatives possessing sulfuration at only the tryptophan Cα 
position are not potent (4-19, 4-20, 4-47 through 4-51).  Additionally, the number of sulfur atoms 
in the bridging polysulfide is variably important.  For example, in comparing 4-25 
(monosulfide), 4-26 (disulfide), 4-27 (trisulfide), and 4-28 (tetrasulfide), it is clear that at least 
two separate sulfur atoms at the Cα positions are necessary for potent activity, although 25 is not 
completely inactive.  This series also illustrates that the degree of sulfuration past 2 is minimally 
impactful on compound potency.  Sulfur derivatives possessing non-labile alkyl groups (4-7, 4-
39 through 4-43, 4-47) do not display any anticancer activity, whereas compounds that could be 
activated in situ to a polysulfide bridge (trithiocarbonate 4-36, dithiocarbonate 4-37, thioacetate 
4-44, and alkyl disulfides 4-45 and 4-46) all show reasonable activity.  Interestingly, thioacetal 
4-38 retains a moderate cytotoxic activity, although this is substantially reduced in comparison to 
related derivatives. 
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 Some additional trends are apparent from the data derived from the extended panel of cell 
lines.  The degree of sulfuration has a larger impact in some of the adherent cell lines tested 
(H460, 786-O, and MCF-7), especially in the case of 4-26, 4-27, and 4-28, which show a 2-fold 
decrease in activity with each additional sulfur atom in the polysulfide bridge.  Interestingly, this 
effect is not seen for the dimers (4-4, 4-5, and 4-6), and the overall potency of these compounds 
is still reasonable.  There were several derivatives which displayed drastically different activity 
across cell lines; however, 4-32 and 4-33 displayed a relatively consistent potency for all cell 
lines tested.  This was particularly striking for their good potency in H460 cells, especially in 
comparison to the activity of structurally similar derivatives. 
 A general summary of the trends observed in the ETP SAR is shown in Figure 4.4. 
 
 
Figure 4.4. Summary of ETP structure-activity relationship.  Adapted from Boyer et al.
2
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4.2.4 Hemolytic Activity 
 Compounds that induce death in a range of diverse cancer cell lines with single-digit 
nanomolar potency are valuable, and an emerging application of such compounds is as antibody-
drug conjugates (ADC).
30-31
  ADCs use a covalently-bound antibody to selectively target a potent 
cytotoxin to a tumor site, as exemplified by Seattle Genetics’ brentuximab vedotin (an ADC with 
monomethyl auristatin E) that was recently approved by the FDA for the treatment of Hodgkin 
lymphoma and anaplastic large cell lymphoma.
30-31
  Some of the compounds described herein 
possess traits that suggest potential as ADCs, including ready synthetic access, detailed 
knowledge of sites that can be modified without loss of activity, and significant potency across a 
broad panel of cancer cell types.  Lack of hemolytic activity is an additional prerequisite for 
success in the ADC arena, as any hemolysis would be a non-starter for an IV drug.  Thus the 25 
derivatives listed in Table 4.2 were evaluated for their ability to induce hemolysis in human 
erythrocytes at concentrations well above their anticancer IC50 values.  As shown in Figure 4.5, 
the compounds show no hemolytic activity.  The concentrations at which hemolytic activity was 
assessed (1 and 10 μM) are, in some cases, over 1000-fold higher than the IC50 values versus 
cancer cells, indicating significant selectivity. 
 
Figure 4.5. Percent hemolysis following treatment with ETPs from Table 4.2.  Error bars 
represent standard error of the mean, n ≥ 3. 
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4.3 Induction of Apoptosis with Most Potent Compounds 
 Apoptosis is a form of programmed cell death (type I) where cysteine proteases 
(caspases) are activated, cleave a host of cellular substrates, and ultimately result in well-defined 
morphological changes in the cells leading to death.  These changes include membrane blebbing, 
chromatin condensation, and externalization of phosphatidylserine in the plasma membrane.
32-33
  
In order to further evaluate the activity of the ETP class of compounds, two of the most active 
compounds from the monomer (4-26 and 4-33) and dimer (4-5 and 4-14) classes were further 
examined for their ability to induce apoptosis (Figure 4.6). 
 
 
Figure 4.6. Structures of dimer ETPs 4-5 and 4-14, and structures of monomeric ETPs 4-26 and 
4-33 tested for their ability to induce apoptosis. 
 
4.3.1 Annexin V Exposure 
 The induction of apoptosis was first evaluated by the level of phosphatidylserine 
externalization (detected by FITC-conjugated Annexin V) that occurs prior to the disruption of 
cell membrane integrity (detected by propidium iodide (PI)).  The progression of cells through 
the AnnV+/PI- quadrant (lower right, Figure 4.7) demonstrates the ability of both monomeric 
and dimeric ETP-containing derivatives to induce apoptosis. 
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Figure 4.7.  ETP derivatives induce caspase-dependent apoptotic cell death.  Analysis of 
phosphatidylserine exposure and propidium iodide inclusion at 24 hours in U-937 cells.  
Compounds were tested at 100-times their 72-hour IC50 values [4-14 (20 nM), 4-5 (75 nM), 4-26 
(250 nM), and 4-33 (500 nM)].  Staurosporine (STS) was used at 50 nM as a positive control for 
apoptosis.  Adapted from Boyer et al.
2
 
 
4.3.2 Western Blot Analysis at 24 Hours 
 Another marker of apoptosis is the cleavage patterns of various intracellular proteins.  
Caspase-3 (C-3), which is one of the executioner caspases that leads to apoptosis, is activated 
from its low-activity zymogen (procaspase-3, PC-3) at an early stage of apoptosis.
32-33
  This 
activation can be visualized by Western blot by the cleavage of PC-3 (35 kDa) to caspase-3 (12 
and 17 kDa).  Caspase-3 in turn cleaves one of its cellular substrates, PARP-1.
32
  Treatment of 
cells with the four ETP derivatives, followed by Western blotting for PC-3/caspase-3 and PARP-
1 reveals that all these compounds induce cleavage of PC-3 and PARP-1 (Figure 4.8). 
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Figure 4.8.  ETP derivatives induce caspase-dependent apoptotic cell death.  Western blot 
analysis of procaspase-3 and PARP-1 cleavage at 24 hours in U-937 cells using β-actin as 
loading control.  Compounds were tested at 100-times their 72-hour IC50 values [4-14 (20 nM), 
4-5 (75 nM), 4-26 (250 nM), and 4-33 (500 nM)].  Staurosporine (STS) was used at 100 nM as a 
positive control for apoptosis.  Adapted from Boyer et al.
2
 
 
 In order to confirm that the observed apoptosis was dose-dependent, 4-14, 4-5, 4-26, and 
4-33 were tested for their ability to cleave procaspase-3 and PARP at two or three different 
concentrations.  As seen in Figure 4.9, all four compounds clearly demonstrate a dose-dependent 
activation of these apoptotic proteins. 
 
Figure 4.9.  ETP derivatives induce dose-dependent caspase-dependent apoptotic cell death.  
Western blot analysis of procaspase-3 and PARP-1 cleavage at 24 hours in U-937 cells using β-
actin as loading control.  Compounds were tested at the concentrations shown.   
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4.3.3 Summary of Induction of Apoptosis 
 The data from Western blotting and phosphatidylserine exposure both suggest that the 
dimeric and monomeric ETPs induce caspase-dependent apoptosis in a dose-dependent manner.  
This was validated for two monomers and two dimers, but has been seen for other compounds 
from Table 4.2 (see section 4.4.2). 
 
4.4 Further Characterization of Entire ETP Class 
 In order to determine the specific mechanism of the dimeric and monomeric ETPs, a 
number of additional experiments were performed in order to probe the general mechanistic 
pathways presented in Section 4.1.1.  These included evaluation of cell cycle arrest, induction of 
oxidative-stress response transcript HO-1, and ROS generation following compound treatment.  
Together, these data suggest that the monomeric and dimeric ETPs may have subtly different 
modes of action, although the cellular mechanism for this behavior is unknown. 
 
4.4.1 Induction of Cell Cycle Arrest 
 Several representative compounds in Table 4.2 were evaluated for their ability to induce 
cell cycle arrest (Figure 4.10).  Cells were treated with compounds for 20 hours, then fixed and 
analyzed using propidium iodide to stain the nuclear DNA.  Interestingly, the dimeric ETPs show 
no change in the distribution of cells through the replicative cycle, whereas the monomeric ETPs 
all show a strong G1-phase arrest.  Although there are a number of factors that can lead to G1-
phase arrest, this differential activity speaks to a differential mechanism of action. 
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Figure 4.10. Representative data showing cell cycle arrest of U-937 cells following 20-hour 
treatment with monomeric or dimeric ETPs.  The monomers all show arrest in G1 (p < 0.02). 
 
4.4.2 Induction of HO-1 Translation 
 One of the mechanistic hypotheses for how ETPs function in the cells is their signaling of 
oxidative stress, either by directly creating reactive oxygen species (ROS), or through the 
covalent modification of cysteines, which indirectly leads to oxidative stress signaling.  One of 
the early protein transcription factors in the pathway of oxidative stress signaling is heme 
oxygenase 1, or HO-1.
34
  U-937 cells were treated with both monomeric and dimeric ETPs for 18 
hours, and the protein levels of PARP, caspase-3, and HO-1 were evaluated by Western blot.  
ETP monomers and dimers both activate procaspase-3 and cleave PARP (Figure 4.11).  This is 
consistent with the data shown in section 4.3.2.  However, there was a substantial difference 
between the monomers and dimers in terms of HO-1 induction.  All of the dimer treatments (4-3, 
4-4, 4-5, 4-6, 4-15, 4-16, 4-17, and 4-18) show high levels of HO-1, regardless of the extent of 
cell death.  In contrast, the monomers only show mild levels of HO-1 induction, even at high 
levels of apoptotic induction (4-26 and 4-64, for example).  The one exception to this is 4-34, 
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which has minimal anticancer activity.  This suggests that there may be differential induction of 
cellular pathways by monomer and dimer ETPs. 
 
Figure 4.11. Representative Western blot showing the activation of procaspase-3 (PC3), 
cleavage of the caspase-3 substrate PARP-1, and induction of HO-1 following treatment with 
ETPs for 18 hours in U-937 cells.  Although most of the compounds induce some amount of 
PARP cleavage, only the dimers show strong induction of HO-1.  Dimers are colored in blue. 
 
4.4.3 ROS Generation 
 In order to determine whether the induction of HO-1 transcription and change in cellular 
glutathione levels was based on increasing levels of reactive oxygen species (ROS) in the cells, 
U-937 cells were treated with representative monomers and dimers for 26 hours.  The cells were 
then analyzed using the ROS dye dihydroethidium, which upon exposure to ROS becomes 
fluorescent (Figure 4.12).  Compounds such as staurosporine, which increase ROS levels during 
apoptosis, and DNQ, which directly induces ROS,
35
 both show a large increase in ethidium 
fluorescence.  In contrast, neither the monomers nor the dimers show a substantial increase in 
ROS levels at this timepoint.  Although this experiment would require further optimization and 
repetition to fully confirm this result, it is suggestive that this set of ETPs does not induce ROS.  
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Furthermore, preliminary results at shorter time points also do not show ROS induction 
following cell treatment with ETPs. 
 
 
Figure 4.12. Representative data of normalized DHE fluorescence following 26-hour treatment 
in U-937 cells.  Staurosporine (STS) and DNQ are positive controls that induce ROS generation 
either indirectly (STS) or directly (DNQ).  The ETPs tested show little to no induction of ROS. 
 
4.4.4 Transcript Profiling 
 One technique for determining the cellular response to external stimuli is to use transcript 
profiling.  This technique characterizes the transcriptional response of a cell following a 6-hour 
exposure to compound.  By analyzing the specific transcripts that are up- and down-regulated, it 
can be possible to obtain a more mechanistic understanding of compound behavior.
36-37
  The top 
up- and down-regulated transcripts in HL-60 cells treated with 4-18 are shown in Table 4.3.   
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Table 4.3. Transcriptional response in HL-60 cells following treatment with 4-18. 
Top Up-Regulated 
 
Top Down-Regulated 
SYMBOL 
Log Fold-
Change 
FDR p-
value 
 
SYMBOL 
Log Fold-
Change 
FDR p-
value 
 
SYMBOL 
Log Fold-
Change 
FDR p-
value 
TSC22D3 2.38 2.59*10
-11
 
 
TTC32 1.17 4.93*10
-7
 
 
MYC -1.99 2.66*10
-11
 
TSC22D3 2.37 7.46*10
-11
 
 
CAMP 1.17 5.95*10
-7
 
 
C3orf54 -1.99 4.11*10
-10
 
HSPA1B 2.36 2.61*10
-13
 
 
DNAJA4 1.17 1.17*10
-11
 
 
PLD6 -1.88 1.09*10
-11
 
INSIG1 2.23 8.09*10
-15
 
 
TMEM170A 1.16 2.25*10
-7
 
 
CD59 -1.77 8.56*10
-11
 
RGS2 2.15 8.09*10
-15
 
 
SGK1 1.16 1.81*10
-6
 
 
MYC -1.71 8.76*10
-11
 
DDIT4 2.13 2.85*10
-15
 
 
EFNB2 1.15 3.10*10
-11
 
 
ALG3 -1.67 5.00*10
-9
 
OKL38 1.97 1.10*10
-16
 
 
CDKN1A 1.15 1.17*10
-10
 
 
FUT4 -1.58 2.36*10
-12
 
BAG3 1.92 3.07*10
-12
 
 
JUN 1.15 3.78*10
-12
 
 
MEF2D -1.55 9.99*10
-10
 
BCL6 1.80 8.03*10
-11
 
 
DNAJB1 1.15 6.56*10
-12
 
 
KANK1 -1.53 9.40*10
-10
 
PTGS2 1.64 8.29*10
-08
 
 
LMTK2 1.14 8.29*10
-8
 
 
MYB -1.49 1.99*10
-10
 
PIM1 1.64 6.94*10
-11
 
 
IER3 1.14 2.93*10
-7
 
 
PLD6 -1.46 4.12*10
-12
 
HMGCS1 1.63 6.17*10
-13
 
 
DNAJB9 1.14 3.67*10
-6
 
 
BCL11A -1.41 1.17*10
-13
 
GPR84 1.60 4.01*10
-11
 
 
FICD 1.14 1.99*10
-6
 
 
HPDL -1.38 4.10*10
-10
 
SLC7A11 1.54 2.48*10
-8
 
 
HMOX1 1.11 2.36*10
-12
 
 
RBM12 -1.38 1.50*10
-9
 
SGK 1.49 1.17*10
-6
 
 
DDIT3 1.10 6.91*10
-5
 
 
MARS2 -1.36 2.17*10
-7
 
RNU1G2 1.47 4.80*10
-10
 
 
HMGCR 1.09 6.06*10
-10
 
 
C7orf68 -1.34 8.14*10
-9
 
RNU1-5 1.46 1.27*10
-9
 
 
KLF6 1.09 4.71*10
-8
 
 
RPS6KB1 -1.34 9.17*10
-9
 
NCF1 1.46 1.84*10
-10
 
 
ANXA2 1.09 1.43*10
-9
 
 
FAM46C -1.26 2.25*10
-7
 
KLF4 1.45 2.18*10
-7
 
 
STC2 1.08 2.85*10
-15
 
 
KIAA0182 -1.25 1.92*10
-6
 
NFKBIZ 1.44 4.28*10
-9
 
 
PMAIP1 1.08 3.54*10
-8
 
 
WT1 -1.24 5.28*10
-6
 
IL1B 1.44 5.68*10
-13
 
 
GCH1 1.08 2.80*10
-8
 
 
BCL11A -1.24 5.45*10
-14
 
SC4MOL 1.44 5.54*10
-12
 
 
RIT1 1.07 1.34*10
-14
 
 
PRICKLE1 -1.21 7.45*10
-10
 
KLF2 1.43 2.58*10
-9
 
 
PLEK 1.06 1.47*10
-8
 
 
PAFAH1B1 -1.18 6.87*10
-9
 
RNU1-3 1.43 1.36*10
-9
 
 
PYROXD1 1.06 1.83*10
-4
 
 
LRRC33 -1.16 9.00*10
-8
 
TLE3 1.42 7.69*10
-8
 
 
SERPINB8 1.06 8.69*10
-9
 
 
NUFIP1 -1.15 5.06*10
-8
 
SC4MOL 1.38 3.18*10
-11
 
 
RNU1A3 1.05 5.11*10
-8
 
 
FLJ39827 -1.15 8.63*10
-8
 
ADM 1.37 1.10*10
-14
 
 
VIM 1.05 9.69*10
-7
 
 
UBE2Q1 -1.14 6.20*10
-9
 
IL1RN 1.35 8.31*10
-10
 
 
FOS 1.04 8.63*10
-8
 
 
CD3EAP -1.14 5.06*10
-7
 
TRIM52 1.35 2.62*10
-10
 
 
HERC5 1.04 7.50*10
-12
 
 
C1orf186 -1.13 3.78*10
-8
 
LOC221710 1.34 4.37*10
-10
 
 
PPP1R15A 1.03 4.30*10
-7
 
 
OLIG2 -1.12 7.81*10
-11
 
LRRC8C 1.34 2.92*10
-10
 
 
EIF5 1.03 1.57*10
-7
 
 
RAB7B -1.11 3.69*10
-8
 
NLRP12 1.32 5.76*10
-9
 
 
SMOX 1.03 4.18*10
-5
 
 
RBM25 -1.10 1.52*10
-6
 
TICAM2 1.31 4.48*10
-9
 
 
KLF6 1.02 1.82*10
-8
 
 
CEBPG -1.07 1.99*10
-9
 
NCF1C 1.29 5.97*10
-9
 
 
OSGIN1 1.02 8.09*10
-15
 
 
PHF17 -1.07 1.55*10
-6
 
MED31 1.27 1.48*10
-12
 
 
FIGNL1 1.01 2.14*10
-8
 
 
MOAP1 -1.06 4.10*10
-10
 
ETNK1 1.26 7.21*10
-8
 
 
TMEM173 1.01 1.89*10
-7
 
 
ARHGAP23 -1.05 2.46*10
-6
 
CCNG2 1.26 2.26*10
-6
 
 
OTUB2 1.01 2.15*10
-6
 
 
KBTBD11 -1.04 5.42*10
-11
 
E2F2 1.25 4.61*10
-9
 
     
CREBZF -1.03 6.14*10
-8
 
LDLR 1.25 1.84*10
-10
 
     
EPS15 -1.03 3.35*10
-6
 
HERPUD1 1.24 2.81*10
-5
 
     
FAR1 -1.03 1.04*10
-6
 
IL1RN 1.24 4.71*10
-8
 
     
REEP5 -1.02 2.97*10
-6
 
AGPAT9 1.23 3.35*10
-10
 
     
PDS5B -1.02 1.60*10
-7
 
SGK1 1.22 1.54*10
-6
 
     
FAM117B -1.01 4.63*10
-8
 
SNTB2 1.22 7.34*10
-10
 
     
FAM46A -1.01 1.01*10
-9
 
BAG4 1.22 3.66*10
-9
 
     
SLC7A2 -1.01 2.21*10
-11
 
HERPUD1 1.22 7.06*10
-7
 
     
TP53RK -1.01 7.61*10
-7
 
LOC652616 1.22 2.88*10
-9
 
     
FAM119B -1.01 8.06*10
-8
 
DNAJC3 1.22 2.49*10
-9
 
     GCLM 1.21 1.53*10
-14
 
  INSIG1 1.18 1.98*10
-12
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 In general, the transcriptional response is consistent with the dimeric ETPs affecting ROS 
or electrophilic response proteins (highlighted in red in Table 4.3).  HMOX-1, the transcript for 
the protein HO-1, is upregulated following treatment with 4-18, as would be expected from the 
Western blot analysis shown in Figure 4.11.  However, this data does not differentiate between 
any of the proposed mechanisms for ETP activity in cells.  In order to more clearly establish the 
different cellular activities of dimeric and monomeric ETPs, it would be helpful to test several 
monomers and dimers head-to-head for their transcriptional response.  Further experiments could 
include connectivity map analysis
36-37
 in order to compare the activity of the monomeric and 
dimeric ETPs to other known biologically active compounds. 
 
4.5 Summary 
 The implementation of a highly modular and general strategy for the synthesis of ETP-
containing alkaloids has enabled the generation of over 60 derivatives within this natural product 
class.  Cell culture assays reveal potent anticancer activity for 25 natural and unnatural ETP 
derivatives in the (sub)nanomolar range against a broad variety of cancer types, and demonstrate 
an instructive SAR.  These derivatives have clarified the importance of the ETP ring sulfuration, 
and have elucidated the mild tolerance to substitution at C3 and C15 in both the monomeric and 
dimeric classes.  The low sensitivity of compound activity to substitutions at N1 and C17 suggest 
that these sites may be ideal for lead optimization.  Finally, the lower molecular weight 
monomers may provide to have more optimal pharmacokinetic properties, in spite of their 
attenuated potency, and provide further avenues for optimization and development of small 
molecule drugs. 
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 The exact mechanism by which the ETP class of alkaloids operates in cells has yet to be 
fully determined, in spite of the considerable attention afforded these compounds by biologists 
and chemists.  The large collection of compounds synthesized by the Movassaghi group and 
characterized here will enable a more thorough evaluation of the specific biological targets of the 
ETP-containing alkaloids.  Our initial results, enabled by this large collection, are summarized in 
Figure 4.13.  All active ETPs show excellent activity in U-937 cells, with the dimeric ETPs 
showing single-digit nanomolar or lower potency.  Additionally, the active ETPs induce 
apoptosis in U-937 cells but do not induce hemolysis in erythrocytes, suggesting that these 
compounds could be selective for cancer cells. 
 
Figure 4.13. Summary of cell culture results using monomeric and dimeric ETPs. 
 
 Our initial results suggest, however, that the dimeric and monomeric ETPs may operate 
through different cellular mechanisms.  Whereas the monomeric ETPs induce clear G1 arrest 
without induction of HO-1, the dimeric ETPs induce expression of HO-1 but do not affect the 
cell cycle.  This bimodal distribution may account for some of the literature discrepancies in 
assigning a mechanism for ETP action. 
Monomeric ETPs Dimeric ETPs
Mid- to low-nanomolar potency in U-937 cells
No observed hemolysis
Dose-dependent apoptosis
Arrest in G1 of cell cycle
Mild or no induction of HO-1
Single-digit nanomolar potency in U-937 cells
No observed hemolysis
Dose-dependent apoptosis
No cell cycle arrest
Strong induction of HO-1
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 In light of the original three mechanistic hypotheses, our data are consistent with the 
dimeric ETPs operating through the induction of oxidative stress.  HO-1 is a canonical indicator 
of oxidative stress within a cell, despite the absence of observed cellular ROS following an 
extended compound treatment.  In order to confirm this mechanism, it would be helpful to 
directly observe the generation of ROS within the cell directly following compound treatment.  
However, the induction of HO-1 does not exclude the possibility of the second mechanism of 
covalent modification and inhibition of cellular proteins, as electrophilic stress can also induce 
HO-1 expression. 
 In contrast, our data suggest that the monomeric ETPs operate in the absence of oxidative 
stress.  Although this is based primarily on the absence of HO-1 induction following treatment, 
the lack of observed cellular ROS further supports this hypothesis.  The induction of cell cycle 
arrest in the G1 phase has been shown to correlate with ROS-based mechanisms;
35
 however, G1 
arrest does not canonically indicate a cellular target. 
 Despite our efforts, our results do not clearly distinguish between an oxidative stress, 
covalent modification, or zinc ejection mechanism for the ETPs.  As a result, more work is 
needed to determine the basis for this differentiation between the monomeric and dimeric 
classes.  In particular, more detailed cellular ROS studies and evaluation of thiol modification of 
proteins would be instructive and consistent with the proposed modes of ETP activity.  However, 
the (sub)nanomolar in vitro potency of the ETPs, in combination with their ability to induce 
apoptosis and their lack of hemolytic activity, make for attractive candidates for further studies 
investigating mode of action and discovering promising small-molecule leads. 
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4.6 Methods 
General reagents and methods for biological assays 
For biological assays, propidium iodide, phenazine methosulfate, and Ribonuclease A were 
purchased from Sigma–Aldrich.  The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium salt was obtained from Promega.  Human erythrocytes were 
purchased from Bioreclamation and used within three days of receipt.  Optical densities were 
recorded on a Spectramax Plus 384 (Molecular Devices, Sunnyvale, CA).  Flow cytometry was 
performed on a BD Biociences LSR II (San Jose, CA) and the data was analyzed as described 
using FACSDiva software (San Jose, CA). 
 
Cell culture information 
Cells were grown in media supplemented with fetal bovine serum (FBS) and antibiotics (100 
μg/mL penicillin and 100 U/mL streptomycin).  Specifically, experiments were performed using 
the following cell lines and media compositions:  U-937, HeLa, H460, and 786-O (RPMI-1640 + 
10% FBS), and MCF7 (EMEM + 10% FBS).  Cells were incubated at 37 °C in a 5% CO2, 95% 
humidity atmosphere. 
 
IC50 value determination for adherent cells using sulforhodamine B 
Adherent cells (HeLa, H460, 786-O, and MCF7) were added into 96-well plates (5,000 cells/well 
for HeLa cell line; 2,000 cells/well for H460, 786-O, and MCF7 cell lines) in 100 μL media and 
were allowed to adhere for 2-3 hours.  Compounds were solubilized in DMSO as 100x stocks, 
added directly to the cells (100 μL final volume), and tested over a range of concentrations in 
triplicate (1% DMSO final) on a half-log scale.  Concentrations tested ranged from 1 pM to 10 
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μM, depending on the potency of the compound.  DMSO and cell-free wells served as the live 
and dead control, respectively.  After 72 hours of continuous exposure, the plates were evaluated 
using the SRB colorimetric assay as described previously.
38
  Briefly, media was removed from 
the plate, and cells were fixed by the addition of 100 μL cold 10% trichloroacetic acid in water.  
After incubating at 4 °C for an hour, the plates were washed in water and allowed to dry.  
Sulforhordamine B was added as a 0.057% solution in 1% acetic acid (100 μL), and the plates 
were incubated at room temperature for 30 minutes, washed in 1% acetic acid, and allowed to 
dry.  The dye was solubilized by adding 10 mM Tris base solution (pH 10.5, 200 μL) and 
incubating at room temperature for 30 minutes.  Plates were read at λ = 510 nm.  IC50 values 
were determined from three or more independent experiments using TableCurve (San Jose, CA). 
 
IC50 value determination for non-adherent cells using MTS 
In a 96-well plate, compounds were pre-added as DMSO stocks in triplicate to achieve a final 
concentration of 1%.  DMSO and cell-free wells served as the live and dead control, 
respectively.  U-937 (5,000 cells/well) cells were distributed in 100 μL media to the compound-
containing plate.  After 72 hours, cell viability was assessed by adding 20 μL of a PMS/MTS 
solution
39
 to each well, allowing the dye to develop at 37 °C until the live control had processed 
MTS, and reading the absorbance at λ = 490 nm.  IC50 values were determined from three or 
more independent experiments using TableCurve (San Jose, CA). 
 
Hemolysis assay using human erythrocytes 
To prepare the erythrocytes, 0.1 mL of human blood was centrifuged (10,000 g, 2 min).  The 
pellet was washed three times with saline (0.9% NaCl) via gentle resuspension and 
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centrifugation (10,000 g, 2 min).  Following the final wash, the erythrocytes were resuspended in 
0.8 mL red blood cell (RBC) buffer (10 mM Na2HPO4, 150 mM NaCl, 1 mM MgCl2, pH 7.4). 
 DMSO stocks of compounds were added to 0.5 mL tubes in singlicate (1 μL, 3.3% 
DMSO final).  The stocks were diluted with 19 μL RBC buffer.  Positive control tubes contained 
DMSO in water, and negative control tubes contained DMSO in RBC buffer.  A suspension of 
washed erythrocytes (10 μL) was added to each tube, and samples were incubated at 37 °C for 2 
hours.  Samples were centrifuged (10,000 g, 2 min), and the supernatant was transferred to a 
clear, sterile 384-well plate.  The absorbance of the supernatants was measured at λ = 540 nm, 
and percent hemolysis was calculated relative to the average absorbance values measured for the 
controls. 
 
Apoptosis in U-937 cells with annexin V-FITC and propidium iodide 
DMSO stocks of compounds were added to a 24-well plate in singlicate (0.2% DMSO final).  
After compound addition, 0.5 mL of a U-937 cell suspension (250,000 cells/mL) was added and 
allowed to incubate for 24 hours.  Following treatment, the cell suspensions were transferred to 
flow cytometry tubes and pelleted (500 g, 3 min).  The media was removed by aspiration, and 
cells were resuspended in 200 μL AnnV binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 
2.5 mM CaCl2) with 5 μg/mL PI and 1:90 dilution of AnnV.  Samples were analyzed using flow 
cytometry. 
 
Western blot analysis of apoptosis and HO-1 induction in U-937  
In a 24-well plate, compounds were added as DMSO stocks (0.2% DMSO final) in singlicate.  
After compound addition, 1.5 mL of a U-937 cell suspension (250,000 cells/mL) was added and 
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allowed to incubate for the indicated period of time.  The cell suspensions were transferred to 1.5 
mL tubes and pelleted (600 g, 3 min). The media was removed via aspiration, and the cells were 
lysed by adding 40 μL of RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% TX-100, 0.5% 
sodium deoxycholate, 0.1% SDS) with 1% Protease Inhibitor Cocktail Set III. Each sample was 
then vigorously vortexed twice for 15 seconds, with a 15-minute incubation on ice following 
each agitation. The cellular debris was pelleted (16,100 g, 5 min), and then 33 μL of the protein 
suspension was transferred to fresh 0.5 mL tubes. The protein levels were quantified using a 
standard BCA (Thermo Scientific), after which the samples were diluted with deionized water to 
achieve equal protein concentrations for all samples.  
 Prior to analyzing the samples, 6x Laemmli sample buffer (350 mM Tris, pH 6.8, 12% 
SDS, 0.012% bromophenol blue, 47% glycerol) with 5% β-mercaptoethanol was added to each 
sample to achieve a final 1x concentration, after which the samples were incubated at 95 °C for 5 
minutes to denature the protein samples. 20-30 μg of protein was loaded onto a 15-well 4–20% 
Tris-HCl gel and run for 1 hour at 120 V. The gel was equilibrated in PBS (pH 7.4) for 5 
minutes, and then transferred to a PVDF membrane for 2 hours at 45 V in cold Towbin transfer 
buffer (192 mM glycine, pH 8.3, 25 mM Tris-Cl, 20% methanol).  
 Generally, blots were probed as followed. The blot was blocked overnight at 4 °C with a 
blocking agent in 0.05% Tris-Buffered Saline Tween-20 (TBST) and then probed with the 
primary antibody at a 1:1000 dilution with a blocking agent in TBST overnight at 4 °C. The blot 
was washed with TBST, and then probed with a secondary rabbit HRP antibody (1:10,000, Cell 
Signaling) in TBST for 1 hour at room temperature. The blot was washed with TBST and PBS, 
and then visualized with Pico luminescent substrate kit (Thermo Scientific). 
Caspase 3 and PARP were blocked in 5% milk, and actin and HO-1 were blocked in 5% BSA. 
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Cell cycle arrest in U-937 cells 
In a 24-well plate, compounds were added as DMSO stocks (0.1% DMSO final) in triplicate.  
After compound addition, 0.5 mL of a U-937 cell suspension (500,000 cells/mL) was added and 
allowed to incubate for 20 hours.  The cell suspensions were transferred to 2 mL tubes and 
pelleted (600 g, 3 min). The media was removed via aspiration, and the cells were fixed with 
cold ethanol (70%, 0.5 mL).  Samples were stored in the freezer overnight.  Prior to analyzing 
the samples, the cells were pelleted (1500 g, 5 min) and the supernatant was aspirated.  The cells 
were incubated with 50 μL Ribonuclease A (1 mg/mL in PBS) for 3 hours before being taken up 
in 150 μL propidium iodide solution (25 μg/mL in PBS) and analyzed by flow cytometry.  Cells 
were gated for whole, single cells prior to analysis of the distribution through the cell cycle. 
 
Analysis of the induction of ROS in U-937 cells using dihydroethidium 
In a 24-well plate, compounds were added as DMSO stocks (0.2% DMSO final) in singlicate.  
After compound addition, 0.5 mL of a U-937 cell suspension (500,000 cells/mL) was added and 
allowed to incubate for 26 hours.  The cell suspensions were transferred to flow cytometry tubes 
and washed with warm HBSS.  The cells were treated with 0.5 mL of 250 nM DHE in HBSS and 
were allowed to process for 30 minutes.  The cells were put on ice, and then analyzed by flow 
cytometry.  The average ethidium fluorescence increased over time between the ethidium 
controls, so the absolute fluorescence was normalized based on a linear correlation between 
DMSO controls read at before and after the samples.  
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Transcript Profiling 
HL-60 cells (3,000,000 cells/sample) were incubated in the presence of prismatomerin (5 μM), 
plumericin (0.5 μL), or DMSO vehicle (0.2% final DMSO v/v) for 6 h in a 12-well plate. 
Aliquots (500 μL) were taken at 6 and 24 hours and assessed for viability by annexin 
V/propidium iodide (AV/PI) staining and flow cytometry in order to ensure that the compounds 
were non-toxic at 6 hours and toxic at 24 hours. After 6 hours, 5 mL of cells were pelleted and 
RNA isolated with on column DNase digestion. RNA integrity was assessed using an Agilent 
Bioanalyzer.  Following RNA isolation, whole genome transcript profiling was performed on the 
Illumina HumanHT-12 bead array for compounds and DMSO control from three independent 
experiments. The raw bead-level files were processed with Illumina® BeadStudio 3, Gene 
Expression Module v3.2.61, without background correction or normalization, to get one value 
per beadtype for each array. These 48,803 beadtype values were then input into R, using the 
beadarray package
40
 from the Bioconductor +Project.  The vsn algorithm was used for 
background correction,
41
 12 normalization and transformation of the beadtype values to the 
glog2 scale. Differential expression was assessed using a mixed linear model using the Limma 
package, which uses an empirical Bayes correction that helps to improve power by borrowing 
information across beadtypes.
42
  All the desired pair-wise comparisons between the 8 treatment 
groups (control + prismatomerin + plumericin + unrelated compounds) were pulled as contrasts 
from the model and the p-values were corrected for multiple hypotheses testing using the False 
Discovery Rate method separately for each contrast.
43
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Chapter 5: Biological Studies of Prismatomerin and Plumericin 
 
5.1 Introduction of Prismatomerin and Plumericin 
5.1.1 Iridoids and Biological Systems 
 The iridoids are a class of terpene natural products that share a common [4.3.0] bicyclic 
core.  All iridoids are biosynthesized from geranyl pyrophosphate and mevalonic acid, but many 
have additional rings appended to the core and contain glycosylations (Figure 5.1).
1
  Although 
iridoids have commonly been studied for their anti-inflammatory activity,
1-2
 many members also 
show antifungal, anticancer, neuroprotective, and other biological activities.
2-3
 
 
Figure 5.1. Biosynthesis of iridoids, and several representative members. 
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5.1.2 Prismatomerin and Plumericin 
5.1.2.1 Isolation of Prismatomerin 
 Discovered in 2007 from the leaves of Prismatomeric tetrandra, prismatomerin (Figure 
5.2) possesses a complex tetracyclic structure known only in three other natural products: 
plumericin, isoplumericin, and oruwacin.
4
 
 
Figure 5.2.  Structures of tetracyclic iridoids (prismatomerin, plumericin, isoplumericin, and 
oruwacin). 
 
5.1.2.2 Initial Biological Characterization of Prismatomerin 
 Initial characterization of the biological activity of prismatomerin showed mid- to high-
nanomolar toxicity against a variety of cancer cell lines, a result confirmed by screening against 
the NCI-60 cell panel.
4
  Prismatomerin also demonstrated somewhat selective growth inhibition 
of leukemia cell lines over solid tumor cell lines.  Further experiments showed significant 
nuclear fragmentation following treatment with prismatomerin and “mitotic cells showing 
normal chromosomes in a metaphase-like state that did not display a normal mitotic spindle.”4  
However, no evidence was provided to demonstrate that the indicated cells were undergoing 
mitosis, and this proposed novel mode of action, whereby prismatomerin disrupts the mitotic 
spindle without affecting the microtubules themselves, was never confirmed. 
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5.1.2.3 Biological Characterization of Plumericin 
 The iridoids plumericin and isoplumericin have been repeatedly isolated and evaluated in 
a number of biological assays.  Generally, plumericin is two-fold more potent than isoplumericin 
as a cytotoxin,
5-6
 an antibacterial,
5
 an anti-leishmanial,
7
 and an antifungal.
8
  Despite these 
numerous evaluations, the mechanism for how plumericin operates in cells has never been 
reported. 
 
5.1.3 Approach for Assessing Prismatomerin and Plumericin 
 The original isolation chemist, Karson Krone, provided us with samples of both 
prismatomerin and plumericin.  Our initial goals in evaluating these compounds were to compare 
these two iridoids in their ability to induce death of cancer cells in culture, and investigate their 
mode of action. 
 
5.2 Efforts to Confirm Prismatomerin’s Reported Biological Activity 
5.2.1 Initial Toxicity Tests 
 Based on the structure of this compound and its potentially interesting mechanism of 
action, samples of prismatomerin and plumericin (also isolated in the 2007 report) were obtained 
from Prof. Karsten Khrone.  Initially, the toxicity of these compounds (24-hour continuous 
exposure) was tested in six different blood and solid cancer cell lines (Table 5.1).  Prismatomerin 
and plumericin showed high nanomolar or single digit micromolar inhibition in all lines tested, 
with the greatest toxicity observed in U-937 cells (lymphoma).  Generally, plumericin was twice 
as potent as prismatomerin.  In contrast, neither plumericin nor prismatomerin induce hemolysis 
in red blood cells up to 333 μM (Figure 5.3). 
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Table 5.1.  Prismatomerin and plumericin toxicity in various cancer cell lines in culture
a
 
Cell Line Prismatomerin Plumericin 
U-937 (lymphoma)
b 
0.71 ± 0.27 µM 0.355 ± 0.074 µM 
HL-60 (leukemia)
b 
3.1 ± 1.5 µM 1.10 ± 0.17 µM 
HeLa (cervical) 1.3 ± 0.3 µM 0.66 ± 0.29 µM 
SK-MEL-5 (melanoma) 2.5 ± 1.1 µM 1.1 ± 0.2 µM 
MCF7 (breast) 1.55 ± 0.06 µM 0.30 ± 0.18 µM 
3T3 (mouse fibroblast) 2.0 ± 0.3 µM 0.96 ± 0.42 µM 
a
 Cell lines were incubated with compound for 24 hours, biomass was quantified with SRB, and 
IC50 values were calculated from logistical dose-response curves. Error is standard deviation of 
the mean, n≥3.  b Cell viability determined by MTS. 
 
 
 
Figure 5.3.  Plumericin and prismatomerin (333 μM) do not induce hemolysis in red blood cells 
following a 2-hour incubation. 
 
5.2.2 Mechanism of Cell Death 
 Flow cytometry was employed to assess the type of cell death induced by these 
prismatomerin and plumericin.  Many anticancer compounds induce caspase-dependent 
apoptotic (type I) cell death, where low activity zymogens of caspases are activated, leading to 
cleavage of a multitude of cellular substrates, cell blebbing and shrinkage, and death.
9-10
  Type I 
cell death is generally considered to be nonimmunogenic and often a useful method for killing 
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cancer cells.
10
  The progression of treated cells through apoptosis was monitored by following 
the exposure of phosphotidylserine (PS) onto the cell exterior, as measured by the binding of 
FITC-labeled Annexin V, relative to membrane permeabilization, as measured by propidium 
iodide (PI) incorporation.  PS exposure in the absence of membrane permeabilization is 
characteristic of apoptosis.  As shown in Figure 5.4, cells treated with prismatomerin and 
plumericin induce apoptosis in HL-60 cells in a dose-dependent manner.  Co-treatment of cells 
with these compounds and Q-VD-OPh (QVD), a pan-caspase inhibitor, protects cells from 
apoptotic death, indicating that cell death is mediated by caspases.  Prismatomerin fluoresces in 
the red channel, leading to a bulk shift in the PI fluorescence that correlates to compound 
concentration even in the absence of cell death; however, this can be controlled for by adjusting 
the gating during the data analysis. 
 
Figure 5.4.  Apoptotic death following treatment with compounds, and rescue from death 
following 24-hour continuous treatment with 10 µM Q-VD-OPh (QVD) in HL-60 cells. 
Prismatomerin fluorescence leads to a net increase in the PI channel, which is compensated for 
by adjusting the analysis gates. 
  
5.2.3 Cell Cycle Arrest 
 The effect of prismatomerin and plumericin on the cell cycle of treated cells was also 
evaluated.  Arrest in certain phases of cell replication is associated with particular targets, such 
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as inhibition of topoisomerase I and S-phase arrest,
11
 or disruption of tubulin networks and 
G2/M-arrest.
12
  Camptothecin (CPT, a known topoisomerase I inhibitor
13
) and colchicine (Colch, 
a known tubulin destabilizer
14-15
) were used as positive controls for arrest in S- and G2/M-
phases, respectively.  HeLa cells were treated with compound (for 24 hrs) at approximately the 
IC50 value, and the cells were fixed and stained.  The positive controls showed strong arrest, 
whereas prismatomerin and plumericin demonstrated only mild G2/M arrest (Figure 5.5).  These 
results are consistent with the reported mechanism of action for prismatomerin, which would 
require G2/M arrest; however, it is unlikely that a compound which genuinely affects the mitotic 
spindles would show this type of weak arrest. 
 
 
Figure 5.5. Cell cycle arrest for prismatomerin and plumericin compared to the known 
cytotoxins camptothecin (CPT) and colchicine (Colch) following 24-hour treatment in HeLa 
cells.  * p < 0.01, compared to DMSO control. 
 
5.2.4 Tubulin Microscopy 
 Based on the weak cell cycle arrest data and the microscopy observation from the original 
isolation paper, a number of experiments were conducted in order to determine the effect of 
prismatomerin and plumericin on microtubules.  The standard method for evaluating tubulin 
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polymerization, an in vitro assay using purified microtubules, gave inconclusive and variable 
results. 
 
5.2.4.1 Tubulin Dynamics by Microscopy 
 Whole cell images in HeLa cells following treatment with prismatomerin or plumericin 
were obtained using confocal microscopy.  Colchicine and paclitaxel, which destabilize and 
stabilize tubulin networks in cells, respectively, were used as positive controls.  This experiment 
was performed at a range of concentrations (25-200% 24 hour IC50 value) and time (12-48 hours) 
and gave very consistent results in all of the tested conditions.  In this 12-hour treatment, the 
control compounds show a decrease and increase in tubulin fluorescence as expected, whereas 
prismatomerin and plumericin show no perturbation of the tubulin network.  Additionally, cells 
were consistently observed undergoing mitosis with normal mitotic spindles, shown in blue 
boxes, which directly contradicts the reports in the original isolation paper (Figure 5.6).   
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Figure 5.6.  Microscopy of synchronized HeLa cells following 12-hour treatment with 
compounds.  Tubulin stained green with anti-α-tubulin FITC conjugate antibody, and DNA 
stained red with propidium iodide.  Blue boxed indicate cells undergoing mitosis following 
compound treatment.  All exhibit normal mitotic spindles.  Enlarged images of prismatomerin 
are shown in the bottom row. 
 
5.2.4.2 Tubulin Polymerization by Flow Cytometry 
 Additionally, a novel flow cytometry-based assay was designed to quantify tubulin 
polymerization in whole cells (see Chapter 6 for its development).  Briefly, cells were treated 
near the 24-hour IC50 value in HL-60 cells, fixed, and stained with PI and a FITC-labeled tubulin 
antibody.  This allows for simultaneous analysis of cell cycle arrest and changes in the extent of 
tubulin polymerization.  The cell cycle arrest data displayed the expected G2/M arrest with 
colchicine and paclitaxel, while prismatomerin and plumericin showed no cell cycle arrest.  
Paclitaxel and colchicine show the expected increase and decrease in tubulin polymerization, 
DMSO
Nuclear stain only
20 µm
Paclitaxel (100 nM) Pris (1 μM)
Colch (1 μM) Pris (500 nM)
Pris (500 nM, Zoom) Pris (1 μM, Zoom)
10 µm 10 µm
Plum (500 nM)
Plum (100 nM)
10 µm
Plum (100 nM, Zoom)
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respectively; however, prismatomerin and plumericin exhibit no change in tubulin 
polymerization (Figure 5.7). 
 
Figure 5.7.  Analysis of tubulin polymerization by flow cytometry for prismatomerin and 
plumericin compared to the known tubulin disruptors paclitaxel (Taxol) and colchicine (Colch) 
following 18-hour treatment in HL-60 cells.  * p < 0.01, compared to DMSO control.  Error bars 
represent standard error, n=3. 
 
5.2.5 Tubulin Conclusions and Outlook 
 Together, the data suggest that although prismatomerin and plumericin mildly affect the 
cell cycle in some cell lines, they do not directly perturb the tubulin network or the mitotic 
spindles in treated cells, as was suggested in the original isolation paper.  As a result, we 
employed a series of techniques to determine the cellular and genetic response to these 
compounds and identify new putative targets for the activity of prismatomerin and plumericin. 
 
5.3 Mechanistic Studies: NCI-60 Panel 
5.3.1 NCI-60 and COMPARE Background 
 One strategy for determining the mode of action for a new compound is to tests its 
cytotoxic effects against the NCI-60 cell line panel.  This set of 60 cell lines, established in 1990, 
spans a range of cancer types and can help determine compound selectivity.
16
  More recently, a 
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COMPARE analysis
17-18
 was developed to compare the relative potencies of known cytotoxins
19
 
against the NCI-60 to new compounds with unknown mode of action.  This analysis has been 
used successfully in a number of examples in order to determine unknown modes of action for 
new compounds by relating them to compounds whose modes of action were characterized.
16
 
 
5.3.2 COMPARE Analysis with Prismatomerin and Plumericin 
 The original isolation scientists submitted samples of prismatomerin and plumericin for 
screening against the NCI-60 cancer cell line panel.
4, 16
  However, this data was never further 
analyzed to determine whether the sensitivity of individual cell lines to these compounds 
correlated with the cell line sensitivities of small molecules with known modes of action.  Data 
for 50% growth inhibition (GI50), total growth inhibition (TGI), and 50% death (LC50) for 
prismatomerin and plumericin were used as inputs in the COMPARE database,
17-18
 and the 
correlations between these two compounds and known cytotoxins
20
 are shown in Table 5.2.  A 
value of 1 is considered a perfect match (ie, both compounds exhibit the same pattern of activity 
against the panel), while a value of -1 is considered to be an anti-correlation.  Generally, 
correlations above 0.6 are indicative of related activity,
21-24
 although wide variability can be seen 
with this technique.
25-26
  As seen in Table 5.2, plumericin and prismatomerin show only mild 
correlations or anti-correlations, respectively.  This is somewhat surprising given the high 
similarity in compound structure. 
 In order to determine if broader trends could be identified in the COMPARE data, the top 
20 hits were grouped by target: alkylators, RNA/DNA inhibitors, antioxidants, and 
topoisomerase I/II inhibitors.  Although plumericin shows weak positive correlations with a 
number of targets, prismatomerin shows mostly anticorrelations with various targets, thereby 
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making it difficult to make broad conclusions from this data for prismatomerin.  The best 
correlations associated with compound potency (LC50) for plumericin were topoisomerase I/II 
inhibitors, so this target was investigated first. 
 
Table 5.2.  Top 20 COMPARE hits for prismatomerin and plumericin 
 
 
5.3.3 Topoisomerase II Target Validation 
 Since topoisomerase II inhibitors are known to arrest cells in the G2/M phase of the cell 
cycle,
27
 these compounds were analyzed in a topoisomerase II inhibition assay, as shown in 
Figure 5.8.  In this assay, catenated DNA (kDNA) is exposed to the topoisomerase II enzyme.  
When the enzyme functions normally, the catenated DNA is cleaved into individual rings, which 
Plumericin
GI50 LC50
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methyl-CCNU -0.532 -0.552
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migrate to the bottom of an agarose gel.  However, when this process is inhibited, the catenated 
DNA cannot travel down the gel.  While a known topoisomerase II inhibitor, doxorubicin, was 
able to inhibit the decatenation of DNA as visualized on an agarose gel, neither plumericin nor 
primatomerin showed any inhibition, even at their highest concentration. 
 
Figure 5.8.  In vitro topoisomerase II inhibition.  (a) Decatenation reaction catalyzed by 
Topoisomerase II.  (b) Agarose gel following compound incubation with enzyme and kDNA. 
 
5.3.4 COMPARE Conclusion and Outlook 
 COMPARE enables a broad metric for analyzing compound response in cells treated with 
prismatomerin and plumericin.  However, this technique only looks at cell death, which may be 
partly responsible for the poor compound correlations.  Additionally, one of the associated 
targets, topoisomerase II, is not inhibited by either compound.  As a result, we turned to other, 
higher-content techniques to determine how prismatomerin and plumericin exert their activity. 
 
5.4 Mechanistic Studies: Transcript Profiling 
5.4.1 Transcript Profiling Approach 
 Transcript profiling is a technique where the mRNA of compound-treated cells is 
analyzed to determine the genetic response of the cells.  By evaluating transcripts that are 
significantly up- or down-regulated following compound treatment, it is possible to determine 
which pathways the compounds act on.  This analysis can be done for any cell lines; however, 
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one common secondary assay, CMAP, is most commonly performed with HL-60, MCF7, and 
PC3 cells.
28-29
  As a result, prismatomerin and plumericin concentrations were optimized to give 
healthy cells at 6 hours and cell death at 24 hours.  This allows for ample transcriptional response 
when the mRNA is harvested while ensuring that compounds are affecting the cells. 
 Following a six-hour treatment of HL-60 cells with prismatomerin (5 µM) or plumericin 
(0.5 µM), mRNA was harvested and a full transcript profile was obtained.  A large 
transcriptional response was observed for both compounds (Tables 5.3 [prismatomerin] and 5.4 
[plumericin]), and although the magnitude of the change varied, prismatomerin and plumericin 
show extremely similar trends in their transcriptional response in the top 200 up- and down-
regulated genes (Spearman rank correlation value
30
 of 0.953).  The high Spearman value strongly 
suggests that prismatomerin and plumericin induce cell death through the same mechanism. 
 Heme oxygenase I (HO-1, HMOX1), a transcription factor that is activated in response to 
cellular stressors, showed the greatest fold-increase.  In addition to HMOX1, numerous other 
oxidative-stress response transcripts were upregulated, including OKL38, HSPA1B, OSGIN1, 
SRXN1, and a number of ferratins.  This substantial response suggests that HO-1 or reactive-
oxygen species (ROS, a common inducer of HO-1 expression) may be responsible for cell death 
induced by prismatomerin and plumericin.  Further analysis of all up-regulated transcripts for 
both compounds shows numerous correlations to genes known to be associated with the Keap1-
Nrf2 pathway,
31
 which plays a crucial role in the cellular response to chemical or oxidative stress 
(Table 5.5). 
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Table 5.3.  Top up- and down-regulated signatures for prismatomerin 
Symbol Protein Function P value 
Fold 
change 
HMOX1 heme oxygenase  1 antioxidant <1.00*10-07 16.1 
OKL38 oxidative stress induced growth inhibitor 1 oxidative stress <1.00*10-07 11.4 
HSPA1B heat shock 70kDa protein 1B thermal or oxidative stress <1.00*10-07 5.6 
OSGIN1 oxidative stress induced growth inhibitor 1 oxidative stress <1.00*10-07 5.5 
RNU1-5 RNA, U1 small nuclear 5   <1.00*10-07 5.2 
RNU1-3 RNA, U1 small nuclear 3   <1.00*10-07 5.0 
RNU1G2 RNA, U1G2 small nuclear   <1.00*10-07 4.9 
ADM adrenomedullin hypotensive and vasodilatator agent <1.00*10-07 4.7 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 apoptotic regulation 1.00*10-07 4.2 
BAG3 BCL2-associated athanogene 3 apoptotic regulation <1.00*10-07 4.0 
GCLM glutamate-cysteine ligase, modifier subunit glutathione synthesis <1.00*10-07 4.0 
GABARAPL1 GABA(A) receptor-associated protein like 1 neurotransmission <1.00*10-07 4.0 
RIT1 Ras-like without CAAX 1 activation of EPHB2 and MAPK14 
signaling 
<1.00*10-07 3.8 
RNU1A3 RNA, U1A3 small nuclear   1.00*10-07 3.8 
SRXN1 sulfiredoxin 1 homolog (S. cerevisiae) oxidative stress <1.00*10-07 3.7 
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 thermal or oxidative stress <1.00*10-07 3.5 
LOC729009 PREDICTED: misc_RNA   <1.00*10-07 3.4 
FTH1 ferritin, heavy polypeptide 1 intracellular iron storage <1.00*10-07 3.4 
RN7SK RNA, 7SK small nuclear   8.73*10-04 3.4 
FTHL12 ferritin, heavy polypeptide-like 12 intracellular iron storage 4.00*10-07 3.4 
FTHL7 ferritin, heavy polypeptide-like 7 intracellular iron storage <1.00*10-07 3.4 
NQO1 NAD(P)H dehydrogenase, quinone 1 oxidoreductase <1.00*10-07 3.2 
FTHL12 ferritin, heavy polypeptide-like 12 intracellular iron storage 5.00*10-07 3.2 
SLC7A11 solute carrier family 7 member 7 cationic amino acid transporter 1.00*10-07 3.2 
PLD6 phospholipase D family, member 6 
 
<1.00*10-07 - 3.7 
MYC v-myc protein transcriptional activator 1.00*10-07 - 3.3 
IRF8 interferon regulatory factor 8   <1.00*10-07 - 3.2 
PLD6 phospholipase D family, member 6   <1.00*10-07 - 3.0 
CD59 CD59 molecule, complement regulatory protein   2.00*10-07 - 2.9 
MYC v-myc protein transcriptional activator 2.00*10-07 - 2.8 
ALG3 asparagine-linked glycosylation 3 homolog   4.10*10-06 - 2.8 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin)   1.00*10-07 - 2.7 
HPDL 4-hydroxyphenylpyruvate dioxygenase-like   1.00*10-07 - 2.7 
CCL2 chemokine (C-C motif) ligand 2   4.80*10-06 - 2.6 
C3orf54 chromosome 3 open reading frame 54   5.00*10-07 - 2.6 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein)   <1.00*10-07 - 2.5 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2   1.00*10-07 - 2.5 
PITX1 paired-like homeodomain transcription factor 1   <1.00*10-07 - 2.5 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein)   <1.00*10-07 - 2.5 
LOC730525 PREDICTED: hypothetical protein LOC730525   3.00*10-07 - 2.4 
SLC29A2 solute carrier family 29 (nucleoside transporters), member 2   <1.00*10
-07 - 2.4 
CCR2 chemokine (C-C motif) receptor 2   6.90*10-06 - 2.3 
CCR2 chemokine (C-C motif) receptor 2   2.00*10-07 - 2.3 
METTL1 methyltransferase like 1   2.00*10-07 - 2.3 
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Table 5.4.  Top up- and down-regulated signatures for plumericin 
Symbol Protein Function P value 
Fold 
change 
HMOX1 heme oxygenase 1 antioxidant <1.00*10-07 11.2 
OKL38 oxidative stress induced growth inhibitor 1 oxidative stress <1.00*10-07 10.7 
ADM adrenomedullin hypotensive and vasodilatator agent <1.00*10-07 4.8 
OSGIN1 oxidative stress induced growth inhibitor 1  oxidative stress <1.00*10-07 4.8 
RNU1G2 RNA, U1G2 small nuclear   <1.00*10-07 4.2 
HSPA1B heat shock 70kDa protein 1B thermal or oxidative stress 8.00*10-07 4.2 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 apoptotic regulation 1.00*10-07 4.1 
BAG3 BCL2-associated athanogene 3 apoptotic regulation 1.00*10-07 3.8 
RNU1-3 RNA, U1 small nuclear 3   4.00*10-07 3.8 
GCLM glutamate-cysteine ligase, modifier subunit glutathione synthesis <1.00*10-07 3.8 
RNU1-5 RNA, U1 small nuclear 5   3.00*10-07 3.8 
SRXN1 sulfiredoxin 1 homolog (S. cerevisiae) oxidative stress <1.00*10-07 3.6 
GABARAPL1 GABA(A) receptor-associated protein like 1 neurotransmission <1.00*10-07 3.6 
NQO1 NAD(P)H dehydrogenase  1 oxidoreductase <1.00*10-07 3.4 
LOC729009 PREDICTED: misc_RNA   1.00*10-07 3.3 
RIT1 Ras-like without CAAX 1 
activation of EPHB2 and MAPK14 
signaling <1.00*10-07 3.3 
FTHL7 ferritin, heavy polypeptide-like 7 intracellular iron storage <1.00*10-07 3.2 
FTH1 ferritin, heavy polypeptide 1 intracellular iron storage <1.00*10-07 3.2 
FTHL12 ferritin, heavy polypeptide-like 12 intracellular iron storage 1.60*10-06 3.1 
FTHL8 ferritin, heavy polypeptide-like 8 intracellular iron storage 4.15*10-05 3.0 
FTHL12 ferritin, heavy polypeptide-like 12  intracellular iron storage 3.30*10-06 3.0 
SLC7A11 solute carrier family 7 member 7 cationic amino acid transporter 4.00*10-07 2.9 
RNU1A3 RNA, U1A3 small nuclear   5.60*10-06 2.9 
FTHL2 ferritin, heavy polypeptide-like 2 intracellular iron storage 4.40*10-06 2.9 
IRF8 interferon regulatory factor 8   <1.00*10-07 - 3.3 
PLD6 phospholipase D family, member 6   2.00*10-07 - 3.2 
MYC v-myc protein transcriptional activator 8.00*10-07 - 2.8 
MYC v-myc protein transcriptional activator 8.00*10-07 - 2.7 
PLD6 phospholipase D family, member 6   1.00*10-07 - 2.6 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2   4.00*10-07 - 2.6 
ALG3 asparagine-linked glycosylation 3 homolog    2.18*10-05 - 2.5 
CD59 CD59 molecule, complement regulatory protein   2.20*10-06 - 2.5 
HPDL 4-hydroxyphenylpyruvate dioxygenase-like   6.00*10-07 - 2.5 
CCR2 chemokine (C-C motif) receptor 2   4.40*10-06 - 2.5 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2   3.00*10-07 - 2.4 
CCR2 chemokine (C-C motif) receptor 2   1.00*10-07 - 2.4 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein)   <1.00*10-07 - 2.4 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein)   <1.00*10-07 - 2.4 
KANK1 KN motif and ankyrin repeat domains 1   4.00*10-07 - 2.3 
CCL2 chemokine (C-C motif) ligand 2   4.60*10-05 - 2.3 
PRAM1 PML-RARA regulated adaptor molecule 1   2.00*10-07 - 2.3 
FLJ39827 hypothetical protein FLJ39827   1.61*10-05 - 2.2 
PITX1 paired-like homeodomain transcription factor 1   3.00*10-07 - 2.2 
SLC29A2 solute carrier family 29 (nucleoside transporters), member 2   1.00*10-07 - 2.2 
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Table 5.5. Genes affected by prismatomerin and plumericin in the Keap1-Nrf2 pathway.  
  
Plumericin Prismatomerin 
Symbol Name Fold Change P value Fold Change P value 
EPHX1 Epoxide hydrolase 1 1.4 0.003 1.4 0.003 
FTH1 Ferritin, heavy polypeptide 1 3.2 <1.00*10-07 3.4 <1.00*10-07 
GCLC Gluatamate-cysteine ligase, catalytic subunit 1.5 0.005 1.5 0.002 
GCLM Gluatamate-cysteine ligase, modifier subunit 3.8 <1.00*10-07 4.0 <1.00*10-07 
    2.4 5.00*10-07 2.8 1.00*10-07 
GSR Glutathione reductase 1.5 0.001 1.6 0.0002 
HMOX1 Heme oxygenase 1 11.2 <1.00*10-07 16.1 <1.00*10-07 
IDH1 Isocitrate dehydrogenase 1 1.4 0.002 1.5 0.0002 
    1.2 0.107 1.4 0.002 
MAFG Transcription factor 2.1 3.00*10-07 2.1 1.00*10-07 
  
2.0 2.90*10-06 2.1 1.10*10-06 
    1.6 0.0007 1.4 0.008 
NQO1 NAD(P)H dehydrogenase, quinone 1 3.4 <1.00*10-07 3.2 <1.00*10-07 
SLC25A25 Mitochondrial carrier 1.4 0.010 1.5 0.005 
    1.4 0.002 1.5 0.0003 
SLC48A1 Heme transporter 2.0 8.90*10-06 2.2 1.00*10-06 
SLC7A11 Anioninc amino acid transporter 2.9 4.00*10-07 3.2 1.00*10-07 
SRXN1 Sulfiredoxin 1 3.6 <1.00*10-07 3.7 <1.00*10-07 
TXNRD1 Thiodredoxin reductase 1 2.1 <1.00*10-07 2.4 <1.00*10-07 
    2.1 1.00*10-07 2.4 <1.00*10-07 
 
5.4.2 HO-1 Induction 
 HO-1 is an inducible heme oxygenase that is produced in cells following oxidative stress.  
Western blotting following compound treatment in U-937 cells confirmed that the increase in the 
transcript levels of HMOX1 corresponds to increased production of the protein HO-1 (Figure 
5.9).  This is not a general response to cytotoxins, as the etoposide did not induce HO-1 
transcription.  Co-treatment with the antioxidant N-acetyl cysteine (NAC) suppressed protein-
level expression of HO-1; however, co-treatment with the caspase inhibitor QVD-OPh, which 
prevents cell death in treated cells, does not affect HO-1 activation.  This suggests that the stress 
response that activates HO-1 occurs before caspase activation and cell death. 
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Figure 5.9.  Western blot analysis of protein levels following 6-hour treatment with compound 
in U-937 cells.  Hemin, a compound known to induce HO-1 expression, was used as a positive 
control.   
 
5.4.3 Reactive Oxygen Species (ROS) 
 In order to evaluate the relationship between oxidative stress and cellular response 
following treatment with plumericin and prismatomerin, a number of additional assays were run 
to analyze ROS levels in treated cells.   
 
5.4.3.1 ROS in Whole Cells 
 In order to determine the ability of prismatomerin and plumericin to induce ROS in 
whole cells, the cellular probe dihydroethidium (DHE) was used in U-937 cells.  In the presence 
of ROS, DHE is oxidized, leading to fluorescence.  Cells were treated with compound and then 
analyzed for their fluorescence at 20, 40, and 60 minutes.  By evaluating cells within an hour 
after treatment, it is possible to observe ROS prior to cell death; this is important because ROS is 
generated as cells die.  As shown in Figure 5.10, neither prismatomerin nor plumericin induce 
cellular ROS, whereas the known ROS inducer DNQ
32
 does. 
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Figure 5.10. Prismatomerin and plumericin do not induce ROS in whole cells.  U-937 cells were 
treated for 0-60 minutes with compound and analyzed with DHE.  Error bars represent standard 
error, n=3. 
 
5.4.3.2 ROS and Hypoxia 
 One measure of the cellular ROS response to a small molecule is its relative potency in 
normoxia (20% O2) and hypoxia (1% O2).  Compounds that induce cell death via ROS (eg, 
DNQ
33
) are less potent in hypoxia than normoxia due to the lower levels of oxygen available for 
conversion into ROS.  Alternately, compounds that require a low oxygen environment to be 
active (eg, tirapazamine
34
) are more potent in hypoxia than normoxia.  Neither prismatomerin 
nor plumericin show a significant change in potency between normoxia and hypoxia (Table 5.6), 
suggesting that ROS is not a major factor in the cellular response. 
 
 
 
 
0
50
100
150
200
250
300
350
DMSO DNQ 1
µM
DNQ 10
µM
Plum 0.5
µM
Plum 1
µM
Plum 2.5
µM
Pris 0.5
µM
Pris 1
µM
Pris 2.5
µM
N
o
rm
al
iz
ed
 F
lu
o
re
sc
en
ce
 
0 min
20 min
40 min
60 min
265 
 
Table 5.6.  Comparison of 24-hour prismatomerin and plumericin IC50 in HeLa cells with 
normoxia or hypoxia
a
 
Treatment IC50 in 20% O2 IC50 in 1% O2 Fold Protection in Hypoxia 
Prismatomerin 523 nM 676 nM +1.3 
Plumericin 193 nM 380 nM +2.0 
Tirapazamine 54 µM 3.8 µM –14.2 
a
 HeLa cells were preincubated in either normoxic or hypoxic conditions overnight, treated with 
compound for 24 hours, biomass was quantified with SRB, and IC50 values were calculated from 
logistical dose-response curves. 
 
5.4.3.3 ROS and Antioxidants 
 Prismatomerin and plumericin were both tested in the presence and absence of two 
common antioxidants in order to confirm that ROS is not critical to their activity.  Compounds 
for which ROS is a major factor in cell death will show reduced activity when administered in 
the presence of an antioxidant.  Cells were both pre-treated and co-treated with either vitamin E 
or N-acetyl cysteine (NAC).  Treatment of compounds with the antioxidant vitamin E did not 
change the IC50 values of either compound.  However, a reduction in toxicity was observed 
following both pretreatment and co-treatment with NAC (Table 5.7).  These studies suggest that 
while ROS is not a major factor in cell death, NAC does offer protection to the cells in a manner 
separate from its antioxidant properties. 
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Table 5.7.  Comparison of 24-hour prismatomerin and plumericin IC50 in HeLa cells in the 
presence of antioxidants
a
  
Treatment Alone 
5 mM 
NAC 
Fold 
Protection 1 mM Vit E 
Fold 
Protection 
Prismatomerin 1.69 µM > 20 µM >11.8 1.56 µM -1.1 
Plumericin 0.09 µM 1.42 µM 15.8 0.07 µM -1.3 
Prismatomerin
b
 ~ 4 µM 8.1 µM ~2 4.1 µM 1.0 
Plumericin
b
 0.30 µM 3.3 µM 11 0.19 µM -1.6 
a
 HeLa cells were pretreated with an antioxidant for 2 hours, followed by treatment with 
compound and antioxidant for 24 hours.  Biomass was quantified with SRB and IC50 values were 
calculated from logistical dose-response curves.  
b
 Antioxidant was washed out following 
pretreatment, and cells were treated with compound for 2 hours and then allowed to recover for 
22 hours with antioxidant or media alone. 
 
5.4.4 Nucleophilic Addition 
5.4.4.1 NAC Conjugate Addition to Prismatomerin 
 One explanation for the protective effect of NAC is the deactiviation of prismatomerin 
and plumericin via the nucleophilic addition of NAC to the α,β-unsaturated esters.  Although the 
manner in which prismatomerin and plumericin chemically interact with cellular targets is 
unknown, it is possible that this electrophilic functional group could play a vital role.  If this is 
the case, the addition of NAC would render the compounds inactive, leading to the observed 
cytoprotective effect.  To test this hypothesis, compounds in DMSO stocks were exposed to 
NAC and then analyzed by UV/Vis in order to observe an NAC adduct based on the loss of the 
extended chromaphore following compound addition.
35
  As shown in Figure 5.11, a dramatic and 
rapid effect is observed by UV/Vis for NAC addition into prismatomerin.  (Plumericin was not 
studied because it does not absorb in the visible spectrum.)  Conjugate addition to the exocyclic 
unsaturated ester destroys the extended conjugation, leading to a reduction in absorption at 330 
nm.  This effect is not reversible, even after 24 hours, suggesting that NAC provides cellular 
protection by directly interacting with the compounds and rendering them inactive. 
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Figure 5.11.  N-acetyl cysteine conjugate addition to prismatomerin.  Compound (50 µM) was 
diluted in a 50 mM phosphate buffer, and 5 mM NAC was added.  Loss of extended 
chromaphore was monitored by UV/Vis. 
 
5.4.4.2 Connectivity Map Correlation 
 The transcript profiles of prismatomerin and plumericin were compared to the transcript 
profiles of >1300 small molecules with known modes of action, through the connectivity map 
(CMAP) database.
29
  Similarities in transcriptional response can suggest similar modes of action, 
making the CMAP a powerful tool for investigating the molecular target of a compound.
17, 25, 28, 
36
  These results, shown in Tables 5.8 and 5.9, suggest that prismatomerin and plumericin have a 
similar mode of action to 15-deoxy-Δ12,14-prostaglandin J2 (PG-J2, Figure 5.12), a compound 
known to activate the Keap1-Nrf2 pathway.
31
  PG-J2 is highly correlated to both prismatomerin 
and plumericin in HL-60 cells, which were used to acquire the transcript profiling results.  PG-J2 
is known to modify thiol residues in a variety of proteins, presumably through conjugate addition 
of these cellular nucleophiles into the α,β-unsaturated ketone of PG-J2.
37
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Table 5.8.  CMAP results for prismatomerin based on top 150 up- and down-regulated genes 
Rank Name Cell Line Mean n Enrichment p 
1 PG-J2 HL-60 0.937 3 1.000 <0.00002 
2 Thioridazine HL-60 0.651 4 0.985 <0.00002 
3 Tanespimycin HL-60 0.580 12 0.899 <0.00002 
4 Vorinostat MCF7 0.379 7 0.884 <0.00002 
5 PG-J2 MCF7 0.507 8 0.830 <0.00002 
6 Trichostatin A HL-60 0.444 34 0.754 <0.00002 
7 Trichostatin A MCF7 0.340 92 0.737 <0.00002 
8 LY-294002 HL-60 0.492 13 0.715 <0.00002 
9 Tanespimycin MCF7 0.307 36 0.543 <0.00002 
10 Geldanamycin MCF7 0.342 10 0.709 0.00002 
 
 
Table 5.9.  CMAP results for plumericin based on top 150 up- and down-regulated genes 
Rank Name Cell Line Mean n Enrichment p 
1 PG-J2 HL-60 0.900 3 1.000 <0.00002 
2 Thioridazine HL-60 0.577 4 0.973 <0.00002 
3 Tanespimycin HL-60 0.533 12 0.904 <0.00002 
4 PG-J2 MCF7 0.483 8 0.872 <0.00002 
5 Vorinostat MCF7 0.336 7 0.870 <0.00002 
6 Geldanamycin MCF7 0.336 10 0.789 0.00002 
7 Trichostatin A HL-60 0.384 34 0.745 <0.00002 
8 Trichostatin A MCF7 0.296 92 0.711 <0.00002 
9 LY-294002 HL-60 0.431 13 0.651 <0.00002 
10 Tanespimycin MCF7 0.276 36 0.572 <0.00002 
 
 
 
Figure 5.12. Structure of 15-deoxy-Δ12,14-prostaglandin J2 (PG-J2). 
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5.4.5 Transcript Profiling Conclusion and Outlook 
 Transcript profiling enables a more detailed genetic look at the cellular response to 
treatment with prismatomerin and plumericin.  Interestingly, both compounds show a similar 
transcriptional response, and the expression of oxidative-stress related genes may be due to the 
electrophilic nature of the compounds.  This phenotype is consistent with the COMPARE results 
in Table 5.2 showing mild correlations between prismatomerin and plumericin and alkylating 
agents. 
 Teasing apart the relative contributions of ROS and the electrophilic response can be a 
challenge, as compounds that serve as conjugate addition acceptors can elicit similar cellular 
effects to those observed following ROS generation,
38-40
 explaining the up-regulation of 
oxidative stress genes and activation of the Keap1-Nrf2 pathway.
31
  While a subset of the 
transcripts induced by prismatomerin and plumericin are also induced by ROS-generating 
compounds (e.g., HMOX1), these compounds induce an overall pattern distinct from ROS 
inducers (such as glutathione production and up-regulation of drug metabolizing enzymes). 
 
5.5 Mechanistic Studies: Cytological Profiling 
5.5.1 Cytological Profiling Overview 
 In contrast with the transcript profiling technique discussed in section 5.4, cytological 
profiling offers a high-content method for evaluating targets affected by small molecule 
treatment.  This technique is based on recent advances in microscopy and automated image 
analysis, and correlates the phenotypic response of new compounds to those of known bioactive 
compounds.
41-42
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 Samples were prepared and sent to Walter Bray and Scott Lokey at UCSC for analysis.  
HeLa cells were treated with compound for 24 hours, and then the cells were stained with a 
variety of dyes, including EdU, Hoechst, anti-PH3, and anti-tubulin to visualize DNA 
replication, DNA, mitosis, and tubulin, respectively.  Scores of cytological features were 
measured and clustered, enabling the grouping of compounds with similar phenotypic responses. 
 
5.5.2 Cytological Profiling Response 
 Prismatomerin and plumericin were both tested in a 2-fold dilution series beginning at 
1.67 μM, a concentration at which both compounds induce cell death in HeLa cells.  The 
aggregate cytological response for both compounds is shown in Figure 5.13.  Higher 
concentrations of prismatomerin and plumericin cluster separately from known bioactive 
compounds, and lower concentrations show only weak changes in cytological features. 
 Generally, the cytological profiling data shows very little perturbation on nuclear size and 
degree of nucleation in treated cells (Figure 5.13B and H).  This data confirms earlier 
observations (section 5.2.4) that prismatomerin and plumericin do not affect tubulin networks 
(Figure 5.13C and E), nor do they affect actin or DNA replication (Figure 5.13E and G).  
Surprisingly, cells treated with prismatomerin and plumericin show a smaller fraction of cells 
undergoing mitosis; however, this may be a batch effect as all of the compounds tested on this 
plate showed the same reduction (Figure 5.13D).  The strongest response shown by these 
compounds was the increased PH3 staining in the cytosol and nuclei (Figure 5.13A and I, 
respectively).  Phosphorylated histone H3 (PH3) is associated with late G2 and early mitosis, and 
the increased staining of this feature is consistent with the partial cell cycle arrest discussed 
previously (section 5.2.3). 
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Figure 5.13.  Cytological profiles of prismatomerin and plumericin.  Compounds were tested for 
24 hours in a 2-fold dilution series starting at 1.67 μM.  Red indicates a +1 change from the 
control, white indicates no change from the control, and blue indicates a -1 change from the 
control for each of the 250 cellular features.  A: PH3 staining in the cytosol.  B: Average nuclear 
intensity.  C: Tubulin and actin.  D: Percent mitotic cells.  E: Actin.  F: Tubulin.  G: DNA 
replication (EdU).  H: Multinucleated cells.  I: PH3 staining in the nucleus. 
 
5.5.3 Cytological Profiling Conclusion and Outlook 
 Cytological profiling enables the evaluation of many cellular features in a high-
throughput manner as well as the correlation of an unknown compound mechanism to known 
bioactives.  In the case of prismatomerin and plumericin, however, the lack of clustering between 
these compounds and the bioactives does not provide a mean of further refining the mode of 
action.  However, the data does confirm previous results suggesting that prismatomerin and 
plumericin do not affect tubulin networks but do arrest cells in G2/M. 
 
5.6 Conclusions and Future Directions 
 Prismatomerin and plumericin, which are tetracyclic iridoid natural products, induce 
apoptosis in cancer cell lines without affecting normal red blood cells.  Although they cause mild 
G2/M arrest, they do not affect normal mitotic morphology, as suggested in the original isolation 
paper.  Instead, it appears that their α,β-unsaturated lactone is key for their activity.   
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 Electrophilic small molecules are often considered to be hazards in drug discovery 
efforts, due to their hypothesized promiscuity and high reactivity.
43
  However, many natural 
products contain electrophilic functional groups and have shown extraordinary promise in vitro 
and in vivo for the treatment of a variety of diseases.
43-44
  Indeed, their lack of a single target in 
some cases may be a beneficial feature for a drug, assuming that the electrophile is not too 
reactive.
44
  Numerous approved bioactive small molecules, such as aspirin, penicillin, and 
gemcitabine contain electrophilic groups,
43-44
 and several novel electrophilic small molecules are 
in Phase III clinical trials.
43, 45
  For example, the electrophilic covalent modifier of Her2 and 
EGFR afatinib has shown a 4.2 to 6.7 month extension in progression-free survival for metastatic 
lung carcinoma relative to cisplatin.
46-47
 
 Interestingly, prismatomerin and plumericin cause the up-regulation of numerous 
transcripts coding for proteins within the Keap1-Nrf2 pathway, including HO-1, GCLC, and 
NQO1.  Although release of Nrf2 from Keap1 inhibition is canonically understood to be crucial 
for cellular detoxification, the hijacking of this pathway by cancer to promote oncogenesis and 
inactive chemotherapeutics has made it an intriguing therapeutic target.
31
  Clinical trials of small 
molecules activating this pathway are underway for chronic kidney disease, multiple sclerosis, 
and cancer, with variable success.
31
  The only clinical trial for an anticancer agent is with the 
Nrf2 activator bardoxolone methyl for advanced solid tumors (NCT00508807), suggesting that 
additional development is worthwhile in this area in order to fully explore the anticancer 
potential of compounds that activate the Keap1-Nrf2 pathway. 
 Prismatomerin and plumericin offer another tool for understanding the relationship 
between Keap1-Nrf2 and apoptosis.  Unlike some electrophiles that induce cellular ROS or 
inhibit individual specific enzymes,
33
 the studies described herein indicate that prismatomerin 
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and plumericin operate primarily via induction of the electrophilic response.  These observations 
suggest that the electrophilic response and activation of the Keap1-Nrf2 pathway caused by 
prismatomerin and plumericin is a viable anticancer strategy. 
 
5.7 Methods 
For biological assays, paclitaxel, colchicine, camptothecin, nocodazole, propidium iodide, 
phenazine methosulfate, monoclonal anti-α-tubulin−FITC antibody, Ribonuclease A (from 
bovine pancreas), and Cocktail Set III Protease Inhibitor were purchased from Sigma Aldrich.  
QVD-OPh was purchased from Calibiochem.  Whole blood was purchased from Bioreclamation.  
Vincristine was purchased from Avachem Scientific.  Gluteraldehyde was purchased from Ted 
Pella, Inc.  The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium salt was obtained from Promega.  Topoisomerase II was purchased from 
Topogen.  Optical densities were recorded on a Spectramax Plus 384 (Molecular Devices, 
Sunnyvale, CA).  Flow cytometry was performed on a BD Biociences LSR II (San Jose, CA) and 
the data was analyzed as described using FACSDiva software (San Jose, CA). 
 
Cell Culture Information 
Cells were grown in media supplemented with fetal bovine serum (FBS) and antibiotics (100 
µg/mL penicillin and 100U/mL streptomycin).  Specifically, experiments were performed using 
the following cell lines and media compositions:  HL-60 (IMDM + 10% or 20% FBS), 3T3 
(DMEM + 10% FBS), SK-MEL-5, U-937, MCF-7, and HeLa (RPMI-1640 + 10% FBS).  Cells 
were incubated at 37 °C in a 5% CO2, 95% humidity atmosphere. 
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IC50 value determination for adherent cells using Sulforhodamine B (SRB) 
Adherent  cells (HeLa, SK-MEL-5, MCF-7, and 3T3) were added into 96-well plates (10,000 
cells/well) in 80 µL media and were allowed to adhere for 3 hours.  Compounds were solubilized  
in DMSO, diluted into 20 µL media before combining with cells (100 µL final volume), and 
tested over a range of concentrations in quintuplicate replicates between 0-100 µM (1% DMSO 
final) on a half-log scale. DMSO and a known cytotoxin served as the live and death control, 
respectively.  After 24 hours, the plates were evaluated using the SRB colorimetric assay as 
described previously.
48
  Briefly, media was removed from the plate, and cells were fixed by the 
addition of 100 µL cold 10% trichloroacetic acid in water.  After an overnight incubation at 4 °C, 
the plates were washed in water and allowed to dry.  Sulforhordamine B was added as a 0.057% 
solution in 1% acetic acid (100 µL), incubated at room temperature for 30 minutes, washed in 
1% acetic acid, and allowed to dry.  The dye was solubilized by adding 10 mM Tris base solution 
(pH 10.5, 200 µL) and incubating at room temperature for 30 minutes.  Plates were read at λ = 
510 nm.  IC50 values were determined from three or more separate experiments using 
TableCurve (San Jose, CA). 
 
IC50 value determination for non-adherent cells using MTS 
In a 96-well plate, compounds were pre-added as DMSO stocks in quintuplicate replicates to 
achieve a final concentration of 1%.  DMSO and a known cytotoxin served as the live and death 
control, respectively.  HL-60 (50,000 cells/well) or U-937 (10,000 cells/well) cells were 
distributed in 100 µL media to the compound-containing plate.  After 24 hours, cell viability was 
assessed by adding 20 µL of a PMS/MTS solution
49
  to each well, allowing the dye to be 
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developed at 37°C until the live control had processed MTS, and reading the absorbance at λ = 
490 nm.  IC50 values were determined using TableCurve (San Jose, CA). 
 
Hemolysis assay using human erythrocytes 
To prepare the erythrocytes, 0.1 mL of human blood was centrifuged (10,000 g, 2 min).  The 
pellet was washed three times with saline (0.9% NaCl) via gentle resuspension and 
centrifugation (10,000 g, 2 min).  Following the final wash, the erythrocytes were resuspended in 
0.4 mL red blood cell (RBC) buffer (10 mM Na2HPO4, 150 mM NaCl, 1 mM MgCl2, pH 7.4). 
DMSO stocks of compounds were added to 0.5 mL tubes in singlicate (1 μL, 3.3% DMSO final).  
The stocks were diluted with 19 μL RBC buffer.  Positive control tubes contained DMSO in 
water, and negative control tubes contained DMSO in RBC buffer.  A suspension of washed 
erythrocytes (10 μL) was added to each tube, and samples were incubated at 37 °C for 2 hours.  
Samples were centrifuged (10,000 g, 2 min), and the supernatant was transferred to a clear, 
sterile 384-well plate.  The absorbance of the supernatants was measured at λ = 540 nm, and 
percent hemolysis was calculated relative to the average absorbance values measured for the 
controls. 
 
Apoptosis in HL-60 cells with Annexin V-FITC and propidium iodide (AnnV/PI) 
DMSO stocks of compounds were added to a 24-well plate in singlicate (0.2% DMSO final).  
For caspase-dependent protection studies, samples were co-treated with 10 µM QVD-OPh.  
After compound addition, 0.5 mL of an HL-60 cell suspension (500,000 cells/mL) was added 
and allowed to incubate for the indicated time (6 to 48 hours).  Following treatment, the cell 
suspensions were transferred to flow cytometry tubes and pelleted (500 g, 5 min).  The media 
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was removed by aspiration, and cells were resuspended in 500 µL AnnV binding buffer (10 mM 
HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) with 2 µg/mL PI and 1:167 dilution of AnnV.  
Samples were analyzed using flow cytometry. 
 
Cell cycle arrest in U-937 cells 
In a 24-well plate, 10 µL of compound stocks in DMSO were added in triplicate (1% DMSO 
final), followed by the addition of 0.99 mL of a U-937 cell suspension (500,000 cells/mL).  The 
cells were incubated for the indicated time (6 to 24 hours).  Following treatment, the samples 
were transferred to 2 mL tubes and pelleted (200 g, 5 min).  The media was removed via 
aspiration, after which the cells were fixed by gradually adding 1 mL cold 70% ethanol in water 
while vortexing.  After an overnight incubation at 4 °C, the cells were pelleted (1500 g, 7 min) 
and washed with PBS by centrifugation in order to remove the ethanol.  The samples were 
resuspended  in 50 µL of 10 mg/mL RNase A and incubated for 1.5 hours at room temperature.  
The samples were then taken up in 300 µL of 50 µg/mL PI in PBS, transferred to flow tubes, and 
analyzed by flow cytometry to determine cell populations. 
 
S-Phase Synchronization for HeLa 
To synchronize adherent and suspension cells, we followed the procedure described previously.
50
  
For synchronization directly in 12- or 6-well plates, the above procedure was modified such that 
adherent cells were plated at 5% confluency.  The remaining timings of treatments remained the 
same. 
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Tubulin Microscopy 
Round, 1.5 mm coverslips (No. 1.5) were sterilized with ethanol and placed in a 12-well plate.  
HeLa cells (100,000 cells/well) were added and allowed to adhere for a minimum of four hours.  
In some cases, HeLa cells were synchronized by the thymidine-block described earlier.  
Compounds were then added as DMSO stocks to achieve a final DMSO concentration of 1%, 
and the plates were placed in an incubator for the indicated time. 
Following incubation, the media was removed, and the coverslips were washed with 1 mL 
Microtubulin Stabilizing Buffer (MTSB, 80 mM PIPES, pH 6.8, 1 mM MgCl2, 5 mM EGTA, 
0.5% TX-100).  The coverslips were then fixed with 1 mL MTSB + 0.5% glutaraldehyde for 10 
minutes at room temperature, after which the fixative was removed and the sample was 
quenched with the addition of 1 mL of 1 mg/mL NaBH4 in PBS.  The coverslips were allowed to 
incubate at room temperature for 7 minutes, at which time the solution was removed by 
aspiration.  The coverslips were washed with PBS, and then stored under PBS at 4 °C. 
Coverslips were transferred to parafilm-lined culture dishes (cell-side up), and 25 µL of 0.5 
mg/mL RNase A in Antibody Diluting Solution (AbDil, PBS, pH 7.4, 0.2% TX-100, 2% BSA, 
0.1% NaN3) with 1:50 dilution of anti-α-tubulin-FITC antibody was added to all samples, except 
for the nuclear-stain only sample, which was treated with antibody-free RNase A.  The samples 
were allowed to incubate at room temperature in the dark for 2.5 hours, after which the 
coverslips were washed with PBS + 0.1% TX-100.  The samples were then incubated for 10 
minutes with 50 µL of 50 µg/mL PI in AbDil, except for tubulin-stain only sample, which was 
treated with PI-free AbDil .  The coverslips were washed with PBS + 0.1% TX-100, at which 
point they were mounted onto microscopy slides using Dako fluorescent mounting media, 
allowed to cure, and imaged on the Zeiss confocal LSM 510 (Jena, Germany). 
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Tubulin Polymerization by Flow Cytometry 
Compounds  were added as DMSO stocks (1% DMSO final) to a 24-well plate, followed by the 
addition of 1.0 mL of a HL-60 cell dilution in fresh media (1,000,000 cells/mL).  Cells were 
incubated for 18 hours, transferred to 2 mL tubes, and pelleted (600 g, 3 min).  The media was 
removed via aspiration, and the cells were fixed by adding 1 mL of 0.5% glutaraldehyde in 
Microtubule Stabilizing Buffer (MTSB, 80 mM PIPES, pH 6.8, 1 mM MgCl2, 5 mM EGTA, 
0.5% TX-100).  Following a 10 minute incubation at room temperature, the glutaraldehyde was 
quenched by the addition of 0.85 mL of 1 mg/mL NaBH4 in PBS.  The cells were pelleted (1000 
g, 7 min), and the supernatant was removed by gentle aspiration.  The cells were washed with 
PBS, then resuspended in 25 µL of 500 µg/mL RNase A and 1:50 anti-α-tubulin-FITC antibody 
in Antibody Diluting Solution (AbDil, PBS, pH 7.4, 0.2% TX-100, 2% BSA, 0.1% NaN3) and 
incubated for 2 hours at room termperature.  The samples were further diluted in 300 µL of 50 
µg/mL PI in PBS, transferred to flow tubes, and analyzed by flow cytometry.  Whole cells were 
identified based on their FSC and SSC traces, as well as propidium iodide staining (single cells 
based on pulse width and height).  Tubulin levels were based on the geometric mean of the 
antibody-FITC fluorescence. 
 
COMPARE Analysis 
Imported NCI60 data for GI50 and LC50 to the COMPARE algorithm, and performed a standard 
COMPARE analysis.
16-18
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Topoisomerase II 
To evaluate topoisomerase II inhibition, the Topogen decatenation protocol was followed with 
minor modifications.  DMSO stocks were diluted in deionized water, and then 7.5 µL of dilution 
were added to a 0.5 mL tube to achieve a final DMSO concentration of 0.1%, followed by the 
addition of kDNA (1 µL) and ATP (1 µL).  Finally, topoisomerase II was diluted 1:20 in buffer, 
and then 10.5 µL of the dilution was immediately added to premixed compound, kDNA, and 
ATP.  The samples were incubated at 37 °C for 30 minutes, and then quenched with 5 µL of 5x 
stopping buffer.  The samples were analyzed by agarose gel electrophoresis on 1% agarose gels 
followed by staining with 10 µg/mL ethidium bromide and visualization by UV. 
 
Transcript Profiling 
HL-60 cells (3,000,000 cells/sample) were incubated in the presence of prismatomerin (5 μM), 
plumericin (0.5 μL), or DMSO vehicle (0.2% final DMSO v/v) for 6 h in a 12-well plate. 
Aliquots (500 μL) were taken at 6 and 24 hours and assessed for viability by annexin 
V/propidium iodide (AV/PI) staining and flow cytometry in order to ensure that the compounds 
were non-toxic at 6 hours and toxic at 24 hours. After 6 hours, 5 mL of cells were pelleted and 
RNA isolated with on column DNase digestion. RNA integrity was assessed using an Agilent 
Bioanalyzer.  Following RNA isolation, whole genome transcript profiling was performed on the 
Illumina HumanHT-12 bead array for compounds and DMSO control from three independent 
experiments. The raw bead-level files were processed with Illumina® BeadStudio 3, Gene 
Expression Module v3.2.61, without background correction or normalization, to get one value 
per beadtype for each array. These 48,803 beadtype values were then input into R, using the 
beadarray package
51
 from the Bioconductor +Project.  The vsn algorithm was used for 
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background correction,
52
 12 normalization and transformation of the beadtype values to the 
glog2 scale. Differential expression was assessed using a mixed linear model using the Limma 
package, which uses an empirical Bayes correction that helps to improve power by borrowing 
information across beadtypes.
53
  All the desired pair-wise comparisons between the 8 treatment 
groups (control + prismatomerin + plumericin + unrelated compounds) were pulled as contrasts 
from the model and the p-values were corrected for multiple hypotheses testing using the False 
Discovery Rate method separately for each contrast.
54
 
 
Western Blot Analysis 
U-937 cells were pretreated in fresh media with 5 mM NAC for 12 hours.  Two hours prior to 
treatment, the cells were resuspended in fresh NAC-free media (900,000 cells/mL) and allowed 
to recover.  In a 24-well plate, compounds were added as DMSO stocks (1% DMSO final), 
followed by the addition of the cell suspension alone or supplemented with either 10 mM NAC 
or 10 µM QVD-OPh.  Following a 6 hour incubation, the cell suspensions were transferred to 2 
mL tubes and pelleted (600 g, 3 min).  The media was removed via aspiration, and the cells were 
washed with PBS and transferred to 1.7 mL tubes.  The cells were lysed by adding 40 µL of 
RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% TX-100, 0.5% sodium deoxycholate, 
0.1% SDS) with 1% Cocktail Set III Protease Inhibitor.  Each sample was then vigorously 
vortexed twice for 15 seconds, with a 15-minute incubation on ice following each vortex.  The 
cellular debris was pelleted (16,100 g, 5 min), and then 33 µL of the protein suspension was 
transferred to fresh 0.5 mL tubes.  The protein levels were quantified using a standard BCA 
(Thermo Scientific), after which the samples were diluted with deionized water to achieve equal 
protein concentrations for all samples. 
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Prior to analyzing the samples, 6x Laemmli sample buffer (350 mM Tris, pH 6.8, 12% SDS, 
0.012% bromophenol blue, 47% glycerol) with 5% β-mercaptoethanol was added to each sample 
to achieve a final 1x concentration, after which the samples were incubated at 95 °C for 5 
minutes to denature the protein samples.  30-50 µg of protein was added onto a 15-well 4-20% 
Tris-HCl gel and run for 1 hour at 120 V.  Equilibrated gel in Towbin transfer buffer (192 mM 
glycine, pH 8.3, 25 mM Tris-Cl, 20% methanol) for 30 minutes, and then transferred gel to a 
PVDF membrane for 2 hours at 60 V. 
Generally, blots were probed as followed.  The blot was blocked overnight at 4 °C with a 
blocking agent in 0.1% Tris-Buffered Saline Tween-20 (TBST) and then probed for the primary 
antibody at a given dilution with a blocking agent in 0.1% TBST overnight at 4 °C HO-1 (5% 
BSA, 1:1000 dilution) and β-actin (5% BSA, 1:5000).  The blot was washed with TBST, and 
then probed with a secondary rabbit HRP antibody (1:10,000, Cell Signaling) in 0.05% TBST for 
1 hour at room temperature.  The blot was washed with TBST and PBS, and then visualized with 
Pico luminescent substrate kit (Thermo Scientific). 
 
ROS – Dihydroethidium in U-937 cells 
To evaluate cellular levels of ROS, U-937 cells were washed with HBSS and resuspended in 
HBSS (500,000 cells/mL).  Compounds were added as 500x DMSO stocks to flow cytometry 
tubes.  Just prior to reading samples, dihydroethidium (DHE, 250 nM final) was added to the cell 
suspension, and cells were added to the compound stocks (0.5 mL final volume).  Samples were 
analyzed by flow cytometry at 0, 20, 40, and 60 minutes and were incubated at 37°C between 
reads.  Whole cells were identified by FSC and SSC, and the ethidium fluorescence was 
evaluated and normalized for the DMSO control and the 0 minute timepoint for each sample. 
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ROS – Hypoxia/Normoxia and Antioxidant Protection in HeLa 
IC50 values in HeLa cells (10,000 cells/well in 100 µL media) were determined by the SRB 
method as described earlier with the following differences. 
For hypoxia/normoxia, the cells were allowed to adhere and equilibrate for 10 hours in either 
normoxic conditions (20% O2) or hypoxic conditions (1% O2) prior to the rapid addition of 
compounds in DMSO stocks.  The plates were returned to either the normoxic or hypoxic 
incubator for 24 hours. 
For antioxidant protection, the cells were allowed to adhere for 4 hours, the media was removed 
by aspiration, and then replaced with either fresh media or media containing an antioxidant.  The 
plates were returned to the incubator for a 2-hour pretreatment, following which compound was 
added in DMSO stocks.  Cells were incubated with the compound for either 24 hours or 2 hours.  
In the latter case, after co-treatment with compound and antioxidant for 2 hours, the compound 
was washed out, and cells were allowed to recover in either antioxidant-containing or 
antioxidant-free media for 22 hours. 
 
UV-Vis analysis of Thiol Addition 
In a UV-transparent 96-well plate, 1 µL of compound in DMSO stocks was added to achieve a 
final concentration of 50 µM followed by 199 µL of 50 mM potassium phosphate buffer (pH 7).  
The plate was read on a spectrophotometer from 200-500 nm at either room temperature or at 37 
°C.  Then, 10 µL of either NAC (105 mM) or DTT (420 mM) was added to achieve a final 
concentration of 5 mM or 20 mM, respectively.  The reaction was monitored every 5-15 minutes 
for the first hour, and then at 2, 4, 8, and 24 hours. 
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Connectivity Map 
To facilitate mapping of the results from gene expression profiling with those of the Connectivity 
Map database, probes were matched from Illumina’s Human HT-12 array to Affymetrix’s 
U133Plus2.0 array. The top 150 up- and down-regulated probe set IDs according to fold-change 
which mapped onto the Affymetrix array were used as seeds for the connectivity map (CMAP) 
database matching.  The top single-instance and cell-line specific matches are reported. 
 
Cytological Profiling 
Stocks of prismatomerin and plumericin were prepared at a 2-fold dilution series beginning at 
250 mM.  These compounds, along with 30 other compounds from the Hergenrother lab, were 
sent to Scott Lokey and Walter Bray at University of California Santa Cruz for analysis as 
detailed in their publication.
42
  Briefly, HeLa cells in 384-well plates were treated for 24-hours at 
1:150 dilution from the stock solutions.  Following treatment, cells were stained with either 
nuclear or cytoskeletal stains and imaged using ImageXpress.  The results were converted to 
feature scores, clustered with Cluster 3.0 software, and analyzed using Java TreeView. 
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Chapter 6: Analytical Method to Determine Tubulin Binding in Cells 
 
Portions of this chapter are reprinted from Morrison, K.C.; Hergenrother, P.J. “Whole cell 
microtubule analysis by flow cytometry,” Analytical Biochemistry, 2012, 420, 26-32, with 
permission from Elsevier. 
 
6.1 Introduction to Tubulin as a Target 
6.1.1 Agents that Bind Tubulin 
  Microtubules serve a vital function in controlling cell dynamics and trafficking, and are 
central to the process of separating DNA into daughter cells during cell division.  Microtubules 
are composed of a heterodimer of tubulin units, which rapidly assemble and disassemble to form 
the cellular microtubule networks (Figure 6.1a).  These essential roles in critical cellular 
functions have made microtubules arguably the single most important anticancer target for 
current chemotherapeutics.
1
 
 
 
Figure 6.1.  Dynamic microtubule assembly and disassembly, and binding sites for common 
microtubule disruptors. 
 
(a) (b)
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  Numerous compounds have been developed over the past half century that bind to this 
dynamic cellular structure; these compounds induce mitotic arrest and cell death.  Three primary 
binding sits have been identified (Figure 6.1b): the vinblastine site, which binds to the (+) end 
and inhibits the addition of new tubulin monomers; the tubulin-colchicine complex, which forms 
on the monomers and prevents incorporation of the tubulin into the microtubules; and the 
paclitaxel binding site, which binds to the interior of the microtubule and prevents 
depolymerization.  The first classes of molecules discovered to perturb the normal state of 
tubulin polymerization were the Vinca alkaloids in 1958
2
 and the taxanes in 1979 (Figure 6.2).
3
  
These compounds respectively destabilize and stabilize the dynamic tubulin structure, resulting 
in growth arrest in the M-phase of the cell cycle.  These “antimitotics” and their derivatives have 
transformed cancer treatment, and have inspired the discovery of a number of other classes of 
tubulin-binding compounds.
4
  Indeed, twelve microtubule-binding anticancer agents across five 
structural classes are now approved by the FDA.
4
 
 
6.1.2 Selectivity of Tubulin-Binding Agents for Cancer Cells 
 Although the success of tubulin-binding agents in the clinic is well established, a 
vigorous debate has emerged in the last several years regarding their selectivity and their specific 
mechanism of killing cancer cells.  Antimitotics, and other generally cytotoxic drugs, were 
believed to specifically target rapidly-dividing cells over normal, quiescent cells,
5
 and this 
hypothesis has been well-established in cell culture and murine models.
6
  However, the doubling 
time of human cancers is substantially slower than those in preclinical models (on the order of 
weeks to months, rather than hours or days), implying that the number of actively-dividing cells 
in cancers is quite low.
5-6
  Additionally, the clinical response to anti-tubulin agents is highly 
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variable and is not correlated to the mitotic index of the cancer, as would be expected for an 
antimitotic agent.
7
 
 Together, these results have presented a paradox: how do drugs that act during mitosis, 
and thus are tired to proliferation rates, work on cancers that proliferate slowly?  Fojo and 
coworkers have suggested that anti-tubulin agents actually behave by affecting microtubule 
dynamics during all stages of the cell cycle, and it is this targeting of quiescent cells that leads to 
the reduction in tumor size.
6
  This suggestion, and its implication for the development of related 
compounds, has been hotly debated.
8-10
  Ultimately, an improved understanding how tubulin-
binding agents work in the clinic is critical for informing the further development of related 
drugs.
5, 7
 
 
6.1.3 Limitations to Tubulin-Binding Agents 
  Despite their utility, there is an increasing prevalence of resistance in the clinic to these 
tubulin-binding anticancer compounds, typically due to membrane efflux pumps, alterations in 
the microtubule structure, or mutations in the apoptotic pathway.
4, 11
  In addition, many 
antimitotics induce significant neuropathy in the peripheral nerves,
4, 12-13
 despite their poor 
permeability into the central nervous system and export by P-glycoprotein transporters.
14-15
  This 
toxicity is hypothesized to be due to the higher levels of tubulin in neuronal cells and subsequent 
impairment of axonal transport.
4, 12
  A number of novel classes of tubulin-binding compounds 
have been developed in response to these deficiencies of existing molecules; however, they are 
still in the early stages of development.
4 
 
291 
 
Figure 6.2. Compound structures of tubulin destabilizers, tubulin stabilizers, and other non-
tubulin binding anticancer agents. 
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6.2 Analytical Methods to Determine Perturbations to Microtubules 
6.2.1 In vitro Method to Analyze Tubulin Polymerization 
  Despite the obvious importance of antimitotics as anticancer agents, standard methods to 
assess the effect of compounds on tubulin polymerization are laborious, low-throughput, and 
expensive.  The most common assay for assessing tubulin polymerization in vitro uses purified 
bovine tubulin, which when polymerized in the presence of GTP shows an increase in turbidity 
at 340 nm.
16-18
  This technique allows for a direct evaluation of the tubulin/microtubule dynamic, 
without interference from microtubule-associated proteins (MAPs) or other complicating factors.  
However, the cost of bovine tubulin used in this assay is prohibitive to the evaluation of the 
thousands of compounds in typical high-throughput screening.  Additionally, this technique is 
logistically difficult to perform simultaneously on large numbers of compounds,
19
 although 
improvements using fluorescence to monitor polymerization have simplified this process.
20
 
 
6.2.2 Cell-Based Assays to Analyze Tubulin Polymerization 
  In contrast to the in vitro method, whole cell methods enable the evaluation of 
compounds in the more complex cellular environment.  The effects of compounds on 
microtubule stabilization or destabilization in cells can be measured through confocal 
microscopy using a fluorescently-labeled antibody to α-tubulin.21  Although this method 
provides a qualitative measure of the extent of tubulin polymerization, it is difficult to quantify, 
and sample preparation can be lengthy and low-throughput.
21-23
  More recent developments have 
enabled high content microscopy techniques allowing for the quantification of polymerized 
tubulin in single cells; however, this approach can only evaluate a limited region of the cell,
24-26
 
and generates large, complex data sets which can be challenging to analyze rapidly.
27
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Microscopy techniques have been further optimized to evaluate tubulin dynamics in live cells.
28
  
Other whole cell methods have used indirect monitoring of mitosis-related factors, including 
response to dibutyryl-cAMP
29
 and phosphorylation of nucleolin.
30-31
  Radioactive ligand binding 
to cells has also been utilized, but the cells must be lysed in order to analyze the tubulin by 
Western blot.
32
  A recently reported method uses impedance-based time-dependent cell response 
profiling (TCRP) to identify novel microtubule destabiliziers; however, this technique responds 
generally to mitotic arrest averaged across many cells rather than specifically probing 
interactions with microtubules or MAPs.
33-34
 
 
6.3 Whole Cell Microtubule Assay by Flow Cytometry 
  Here we present a novel flow cytometry-based technique for the analysis of tubulin 
polymerization using α-tubulin staining.  This technique allows for the rapid and quantitative 
analysis of polymerized tubulin biomass, enabling facile comparison of compounds that affect 
tubulin polymerization, and an evaluation of the rate at which the tubulin dynamic is perturbed.  
In addition, the method is amenable to the rapid assessment of small molecules, and thus could 
be used to identify novel compounds that affect tubulin polymerization dynamics. 
 
6.3.1 Overview of Technique 
  The dual-stain flow cytometry method to rapidly assay tubulin polymerization in whole 
cells is shown schematically in Figure 6.3.  Cells are incubated with compound for 18 hours, 
tubulin monomers are washed out of the cells using a mild lysis buffer,
35-36
 and cells are treated 
with glutaraldehyde, a fixative known to preserve the microtubule network in cells.
37
  After 
quenching the glutaraldehyde, samples are incubated overnight in the presence of ribonuclease A 
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(to cleave cellular RNA), and sequentially exposed to a FITC-labeled tubulin antibody and 
propidium iodide (a nuclear stain); samples are then analyzed by flow cytometry.  Compounds 
that destabilize tubulin polymerization are expected to show a decrease in fluorescence relative 
to the control, whereas microtubule stabilizers should show an increase in fluorescence, 
consistent with the change in concentration of tubulin biomass in the polymerized microtubules.   
 
 
Figure 6.3.  Schematic for assessing tubulin polymerization by flow cytometry.  Following 
compound treatment, cells are stained and analyzed by flow cytometry to simultaneously detect 
changes in (a) tubulin fluorescence with a destabilizer (red) or a stabilizer (blue) relative to the 
control (black) and (b) cell cycle progression. 
 
6.3.2 Analysis of Small Molecule Effect on Tubulin Polymerization 
6.3.2.1 Classical Microtubule and Tubulin Binders Versus Other Cytotoxins in HeLa Cells 
 A panel of six well-characterized cytotoxic compounds were evaluated in the whole cell 
tubulin polymerization assay described above: compounds that destabilize microtubules 
(colchicine and vincristine, Figure 6.2), compounds that stabilize microtubules (taxol and 
epothilone A,
38
 Figure 6.2), and compounds that do not affect tubulin but cause cell cycle arrest 
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(camptothecin, S-phase arrest
39
; doxorubicin, G2-phase arrest,
40
 Figure 6.2).  Analysis of these 
compounds in HeLa (human cervical cancer cell line) using the flow cytometry method depicted 
in Figure 6.3 allows for a rapid and quantitative analysis of tubulin polymerization levels, with 
concurrent cell cycle analysis (in order to identify compounds that cause mitotic arrest in 
addition to perturbing tubulin dynamics).  As shown in Figure 6.4a, all compounds arrested 
HeLa cells in the expected phase of the cell cycle.  The results of the whole cell tubulin 
polymerization assay are shown in Figure 6.4b.  The microtubule destabilizers colchicine and 
vincristine induced a significant reduction in the fluorescence signal in this assay, while the 
known microtubule stabilizers taxol and epothilone A showed a substantial increase in signal; 
these differences are observed both when examining all cells (left side of Figure 6.4b), and when 
analyzing just those cells in the G2/M phase of the cell cycle, which typically have higher 
amounts of polymerized tubulin (right side of Figure 6.4b).  In contrast, compounds that induce 
cell death through other modes of action show no effect in this assay: camptothecin induced no 
change in fluorescence signal, nor did doxorubicin (Figure 6.4b).  These results are consistent 
with the changes in fluorescence signal observed by microscopy (Figure 6.5).  Taxol and 
epothilone A both show an increase in tubulin signal, as well as an increase in the number of 
cells undergoing mitotic arrest, whereas colchicine and vincristine both show a decrease in signal 
relative to the vehicle control.  Camptothecin and doxorubicin show no change in signal intensity 
and no increase in the number of cells arrested in mitosis. 
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Figure 6.4.  Representative data for whole cell analysis of tubulin polymerization after treatment 
with various anticancer agents.  HeLa (human cervical cancer) adherent cells were treated with 
colchicine (50 nM), vincristine (200 nM), taxol (50 nM), epothilone A (50 nM), camptothecin 
(50 nM), or doxorubicin (200 nM) for 18 hours.  (a) Cell cycle arrest in HeLa cells following 18 
hour treatment, as assessed by propidium iodide staining and flow cytometry.  (b) Tubulin 
fluorescence in HeLa cells following 18 hour treatment, as assessed by anti-α-tubulin staining 
and flow cytometry, as described in text.  Error bars represent standard deviation of the mean, 
n=3.   * Indicates p<0.01 relative to DMSO control, based on a two-tailed Student’s t-test. 
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Figure 6.5.  Microscopy of HeLa cells following 18-hour treatment with compounds.  In these 
images tubulin is stained with anti-α-tubulin FITC conjugate antibody.  HeLa cells were treated 
with colchicine (50 nM), vincristine (200 nM), taxol (50 nM), epothilone A (50 nM), 
camptothecin (50 nM), doxorubicin (200 nM), or STLC (5 µM).  Scale bar is 20 µm. 
 
6.3.2.2 Non-Tubulin Binding Mitotic Arrestors in HeLa Cells 
  There are some compounds that induce mitotic arrest without directly affecting tubulin 
dynamics.  S-trityl-L-cysteine (STLC) and monastrol bind to the Eg5 motor kinase, resulting in 
the formation of monoasters during cell division (Figure 6.5).
30, 41
  After verifying that STLC 
induced the expected G2/M arrest (Figure 6.6a), HeLa cells treated with STLC were evaluated in 
the whole cell tubulin polymerization assay.  In this assay STLC induced a smaller but 
DMSO Ab-free
CPT Dox STLC
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statistically-significant increase in the overall fluorescence, a result still seen after accounting for 
the induced M-phase arrest (Figure 6.6b).    This result demonstrates the potential of this assay to 
identify compounds that affect tubulin structure without directly binding microtubules. 
 
Figure 6.6.  Representative data for HeLa cells treated with 5 µM STLC for 18 hours.  (a) Cell 
cycle arrest in G2/M following compound treatment, as assessed by propidium iodide staining.  
(b) Enhancement in tubulin fluorescence was observed following analysis of the whole 
population of cells, as well as those cells specifically in G2/M.  Error bars represent standard 
deviation of the mean, n=3.   * Indicates a p<0.05 relative to DMSO control, based on a two-
tailed Student’s t-test. 
 
6.3.2.3 Analysis of Cytotoxins in U-937 Cells 
  Although the results presented in Figures 6.4, 6.5 and 6.6 were generated from HeLa cells 
(grown as adherent cultures), suspension cell lines can also be conveniently evaluated using this 
technique. As shown in Figure 6.7, treatment of U-937 (human lymphoma cancer cell line) cells 
with the same panel of cytotoxins produces a result similar to HeLa cells.   
0
50
100
150
200
All Cells G2/M
A
n
ti
-T
u
b
u
li
n
 
F
lu
o
re
s
c
e
n
c
e
(A
rb
it
a
ry
U
n
it
s
)
DMSO
STLC
0
20
40
60
80
100
DMSO STLC
%
 C
e
ll
s
G1
S
G2/M
*
(a) (b)
*
299 
 
 
Figure 6.7.  Representative data for whole cell analysis of tubulin polymerization following 18-
hour compounds treatment in U-937 (human lymphoma) suspension cells.  Cells in the G2/M 
phase of the cell cycle were analyzed via the whole cell tubulin quantitation method described in 
the text after treatment with colchicine (100 nM), vincristine (100 nM), taxol (50 nM), 
epothilone A (50 nM), camptothecin (50 nM), doxorubicin (200 nM), or STLC (5 μM).  Error 
bars represent standard deviation of the mean, n=3.   * Indicates a p<0.05 relative to DMSO 
control, based on a two-tailed Student’s t-test. 
 
6.3.3 Determining IC50 Values of Tubulin-Binding Small Molecules 
  When comparing compounds that affect tubulin polymerization, it is useful to determine 
IC50 values from dose response curves generated from an in vitro assay.   However, this in vitro 
experiment requires a large amount of tubulin, is inconvenient when assessing many compounds 
simultaneously, and the IC50 values obtained do not match the cellular cytotoxicity IC50 values.
19, 
42-45
  Alternately, stabilized cytoskeletons can be isolated and analyzed by ELISA, but this 
method is low-throughput and requires the isolation of tubulin polymers in cell lysate.
46
  In 
contrast, multiple compounds can be conveniently compared using this whole cell tubulin 
polymerization assay.  For this experiment, cells were treated for 18 hours with a range of 
concentrations of taxol and colchicine, as well as recently described compounds 8H and 22 
(Figure 6.2), small molecules known to destabilize microtubule formation much less potently 
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than colchicine and vincristine.
47
  As shown in Figure 6.8, an obvious dose-response is apparent 
for all compounds using the whole cell tubulin assay, with IC50 values of: taxol = 9.6 ± 2.8 nM; 
colchicine = 21.6 ± 0.8 nM; compound 8H = 9.8 ± 3.6 µM; compound 22 = 8.0 ± 2.6 µM.  These 
values are generally 10-100x lower (more potent) than their observed effect in the in vitro 
tubulin polymerization assay (taxol = 400 nM
48
; colchicine = 1.4 µM
42
; compound 8H  > 25 
µM
47
) and more faithfully reflect the cell culture efficacy and toxicity of these compounds:  the 
72-hour IC50 values for cell death induction are taxol = 10 nM
42
; colchicine = 20-70 nM
42
; 
compound 8H = ~3.0 µM
47
; and compound 22 = 1.8-5.6 µM.
47
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Figure 6.8.  Representative data of dose-response curves for U-937 cells treated with increasing 
concentrations of (a) the microtubule stabilizer taxol, and (b) the microtubule destabilizers 
colchicine, compound 8H, and compound 22.  IC50 values were calculated using the average and 
standard deviation of three independent experiments fit with a logistic dose response curve.  
Error bars represent standard deviation of the mean, n=3. 
 
6.3.4 Determining Kinetics of Microtubule Perturbation 
  Microtubule polymerization kinetics are extremely difficult to follow in whole cells; 
generally, the timing of tubulin polymerization/depolymerization in response to compound is 
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monitored in vitro.
16-17, 19, 42-45
  Limited examples do exist in which the dynamics of microtubules 
are measured following compound exposure in mammalian cells; however, these reports focus 
on a single compound,
49-50
 analyze tubulin levels in cell lysate,
51
 or fail to demonstrate consistent 
responses to a range of tubulin binders.
52
  As such, direct head-to-head comparisons of the effect 
of various anticancer drugs on the kinetics of microtubule polymerization have not been made.  
Given the simplicity and throughput of this new whole cell method for evaluation of microtubule 
polymerization, it is ideally suited to this type of kinetic analysis.  To assess the kinetics of 
microtubule perturbation by small molecules, cells were fixed after varying periods of compound 
exposure, and their tubulin levels were monitored (Figure 6.9a).  The tubulin destabilizers 
colchicine and vincristine show tubulin destabilization that is complete in 4-6 hours; this timing 
is approximately consistent with the observed cell cycle arrest Figure 6.9b.  The tubulin 
stabilizers taxol and epothilone A evoke a significantly more rapid response in cells.  A 
stabilization phenotype is observed within 15 minutes of treatment for both compounds, and a 
maximum response is reached within 1 hour (Figure 6.9a); these cells show G2/M cell cycle 
arrest at  3-4 hours (Figure 6.9b).  This rapid response aligns with taxol’s ability to suppress 
plus-end dynamics within five minutes of compound exposure.
49
  Finally, treatment with STLC 
shows a much slower response (>6 hours) that lags behind G2/M arrest; this is consistent with 
the indirect nature of STLC modification of tubulin dynamics.   
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Figure 6.9. Representative data of time-dependent response of (a) tubulin polymerization and (b) 
cell cycle arrest in U-937 cells following compound treatment with colchicine (100 nM), 
vincristine (200 nM), taxol (50 nM), epothilone A (50 nM), and STLC (5 µM).  The data were 
normalized to the DMSO control at each timepoint.  In order to control for cell cycle arrest in 
anti-tubulin fluorescence, only cells in G2/M were analyzed.  Error bars represent standard 
deviation of the mean, n=3.  
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6.4 Whole Cell Analysis of Tubulin Binding in a Medium-Throughput Format 
  Given the importance of tubulin polymerization modifiers as anticancer agents, there is 
significant interest in finding new compounds that have this property.  This could either be 
completely de novo, from an unbiased screen, or through assessment of a library of compounds 
designed to perturb tubulin dynamics.  Neither the in vitro tubulin polymerization assay nor the 
microscopy method is well-suited for the direct comparison of antimitotics due to cost, low 
correlation to in-cell efficacy, low signal-to-noise, or the inability to generate IC50 values.
27
  This 
new flow cytometry method, when paired with an auto-sampler, provides a medium-throughput, 
single-cell, high signal-to-noise method for the characterization of small libraries of tubulin 
binders that addresses the limitations of in vitro tubulin polymerization and microscopy.  To 
demonstrate the utility of this method in a medium-throughput format, a “needle-in-a-haystack” 
assay was performed whereby known tubulin stabilizers and destabilizers were spiked into a 
plate containing test compounds from an in-house library and vehicle controls.  The treated cells 
(U-937) were then analyzed to evaluate the extent of tubulin polymerization in whole cells.  As 
shown by the data in Figure 6.10, the compounds known to affect tubulin polymerization are 
easily identified as hits in such an experiment.  
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Figure 6.10.  Tubulin stabilization and destabilization is detectable in a medium-throughput 
readout using the whole cell tubulin polymerization assay and an auto-sampler.  DMSO vehicle 
control wells are shown in triplicate (red bars), as are taxol (50 nM) and colchicine (100 nM) 
control wells (blue and green bars, respectively).  The PI control well (black bar) contains no α-
tubulin antibody.  All other wells contain 1 µM of compound from an in-house compound 
collection, with spiked wells containing taxol or colchicine at control concentrations.  The 
colchicine and taxol “hits” are greater than 3 standard deviations from DMSO mean. 
 
6.5 Advantages and Caveats 
6.5.1 Clinical Translation 
  The importance of tubulin binding compounds in anticancer therapy is unquestioned, 
given the clinical success of taxol, vinblastine, and other drugs that disrupt proper tubulin 
polymerization/depolymerization dynamics.  In addition, there are emerging roles for tubulin 
binders in the treatment of diseases other than cancer.
53-54
  While the current classes of tubulin 
binding agents are life-saving drugs, many of these compounds suffer from poor oral 
bioavailability, neurotoxicity, and loss of efficacy over time due to resistance.  There is a clear 
and pressing need for the continual development of next-generation tubulin-binding small 
molecules. 
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6.5.2 Comparison to Existing Techniques 
  The two standard methods for assessing the influence of a compound on tubulin 
polymerization, a turbidity-based in vitro assay and fluorescence microscopy, both suffer from 
certain limitations.  Assessment of tubulin polymerization in vitro requires large quantities of 
precious tubulin and does not directly correlate to the efficacy of compounds in the more 
complex cellular environment.  In addition, this method typically uses bovine tubulin, when the 
effect of a compound on human tubulin is what is of actual interest.  Although fluorescence 
microscopy does provide a whole-cell approach for the analysis of tubulin polymerization, it has 
a slower analysis speed, is limited to adherent cells, and the readouts are difficult to quantify, 
complicating head-to-head comparison of compounds.  In contrast, flow cytometry serves as a 
powerful tool to rapidly and quantitatively analyze a variety of cellular phenotypes based on 
staining cells with an appropriate fluorescently-labeled antibody.  The combination of a tubulin 
antibody with a DNA dye allows for the detection of compounds which cause mitotic arrest that 
also affect microtubules.  
  When compared to existing methods for the identification and assessment of tubulin-
binding compounds, the flow cytometry technique described herein has several advantages.  
First, because it is a whole cell technique, the potency of compounds in this assay is more likely 
to reflect their potency in cytotoxicity experiments.  For example, it is well documented that the 
in vitro tubulin polymerization assay returns IC50 values for compounds that are often 2-3 orders 
of magnitude higher (less potent) than the cell death IC50.
42-43, 55-56
  As demonstrated in Figure 
6.8 and mentioned in the text, the tubulin polymerization IC50 values for colchicine, taxol, 
compound 8H and compound 22 in this new flow cytometry assay closely mimic their cell death 
IC50 values.  Second, the kinetic response of whole cells to tubulin-binding compounds is easily 
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monitored and can be directly linked to cell cycle arrest.  This key feature allows for the direct 
comparison of the kinetic effect of compounds on microtubule dynamics in cells.  Third, as there 
is no need for purified tubulin, this flow cytometry based assay is extremely cost effective, as the 
primary cost is based only on a commercially-available fluorescently-labeled tubulin antibody.  
Finally, the ability to interface with existing high-throughput platforms should allow this flow 
cytometry method to be utilized in a high-throughput fashion to identify novel compounds that 
perturb tubulin polymerization.  The cost of the in vitro turbidity method makes HTS prohibitive, 
and higher throughput methods such as TCRP, dibutyryl-cAMP, and nucleolin staining probe 
general mitotic arrest rather than specific interactions with tubulin. 
 
6.5.3 Limits of Described Technique 
  There are some caveats with this new method.  As a laser-based system, compound 
autofluorescence can artificially enhance the observed signal.  This can be easily accounted for 
through the use of tubulin antibodies with red fluorescent probes.  Compounds that induce 
alternate aberrant tubulin phenotypes through binding of microtubule-associated proteins (such 
as monoaster formation following disruption of Eg5) are identified in this assay.  Given that most 
tubulin-binding compounds act by interrupting tubulin dynamics, the discovery of compounds 
that generate aberrant tubulin phenotypes by binding to alternate proteins could identify novel 
anticancer targets.  For example, compounds which inhibit Eg5 are currently in Phase I/II trials.
57
  
These studies have shown good tolerance of Eg5 inhibitors,
58-59
 although preliminary Phase II 
studies on refractory cancers show only minimal efficacy.
60-62
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6.5.4 Broader Application 
  The method described herein offers a new means by which to discover and assess, in a 
cellular milieu, compounds that perturb microtubule dynamics.  Given the importance of tubulin 
binders as anticancer agents and the laborious nature of standard tubulin polymerization assays, 
this method should be useful in the discovery and characterization of novel antineoplastic 
compounds that act through the disruption of the tubulin/microtubule dynamic. 
 
6.6 Methods 
General Reagents and Methods 
Taxol, colchicine, camptothecin, doxorubicin, epothilone A, S-trityl-L-cysteine, propidium 
iodide, monoclonal anti-α-tubulin−FITC antibody, and Ribonuclease A (from bovine pancreas) 
were purchased from Sigma Aldrich.  Vincristine was purchased from Avachem Scientific.  
Gluteraldehyde was purchased from Ted Pella, Inc.  Flow cytometry was performed on a BD 
Biociences LSR II (San Jose, CA) and the data was analyzed as described using FACSDiva 
software (San Jose, CA). 
 
Cell culture information 
Cells (U-937, human lymphoma and HeLa, human cervical cancer) were grown in RPMI-1640 
media supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 µg/mL penicillin 
and 100U/mL streptomycin).  Cells were incubated at 37 °C in a 5% CO2, 95% humidity 
atmosphere. 
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Whole cell analysis of tubulin polymerization 
For HeLa cells, cells were plated (100,000 cells/mL in 1 mL media) and allowed to adhere in a 
12-well plate for a minimum of 4 hours.  Compounds were then added as DMSO stocks (0.1%-
1% DMSO final).  For U-937 cells, compounds were added as DMSO stocks (1% DMSO final) 
to a 24-well plate, followed by the addition of 0.5 mL of a cell dilution in fresh media (500,000 
cells/mL).  In both cases, the cells were incubated for 18 hours.  After incubation, the cells were 
transferred to 2 mL tubes and pelleted (600 g, 3 min).  In the case of treated HeLa cells, the 
media was removed by aspiration 15 minutes prior to the indicated timepoint, and cells were 
trypsinized for 15 minutes with 0.2 mL of 0.5% trypsin with EDTA prior to pelleting.  The 
media was removed via aspiration, and the cells were fixed by adding 1 mL of 0.5% 
glutaraldehyde in Microtubule Stabilizing Buffer (MTSB, 80 mM PIPES, pH 6.8, 1 mM MgCl2, 
5 mM EGTA, 0.5% TX-100).  Following a 10 minute incubation at room temperature, the 
glutaraldehyde was quenched by the addition of 0.7 mL of 1 mg/mL NaBH4 in PBS.  The cells 
were pelleted (1000 g, 7 min), and the supernatant was removed by gentle aspiration.  The cells 
were resuspended in 20 µL of 50 µg/mL RNase A in AbDil and incubated overnight at 4 °C.  
Prior to reading, 5 µL of a 1:50 dilution of anti-α-tubulin-FITC antibody in Antibody Diluting 
Solution (AbDil, PBS, pH 7.4, 0.2% TX-100, 2% BSA, 0.1% NaN3) was added to each sample 
to achieve a final dilution of 1:250, and the cells were incubated in the dark for 3 hours.  The 
samples were further diluted in 200 µL of 50 µg/mL PI in PBS, transferred to flow tubes, and 
analyzed by flow cytometry.  To ensure that the HeLa cells were in suspension as single cells, 
the samples were vortexed prior to analysis.  Whole cells were identified based on their FSC and 
SSC traces, as well as propidium iodide staining (single cells based on pulse width and height).  
Cells in G2/M-phase were identified based on the 4N propidium iodide stain.  Tubulin levels 
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were based on the geometric mean of the antibody-FITC fluorescence and were normalized to a 
value of 100 for the vehicle control. 
 
Micoscopic analysis of tubulin polymerization 
Round, 1.5 mm coverslips (No. 1.5) were sterilized with ethanol and placed in a 12-well plate.  
HeLa cells (100,000 cells/well) were added and allowed to adhere for a minimum of four hours.  
Compounds were then added as DMSO stocks to achieve a final DMSO concentration of 1%, 
and the plates were incubated for the indicated time.  Following incubation, the media was 
removed, and the coverslips were washed with 1 mL Microtubulin Stabilizing Buffer (MTSB, 80 
mM PIPES, pH 6.8, 1 mM MgCl2, 5 mM EGTA, 0.5% TX-100).  The coverslips were then fixed 
with 1 mL MTSB + 0.5% glutaraldehyde for 10 minutes at room temperature, after which the 
fixative was removed and the sample was quenched with the addition of 1 mL of 1 mg/mL 
NaBH4 in PBS.  The coverslips were allowed to incubate at room temperature for 7 minutes, at 
which time the solution was removed by aspiration.  The coverslips were washed with PBS, and 
then stored under PBS at 4 °C.  Coverslips were transferred to parafilm-lined culture dishes (cell-
side up), and 25 µL of 0.5 mg/mL RNase A in Antibody Diluting Solution (AbDil, PBS, pH 7.4, 
0.2% TX-100, 2% BSA, 0.1% NaN3) with 1:50 dilution of anti-α-tubulin-FITC antibody was 
added to all samples, except for the nuclear-stain only sample, which was treated with antibody-
free RNase A.  The samples were allowed to incubate at room temperature in the dark for 2.5 
hours, after which the coverslips were washed with PBS + 0.1% TX-100.  The samples were 
then incubated for 10 minutes with 50 µL of 50 µg/mL PI in AbDil, except for tubulin-stain only 
sample, which was treated with PI-free AbDil .  The coverslips were washed with PBS + 0.1% 
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TX-100, at which point they were mounted onto microscopy slides using Dako fluorescent 
mounting media, allowed to cure, and imaged on the Zeiss confocal LSM 510 (Jena, Germany). 
 
Timecourse for whole cell analysis of tubulin polymerization 
To adapt this procedure to a timecourse format, U-937 cells were plated and treated as described 
above.  Cells were treated for 1-8 hours (colchicine and STLC), 0-8 hours (vincristine), or 0-60 
minutes and 7 hours (taxol and epothilone A).  The initial timepoint at “0” minutes corresponds 
to pelleting of the cells immediately after compound addition, followed by fixation, which 
corresponds to a 3-minute incubation time.  For all other timepoints, following the appropriate 
incubation, cells were transferred to 2 mL tubes and pelleted (800 g, 2 min).  Following media 
removal by aspiration, the samples were processed as described above. 
 
Medium throughput screening using whole cell analysis of tubulin polymerization 
To adapt this procedure to a 96-well plate format, U-937 cells were plated and treated as 
described above with two modifications.  Following fixation, the cells were resuspended in 25 
µL of 250 µg/mL RNase A in AbDil with a 1:250 dilution of anti-α-tubulin-FITC antibody and 
incubated at room temperature in the dark for 3.5 hours.  The samples were further diluted in 200 
µL of 50 µg/mL PI in PBS and then transferred to a 96-well plate.  The plate was analyzed by 
flow cytometry on a BD Biosciences LSR II (San Jose, CA) which was equipped with an 
autosampler. 
 
. 
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Statistical analysis 
P-values were calculated relative to the vehicle control using a two-tailed Student’s t test.  A P-
value of less than 0.05 or 0.01 was considered significant.  IC50 values are reported as average ± 
SEM. 
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